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Manufacturing of Non-Egg Based Influenza Vaccine
Abstract
Influenza is an annual health hazard with only about one-third of people in the United States receiving
vaccinations for this pathogen. Epidemics are estimated to affect between 5% and 15% of the global
population annually. Annually, the WHO estimates epidemics to result in between 3 and 5 million severe
cases which lead to between 250,000 and 500,000 deaths. In industrialized countries, most of these
deaths occur among victims who are chronically ill or are 65 years of age or older. In developing
countries, particularly in tropic areas where transmission occurs year round, there is a higher rate of death
to infection. For example in 2002, Madagascar experienced 800 deaths in 27,000 recorded cases of
influenza over a 3 month period (WHO).
Recently, international awareness, spearheaded by the World Health Organization (WHO), has been paid
to influenza since the pandemic outbreak and subsequent vaccine shortage during the H1N1 outbreak.
Since then the WHO has published a set of guidelines to encourage production of safer and increasingly
potent influenza vaccines for a greater number of recipients each year. WHO is attempting to increase
public and private sector awareness of the importance of influenza vaccination to prevent any
subsequent pandemics.
Current vaccines are produced in live, embryonated chicken eggs resulting in potential allergic reactions
from animal products in the vaccines. Furthermore, this process is time-consuming and labor intensive,
and the live, attenuated virus is considered to be a potential health risk for populations with suppressed
immune function such as children, the elderly, and those who are sick or immunocompromised. Egg
shortages can cause massive vaccine shortages, especially since only two companies currently produce
most of the United States' influenza vaccines. We propose that virus- like particles offer a more robust
and safer alternative to current vaccine manufacturing. Currently, FluBlok is a product that utilizes
recombinant influenza antigens to produce a vaccine. We plan to take this strategy another step to
creating replication-deficient, native conformation viruses to induce an immune response. These particles
will retain all structural similarity to native virus and have been shown to produce more robust responses
with smaller doses. Furthermore, these particles will carry no risk of influenza infection upon
administration. Virus-like particles will become the next generation of vaccines, such as those for human
papilloma virus currently manufactured, and should rectify the problems associated with egg-based
production of influenza vaccines.
The proposed process is a fed-batch operation that will create about 100 million influenza vaccines
during each influenza infection season from November to February, using insect cell lines and the
baculovirus expression vector system (BEVS) to induce lytic formation of virus-like particles. This process
will be performed in a single-use, disposable fermentation train with single-use components integrated in
the purification process to take advantage of the timesaving techniques and disposable equipment. The
production of influenza vaccines is time-sensitive with a limited duration of vaccine production from
WHO's publishing strains to product shipment. Single-use equipment will be used to allow maximization
of production time and minimization of down-time in this process.
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traditional  egg  based  platform  for  the  flu  vaccine.  We  propose  an  innovative  process  that  uses  
insect  cells  and  the  baculovirus  expression  system  to  produce  virus-like  particles,  mimicking  
influenza.  The  process  is  designed  in  such  a  way  as  to  easily  incorporate  annual  changes  in  
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The  enclosed  report  documents  our  entire  design  process  and  decisions  that  were  made  during  the  
formulation  of  the  vaccine  and  manufacture  facility.    The  report  also  contains  a  competitive  
analysis,  market  analysis,  and  financial  models  of  the  vaccine  company.  
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1.0 A bstract
Influenza is an annual health hazard with only about one-third of people in the
United States receiving vaccinations for this pathogen. Epidemics are estimated to affect
between 5% and 15% of the global population annually. Annually, the WHO estimates
epidemics to result in between 3 and 5 million severe cases which lead to between
250,000 and 500,000 deaths. In industrialized countries, most of these deaths occur
among victims who are chronically ill or are 65 years of age or older. In developing
countries, particularly in tropic areas where transmission occurs year round, there is a
higher rate of death to infection. For example in 2002, Madagascar experienced 800
deaths in 27,000 recorded cases of influenza over a 3 month period (WHO).
Recently, international awareness, spearheaded by the World Health Organization
(WHO), has been paid to influenza since the pandemic outbreak and subsequent vaccine
shortage during the H1N1 outbreak. Since then the WHO has published a set of
guidelines to encourage production of safer and increasingly potent influenza vaccines
for a greater number of recipients each year. WHO is attempting to increase public and
private sector awareness of the importance of influenza vaccination to prevent any
subsequent pandemics.
Current vaccines are produced in live, embryonated chicken eggs resulting in
potential allergic reactions from animal products in the vaccines. Furthermore, this
process is time-consuming and labor intensive, and the live, attenuated virus is
considered to be a potential health risk for populations with suppressed immune function
such as children, the elderly, and those who are sick or immunocompromised. Egg
shortages can cause massive vaccine shortages, especially since only two companies
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FXUUHQWO\SURGXFHPRVWRIWKH8QLWHG6WDWHV¶LQIOXHQ]DYDFFLQHV We propose that viruslike particles offer a more robust and safer alternative to current vaccine manufacturing.

Currently, FluBlok is a product that utilizes recombinant influenza antigens to produce
a vaccine. We plan to take this strategy another step to creating replication-deficient,
native conformation viruses to induce an immune response. These particles will retain all
structural similarity to native virus and have been shown to produce more robust
responses with smaller doses. Furthermore, these particles will carry no risk of influenza
infection upon administration. Virus-like particles will become the next generation of
vaccines, such as those for human papilloma virus currently manufactured, and should
rectify the problems associated with egg-based production of influenza vaccines.
The proposed process is a fed-batch operation that will create about 100 million
influenza vaccines during each influenza infection season from November to February,
using insect cell lines and the baculovirus expression vector system (BEVS) to induce
lytic formation of virus-like particles. This process will be performed in a single-use,
disposable fermentation train with single-use components integrated in the purification
process to take advantage of the timesaving techniques and disposable equipment. The
production of influenza vaccines is time-sensitive with a limited duration of vaccine
SURGXFWLRQIURP:+2¶VSXEOLVKLQJVWUDLQVWRSURGXFWVKLSPHQW6LQJOH-use equipment
will be used to allow maximization of production time and minimization of down-time in
this process.
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2.0 Introduction
Vaccines are an increasingly important cost-effective prophylactic measure
against widespread disease, particularly for diseases of high morbidity or mortality or of
pandemic proportions. Influenza is a virus that fits the latter category, for many of its
strains have caused global pandemics and it recurs on a yearly basis. The entire
population is at risk of contracting influenza, and it is especially virulent in children and
the elderly, especially since it spreads as an aerosol. Influenza is responsible for about
17,000 to 51,000 deaths annually in the United States and global pandemic death tolls
reach the millions (Kang).
Influenza is a lipid-encapsulated RNA virus consisting of four surface proteins
essential for infection and replication: M1, M2, neuraminidase (NA) and hemagglutinin
(HA). There exist two subclasses of influenza, A and B. Each year, the World Health
Organization (WHO) issues a recommendation of the influenza A and B HA and NA
variants most likely to cause disease. Classically, based on these recommendations,
trivalent influenza vaccines have been produced in embryonated chicken eggs, consisting
of two influenza A variants and a single influenza B variant, which are then activated and
adjuvanted to increase the immune response. These vaccines are inefficient in children
and the elderly, and antigenic drift can greatly decrease their efficacy in the rest of the
population. Lately, egg shortages combined with increasingly virulent influenza strains
(H1N1) have rendered this method of vaccine production archaic and inefficient for
meeting the ever-increasing demand for yearly vaccination. A new method of vaccine
production involving industrial cell culture would greatly increase the number of
vaccines available.
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Current influenza vaccines are either produced from inactivated egg-grown virus
particles or from trivalent recombinant HA proteins (rHA) grown in mammalian cells
(Flucelvax, approved November 2012). While the recombinant protein vaccine is egg-

free, it requires expensive mammalian cell culture and yields a protein product that is not
entirely in its native conformation. Recently, virus-like particles (VLPs) have become a
popular alternative to traditional inactivated or recombinant protein vaccines such as the
human papilloma virus (HPV) vaccine currently on the market. VLPs can display any
protein of interest on their surface in the native conformation found on the mimicked
virus. However, these VLPs do not contain the necessary components for replication or
infection (see Figure 2.1), so serve as a method to safely introduce antigenic material to
WKHERG\DVLILWZHUHDQDFWLYHYLUXV '¶$RXVW 

F igure 2.1 Virus particles(left) compared to VLPs (right). Note the missing
genomic material in the VLPS as well as the simplified proteins in the
membrane compared to the fully functional virus. The electron micrographs
demonstrate their similarity in macrostructure. Reprinted from Landry, N.
PLoS One.Volume 8, 2010.
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VLPs present a much smaller chance of infection or side-effects when compared with the
other vaccines available, and their immunogenic response is considerably more robust, on
the order of a five-fold increase (Kushnir). Influenza is a lipid membrane-enclosed virus,
obtaining this coating from the infected cell as it buds involving no internal protein
capsid. This simplicity of viral structure allows for a simplified purification process, since
it is considerably more thermodynamically stable than a VLP containing capsid proteins,
keeping the downstream processing equipment similar to that used for rHA or inactivated
virus vaccines (Roldao).
In the case of influenza VLPs, studies have demonstrated that the M1 matrix ion
channel proteins in combination with HA are necessary and sufficient to induce VLP
formation (Galarza). These VLPs tend to form with diameters between 80 and 120nm,
about the same size as the influenza virus particles. Since these requirements for VLP
budding are minimal, most of the protein production of the cells can be directed towards
the production of HA rather than M1, such that the majority of the protein produced is
HA on the surface of individual VLPs. The efficacy of vaccine is related to its ability to
present HA in its native conformation to the immune system. The immunogenicity of
VLPs is already about five-fold greater than that of rHA proteins or inactivated viruses.
HA production will be dominant in the insect cells by insuring the upstream promoter is
activated earlier in the life cycle of the virus than the promoter upstream of the M1
protein. Then, upon progression of the virus, HA will be considerably more concentrated
than M1, creating VLPs densely populated with HA surface proteins for a more robust
vaccine.
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The baculovirus expression vector system consists of the infection of an insect
cell line with the baculovirus, which is only virulent to insect cells. These baculoviruses
are recombinant and contain a DNA that the host cell will produce. Upon infection the
host insect cells will produce large amounts of protein encoded by the recombinant
baculovirus DNA. These proteins, mostly HA and in much smaller quantities, a matrix
protein, will induce the formation of VLPs at sites of aggregation near the insect cell
membrane. This process will result in VLPs made of insect cell membrane with the
desired antigenic material to immunize against influenza on the surface. The
baculoviruses are consumed in the process of VLP formation. The design and execution
of the baculovirus constructs for each HA subtype and the method of promoter selection

to provide the correct relative amounts of HA and M1 production are outside of the scope
of this project, but have been mentioned for completeness of theoretical design.
Furthermore, the verification of VLP budding and the average concentration of HA on
the surface of each VLP would be carried out on the bench-top using HA activity assays
and electron microscopy to determine the exact characteristics of the influenza VLPs.
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2.1 Project C harter
Project Name: Influenza Virus-Like Particle Vaccine Biopharmaceutical Process
Project Team: Erin Kinnevy, Ian Penkala, April Soohoo, John Vogel
Project Goal: Design a biopharmaceutical plant and process to produce egg-free influenza
vaccines
Project Scope:
In-Scope
x
x
x
x
x
x
x

Observe cGMP in producing influenza vaccines, obeying all safety and health
regulations
Design the production stream from small scale fermentation to final product
purification
Design both a pilot- and a manufacturing-scale plant
Deliver a product from R&D to final production in under six months
Maintain a profit margin
Price the vaccine competitively with egg-based vaccines
Create an animal-free influenza vaccine

Out-of-Scope
x
x
x
x
x
x
x
x

Baculovirus research and formulation
Influenza strain research
Toxicology studies
Proof-of-Concept studies
Clinical trials
Product packaging & distribution
Cell-line screening and testing
Air flow profiles of facility

Deliverables
x
x
x
x
x

Production timeline & individual batch timeline
Achievement of regulatory requirements
Technical feasibility assessment & supporting literature
Business feasibility assessment & cost sensitivity analysis
WHO vaccine guideline fulfillment
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2.2 Innovation Map
Overall, the production of a non-egg based influenza vaccine is innovative, as it is
a relatively new to the market. In regards to the production facility, the upstream
SURFHVV¶VLQQRYDWLRQVDUHVSHFLILFWRWKHsingle-use, stirred-tank bioreactors, and choice of
other single-use technologies.
The downstream process follows the same path as traditional influenza vaccines,
and thus the only innovation is the use of disposable technology as opposed to stainless
steel equipment. As a result, an innovation map for the downstream process has not been
included; the single-use technology innovations have the same advantages as in the
upstream process.
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F igure 2.2 Upstream Process Innovation Map. The innovation map identifies key features of the upstream process for
the non-egg based influenza vaccine system based on the process design and equipment choice.
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2.3 E xpression System Selection
A major focus of biopharmaceutical companies is to develop new technologies as
alternatives to egg-based culture for production of viral vaccine antigens. Alternatives
currently under development involve direct expression of selected viral antigens in
mammalian cells, insect cells, plant cells, and avian cells. For the purposes of this design
project, all of these alternatives were explored for their potential to overcome both the
safety and efficacy limitations of egg-based vaccine production.
The mammalian cell lines under investigation included Madin-Darby Canine
Kidney (MDCK) cells, Vero cells, and PERC6 cells. While these cell lines have been
associated with high-titer productivity of influenza strains, few studies have reported on
large-scale production. Other possible limitations involved with mammalian cell lines
include the difficulty in selecting defined cell lines with the ability to propagate in a
chemically defined medium under serum-free conditions and the vigorous testing
required for clearance of adventitious or oncogenic agents (Montomoli). Plant cell lines
and prokaryotic cell lines were eliminated based on the difficulties involving land and
WUDQVSRUWDWLRQURXWHVVHSDUDWLRQVDQGSURWHLQIROGLQJ '¶$RXVW 
Avian and insect cell lines showed the most benefits with high suspension growth,
scalability, inexpensive growth conditions, and rapid turn-over rates. After analyzing the
benefits and challenges associated with each of the alternatives, the insect cell line, SF2,
similar to the SF+ line developed by Protein SciencesTM, was designed by the R&D
group as the VLP production system. Rather than using a cell culture-based platform,
hemagglutinin (HA), the active component of the influenza vaccine, will be produced
using recombinant DNA methods and the baculovirus expression vector system (BEVS).
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Table 2.1 shows several influenza vaccines that are in development by different
biopharmaceutical companies (PCAST).
T able 2.1 Competing influenza vaccines made from non-egg based platforms that are currently in development, in
clinical trials or on the market (PCAST).

V accine/M anufacturer

T ype

F luBlok/Protein
Sciences
PanBlock/Protein
Sciences

Soluble protein
(HA), trivalent
Soluble protein
(HA)

Influenza/Novavax

VLP

Pandemic & Seasonal
Influenza/L entigen
Pandemic & Seasonal
Influenza/M edicago

VLP

Mode of
Preparation
Insect Cell
Culture/Baculovirus
Insect Cell
Culture/Baculovirus
Insect Cell
Culture/Baculovirus
Human Cell
Culture/Lentivirus

A djuvant
None
None
None
None

VLP

Plant Cell Culture

None

Pandemic & Seasonal
Influenza/V axinnate

Soluble human
and avian protein
(HA)

E. Coli

Flagellin

Universal
Influenza/Dynavax

Soluble protein

E. Coli

CpG

The insect cells will be cultured in bioreactors and infected with the recombinant
baculovirus, which is then purified and formulated into a vaccine. The specific cell line to
be used for the vaccine production is SF2, a cell line derived from SF9 cells with a
specific phenotype and genotype ideal for biomanufacturing. SF2 cells have been proven
to be non-tumorigenic, free of adventitious agents and retroviruses, and can remain stable
for at least 50 passages, according to prior studies during the development phase of this
cell line.
The BEVS platform offers several advantages over the other methods: (1) the
recombinant HA is highly purified without egg derivatives, (2) the cloning, expression,
and manufacturing of the recombinant HA is less time-consuming, (3) the production

	
  
system is highly scalable, (4) recombinant HA in insect cells has been tested in clinical
trials with a positive safety record (McPherson).
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2.4 Baculovirus E xpression System
The baculovirus expression system (BEVS) has been chosen as the basis for the
influenza vaccine production for its proven effectiveness in a variety of research
applications. Baculovirus expression vectors have been used extensively for the
production and characterization of virus-like particles (VLPs). The expression of
baculovirus in insect cell cultures in particular represents a robust method for producing
recombinant glycoproteins, and has been shown to be a reliable system for recombinant
protein expression (Kushnir).
The pharmaceutical industry has shown that BEVS is an industrially relevant
SODWIRUPIRUWKHSURGXFWLRQRIFRPSOH[ELRORJLFV9DFFLQHVVXFKDV*OD[R6PLWK.OLQH¶V
CervarixTM, a bivalent human papillomavirus vaccine was produced using the BEVS and
was approved in 2009 for commercialization in the USA. Other candidate vaccines
produced using the BEVS such as PanBlockTM and NovavaxTM are in late-stage
development, and one, FluBlokTM, has been approved by the FDA. The biosafety of
baculoviruses provide additional advantages to using this system. Baculoviruses are
incapable of infecting mammals and plants and they have a restricted range of hosts that
they can infect, which is typically restricted to a closely related insect species. The welldocumented safety profile of this expression system has lead to its increasing use in the
production of biologics and other research applications (Kost).
The expression system works by designing baculoviruses to display foreign peptides
and proteins on virus particles. When using the BEVS for vaccine production,
mathematical models are used to help predict optimal conditions, aid in the control and
operation of the process and help to formulate novel hypotheses. The overall
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development process is predominantly characterized by the cell growth period, which is
followed by the addition of the virus. The cell growth period is typically modeled
exponentially and constrained by either depletion of a limiting nutrient or by
accumulation of toxic metabolic by-products. In the case of insect cells, however, no
limiting nutrients or toxic metabolic by-products have currently been identified (Kost,
Aucoin).
An additional concern when using the BEVS is the distribution of virus and
quantification of baculovirus. The uptake of the virus once it is added to the system can
have many important implications on further processing. For example, the amount of
baculovirus added to the system can dramatically affect the production capacity of the
system. However, the multiplicity of infection and the distribution between the insect
cells in the population and the virus are aspects of this process that remain outside the
scope of this design project.
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3.0 Concept Stage
3.1 Total M ar ket and Competitive A nalysis
The company is targeting the annual production of seasonal influenza vaccines in
the North American and European markets. In addition, the company must be able to
respond to a pandemic. In 2004, the world market for influenza vaccines was $1,525
million in revenues, and in 2008, $3,400.1 million. Based on a compound annual growth
rate of 14.0% from 2008-2013, it is projected that in 2013 the world market for influenza
vaccines will reach $6,546 million in revenues (World Market), of which approximately
two thirds, or $4,364 million can be estimated as part of the target markets.
Currently, the market is dominated by the production of influenza vaccines in an
egg-based platform. However, this platform limits the population the vaccine is available
to due to egg and feather allergies. In addition, this platform is also associated with long
lead times, difficulties scaling up, and a less consistent, reproducible means of vaccine
production, along with vulnerabilities from egg shortages from issues such as the avian
flu. In particular, the egg-based platform struggles to create enough vaccines in a timely
manner for a pandemic situation (Harding).
Vaccine companies are now branching out to produce flu vaccines using
alternative expression systems from cell cultures in order to overcome these challenges.
The FDA recently approved two seasonal flu vaccines produced from cell culturesFlucelvaxTM, by NovartisTM, produced from MDCK cells, in November 2012, and
FluBlokTM, by Protein SciencesTM, produced from insect cells, in January 2013
(Willyard). With growing research in the field of cell culture vaccine production, the
company must be able to compete with both these vaccines, as well as vaccines produced

	
  

16	
  

from the egg-based platform. Influenza vaccines produced from cell cultures remains a
largely new innovative field, which leaves room for this company to grow and expand
into this market share. Furthermore, this company has the potential to expand into the
market for other vaccines, since this method of production is also feasible system for
other types of vaccines besides influenza.
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3.2 Principal Competition Production L evel and Sales
As a world-leading vaccine company, production must meet or exceed that of
other major companies. Currently, NovartisTM, Sanofi PasteurTM, AstraZenecaTM,
GSKTM, and CSLTM are leaders in the flu vaccine market (Kresse). In 2011, Sanofi

PasteurTM produced over 200 million seasonal vaccine doses (Sanofi Pasteur fact sheet).
Based on this number and annual growth of the market, it is estimated that the company
will need to produce 100 million vaccine doses for the North American and European
markets in 2013.
In response to the A(H1N1) 2009 pandemic, Sanofi Pasteur recorded the
production of over 250 million vaccine doses (Sanofi Pasteur fact sheet). This number
represents an estimated maximum production level this new platform must be able to
meet. Overall, in order to remain competitive in the market, the company must be able to
produce each flu vaccine at a cost of $1 per dose.
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3.3 C ustomer Requirements
As an alternative to the egg-based flu vaccine, this new insect cell based flu
vaccine must meet the same general customer requirements. These would include

manufacturing protocols following FDA guidelines as well as FDA approval of the final
flu vaccine product. In addition, the vaccine must also be stable, and either meet or
exceed the industry standard for quality for a price similar to those of current competitive
egg-based vaccine products.
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3.4 Block F low Diagram

F igure 3.1 Block Flow Diagram. Outlines the process flow of the upstream and downstream systems. Note that three
separate upstream and downstream process designs will operate in the facility to run each of the influenza strains.
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4.0 Process F low Diagrams
The following pages contain the process flow diagrams and material balances
describing the manufacturing platform for the production of the non-egg based influenza
vaccine. Although not shown in the block separate process flow diagrams, four lines will
be included in the upstream and downstream processes. This is to ensure complete
separation and purification of each of the viral strains to be included in the final product
and a back-up line for the sake of a potential pandemic outbreak.

	
  

4.1Upstream Process

F igure 4.1 Upstream Process Diagram. Outlines the process flow of the upstream system using SuperPro Designer.
Note that three separate upstream process designs will operate in the facility to run each of the influenza strains.
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4.2 Downstream Process

F igure 4.2 Downstream Process Diagram. Outlines the process flow of the downstream system using SuperPro
Designer. Note that three separate downstream process designs will operate in the facility to run each of the influenza
strains.
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4.3 O verall M aterial Balance

T able 4.1 Overall Component Balance. Outlines initial values, final values, inputs, outputs, and change in values for
each component in the overall system.

O verall Component Balance (kg/batch)
Component

Input

O utput

Produced

Consumed/Lost

O ut-In

EXCELL
M edium

102.71

34.51

0

68.20

0

Biomass

.0.0000126

12.60

12.60

0

0

V L P ( 3 strains)

0

0.42

0.60

0.18

0

G lucose

19.10

0

0

19.10

0

Pluronic F-68

3.3348

3.3348

0

0

0

D ry A ir

13360.149

10554.52

0

2805.63

0

Sodium
Bicarbonate

1.10

0

0

1.10

0

T riton X-100

10500

10500

0

0

0

T N BP

3150

3150

0

0

0

W ater

3334.8

3334.8

0

0

0
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4.4 Utility Requirements
(I)

A mount Per 3
Batches (Liters)

Number Sets of
Batches

Total (L)

Cost
(USD/L)

Water
(Low
E ndotoxin)

3334.8

6

20008.8

15.125

(I I)

H eat E xchanger
Requirement (kg/sec)

H eat E xchanger
Requirement
(L/sec)

O peration T ime
(Seconds)

Number of
H eat
E xchangers

Total (L)

Cost (USD
per foot
cubed)

Water

0.88673809

0.88673809

15778800

9

12592496
6.8

0.03

(I I I)

E lucidation and
Column Water (L per
train)

Number of
Downstream T rains

Number of
Batches

Total (L)

Cost

Water
(Low
E ndotoxin)

20

3

6

360

15.125

(I I I)

A mperage per Pump
(A mperes)

Voltage per Pump
(Volts)

Power Per
Pump (k W)

Number of
Pumps

O peratio
n T ime
(H rs)

Power
Needed
(k W-hr)

0.7475

27

4383

88459.8975

E lectricity

6.5

115

(I V)

Estimated A dditional
Plant E lectricity
(k W-hr)

Estimated Plant
O peration
E lectricity Cost

E lectricity

5547335.738

338387.48

Utility

A nnual Requirement

A nnual Cost (USD)

Water (L)

125924966.8

$133,410.07

20368.8

$308,078.10

5635795.635

$343,783.53

Low
E ndotoxin
Water (L)
E lectricity
(k W-hr)

(From Lang: 2%
of Equipment
Cost)
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5.0 Process Descriptions
5.1 Upstream Process
The upstream process is used to culture SF2 cells, and then infect the cells to
produce VLPs. For each of the three influenza strains produced each year, a separate
upstream process is run. The process begins with a vial thaw of 1.4x107 cells, scaled up
to 1.4x1013 cells with fermentation using a series of shake flasks and bioreactors. After
cell growth is complete, cells are infected to produce VLPs before entering the
downstream process for isolation and purification.

5.1.1 Shake F lasks (P-1/T T R-101, P-2/SF R-101, P-3/SF R-102)
The scaling of SF2 cells begins in shake flasks sized at 250mL, 2L, and
3L. Shake flasks will have a working volume that is a fraction of the flask size (50mL,
250 mL, 1000mL respectively) and will be used to grow cells at a ten-fold for each scaleup. Each scaling will take 3.32 days.

5.1.2 Bioreactors
Following the use of the shake flasks, bioreactors will be used to continue the
scale-up of the number of SF2 cells for vaccine production. Each bioreactor will be filled
to a particular working volume, and will be used to grow cells to a final a ten-fold
concentration. For this growth rate, the time spent in each bioreactor is 3.32 days. The
bag bioreactors will receive media in a fed-batch process while under constant
monitoring and feedback control of temperature, pH, dissolved oxygen (DO), and
biomass. In the final 2000L bioreactor in each upstream process train, a virus titer will be
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added to each bioreactor in order to provide a multiplicity of infection (MOI) of one. This
will insure that the maximum number of cells will be infected without causing excessive
infection. The contents will continue to be fermented for three days to insure maximum
VLP production then harvested and sent to the downstream process train.

5.1.3 H arvest Bags
Harvest bags will be used to line the bioreactors as part of the single-use
technology implementation. The bags are fitted with ports and disposable probes for
simple interfacing with the bioreactor shells. This technology will eliminate CIP, SIP,
and WFI requirements in the upstream process, decreasing both costs and batch turnover
time. The harvest bags come sterilie-wrapped and ready to line the bioreactors. The bags
will be changed in between batches, and will be disposed as solid biohazard waste.

5.1.4 Media Prep
Dry media for SF2 cells will be enriched with sodium bicarbonate to maintain pH
and mixed with filtered air and sterile water before being fed to the bioreactors. The
media comes enriched with appropriate amounts of glucose, glutamine, pyruvate,
calcium, and Pluronic F-68 to reduce shear. The media will be diluted in a ratio of 30.8
grams of media to one liter of water. Media will be sterile filtered and warmed to 28ºC
before addition to the flask or bioreactor.
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5.1.5 Media Holding Bags

Media holding bags made of biologically inert low-density polyethylene (LDPE)
will be used to line the holding totes in order to create a disposable process. This will
eliminate CIP, SIP, and WFI requirements, thus decreasing costs and batch turnover time.
These bags can be discarded in the solid biohazard waste stream and can be replaced
within an hour. The bags will be pressurized slightly to maintain positive pressure,
preventing contamination.
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5.2 Downstream Process
The downstream process for the purification of influenza viruses includes
clarification, concentration methods centered on diafiltration and centrifugation, chemical
inactivation and treatment, further chromatography separations, and final polishing.
Competing vaccine production companies generally require: whole virion inactivated cell
culture-derived human influenza vaccines (1) 15 µg of HA per strain and dose, (2) total
protein content no more than 100 µg of protein per virus strain and human dose, (3)
bacterial endotoxins must be less than 25 IU per human dose, and (4) residual host cell
DNA must be less than or equal to 10 ng per single human dose (Wolff).

5.2.1 Disk-Stack C entrifugation
To concentrate the influenza virus, high-speed centrifugation is used.
Centrifugation is a preferred method for clarifying cell cultures from batch sizes of 2,000
L or larger. When a disk-stack centrifuge is used, cell debris in the centrifuge is
minimized for better cell recovery and concentrate clarification 2¶%ULHQ).

5.2.2 Depth F iltration
Depth filtration is used to concentrate insoluble larger particles from the
suspending medium. This process is conducted in two phases: first a filter with an openpore structure removes cell debris, then a filter with a tighter pore structure removes
colloidal matter. The disposable depth filtration system consists of a set of inlet and outlet
single-use manifolds with vents and a flexible number of capsule filters placed between
the manifolds. Permeate flux, transmembrane pressure, and pore size are important
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parameters that influence process efficiency. To minimize losses, a pore diameter of 172
nm or less should be used for influenza A and B. An optimal pore size of 300 kDa and a
wall shear rate of 5700 Hz have been previously identified for influenza strains. Under
these conditions, virus losses based on HA activity were negligible (Vincente 2011), with
total protein and host cell DNA reduction of 90% and 93% (Wolff 2008).

5.2.3 V irus Inactivation
To prohibit the advancement of untreated viral particles into the downstream
purification process, any remaining baculovirus must undergo inactivation. Incubation for
30 minutes in 1% Triton X-100 and 0.3% tri(n-butyl)phosphate (TNBP) is sufficient to
inactivate all remaining baculovirus particles in the fermentation broth. The filtrate will
be transferred to a 1000L tank and charged with Triton X-100 and TNBP at 1% and 0.3%
respectively post-mixing. Incubation at room temperature for 30 minutes will disrupt any
remaining virus. This process can continue for several hours without damaging the VLPs
at the detergent concentrations used (Rueda 2000, Pantua 2006)

5.2.4 A nion E xchange C hromatography
Ion exchange chromatography is a separation method, which relies on charge
interactions between the virus particle and the charges on the chromatography resin. This
step follows size exclusion chromatography to remove residual host cell DNA, protein
contaminants, amino acids, and ions remaining from the fermentation reactions in a
positive and negative mode. The detergents used to inactivate remaining baculovirus
particles and inactivated baculovirus particles will also be removed during this
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chromatography step. Influenza VLPs have an acidic pI of 5.0, making anionic exchange
more favorable for this process. The Sepharose Q ion exchange matrix is used with a
loading buffer conditioned with 0.65 M NaCl. The resin capacity can be improved with
optimal loading and washing conditions, which have been found to be at a pH of 6.0
(Bernd, Kalfbuss, Wolff). This process will largely remove media components and host
cell DNA.

5.2.5 Size E xclusion C hromatography
Size exclusion chromatography (SEC) is used to separate the virus particles from
contaminating host cell proteins and nucleic acids as well as inactivated baculovirus
particles. Sepharose chromatography with a fractionation range of 70-40,000 kDa
typically leads to a viral recovery of approximately 38%. The combination of
ultrafiltration with size-exclusion chromatography leads to an overall virus recovery of
36% with a protein and DNA reduction of 96% and 99%, respectively (Liu, Wolff).

5.2.6 T angential F low F iltration
Following the chromatography units, tangential flow filtration is carried out to
further concentrate the VLPs. Tangential flow filtration with microfiltration membranes
produces a clear stream that requires minimal filtration before loading on a column. The
buffer composition for this process is composed of 137 mM sodium chloride, 2.7 mM
potassium chloride, 1.5 mM potassium dihydrogen phosphate, and 10 mM sodium
phosphate dibasic (2). In this type of filtration, the fluid is pumped tangentially along the
surface of the membrane and an applied pressure serves to force a portion of the fluid
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through the membrane to the filtrate side. Molecules that are too large to pass through the
membrane pores are swept away by the tangential flow (T. Brien, L. Brown, D. Battersby
et al.).

32	
  

	
  

6.0 Major Unit Descriptions
6.1 E quipment Selection
The selection of insect cells for the process allows for the choice between
stainless steel and disposable equipment based facilities. Traditionally, stainless steel
facilities are used for vaccine production, however currently there is a greater push in the
industry to move towards disposable facilities, particularly in the areas of contract
development and manufacturing.
With these two types of equipment sets available, there are three options that may
be used moving forward for a commercial manufacturing facility. The first option uses
traditional stainless steel equipment, which requires both SIP and CIP
accommodations. The second option utilizes all disposable technologies, and the third
option uses a combination of both traditional and disposable equipment.
Traditional facilities are advantageous in that large companies most commonly
use them, and thus are already approved by regulatory agencies. In addition, the stainless
steel equipment provides barriers for pathogens from the environment. The traditional
facilities also are more environmentally friendly than disposable systems, since there
would be less solid wastes and plastic accumulation (Mauter).
However, despite challenges that arise from using innovative technology such as
disposable systems, disposable facilities offer several advantages. For example,
disposable equipment provides several areas for cost savings, including initial equipment
capital, process footprint, plant design costs, and removing the requirement for costly and
timely CIP and SIP processes. In addition, disposable facilities increase efficiency of
production by reducing process turnaround time and increasing safety in product
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changeover by eliminating cross-contamination and easing site-to-site transfer of

materials (Whitford, Eibl). Despite rises in environmental impact from solid wastes from
disposable equipment, these systems offer the advantage of decreasing the use of
environmentally toxic cleaning agents and a lesser need for water treatments
(Mauter). The single use equipment comes sterilized and will be replaced for each batch,
thus eliminating exhaustive cleaning and validation procedures.
Disposable systems are a newer technology and the industry is still cautious about
them. At the present time, disposable equipment has scalability limitations with an upper
limit of a 2000L vessel. +RZHYHUIRUWKLVFRPSDQ\¶VIDFLOLW\WKLVSURYHVWREH
irrelevant. Another major concern with the use of disposable equipment is the potential
of extractables and leachables into the vaccine development process. Currently, there is a
greater push for regulations and guidelines to minimize potential problems (Martin).
An in depth economic analysis was completed to further compare the different
types of facilities. Based on a quantitative analysis comparing single-use disposable
technology versus traditional stainless steel vessels for a monoclonal antibody process on
a 2000L fermentation scale from 2012 (Sinclair, Monge). This study estimates the
investment cost of the disposable facility at approximately $25.6 million versus a
stainless steel facility at approximately $32.5 million. The difference in cost is largely
due to the removal of costly procedures such as CIP and SIP. Using a 7-year MACRS
table, these estimations were used as total depreciable capital. Profits were estimated
based on production of 100 million doses, priced at $8.12 each, for a total profit of $1.2
billion each year. After depreciation, profits, interest rates, and tax rates are taken into
account, the present value of the disposable facility is found to cost approximately $21.2
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million, while the present value of the traditional facility is found to be $26.9 million (see
Appendix A). Based on this the cost analysis and other benefits such as increased
efficiency and faster batch turn around, a single-use disposable facility was chosen for the
FRPSDQ\¶VYDFFLQHSURGXFWLRQ
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6.2 Upstream Process
6.2.1 Shake F lasks (P-2/SF R-101, P-3/SF R-102, P-4/SF R-103)
Polycarbonate flasks (250mL, 2L, 3L) will be purchased from Corning for
growing SF2 cell in suspension culture, passaging cell lines, and seeding the 50L
bioreactor. These flasks are gamma-irradiation sterilized and individually packaged to

ensure no culture contamination. The lids are filter-vented to insure sterility and prevent
contamination while allowing adequate gas exchange. They will be incubated in shaking
incubators at 28°C at 90rpm. These flasks will be manipulated within a biosafety cabinet
and are disposable in the biohazard waste stream.

6.2.2 Aseptic T ransfer E quipment (S-101, S-102, S-104)
As shown in the process flowsheet, the streams labeled as S-101, S-102, and S104 will be used Biosafe® Aseptic Transfer Equipment for transferring the material from
the shake flasks. The equipment will be supplied from Sartorius Stedim with the purchase
of storage tanks and bags. The aseptic transfer ports offer reliable and easy-to-use
solutions for secure transfer of fluids. They are cost effective and have enhanced sterility
assurance. All materials are compliant with 21 CFR Part 177.2600, 21 CFR Part
177.1630, and CFR Part 177.2470. The recommended temperature range for this
equipment is 5-30ºC, which is compliant with the 28ºC temperature associated with the
insect cell culture and processing. The materials of construction are stainless steel AISI
316 L, PETP, and silicone/EPDM for the gaskets.
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6.2.3 M ain Bioreactors (P-6/SF R-103, P-7/SF R-104, P-17/SF R-105)
The 50L, 500L, and 2000L bioreactors are the Xcellerex model from GE Life

Sciences, and are sized at maximum capacity to enable room for larger culture sizes and
future scale-up. The minimum working volumes are 20% of the maximum working
volumes: 10L, 100L, and 400L respectively. The reactors are placed in series from 50L to
2000L, with each UHDFWRU¶VILQDOSURGXFWVHHGLQJWKHQH[WUHDFWRUDIWHUWKUHHGD\VRI
fermentation. These reactors are outfitted for disposable operation such that only the
plastic liners need to be replaced between batches, cutting the time required between
batch operations to just under one hour. This disposable technology also eliminates the
necessity of both SIP and CIP procedures.
These reactors are outfitted with 2 pH probes, 2 DO probes, three pumps, an
integrated electrical safety circuit, temperature control hardware, a sparger, and an
agitator.
The disposable culture bags have an inert USP Class VI low-density polyethylene
culture contact surface, a disposable pressure sensor, four Brooks mass flow controllers,
complementary tubing, multiple culture access ports, filtered gas lines, multiple supply
ports, and an agitation system. The agitation system consists of a high-density
polyethylene impeller mounted at the bottom with a set of microporous stainless steel
disks. Control of the system is based on the Rockwell/Allen Bradley Controller with
Wonderware HMI. The controller allows for a closed loop monitoring and control of
agitation, gas mixing, liquid agitation & removal, pH, weight, sparging, gas overlay,
temperature, and DO. The control system also features real-time data collection,
reporting, and trending, using PID control to aggressively maintain steady-state
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conditions. The reactors will be purchased from GE at $213,519, $233,717, and
$930,446, respectively.
In the last bioreactor in the upstream process, the cells will be infected at the
beginning of day 2 after beginning fermentation in the vessel. This will be preformed
under aseptic conditions with a high-titer virus stock developed and prepared by R&D.

This stock will contain the baculoviruses necessary for the infected cells to produce VLPs
with the correct HA surface protein. The cells will be infected at a MOI of one to insure
adequate infection: not many cells will survive the lytic VLP production process, and
there will be no excess of virus remaining post-production. This MOI allows simple and
efficient deactivation of the virus and separation of the few remaining host cells while
providing a maximum number of active VLPs.

6.2.4 Pump (S-105, S-106)
The pumps connecting the final shake flask in the line to the first bioreactor and
the first bioreactor to the 500 L bioreactor will be purchased from Cole-Palmer TM for
$4,640. Cole-Palmer TM provides peristaltic pumps for large-scale biopharmaceutical
processes to ensure sterility and a high degree of precision. The Masterflex® B/T® (12321 rpm, 115 V) with variable-speed wash-down will be used to transfer the cell broth to
the bioreactors. This model includes a new Rapid-Load pump head for fast and easy
tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-transfer and the
gentle peristaltic action is ideal for pumping shear sensitive fluids.
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6.2.5 H arvest Bags
Harvest bags are fitted to particular bioreactors, and thus will be purchased

alongside each bioreactor from the same manufacturer. From Xcellerex, 50L, 500L, and
2000L fully-integrated XDR bioreactor bags will be purchased for $447 each. These
harvest bags are of USP Class VI, and have a LDPE fluid contact layer. The bags are
also gamma irradiated, and follow validation guides. Each bag includes C-flex tubing,
aspetic connectors, multiple feed/addition lines, a harvest line, filters (exhaust, sparge,
overlay), a pressure sensor, sampling and probe ports, a thermowell, and a proprietary
XDR impeller/sparge system.

6.2.6 Pumps (S-103, S-112, S-113)
The pumps connecting the media holding tank to the 3L shake flask and 50L and
200L bioreactors will be purchased from Cole-Palmer TM for $4,640. Cole-Palmer TM
provides peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility
and a high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with
variable-speed wash-down will be used to transfer the material from the 500 L media
tank to the shake flasks and reactors. This model includes a new Rapid-Load pump head
for fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulktransfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.

6.2.7 Media Holding Bags
Flexel® bags from Sartorious will be purchased with the plastic holding tanks for
a combined cost of $1,682 or $2,915, depending on the volume. These are single use
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bags designed for processing, mixing, storage, and transport of large volume of

biopharmaceutical solutions. After use, the media holding bags will be disposed as solid
biohazard waste.

6.2.8 500 L Holding T anks (P-8/V-101, P-10/V-102)
For media and intermediate cell culture storage, the Plastic Palletank® from
Sartorious will be used. For the first line, transferring media to the Shake Flask, and first
two bioreactors, a 500 L storage tank will be purchased for $2,915. This tank is designed
for storage and processing of biopharmaceutical fluids, and can be used for both media
storage and bulk intermediate hold in the upstream process. They are designed to be
lined with Flexel® 3D bags, and meet in-process and storage requirements while
minimizing required floor space in a plant.

6.2.9 Pump (S-107, S-108, S-114, S-115)
The pump connecting media to the filtration unit will be purchased from ColePalmer TM for $4,640. Cole-PalmerTM provides peristaltic pumps for large-scale
biopharmaceutical processes to ensure sterility and a high degree of precision. The
Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be used to
transfer the material from the media tank to the filtration unit. This model includes a new
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is
suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping
shear sensitive fluids.
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6.2.10 Sterile F iltration (P-9/M F-101, P-14/M F-102)

Sterile filtration is a further clarification step that will be used for reactor medium.
The upstream process will consist of two media storage tanks per line, one for media
transferred to the final shake flask and first two bioreactors in series, and the second for
media transferred to the production bioreactor.
The filtration system is made of cellulose fibers that are designed to trap
submicron particles in their crevices. The Encapsulated Zeta Plus (EZP) System will be
purchased from 3M Purification Inc. for $9,000.
This is a single-use system designed for production scale biomanufacturing,
which consists of a filter holder, top and bottom manifolds and capsules. The EZP system
features ergonomically designed holders that can pivot for easy loading and unloading,
and a translucent plastic shell for convenient liquid level detection. The large holder
(model 16EZB) accommodates up to 17.5 m2 of filter media and has the capability of
processing up to 5000 L of liquid. The system requires the Zeta Plus EXT filter media
(Zeta Plus 60SP02A), which is available in a single-use format (EZP Data Sheet).

6.2.11 3000 L Holding T anks (P-13/V-103, P-15/V-104)
For media and intermediate cell culture storage before transfer to the 2000 L
Bioreactor, the Palletank® In-Process Fluid Handling Tank from Sartorious Stedim will
be used. This tank is designed for storage and processing of biopharmaceutical fluids, and
can be used for both media storage and bulk intermediate hold in the upstream
process. They are designed to be lined with Flexel® 3D bags, and meet in-process and
storage requirements while minimizing required floor space in a plant.
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6.2.12 H eat E xchanger (P-11/H X-101, P-16/H X-102)
For warming the medium prior to tank charging and cooling of the fermentation

broth to prepare for downstream processing, it will be necessary to add heat to the liquid
media streams through cGMP certified heat exchanger units. These units will operate
such that the contents remain sterile throughout the heat transfer process and will be
optimized to handle the maximum flow rates from the pump units. The heat exchangers
were designed by our team and the unit most closely resembling our heat transfer area
calculations will be purchased from Enerquip for this purpose.

6.2.13 Cooler (P-18/H X-103)
A cooler is necessary to chill the jackets of medium storage tanks and to chill the
fermentation broth after completion of the upstream process. It will function as a
refrigeration unit that sends coolant through pipes leading to vessel jackets. This system
will allow the process to be flexible in terms of cooling requirements in case of added
load or added storage vessels during periods of high demand.
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6.3 Downstream Process
After the upstream process is complete, the medium will be aseptically transferred
to a different location for the downstream purification. This will be done through a
single-use transfer system with presterilized connectors and tubing. In addition to faster
production, this system eliminates time that would be spent on CIP and SIP and reduces
the risk of cross contamination.

6.3.1 Disk-Stack C entrifuge (P-1/DS-101)
Centrifugation with disk-stack bowls is used as the first step in the downstream
processing. This method is preferred in biopharmaceutical processing for clarifying cell
cultures from batch sizes larger than 2000 L. The harvested fluid and cultivation broth are
clarified with low-speed centrifugation and the virus is later purified in an
ultracentrifugation step. The virus solution is centrifuged through a sucrose gradient,
which generally ranges from 20-60%, with the target virus at 40-45% sucrose.
The Carr® UniFuge® Pilot from Carr Centritech Separation Systems is purchased
IRUDQGFDQEHUHDGLO\FRQQHFWHGWRWKHSODQW¶VRWKHUVLQJOH-use bioreactor
connections. This single-use disposable module is designed for gentle harvesting of
shear-sensitive biological materials. Due to its single-use feature, this centrifugation
system has no CIP or SIP requirements. The UniFuge® module is completely automated
with flexible cycle parameter entry so that once the module has filled with cells, the
controllers stops the rotor and discharges. The machine operating conditions include a
feed flow range of 0.1-4 liters per minute and a bowl capacity of 1.6 liters (UniFuge®
Data Sheet).
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6.3.2 Pump (S-102)
The pump connecting the centrifuge to the virus inactivator tank will be

purchased from Cole-Palmer for $4,640. Cole-Palmer provides peristaltic pumps for
large-scale biopharmaceutical processes to ensure sterility and a high degree of precision.
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be
used to transfer the material from the centrifuge to the inactivator. This model includes a
new Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is
suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping
shear sensitive fluids.

6.3.3 Detergent Storage T ank (P-12/V-106)
The detergent for viral inactivation will be stored in the Plastic Palletank® from
Sartorius Stedim for $1,682. This storage tank is a single-use piece of equipment to
ensure process and user safety. Sartorius Stedim provides these single-use platforms for
lower initial investment, process optimization, and faster time to market. The Palletank®
is available in volumes of 200L and 500L and must be used with the Flexel® 3D Bags.

6.3.4 Pump (S-103)
The pump connecting the storage tank to the virus inactivator tank will be
purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for
large-scale biopharmaceutical processes to ensure sterility and a high degree of precision.
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be
used to transfer the material from the storage tank to the inactivator. This model includes
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a new Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T®
is suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for
pumping shear sensitive fluids.

6.3.5 V irus Inactivation T ank (P-9/V-103)
To prohibit the advancement of untreated viral particles into the downstream
purification process, any remaining baculovirus must undergo inactivation. Incubation for
30 minutes in 1% Triton X-100 and 0.3% tri(n-butyl)phosphate (TNBP) is sufficient to
inactivate all remaining baculovirus particles in the fermentation broth. The filtrate will
be transferred to a 1000L tank and charged with Triton X-100 and TNBP to final volume
percentages of 1% and 0.3% respectively. Incubation at room temperature for 30 minutes
will disrupt any remaining baculovirus particles. This process can continue for several
hours without damaging the VLPs at the detergent concentrations used (Rueda 2000,
Pantua 2006). The vessels will be purchased from Sartorius Stedim at a cost of $1,682.

6.3.6 Pump (S-104)
The pump connecting the virus inactivator tank to the depth filtration device will
be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps
for large-scale biopharmaceutical processes to ensure sterility and a high degree of
precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down
will be used to transfer the material from the inactivator tank to the filtration device. This
model includes a new Rapid-Load pump head for fast and easy tubing changes. The
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Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic action
is ideal for pumping shear sensitive fluids.

6.3.7 Depth F iltration (P-3/D F-101)
Depth filtration is a further clarification step that follows the initial disk-stack
centrifugation in downstream processing. The depth filtration system is made of cellulose
fibers that are designed to trap submicron particles in their crevices. The Encapsulated
Zeta Plus (EZP) System will be purchased from 3M Purification Inc. for $9,000.
This is a single-use system designed for production scale biomanufacturing,
which consists of a filter holder, top and bottom manifolds and capsules. The EZP system
features ergonomically designed holders that can pivot for easy loading and unloading,
and a translucent plastic shell for convenient liquid level detection. The large holder
(model 16EZB) accommodates up to 17.5 m2 of filter media and has the capability of
processing up to 5000 L of liquid. The system requires the Zeta Plus EXT filter media
(Zeta Plus 60SP02A), which is available in a single-use format.

6.3.8 Pump (S-105)
The pump connecting the depth filter to the holding tank will be purchased from
Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for large-scale
biopharmaceutical processes to ensure sterility and a high degree of precision. The
Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be used to
transfer the material from depth filter to the holding tank. This model includes a new
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is
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suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping
shear sensitive fluids.

6.3.9 Depth F iltration Holding T ank (P-7/V-101)
The fluid from the depth filtration unit will be stored in the Plastic Palletank®
from Sartorius Stedim for $1,682. This storage tank is a single-use piece of equipment to
ensure process and user safety. Sartorius Stedim provides these single-use platforms for
lower initial investment, process optimization, and faster time to market. The Palletank®
is available in volumes of 200L and 500L and must be used with the Flexel® 3D Bags.

6.3.10 Pump (S-106)
The pump connecting the holding tank to the ion exchange chromatography
column will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides
peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variablespeed wash-down will be used to transfer the material from the holding tank to the ion
exchange chromatography column. This model includes a new Rapid-Load pump head
for fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulktransfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.
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6.3.11 C hromatography Resin Storage T ank (P-11/V-105)
The chromatography resin for the first line of ion exchange chromatography

columns will be stored in the Plastic Palletank® from Sartorius Stedim for $1,682. This
storage tank is a single-use piece of equipment to ensure process and user safety.
Sartorius Stedim provides these single-use platforms for lower initial investment, process
optimization, and faster time to market. The Palletank® is available in volumes of 200L
and 500L and must be used with the Flexel® 3D Bags.

6.3.12 Pump (S-107)
The pump connecting the chromatography resin tank to the ion exchange
chromatography column will be purchased from Cole-PalmerTM for $4,640. ColePalmerTM provides peristaltic pumps for large-scale biopharmaceutical processes to
ensure sterility and a high degree of precision. The Masterflex® B/T® (12-321 rpm, 115
V) with variable-speed wash-down will be used to transfer the resin material from its tank
to the chromatography column. This model includes a new Rapid-Load pump head for
fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulktransfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.

6.3.13 A nion E xchange C hromatography Column (P-4/I N X-101)
Ion exchange chromatography is used for further purification and separation of
the product. Ion exchange chromatography uses the principle of binding based on charge
differences between the resin and the product. The ReadyToProcess Q Sepharose FF
chromatography column from GE Life Sciences will be used for this process and
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purchased for $166,000. This system is designed for scale-up and production of
ELRSKDUPDFHXWLFDOVDQGLVSDUWRI*(¶VVLQJOH-use, disposable platform. These columns
are closed units and the design allows easy disposal after completion. The system
includes a column tube, lids, support nets, support screens, stream stoppers, hose
connections, welding tubing, filter holders, media packing valves, a hose for the inlet
tubing, O-rings, and TC gaskets. The column hardware and components are made from

polypropylene, polyetheretherketone, Tygon 2275 Polyolefin, Fluorocarbon rubber, and
Ethylenpropylenediene. The column has a bed volume of 2.5 L, with a minimum liquid
temperature of 4ºC and a maximum pressure of 1.2 bar (17 psi).
The column is pre-packed with bioprocess medium. Capto Q is a strong anion
exchanger, and is resistant to chemical agents used in recovery. This media allows for
fast mass transfer and is intended for capture and intermediate large-scale purification.
The Capto Q media must be stored in 20% ethanol, at a pH between 2 and 12, and at a
temperature between 4ºC and 30ºC. The filtrate containing the VLPs will be sent through
the column at 300cm/h flow rate, and the column will be primed to bind DNA and any
remaining baculovirus after the inactivation step while allowing the VLPs to flow
through the column with less of an ionic affinity (GE Data sheet). The column will then
be eluted into the waste stream and reset for the next batch. This column will remove the
remaining medium components not filtered out during the filtration step or consumed
during the fermentation reaction. The column run time is about 20 minutes per VLP
strain batch based on size and flow rate calculations from column size and flow rate data
shown on the process specification page.
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6.3.14 Pump (S-108)
The pump connecting the ion exchange chromatography product to the holding
tank will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides
peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variablespeed wash-down will be used to transfer the product from the first chromatography
column to the holding tank. This model includes a new Rapid-Load pump head for fast

and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-transfer
and the gentle peristaltic action is ideal for pumping shear sensitive fluids.

6.3.15 Ion E xchange Holding T ank (Sartorius Stedim, P-18/V-107)
The remaining product from the first line of chromatography columns will be
stored in the Plastic Palletank® from Sartorius Stedim for $1,682. This storage tank is a
single-use piece of equipment to ensure process and user safety. Sartorius Stedim
provides these single-use platforms for lower initial investment, process optimization,
and faster time to market. The Palletank® is available in volumes of 200L and 500L and
must be used with the Flexel® 3D Bags.

6.3.16 Pump (S-101)
The pump connecting the holding tank to the size exclusion chromatography
column will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides
peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-
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speed wash-down will be used to transfer the material from the holding tank to the

second chromatography column. This model includes a new Rapid-Load pump head for
fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulktransfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.

6.3.17 C hromatography Resin Storage T ank (Sartorius Stedim, P-10/V-104)
The chromatography resin for the second line of chromatography columns will be
stored in the Plastic Palletank® from Sartorius Stedim for $1,682. This storage tank is a
single-use piece of equipment to ensure process and user safety. Sartorius Stedim
provides these single-use platforms for lower initial investment, process optimization,
and faster time to market. The Palletank® is available in volumes of 200L and 500L and
must be used with the Flexel® 3D Bags.

6.3.18 Pump (S-110)
The pump connecting the chromatography resin tank to the size exclusion
chromatography column will be purchased from Cole-PalmerTM for $4,640. ColePalmerTM provides peristaltic pumps for large-scale biopharmaceutical processes to
ensure sterility and a high degree of precision. The Masterflex® B/T® (12-321 rpm, 115
V) with variable-speed wash-down will be used to transfer the resin from the holding
tank to the column. This model includes a new Rapid-Load pump head for fast and easy
tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-transfer and the
gentle peristaltic action is ideal for pumping shear sensitive fluids.
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6.3.19 Size E xclusion Chromatography Column (P-5/C-101)
Chromatography is performed to bind and elute host cell impurities. The
ReadyToProcess platform from GE Life Sciences is used for its single-use features and

large-scale purification capabilities. Benefits of this column include quick start-up times
and fast on-site maintenance without special tools or trained personnel. The system will
be purchased for $166,000.
The Capto Core 700 chromatography resin from GE Life Sciences will be used
for this process. Capto Core 700 was recommended for its design, which focuses on
intermediate purification and polishing of viruses. Capto Core 700 offers many
performance advantages over typical gel filtration, which often causes a bottleneck in
processing due to low flow rates and limited sample loads. Capto Core 700 is designed
for high capacity, high flow velocities, and a high number of operational cycles. Capto
Core 700 is composed of an inactive shell of highly cross-linked agarose, which excludes
large molecules with a molecular weight cut off of 700 kDA. The inner core is ligand
activated, hydrophobic and positively charged to induce binding of viral contaminants.
The HA molecules on the VLP coat will prevent strong affinity for the column core, as
described in the equipment test presented on the equipment data sheet. The column run
time is about 40 minutes under average flow rate conditions but will be optimized to elute
VLPs on a laboratory scale prior to manufacturing scale production.

6.3.20 Pump (S-111)
The pump connecting the size exclusion chromatography column to the holding
tank will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides
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peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variablespeed wash-down will be used to transfer the product from the column to the holding

tank. This model includes a new Rapid-Load pump head for fast and easy tubing changes.
The Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic
action is ideal for pumping shear sensitive fluids.

6.3.21 Size E xclusion Holding T ank (Sartorius Stedim, P-19/V-108)
The product from the second line of chromatography columns will be stored in
the Plastic Palletank® from Sartorius Stedim for $1,682. This storage tank is a single-use
piece of equipment to ensure process and user safety. Sartorius Stedim provides these
single-use platforms for lower initial investment, process optimization, and faster time to
market. The Palletank® is available in volumes of 200L and 500L and must be used with
the Flexel® 3D Bags.

6.3.22 Pump (S-114)
The pump connecting the holding tank to the tangential flow filtration device will
be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps
for large-scale biopharmaceutical processes to ensure sterility and a high degree of
precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down
will be used to transfer the material from the holding tank to the TFF device. This model
includes a new Rapid-Load pump head for fast and easy tubing changes. The
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Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic action
is ideal for pumping shear sensitive fluids.

6.3.23 T angential F low F iltration (P-6/D F-102)
Tangential flow filtration, also referred to as cross-flow filtration, with
microfiltration membranes is used to clarify the culture broth. A major advantage of this
process is that it requires minimal filtration before loading on a column. The Pellicon
XL50 series from Millipore is purchased for $200,000. The system is capable of
processing batch sizes of 1 to 10,000 liters of feed material. The Pellicon XL50 system is
composed of a positive displacement type pump for low shear operation, pressure
sensors, temperature sensors, and magnetic flowmeters on feed. The filtration tank has a
total volume of 890 L and a working volume of 600 L (Pellicon XL50 Data sheet). The
filtration will be used to reduce the water in the downstream process from 1000 L to 20
L, which will simplify and economize downstream processing. This unit operation will
also reduce the mass of remaining medium components from the fermentation reactions
based on the amount of water lost. The concentration of these ions will be the same on
both sides of the membrane, so a reduction of water from 1000 L to 200 L will result in a
loss of 80% of the medium components considered to be contaminants in the downstream
process.

6.3.24 Pump (S-109)
The pump connecting the tangential flow filtration tank to the holding tank will be
purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for
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large-scale biopharmaceutical processes to ensure sterility and a high degree of precision.
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be
used to transfer the material from the filtration tank to the holding tank. This model
includes a new Rapid-Load pump head for fast and easy tubing changes. The
Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic action
is ideal for pumping shear sensitive fluids.

6.3.25 T angential F low F iltration Holding T ank (P-8/V-102)
The product from the tangential flow filtration unit will be stored in the Plastic
Palletank® from Sartorius Stedim for $1,682. This storage tank is a single-use piece of
equipment to ensure process and user safety. Sartorius Stedim provides these single-use
platforms for lower initial investment, process optimization, and faster time to market.
The Palletank® is available in volumes of 200L and 500L and must be used with the
Flexel® 3D Bags.

6.3.26 Pump (S-112)
The pump connecting the holding tank to the freeze dryer will be purchased from
Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for large-scale
biopharmaceutical processes to ensure sterility and a high degree of precision. The
Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be used to
transfer the material from the holding tank to the freeze dryer. This model includes a new
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is
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suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping
shear sensitive fluids.

6.3.27 Pump (S-113)
The pump connecting the product from the freeze dryer to the filler will be
purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for
large-scale biopharmaceutical processes to ensure sterility and a high degree of precision.
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be
used to transfer the material from the freeze dryer to the filler. This model includes a new
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is
suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping
shear sensitive fluids.
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7.0 A dditional E quipment/Processes
7.1 Formulation & F inal Packaging
Once the Active Pharmaceutical Ingredient has been obtained through
downstream processing, the formulation procedure will be taken care of by another
facility to prepare the product for the domestic market. The product will be shipped to a
Formulation, Filling, and Packaging group where the secondary process parameters will
be performed.

7.2 F ilter Integrity T ester
Filters are used for sterilization of process components, specifically media
ingredients, so it is imperative that these filters work properly to prevent adventitious
agents from forming in the many fermentation stages. The integrity tester from Sartorius
is compatible with the Sartorius filters used in this process. The filter tester is automated
and simple to use. The filters are tested before installation into the process in the interbatch phase of operation. This tester is required per regulatory requirements and to insure
cGMP operating conditions.

7.3 T ube F users/T ube Sealers
The sterile tube fuser is a fully automated device used to connect thermoplastic
tubing in a sterile operation. The use of sterile tube fusing eliminates the need for a
laminar flow cabinet. The tube fuser machine uses infrared technology along with
disposable, single-use blades. The unit can connect large diameter tubing for easy transfer
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of large volumes, and each fusing cycle is approximately two minutes. The tube fuser
will be purchased from Sartorius Stedim for $15,300.

The tube sealer is used in conjunction with the tube fuser to seal bioprocess bags
and bioreactors. The combined unit does not require compressed air or cooling water or
any other additional accessories for operation. The tube sealer will be purchased from
Sartorius Stedim for $10,200.

7.4 Biosafety C abinet
Biosafety cabinets are essential for laboratory scale cell culture work to provide
both sterility and workplace safety. They operate using sterile-filtered laminar air flow to
prevent contamination and provide a clean workspace for cell manipulations. These will
be essential for the small scale manipulations required for seeding the larger fermenters.
Shake flasks will be manipulated within the biosafety cabinet, and samples will be
removed from reactors and manipulated under the biosafety cabinets for cGMP
compliance testing protocols. These cabinets will have an 8 in. sash and will contain all
of the necessary equipment for cell culture manipulations. They will be purchased from
and installed by Thermo Fisher Scientific.

7.5 Incubator
A shaking incubator kept at 28ºC is necessary for optimum cell growth while in
shake flasks. The incubator will remain sterile and have copper surfaces to prevent
microbial and fungal growth and will have a self-autoclaving feature. The incubator will
be used to grow cells in all stages of shake-flask culture and will operate at 90rpm.
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7.6 C ryopreservation Bank

A cryopreservation bank will be used for storage of the insect cell culture. Due to
pre-existent cell culture lines within the facility, the -80ºC and ultra-low -160ºC freezers
from Panasonic will already be provided in the manufacturing plant. Equipment and
protocols for cell preservation will be followed according to Sigma-$OGULFK¶V Cell

Culture Laboratory Handbook-2nd Edition.
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8.0 Unit Specification Sheets
The following pages contain the unit specification sheets for the equipment used
in this vaccine manufacturing facility. Equipment models and prices have been obtained
through contact with vendors, from equipment lists from CDI Engineering Group, or
from sources such as BioProcess International and BioPharm International.
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8.1 Upstream Section
	
  

250  mL  Shake  Flask  (P-2/SFR-101)  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
  
  
Operating  Conditions:  
  
  
  
  
Purchase  Cost:  

	
  
	
  

  
First  phase  of  cell  growth  in  50  mL  from  storage  in  liquid  nitrogen  
  
Corning  
  
Batch  
  
Input  
Quantity  
Medium  
3.08  g  
Biomass  
0.042  g  
Water  
100  g  
Total  
103.1  g  
  
  
Model:  
250mL  Polycarbonate  Erlenmeyer  Flask  with  
Vent  Cap  
Material:  
Polycarbonate  
Flask  Type:  
Sterile  
Working  Volume:  
50  mL  
Total  Volume:  
250  mL  
Sterilization:  
Single  use  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
Speed:  
90  rpm  
pH:  
6.2  
  
  
$595.89  
(50  flasks)  
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2  L  Shake  Flask  (P-3/SFR-102)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
  
  
Operating  Conditions:  
  
  
  
  
Purchase  Cost:  

	
  
	
  

Second  phase  of  cell  growth  to  increase  biomass,  250  mL  working  volume  
  
Corning  
  
Batch  
  
Input  
Quantity  
Medium  
7.7  g  
Biomass  
0.42  g  
Water  
250  g  
Total  
258.1  g  
  
  
Model:  
2L  Polycarbonate  Erlenmeyer  Flask  with  Vent  
Cap  
Material:  
Polycarbonate  
Flask  Type:  
Sterile  
Working  Volume:  
0.25  L  
Total  Volume:  
2  L  
Sterilization:  
Single  use  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
Speed:  
90  rpm  
pH:  
6.2  
  
  
$204.55  
(6  flasks)  
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3L  Shake  Flask  (P-2/SFR-101)  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
  
  
Operating  Conditions:  
  
  
  
  
Purchase  Cost:  

	
  
	
  

  
Third  phase  of  biomass  production,  2  L  working  volume  
  
Corning  
  
Batch  
  
Input  
Quantity  
Medium  
61.6  g  
Biomass  
4.2  g  
Water  
2000  g  
Total  
2065.8  g  
  
  
Model:  
3L  Polycarbonate  Erlenmeyer  (Fernbach  
Design)  Flask  with  Vent  Cap  
Material:  
Polycarbonate  
Flask  Type:  
Sterile  
Working  Volume:  
2  L  
Total  Volume:  
3  L  
Sterilization:  
Single  use  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
Speed:  
90  rpm  
pH:  
6.2  
  
  
$236.60  
(4  flasks)  
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Pump  (S-105)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  to  the  first  bioreactor  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Medium  
308  g  
Biomass  
4.2  g  
Water  
10000.00  g  
Total  
10312.2  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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50  L  Bioreactor  (P-6/SBR-103)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
  
  
  
  
Purchase  Cost:  

	
  
	
  

Fourth  phase  of  biomass  production,  10  L  working  volume  
  
GE  Life  Sciences  
  
Batch  
  
Input  
Quantity  
Medium  
308  g  
Biomass  
42  g  
Water  
10000.00  g  
Total  
10350  g  
  
  
Working  Volume:  
10  L  
Total  Volume:  
50  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1.1  atm  
pH:  
6.2  
Sparging:  
0.3  L  O2  min-1  
Controller:  
Rockwell/Wonderware  
Agitation:  
90  rpm  
  
  
$213,519.00  
(includes  shell,  control  components,  3  pumps)  
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Pump  (S-106)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  first  bioreactor  to  the  second  bioreactor  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Medium  
308  g  
Biomass  
4.2  g  
Water  
10000.00  g  
Total  
10312.2  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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500  L  Bioreactor  (P-7/SBR-104)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
  
  
  
  
Purchase  Cost:  

	
  
	
  

Fifth  phase  of  biomass  production,  100  L  working  volume  
  
GE  Life  Sciences  
  
Batch  
  
Input  
Quantity  
Medium  
3080  g  
Biomass  
420  g  
Water  
100000.00  g  
Total  
103500  g  
  
  
Working  Volume:  
100  L  
Total  Volume:  
500  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1.1  atm  
pH:  
6.2  
Sparging:  
0.3  L  O2  min-1  
Controller:  
Rockwell/Wonderware  
Agitation:  
90  rpm  
  
  
$233,717.00  
(includes  shell,  control  components,  3  pumps)  
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Pump  (S-117)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  second  bioreactor  to  the  third  bioreactor  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Medium  
3080  g  
Biomass  
42  g  
Water  
100000  g  
Total  
103122  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
Sterilization:  
SIP/CIP  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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2000  L  Bioreactor  (P-7/SBR-104)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
  
  
  
  
Purchase  Cost:  

	
  
	
  

Fifth  phase  of  biomass  production,  100  L  working  volume  
  
GE  Life  Sciences  
  
Batch  
  
Input  
Quantity  
Medium  
30800  g  
Biomass  
4200  g  
Water  
1000000  g  
Total  
1035000  g  
  
  
Working  Volume:  
1000  L  
Total  Volume:  
2000  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1.1  atm  
pH:  
6.2  
Sparging:  
0.3  L  O2  min-1  
Controller:  
Rockwell/Wonderware  
Agitation:  
90  rpm  
  
  
$930,466.00  
(includes  shell,  control  components,  3  pumps)  
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Pump  (S-119)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  third  bioreactor  to  the  cooling  unit  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Medium  
30800  g  
Biomass  
4200  g  
Water  
1000000  g  
Total  
1035000  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-103)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  media  storage  tank  to  the  3  L  flask  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
138.6  g  
Water  
4500  g  
Total  
4638.6  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Media  Storage  Tank  (P-8/V-101)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  media  for  the  filtration  unit  
  
Sartorius  Stedim  
  
Batch  
  
Input  
Quantity  
Water  
100000  g  
Media  
3080  g  
Total  
103080  g  
  
  
Model:  
Flexel  3D  Palletank  
Working  Volume:  
100  L  
Total  Volume:  
200  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$1,682.00  
(includes  shell,  control  components,  3  pumps)  
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Media  Storage  Tank  (P-13/V-103)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  media  for  the  filtration  unit  
  
Sartorius  Stedim  
  
Batch  
  
Input  
Quantity  
Filtration  Media  
4.5  L  
Total  
4.5  L  
  
  
Model:  
Flexel  3D  Palletank  
Working  Volume:  
100  L  
Total  Volume:  
200  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$1,682.00  
(includes  shell,  control  components,  3  pumps)  
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Media  Storage  Tank  (P-10/V-102)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  store  media  from  the  filtration  unit  and  supply  to  shake  flask  and  bioreactors  
  
Sartorius  Stedim  
  
Batch  
  
Input  
Quantity  
Water  
1112000  g  
Media  
34250  g  
Total  
1146250  g  
  
  
Model:  
Flexel  3D  Palletank  
Working  Volume:  
100  L  
Total  Volume:  
500  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$2,915.00  
(includes  shell,  control  components,  3  pumps)  
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Final  USP  Storage  Tank  (P-19/V-105)  
  
Function:  

  

  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To hold the product from the 2000 L bioreactor and transfer to downstream process
(centrifugation unit)  
  
Sartorius Stedim  
  
Batch  
  
Input  
Quantity  
Medium  
30800  g  
Biomass  
4200  g  
Water  
1000000  g  
Total  
1035000  g  
  
  
Model:  
Flexel  3D  Palletank  
Total  Volume:  
2000  L  
Sterilization:  
Single  use  bags  
  
  
Temp:  
28°C  
Pressure:  
1.1  atm  
  
  
$2,915.00  
(includes  shell,  control  components,  3  pumps)  
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Pump  (S-118)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  heat  exchanger  to  third  bioreactor  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
1110000  g  
Media  
34188  g  
Total  
1144188  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-116)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  media  storage  tank  to  the  heat  exchanger  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
1110000  g  
Media  
34188  g  
Total  
1144188  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-115)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  filtration  unit  to  the  storage  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
15400  g  
Water  
500000  g  
Total  
515400  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-114)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  media  storage  tank  to  the  filtration  unit  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
15400  g  
Water  
500000  g  
Total  
515400  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-107)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  media  storage  tank  to  the  3  L  flask  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
3080  g  
Water  
100000  g  
Total  
103080  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-108)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  
  
  
  
  

	
  
	
  

To  transfer  material  from  the  filtration  unit  to  the  media  storage  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
3080  g  
Water  
100000  g  
Total  
103080  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-109)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  media  storage  tank  to  the  heat  exchanger  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
3080  g  
Water  
100000  g  
Total  
103080  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-113)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  filtered  media  to  the  second  bioreactor  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
3080  g  
Water  
100000  g  
Total  
103080  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Pump  (S-112)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  filtered  media  to  the  first  bioreactor  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Media  
308 g  
Water  
10000 g  
Total  
10308 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
28°C  
Pressure:  
1  atm  
  
  
$4,640.00  
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Depth  Filtration  Unit  (P-9/MF-101)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  

  
  

  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  sterilize  media  and  remove  bacteria  from  stream  before  entering  bioreactors  
  
3M  Purification,  Inc.  
  
Batch  
  
Input  
Quantity  
Media  
  34266  g  
Water  
1113000  g  
Total  
1147266  g  
  
  
Model:  
Encapsulated  Zeta  Plus  
Material:  
Polycarbonate  
Silicone  
Polypropylene  
Thermoplastic  Elastomer  
Nylon  
Filtration  Area:  
2.5  m2  
Sterilization:  
1  cycle  autoclave  (30  min  @  126°C)  
Size:  
´  
Additional  Features:  
Disposable/Single  use  
  
  
Max  Operating  Temp:  
40°C  
Max  Operating  Temp  
3.1  bar  (45  psi)  
  
  
$9,000.00  
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Depth  Filtration  Unit  (P-14/MF-102)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
Characteristics:  
  

  
  

  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  sterilize  media  and  remove  bacteria  from  stream  before  entering  bioreactors  
  
3M  Purification,  Inc.  
  
Batch  
  
Input  
Quantity  
Media  
500  L  
Total  
500  L  
  
  
Model:  
Encapsulated  Zeta  Plus  
Material:  
Polycarbonate  
Silicone  
Polypropylene  
Thermoplastic  Elastomer  
Nylon  
Filtration  Area:  
2.5  m2  
Sterilization:  
1  cycle  autoclave  (30  min  @  126°C)  
Size:  
´  
Additional  Features:  
Disposable/Single  use  
  
  
Max  Operating  Temp:  
40°C  
Max  Operating  Pressure:  
3.1  bar  (45  psi)  
  
  
$9,000.00  
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8.2 Downstream Section

Disc-Stack  Centrifuge  (P-1/DS-101)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
Characteristics:  
  

  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  remove  cells  and  biomass  solids  
  
Carr Centritech Separation Systems  
  
Continuous  
  
Input  
Quantity  
Biomass  
4200  g  
Water  
1000000  g  
VLP  
200  g  
Medium  
30800  g  
Baculovirus  
trace  
Total  
1035200  g  
  
  
Model:  
Unifuge(R)  
Material:  
USP Class VI:
Polycarbonate
Polyurethane
Silicone
Bioprene
C-Flex
Polypropylene  
Feed  Flow  Range:  
0.1-4  L/min  
Bowl  Capacity:  
1.6  L  
Additional  Features:  
Disposable/Single  use  
  
  
Max  Operating  Temp:  
100ºC  
Max  Operating  Pressure  
N/A    
  
  
$400,000.00  
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Pump  (S-102)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  centrifugation  unit  to  inactivator  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Biomass  
0  
Water  
990200 g  
Medium  
30800  g  
Baculovirus  
trace  
Total  
1021000 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Detergent  Storage  Tank  (P-12/V-106)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  the  detergent  for  the  virus  inactivation  process  
  
Sartorius Stedim  
  
Batch  
  
Input  
Quantity  
Water  
200000 g  
TNBP  
3150 g  
Triton X-100  
10500 g  
Total  
213650 g
  
  
Material:  
Stainless  steel  
Working  volume:  
202.6  L  
Total  volume:  
500  L  
Sterilization:  
SIP/CIP  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$1,682.00  
(shell)  
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Pump  (S-103)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  centrifugation  unit  to  inactivator  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Biomass  
  0  g  
Water  
990200  g  
VLP  
200  g  
Medium  
30800  g  
Baculovirus  
Trace  
Total  
1021200  g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Virus  Inactivation  Tank  (P-9/V-103)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  

  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  inactivate  the  virus  
  
Sartorius Stedim  
  
Batch  
  
Input  
Biomass  
Water  
TNBP  
Medium  
VLP  
Triton X-100  
Baculovirus  
Total  
  
Material:  
Total  volume:  
Sterilization:  
  
Temp:  
Pressure:  
  
$1,682.00  

	
  

Quantity  
0 g  
1100200 g  
3150 g  
30800 g
189 g
10500 g
Trace
1144839 g
  
Stainless  steel  
1100  L  
SIP/CIP  
  
22°C  
1.1  atm  
  
(shell)  
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Pump  (S-104)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  inactivator  tank  to  depth  filter  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Baculovirus  
0 g  
Water  
1100200 g  
TNBP  
3150 g  
Medium  
30800 g  
VLP  
190 g  
Triton X-100  
10500 g  
Total  
1144840 g
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
  

	
  

92	
  

	
  

Depth  Filtration  Unit  (P-3/DF-101)  
  
Function:  

  

  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
  
Characteristics:  
  

  
  

  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  sterilize  supernatant  of  centrifugation  process  and  remove  bacteria  from  
stream  
  
3M  Purification,  Inc.  
  
Batch  
  
Input  
Quantity  
Media  
30800 g  
Water  
1100200 g  
Triton X-100  
10500 g  
TNBP  
3150 g  
VLP  
190 g  
Baculovirus  
Trace  
Total  
114480 g  
  
  
Model:  
Encapsulated  Zeta  Plus  
Material:  
Polycarbonate  
Silicone  
Polypropylene  
Thermoplastic  Elastomer  
Nylon  
Filtration  Area:  
2.5  m2  
Sterilization:  
1  cycle  autoclave  (30  min  @  126°C)  
Size:  
´  
Additional  Features:  
Disposable/Single  use  
  
  
Max  Operating  Temp:  
40°C  
Max  Operating  Pressure:  
3.1  bar  (45  psi)  
  
  
$9,000.00  
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Pump  (S-105)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  filter  to  holding  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Biomass  
0  g  
Water  
200000  g  
TNBP  
573  g  
Media  
5600 g  
VLP  
190 g  
Triton X-100  
1909 g  
Total  
208272 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Depth  Filtration  Holding  Tank  (P-7/V-101)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
Characteristics:  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  the  purified  product  from  the  depth  filtration  device  
  
Sartorius Stedim  
  
Batch  
  
Input  
Quantity  
Water  
200000 g  
TNBP  
573 g  
Media  
5600 g  
VLP  
171 g  
Triton X-100  
1909 g  
Total  
208253 g  
  
  
Material:  
Stainless  steel  
Total  Volume:  
500  L  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$1,682.00  
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Pump  (S-106)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  holding  tank  to  the  IEX  column  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Biomass  
0 g  
Water  
200000 g  
TNBP  
573 g  
Medium  
5600 g  
VLP  
171 g  
Triton X-100  
1909 g  
Total  
208253 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Chromatography  Resin  Tank  (P-11/V-105)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  the  IEX  chromatography  resin  
  
Sartorius Stedim  
  
Batch  
  
Input  
Quantity  
Capto Q Medium  
50 L  
  
  
Material:  
Stainless  steel  
Total  Volume:  
50  L  
Sterilization:  
Column  CIP  medium  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$1,682.00  
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Pump  (S-107)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
Characteristics:  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  resin  tank  to  the  IEX  column  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Capto Q Medium  
50 L  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Anion  Exchange  Chromatography  Column  (P-4/INX-101)  
  
Function:  

  

  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  

  
Characteristics:  
  
  

  
Operating  Conditions:  
  

  
Purchase  Cost:  

	
  
	
  

To specifically bind and elute the product in the anion exchange chromatography
resin  
  
GE Life Sciences  
  
Batch  
  
Input  
Quantity  
Water  
20000 g  
TNBP  
573 g  
Medium  
5600 g  
VLP  
171 g
Triton X-100  
1909 g
Total  
28253 g
  
  
Model:  
ReadyToProcess Q Sepharose FF  
Material:  
Stainless Steel 316 L, glass borosilicate  
Column Volume:  
215.9844949 L  
	
  
Column Height:  
0.4 m  
	
  
Column Diameter:  
0.5 m  
	
  
Sterilization:  
1 M NaOH, 30& isopropanol  
  
  
Minimum  Temp:  
4°C  
Maximum  Pressure:  
1.2  bar  (17  psi)  
Bed Volume:  
78.53981634 L   
Resin:  
Capto Q  
Binding Capacity:  
.22 mmol Cl- /mL medium  
Flow Rate  
0.981747704 LPM  
VLP Run Time  
20.37183272 min  
  
  
  
  
$166,000.00  
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Pump  (S-101)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  IEX  column  to  the  holding  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
20000  
TNBP  
0  
Medium Components  
0  
VLP  
162  
Triton X-100  
0  
Total  
20162 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Ion  Exchange  Holding  Tank  (P-18/V-107)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  the  purified  product  from  the  IEX  column  
  
Sartorius  Stedim  
  
Batch  
  
Input  
Quantity  
Water  
20000 g  
Media  
0 g  
VLP  
162 g  
Total  
20162 g  
  
  
Material:  
Stainless  steel  
Total  Volume:  
500  L  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$1,682.00  
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Pump  (S-108)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  holding  tank  to  the  SEC  column  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
20000 g   
Media  
0 g  
VLP  
162 g  
Total  
20162 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Size  Exclusion  Chromatography  Column  (P-5/C-101)  
  
Function:  

  

  

To specifically bind and elute the product in the size-exclusion chromatography
resin  
  
GE Life Sciences  
  
Batch  
  
Input  
Quantity  
Water  
20000  
Media  
0 g  
VLP  
162 g  
Tris-HCl  
4.8 g
NaCl  
14 g
Total  
20180.8 g
  
  
Model:  
ReadyToProcess Q Sepharose FF  
Material:  
Stainless Steel 316 L, glass borosilicate  
Column Volume:  
12.56637061 L  
Column Height:  
0.4 m  
Column Diameter:  
0.5 m  
Sterilization:  
CIP buffer, 30% isopropanol in 1M NaOH  
  
  
Temp:  
22°C  
pH:  
7.5    
Resin:  
Cross-linked agarose  
Flow Velocity  
0.05 m/min  
Volume Medium  
5 L  
Flow Rate  
0.628318531 LPM  
Run Time  
39.78873577 min  
Binding Capacity:  
13 mg/mL medium  

Purchase  Cost:  

$166,000.00  

  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  

  
Characteristics:  
  
  

  
Operating  Conditions:  
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Pump  (S-111)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  SEC  column  to  the  holding  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
20000 g  
Media  
0 g  
VLP  
154 g  
NaCl  
14 g  
Tris-HCl  
4.8 g  
Total  
20172.8 g  
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Size  Exclusion  Holding  Tank  (P-19/V-108)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
  
  
Characteristics:  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  hold  the  purified  product  from  the  SEC  column  
  
Sartorius  Stedim  
  
Batch  
  
Input  
Quantity  
Water  
20000 g  
Media  
0 g  
VLP  
154 g  
NaCl  
14 g  
Tris-HCl  
4.8 g  
Total  
20172.8 g  
  
  
Material:  
Stainless  steel  
Total  Volume:  
500  L  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$1,682.00  
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Pump  (S-114)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  holding  tank  to  the  TFF  unit  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
20000 g  
Media  
0 g  
VLP  
154 g  
Total  
26544.27 g
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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Tangential  Flow  Filtration  Unit  (P-6/DF-102)  
  
Function:  

  

  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  

  
  

  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  filter  product  of  size  exclusion  chromatography  for  any  remaining  contaminants  
and  to  insure  small  to  no  presence  of  detergents  and  media  ions.    
  
Millipore  
  
Continuous  
  
Input  
Quantity  
Water  
20000 g  
Media  
0 g  
VLP  
154 g  
Total
20146 g
  
  
Model:  
Encapsulated  Zeta  Plus  
Material:  
304  L  Stainless  steel  
Polyethylene  
Nylon  
Polysulfone  
Silicone  
Flow  Rate:  
0.4-4  L/min  
Sterilization:  
No  CIP/SIP  
Surface  area:  
0.1-0.5  m1  
Additional  Features:  
Disposable/Single  use  
  
  
Max  Operating  Temp:  
20-45°C  
Max  Operating  Pressure:  
3.45  bar  (50  psi)  
  
  
$200,000.00  
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Pump  (S-109)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

	
  
	
  

To  transfer  material  from  the  TFF  unit  to  the  holding  tank  
  
Cole-Palmer  
  
Batch  
  
Input  
Quantity  
Water  
10000 g  
Media  
0 g  
VLP  
146 g  
Total  
10146 g
  
  
Model:  
Masterflex®  B/T  ®  
Pump  Type:  
Peristaltic  
Flow  Rate:  
42  L/min  
Power:  
6.5  Amps  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$4,640.00  
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TFF  Holding  Tank  (P-8/V-102)  
  
  
Function:  
  
Vendor:  
  
Operation:  
  
Materials  Handled:  
  
  
  
  
  
Characteristics:  
  
  
Operating  Conditions:  
  
  
Purchase  Cost:  

To  hold  the  purified  product  from  the  TFF  device  
  
Sartorius  Stedim  
  
Batch  
  
Input  
Quantity  
Water  
10000 g  
Media  
0 g  
VLP  
146 g  
Total  
10146 g
  
  
Material:  
Stainless  steel  
Total  Volume:  
500  L  
  
  
Temp:  
22°C  
Pressure:  
1.1  atm  
  
  
$1,682.00  
  

	
  
.
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9.0 Cost Summary
9.1 Upstream Section
Upstream Process Equipment
Name

T ype

Size

Vendor

E quipment Name

Purchase Cost ($/Unit)

P-1/TTR-101

Test Tubes

300 mL

Freund Container

2 ml Sterile Plastic Vials

$255.00 (500 vials)

P-2/SFR-101

Shaker Flask

250 mL

Corning

Polycarbonate Erlenmeyer

$595.89 (50 flasks)

P-3/SFR-102

Shaker Flask

2L

Corning

Polycarbonate Erlenmeyer

$204.55 (6 flasks)

P-4/SFR-103

Shaker Flask

4L

Corning

Polycarbonate Erlenmeyer

$236.60 (4 flasks)

P-6/SBR-103

Bioreactor

50 L

GE Life Sciences

Xcellerex® Skid

$213,519.00

P-7/SBR-104

Bioreactor

500 L

GE Life Sciences

Xcellerex® Skid

$233,717.00

P-17/SBR-105

Bioreactor

2000 L

GE Life Sciences

Xcellerex® Skid

$930,446.00

Bioreactor Bags

50-2000L

GE Life Sciences

Xcellerex® Bags

$1,000.00

P-18/HX-103

Heat Exchanger

1.5 m

Enerquip

Pharmaceutical Enerquip Exchanger

$109,082.86

P-11/HX-101

Heat Exchanger

1.5 m

Enerquip

Pharmaceutical Enerquip Exchanger

$109,082.86

P-16/HX-102

Heat Exchanger

1.5 m

Enerquip

Pharmaceutical Enerquip Exchanger

$109,082.86

P-19/V-105

Storage Tank

200 L

Sartorius Stedim

Flexel 3D Palletank® with tote

$1,682.00

P-10/V-102

Media Storage Tank

200 L

Sartorius Stedim

Flexel 3D Palletank® with tote

$1,682.00

P-15/V-104

Media Storage Tank

500 L

Sartorius Stedim

Flexel 3D Palletank® with tote

$2,915.00

P-9/MF-101

Sterile Filter

3M Purification

ZetaPlus Encapsulated

$4,500.00

P-14/MF-102

Sterile Filter

3M Purification

ZetaPlus Encapsulated

$4,500.00

P-8/V-101

Media Storage Tank

200 L

Sartorius Stedim

Flexel 3D Palletank® with tote

$1,682.00

P-13/V-103

Media Storage Tank

500 L

Sartorius Stedim

Flexel 3D Palletank® with tote

$2,915.00

Raw M aterials
Triton X-100

Millipore

$13311.51

Tributyl phosphate

Millipore

$914.58

Sodium Hydrogen Carbonate

2.5 kg

Millipore

$96.45

Sodium Hydrogen Carbonate

12 kg

Millipore

$548.77

Sodium Hydrogen Carbonate

25 kg

Millipore

$307.63

Sigma-Aldrich

$96,820.00

EXCELL-405 Medium
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9.2 Downstream Section
Downstream Process Equipment
Name
P-1/DS-101
S-102
P-12/V-106
S-103
P-9/V-103
S-104
P-3/DF-101
S-105
P-7/V-101
S-106
P-11/V-105
P-4/INX-101
S-107
S-101
P-18/V-107
P-10/V-104
S-108
S-110
P-5/C-101
S-111
P-19/V-108
S-114
P-6/DF-102
S-109
P-8/V-102
S-112

T ype
Cell Harvest/Primary Recovery
Disk-Stack Centrifuge
Pump
Storage Tank
Pump
Inactivator Tank
Pump
Depth Filter
Depth Filtration Cassettes
Pump
Holding Tank
Chromatography
Pump
Chromatography Resin Tank
Chromatography Resin
Ion Exchange Chromat. Column
Pump
Pump
Holding Tank
Chromatography Resin Tank
Pump
Pump
Size Exclusion Chromat. Column
Chromatography Resin
Pump
Holding Tank
F iltration
Pump
Tangential Flow Filtration (TFF)
Pump
Holding Tank
Pump

Size

V endor

E quipment Name

Purchase Cost ($/Unit)

Carr Centritech

Unifuge®

$400,000.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Sartorius Stedim

Palletank®

$1,682.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Sartorius Stedim

Palletank®

$4,500.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

3M Purification

ZetaPlus Encapsulated

$4,500.00

3M Purification

ZetaPlus

$4,500.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Sartorius Stedim

Palletank®

$1,682.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Sartorius Stedim

Palletank®

$1,682.00

GE Life Sciences

Sepharose Q XL

GE Life Sciences

ReadyToProcess

$166,000.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

200 L

Sartorius Stedim

Palletank®

$1,682.00

200 L

Sartorius Stedim

Palletank®

$1,682.00

Cole-Palmer

MasterFlex® B/T

$12,500.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

GE Life Sciences

ReadyToProcess

$166,000.00

GE Life Sciences

Sepharose 4 FF

Cole-Palmer

MasterFlex® B/T

$4,640.00

Sartorius Stedim

Palletank®

$1,682.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Millipore

Pellicon XL50

$200,000.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

Sartorius Stedim

Palletank®

$4,500.00

Cole-Palmer

MasterFlex® B/T

$4,640.00

200 L
500 L

200 L

200 L

200 L

200 L
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9.3 A dditional E quipment and Processes
Additional Equipment & Processes
Name

T ype

P-17/FDR-101

Freeze Drier

S-113

Pump

Cole-Palmer

P-13/FL-101

Filler

--

P-14/LB-101

Labeling

--

P-15/BX-101

Packaging

--

P-16

Removal

SteriCycle

---

Incubator

Sartorius Stedim

---

Tube Fusers

Sartorius Stedim

---

Tube Sealers

Sartorius Stedim

-----

Cryopreservation
Bank
Temperature
Control Module

Size

V endor

E quipment Name

Purchase Cost ($/Unit)
$4,500.00

Sigma-Aldrich

MasterFlex® B/T

$4,640.00
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10.0 Important Considerations
10.1 Scheduling
10.1.1 G antt C hart

Days	
  

0	
  

10	
  

20	
  

30	
  

40	
  

50	
  

60	
  

Innoculate	
  100	
  mL	
  
Innoculate	
  500	
  mL	
  
Innoculate	
  4L	
  Flask	
  
Fill	
  20L	
  Bioreactor	
  
Ferment	
  20L	
  Bioreactor	
  
Fill	
  200L	
  Bioreactor	
  
Ferment	
  200L	
  Bioreactor	
  
Fill	
  2000L	
  Bioreactor	
  
Ferment	
  2000L	
  Bioreactor	
  
Fill	
  and	
  Store	
  in	
  Hold	
  Tank	
  1	
  
Centrifuge	
  
Fill	
  Inactivation	
  Tank	
  
Inactivation	
  
Tangential	
  Flow	
  Filtration	
  
Fill	
  and	
  Store	
  in	
  Hold	
  Tank	
  2	
  
Ion	
  Exchange	
  Chromatography	
  
Fill	
  and	
  Store	
  in	
  Hold	
  Tank	
  3	
  
Size	
  Exclusion	
  
Fill	
  and	
  Store	
  in	
  Hold	
  Tank	
  4	
  
Tangential	
  Flow	
  Filtration	
  
Fill	
  and	
  Store	
  in	
  Hold	
  Tank	
  5	
  
Packaging	
  into	
  Vial	
  

F igure 10.1 Gantt Chart. Shows scheduling times relative to each process equipment to give overall batch time.

Note: The change time of the bag liner of the bioreactors and storage tanks are 1 hour
each, and they are included in the fill time of the corresponding unit.
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10.2 E nvironmental Concerns
Biosynthesis of our vaccine product results in a number of waste streams. The
process produces a substantial amount of solid biohazard waste which may contain
recombinant baculovirus, insect cells, and metabolic waste products from the
fermentation process. The solid waste components are collected into red biohazard

receptacles within the facility for a biohazard waste removal service, Stericycle, to collect
and treat. This waste will be incinerated to remove any potentially hazardous effects on
the environment so that only greenhouse emissions from incineration are the only
environmental impact. The facility will use StericycleTM as the solid biohazard
management service to insure proper waste disposal protocols are rigidly maintained.
None of the components used in the fermentation steps of this process are
particularly dangerous or toxic to wildlife or the environment, since many of them are
required for cell growth of any organism and are often found in nature. Many of these
components will be heat-treated to sterilize the fermentation broth after removal of the
VLPs through the downstream components. This sterilization procedure will denature
any potential problematic proteins in the mixture. This waste will be neutralized in pH to
insure no detrimental effects to wildlife in the location of disposal. The detergents used in
the deactivation of baculovirus are collected as liquid waste via diafiltration. The filtrate
is collected and retained as hazardous liquid waste.
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10.3 C ur rent Good M anufacturing Practices
The United States Food and Drug Administration (FDA) is responsible for
overseeing and enforcing Good Manufacturing Practices in the United States. Current
Good Manufacturing Processes (cGMP) guidelines are found in the Code of Federal

Regulation 21 Part 211 (21 CFR 211). The purpose of cGMP regulations is to ensure that
drug products are manufactured in a manner making them safe for human consumption
by monitoring how drug products are sterilized and purified.
Sterilization and purity are monitored by paying careful attention to the process,
quality of manufacturing equipment components, raw materials, as well as characteristics
of cell lines used in recombinant processes. The manufacturing facility design and layout,
as well as frequent testing are quintessential in ensuring quality consistent with FDA
cGMP regulations. All authorized persons allowed to enter designated limited access
areas, such as the production floor will have the proper training.
All equipment purchased is certified as being GMP approved by the FDA.
Bioreactors with disposable bags and disposable transfer lines are used to ensure sterility,
while reducing time between batches. The disposable bags and transfer lines are GMP
certified and guaranteed by their manufacturers, therefore there is no need for CIP and
SIP procedures on the bioreactors, which reduces change over time between batches.
Tube fusers as well as sterile tube connectors are used to ensure that chance of
contamination is minimized during transfer.
Specific guidelines pertaining to vaccine manufacture are described by the FDA
LQ³Guidance for Industry, Characterization and Qualification of Cell Substrates and
Other Biological Materials Used in the Production of Viral Vaccines for Infectious
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'LVHDVH,QGLFDWLRQV´7KHJXLGHOLQHVDUHSULPDULO\FRQFHUQHGZLWKPRGHVRILQDFWLYDWLQJ
cells used for recombinant DNA, purity of vaccine, potential sources of contamination,
and validation of purity at many stages during the vaccine manufacture.
We have selected the SF+ insect cell line as our cell substrate. These are not bovine or
human derived; therefore there is low pathogenic transmission risk. This eliminates
adventitious agents affiliated with human or bovine cell lines, as well as retroviruses,
such as HIV, and bovine diseases such as Bovine spongiform encephalopathy which can
be transmitted to humans.
Research and Development (R&D) is responsible for characterizing the growth
characteristics and life expectancy of the SF Plus cells according to 21 CFR
610.18(c)(1)(iii). This includes documenting species of origin, tissue type, tumorigenic
properties, and ability to harbor latent viruses or express infectious prion proteins (PrP).
They will also create a master cell bank (MCB) for each virus strain. Every season, R&D
will renew the MCB. Working Cell Banks (WCB) will be derived from their
corresponding MCB for each batch. All WCB used to create the VLPs for a particular
strain will be derived from their corresponding MCB. R&D will periodically test the
MCB and WCB for cell viability and stability. The history of all WCB will be
documented by Quality Assurance (QA) according to 21 CFR 610.18(c)(1)(i), including
agents used in same biosafety cabinets and conditions under which the cells were
passaged.
R&D will also be responsible for characterizing and documenting the viral seed.
For our production methods, the baculovirus will be used to insert the desired influenza
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'1$VWUDLQLQWR6)3OXVFHOOV7KHYLUDOVHHG¶VVWDELOLW\ZLOOFRQWLQXDOO\EHPRQLWRUHGE\
R&D as well. Other documentation includes amino acids used in the growth media.
To minimize potential contamination, human contact with cells will be minimized. All
employees working with the cells directly or on the production floor are required to wear
the proper attire as set in 21 CFR 211. Once the shaker flasks are inoculated with the SF
Plus cells, the cells will not be exposed to the ambient air. The transfer methods during
the scale up are such that the cells need not be exposed, minimizing potential
contamination opportunities. All cells drawn from the working cell bank (WCB) will be
tested by the Quality Control (QC) group to ensure they do not contain infectious viruses
or retroviruses.
The identity and purity of all raw materials will be checked by QC to ensure that
they fall within the specifications approved by the FDA for the specific vaccine
production method. This will occur before they are moved onto the production floor. No
serums are used, therefore there is no need to concern ourselves with irradiation of raw
materials.
During production, all specific markers relevant to the SF Plus cell line will be
analyzed by QC and tracked throughout the different manufacturing passage levels. The
ability of the cells to produce recombinant protein will be tracked, evaluating each copy
number and the stability at each relevant passage.
Our interpretation of the definition of purity used by the FDA is removing 99% of
cell growth media, cell substrate DNA, as well as any other adventitious agents that may
be the product of cell debris. Size exclusion chromatography will be used because the
VLP vaccine has a diameter of 90 to 120 nanometers and DNA has a diameter of 2.2 to
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2.6 nanometers. This will allow for removal of 99.9% of DNA debris from the cell
substrate. An ion exchange column will be used to remove any charged cell debris.

QC will also use a control set of cells, which are uninfected cell substrate. These
cells will be grown in parallel at the same time as each batch with identical conditions to
the batches of cells that are to be infected. This will emulate the conditions of the
bioreactors and allow QC to determine any adventitious agents naturally produced by the
cell substrate. The cells used for QC must be from the same WCB as the ones used in the
bioreactor for validity of the control test. All assays will be validated and signed off by
Quality Assurance (QA). All tests will be consistent with 21 CFR 610.18(c)(1)(iv).
After harvest, QC will test for adventitious agents in a method consistent with 21
CFR 610.30. Since our production method uses a lytic infection, it is not necessary to
check for surviving cells before harvest. To maintain full compliance with FDA
regulations, QC will ensure there are no surviving cells. Chances are slim due to the lytic
infection, but if surviving cells remain, the batch will be checked for adventitious agents.
At this point the harvested batch can be filtered. Post filtration, QC will test each batch
for bacterial and fungal sterility. Finally, each batch will be tested for residual cellular
proteins and cellular nucleic acids. All residual cells and low levels of cell-substrate DNA
will be removed to assure safety, identity, purity, potency, and quality.
In accordance with 21 CFR, all process automation will be consistent with Part
211.68; Filtration will be consistent with Part 211.72; Storage will be consistent with
Parts 211.80, 211.82, and 211.94; Quality testing will be consistent with Parts 211.84,
211.87, and 211.89; Process time speculations will be consistent with Part 211.111;
Contamination Control will be consistent with Part 211.113; Holding and Distribution
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will be consistent with parts 211,142 and 211,158; Control Units and software will be

consistent with Part 211.160. Standard Operation Procedures will be developed for all
actions necessary during the manufacturing production, including sterilization, facility
cleaning, and training consistent with 21 CFR Parts 211.100, 211.101, 21.110. All
Record keeping will be consistent with 21 CFR Part 211 Subpart J.
All relevant information regarding GMP was found on the FDA website and taken
from C FR- Code of Federal Regulations Title 21.
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10.4 L aboratory and Production F acility L ayout

The diagram shown below is a typical layout of a vaccine manufacturing facility.
The insect cell culture and influenza vaccine development facility will be modeled after
this depiction and retrofit into an existing site used for additional vaccine manufacturing.
For a goal of 100 million doses per year, the facility will have to be approximately 140K
square feet. Single-use equipment will be used throughout the facility to reduce changeover time, fixed piping, cleaning and validation costs, and to increase operational
flexibility.
The layout is designed to maintain multiple disposable bioreactors up to 2000 L in
size. The facility design criteria will meet the BSL-2 requirements with inoculum and cell
culture in class C, cell culture, downstream processing, and media and buffer preparation
in class D. The media and buffer will be stored in controlled, non-classified areas. The
batch duration will be approximately 8 weeks, including change-over times. This
simplifies to 4 weeks allotted to inoculum and cell culture, 2 weeks for bioreactor
production, and 2 weeks for further purification and downstream processing.

F igure 10.2 Design schematic for single-use influenza vaccine manufacturing facility with insect cell culture
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10.5 L abor Costs and Structure
The influenza vaccine facility will operate under the Global Manufacture and

Supply chain. Under this, the two major branches concerned with this process are quality
and manufacturing. The quality side handles paperwork and checks that all products and
processes fall within regulations. Manufacturing¶VVFRSHFRQVLVWVRIDOORSHUDWLRQV
facility and is split between process engineering and procurement. Positions of contract
specialist manager, operators, and contractors within the warehouse will be paid on an
hourly wage, while the general contract specialists, engineers, and the warehouse
manager will be paid on a salary wage.
Positions such as internal auditors and higher management in procurement do not
fall under the fixed costs for this facility. Based on average wages in Durham, North
Carolina, the total cost of a labor force of 71 employees for the year is estimated at $1.75
million. However, since the influenza vaccine production only operates for half the year,
with only four months of production, only a third of the total cost of labor is accountable
to this process, $584,000 (see Appendix A, Labor Costs for calculations). This cost will
go into fixed costs for each year the facility is operating.
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F igure 10.3 Diagram showing the labor structure for the vaccine manufacturing facility. The Global Manufacture and
Supply Group for the vaccine plant branches into two major operations: quality and manufacture.

122	
  

	
  

11.0 E conomic A nalysis
11.1 M ar ket A nalysis
The influenza virus is a seasonal virus that typically affects the upper respiratory
track. In severe cases, it can lead to pneumonia and even death. Annually, the World
Health Organization (WHO) estimates epidemics to affect anywhere from 5% to 15% of
WKHJOREDOSRSXODWLRQ ³:RUOG+HDOWK«´). Most patients affected by the influenza virus
will suffer illness for a week, without requiring medical attention. This can lead to
anywhere from three to five million cases of severe illness; it is estimated that there is an
annual death rate of about 250,000 to 500,000 globally ³,QIOXHQ]D«´). These deaths
usually occur among the chronically ill, the elderly, and the young.
The most common vaccine used to prevent the influenza virus is a trivalent
vaccine containing an A type Subtype H3N2 virus strain, an A type Subtype H1N1 virus
strain, DQGD%7\SHVWUDLQ ³:RUOG+HDOWK«´). The common method for vaccine
production is allowing the virus to proliferate in chicken eggs, and then harvesting the
influenza virus from the chicken embryo. The large costs of treating the cases of
influenza outbreak paired with the threat of pandemic outbreak have also led to a larger
demand for influenza vaccine. New methods, such as the use of MDKC to produce the
virus capsid and elicit an immune response have been investigated as potential methods
to meet the growing demand IRULQIOXHQ]DYDFFLQHV ³,QIOXHQ]D«´).
Between 2010 and 2011, the global market value reached $4 billion US Dollars
(USD) for all seven of the maMRULQIOXHQ]DYDFFLQHPDUNHWV ³,QIOXHQ]D«´). Between
2008 and 2010, the influenza vaccine market grew a stunning 65%, driven primarily by
the threat of a pandemic H1N1 outbreak (Wood). Market growth this large is not
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expected to continue long term, however. The compound annual growth rate is expected
to be RYHUWKHQH[WVL[\HDUV ³6HDVRQDO«´). By 2018, this market value is expected
to reach XSWRELOOLRQ86' ³,QIOXHQ]D«´). Currently, there are only five influenza
vaccine producers in the US market with Sanofi Pasteur capturing the largest market
share of $1 billion USD. It is also estimated that annual influenza outbreak in the USA
costs $80 billioQ86' ³,QIOXHQ]D«´). The large market value is appealing to
pharmaceutical companies that can effectively produce an influenza vaccine.
There are seven major vaccine markets globally. Seen in Figure 10.4
³,QIOXHQ]D«´), the US is the largest market share of an individual country, occupying
about 40% of WKHLQIOXHQ]DYDFFLQHPDUNHW ³,QIOXHQ]D«´). Germany, Italy, Spain,
France, the UK, and Japan are the other major vaccine market players. The European
players (Germany, Italy, Spain, France, and the UK) account for about 50% of the
European LQIOXHQ]DPDUNHWVKDUH ³,QIOXHQ]D«´). The Japanese market accounts for the
remaining 10% of the influenza vaccine market.

F igure 10.4 This shows the market share of the 7 major vaccine markets globally. It was used to show the
feasibility of the market share we expect to capture. ³,QIOXHQ]D«´
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Currently, WHO estimates the USA as being one of the leaders in influenza

vaccination, consuming approximately 40% of total vaccines produced annually, seen in
Figure 10.4. The threat of pandemic flu outbreak has led WHO to issue recommendations
to increase vaccination uSWRRIWKH86SRSXODWLRQ ³,QIOXHQ]D«´). To meet the
increase in demand, we investigated the production of an influenza vaccine via the
baculovirus in the SF+ insect cell line. In order for the vaccine to be lucrative and capture
a share of the influenza vaccine market, production cost of the vaccine must be
competitive with current egg-based production methods.
In 2009, the 149 million doses of the seasonal influenza vaccine were supplied to
Europe, as seen in Figure 10.5 (Hombach). From Figure 10.6 ³,QIOXHQ]D«´), it is seen
that 143 million doses of seasonal influenza vaccine were supplied to the United States in
2009 (Kresse). Based on current market growth rates, 3.9% compounded annual
³6HDVRQDO«´), it is expected that the percentage of people vaccinated in Germany, Italy,
Spain, France, the UK, the United States, and Japan will increase from 28.9% in 2011 to
32.9% by 2018. Based on these expected vaccination rates, the number of vaccines
supplied to Europe and the US will increase from 292 million seasonal influenza doses to
approximately 330 million doses.
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F igure 10.5 This shows the supply of influenza vaccines different countries globally between 2005 and 2009. It was
used to determine the global market share and determine the number of doses that our company could potentially
supple to the market. (Hombach)

F igure 10.6 This shows the number of influenza vaccine doses supplied to the United States in 2009. It also shows the
share of each company. This data was used in determining the number of doses our company can supply to the US.
³,QIOXHQ]D«´

Sanofi PasteurTM was responsible for producing 200 million doses of trivalent
egg-based seasonal influenza vaccinations in 2010, as well as 126 million pandemic
influenza vaccine doses (Sanofi Pasteur). From Figure 10.6 ³,QIOXHQ]D«´), it can be
seen that they supplied 25% of their doses to the United States. For a company to enter
the market and hold a large market share in Europe, a similar number of doses must be
supplied to Europe as well; therefore, our company plans to manufacture and 100 million
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doses of seasonal influenza to the United States and European markets. Half of the doses
will be distributed to Europe, and half will be distributed to the United States.
This is a reasonable market stake, and feasible to produce in a single facility.
Sanofi PasteurTM¶VIDFLOLW\LQ6ZLIWZDWHU3HQQV\OYDQLDLVFDSDEOHRISURGXFLQJ
million doses of trivalent seasonal influenza vaccine doses annually (Sanofi Pasteur). In
2009, members of The International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA) International Vaccine Supply (IVS) Task Force supplied 449
million doses of seasonal influenza vaccine, accounting for 75% of total influenza
vaccines distributed (Palache). Therefore, the market is approximately 600 million
seasonal influenza vaccines, annually. Our production goal of 100 million vaccines
would increase the global market by 16.7%, moving the wRUOGFORVHUWRWKH:+2¶VJRDO
of 750 million doses of influenza vaccine produced annually.
Since only 5 companies globally produce and supply an influenza vaccine, there
is room for entry into the market. Our company will supply 86,184,000 doses of trivalent
seasonal influenza vaccine to the market. This would capture about 14.7% of the global
market share, supplying to only Europe and the United States.
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11.1.1 Investor Interest
Health and Biotechnology sectors are known for their large profits. While it is
true that there are potentially large returns in the pharmaceutical, biotechnology, and
healthcare industries, it comes with a large investment risk. The risk comes from the
5HVHDUFKDQG'HYHORSPHQW 5 ' VLGHZLWKRIWKHILUP¶VILQDQFLDODVVHWYalue

being spent on research (Golec). Outside of the biotechnology industry, an average of 3%
RIDILUP¶VILQDQFLDODVVHWYDOXHZDVVSHQWRQUHVHDUFK
There is more risk on the failure of products to reach the market. Approximately
only 1 in every 10,000 compounds being investigated ± commonly referred to as
investigational new drugs (INV) ± make it to market. When a drug makes it to market, it
is quintessential that the company recovers money lost on research and clinical trials, as
well as sunk costs from failed investigated new drugs. In 2011, the biotechnology market
as a whole increased revenue to a 1% margin over costs, increasing revenue a full 8%
from 2009 (Suresh). The small revenue margin is due to large research costs, clinical
testing costs, and the sunk costs of failed products.
To succeed in a market with high failure rates, successful drugs must have high
mark ups. In 2012, GSKTM and Sanofi PasteurTM had an overall product profit margin of
29% and 32%, respectively, in their vaccine divisions (Angelmar). The overall
pharmaceutical industry mark-up is approximately 30% across the industry (Angelmar).
Therefore, our company must be capable of producing our trivalent influenza vaccine
with at least a 30% profit margin.
From the time a company files for a patent, they have 17 years before other
companies can manufacture a generic form of the drug. Influenza vaccines are different
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because the strain changes annually. Because of antigenic drift, there is no patented

influenza vaccine, or generic brand. The influenza vaccine is less proprietary than other
drug products. The production method of the vaccine, the dosing, and method of delivery
is where the proprietary value lies in the influenza vaccine market. Producing a non-egg
based method with less lag time by using recombinant insect cell culture technology
therefore has large value.
Currently, only egg-based methods and a recombinant mammalian cell culture are
used to produce the influenza vaccine. FluBokTM a recombinant influenza vaccine
produced using Chinese Hamster Ovary (CHO) cells, a mammalian cell culture.
FluBokTM is the only approved non-egg based influenza vaccine on the market. With the
push to move away from egg-based production methods that have large lead times, our
company has room to enter the market.
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11.2 Profitability A nalysis
To determine the profitability of the vaccine manufacturing facility, the
profitability analysis worksheet (Version 3.0), developed by Nickish Consulting was

used. The analysis is broken down into equipment costs and total permanent investment,
working capital, utilities, fixed costs, and other variable costs.
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11.2.1. E quipment Costs and Total Permanent Investment

The purchase cost of all raw materials and equipment was determined by direct
contact with YHQGRUVWKURXJKWKHXVHRI&',(QJLQHHULQJ*URXS¶V(TXLSPHQW/LVWRU
through sources such as BioPharm International or BioProcess International. The bare
module factors for all units were gathered from Chapter 22 of Product and Process

Design Principles.
The Total Permanent Investment accounts for the cost of site preparations, service
facilities, contingencies and contractor fees, and plant start-up. As listed in Chapter 22 of

Product and Process Design Principles, the cost of site preparations will be 5.0% of the
total bare module cost, the cost of service facilities will be 5.0% of the Total Bare
Module cost, the cost of contingencies and contractor fees will be 18.0% of the Total
Depreciable Capital, and the cost of plant start-up will be 10.0% of the Total Depreciable
Capital. Since this manufacturing facility will be retrofit to an existing site, there will be
no cost associated with land.
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E quipment Costs
Fabricated Equipment
Test Tubes/Plastic Vials
Shaker Flasks - 250 mL (pack of 6)
Shaker Flasks - 2 L
Shaker Flasks - 4 L
Disposable Bioreactors -50 L
Disposable Bioreactors -500 L
Disposable Bioreactors- 2000L
Disposable Reactor Bags -50 L
Disposable Reactor Bags -500 L
Disposable Reactor Bags -2000 L
Depth Filtration Unit (DSP)
Depth Filtration Cassettes
Sterile Filtration Unit (USP)
Filtration Cassettes
Chromatography Columns
pH Adjustment Tank

Purchase Cost
$255.00
$160.57
$51.71
$150.25
$213,519.00
$233,717.00
$930,446.00
$1,000.00
$1,000.00
$1,000.00
$4,500.00
-$4,500
-$166,000.00
$20,000.00

Quantity
1
1
6
6
4
4
4
4
4
4
4
4
8
8
8
1

Bare Module Factor
1.00
1.00
1.00
1.00
4.16
4.16
4.16
1.10
1.10
1.10
1.10
1.10
1.10
1.10
1.10
4.16

Bare Module Cost
$255.00
$160.57
$310.26
$901.50
$3,552,956.16
$3,889,050.88
$15,482,621.44
$4,400.00
$4,400.00
$4,400.00
$19,800.00
-$39,600.00
-$1,460,800.00
$83,200.00

Process Machinery
Disk-Stack Centrifuge
Pumps
Virus Inactivation Tank
Holding Tanks
Chromatography Resin Tanks
Tangential Flow Filtration Unit
Heat Exchangers

Purchase Cost
$400,000.00
$4,640.00
$4,500.00
$1,682.00
$1,682.00
$200,000.00
$109,082.82

Quantity
4
27
4
16
8
4
9

Bare Module Factor
2.03
3.30
4.16
4.16
4.16
2.32
3.291

Bare Module Cost
$3,248,000.00
$459,360.00
$74,880.00
$111,953.92
$55,976.96
$1,856,000.00
$3,230,924.00

Spares
Filter Integrity Tester
Bioinactivation System
Tube Fusers
Tube Sealers

Purchase Cost
$4,500.00
$10,000.00
$15,300.00
$10,200.00

Quantity
5
1
1
1

Bare Module Factor
1
3.5
1
1

Bare Module Cost
$22,500.00
$35,000.00
$15,300.00
$10,200.00

Incubator
Storage Tanks
Media Storage Tanks-200 L
Media Storage Tanks-500 L
Freeze Dryer
Biosafety Cabinet
Bag Holders

Purchase Cost
$3,700.00
$1,682.00
$1,682.00
$2,915.00
$4,500.00
$10,000.00
$1,000.00

Quantity
4
8
8
8
4
1
18

Bare Module Factor
1.74
4.16
4.16
4.16
2.05
1.10
1.10

Bare Module Cost
$25,752.00
$55,976.96
$55,976.96
$97,011.20
$36,900.00
$11,000.00
$19,800.00

Storage

Total Permanent Investment
Cost of Site Preparations:
Cost of Service Facilities:
Allocated Costs for utility plants and related facilities:
Cost of Contingencies/Contractor Fees:
Cost of Retrofit:
Cost of Royalties:
Cost of Plant Start-Up:

5.0% of Total Bare Module Costs
5.0% of Total Bare Module Costs
$0
18.0% of Direct Permanent Investment
$0
$0
10.0% of Total Depreciable Capital
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11.2.2 Wor king C apital & Utilities
The working capital of a facility is defined as the sum of the cash reserves,
inventory, and accounts receivable, minus the accounts payable. The cash reserves

typically include 30 days of raw materials, utilities, operation, and maintenance. For the
majority of cases, 30 days of accounts receivable for products at sales price and 30 days
of feedstocks for accounts payable can be assumed. The inventory is assumed to be 7
days worth of liquid and solid products at sales price; however, this was very dependent
on the material being considered. For the raw materials, such as media, cell culture
supplies, and chemical ingredients, an inventory of 30 days was assumed.

11.2.3 O ther V ariable Costs
The other variable costs include the selling/transferring of expenses and the
management incentive compensation. These factors are included in the Profitability
Analysis spreadsheet.
Wor king C apital
Accounts Receivable
Cash Reserves (excluding Raw Materials)
Accounts Payable
VLP for Influenza
Vaccine Inventory
Raw Materials

=>
=>
=>

30
30
30

Days
Days
Days

=>
=>

28
90

Days
Days

O ther V ariable
Costs
General E xpenses
Selling / Transfer
Expenses:
Direct Research:
Allocated Research:
Administrative Expense:
Management Incentive
Compensation:

3.00%
10.00%
0.50%
2.00%

of Sales
of Sales
of Sales
of Sales

1.25%

of Sales
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11.2.4 F ixed Costs
With a total of four months of operation (120 days), and 3 shifts per day, 71
employees will be required in both the Quality and Manufacture sectors. The upstream
and downstream processes will require 6 workers each per shift. The fixed costs also
include the wages and benefits of maintenance, quality control, and technical assistants.
Section 10.5 on labor costs and structure goes into further detail regarding the personnel
and services surrounding all units as well as their respective salaries and benefits.

11.2.5 Depreciation
The MACRS Tax-Basis Depreciation for 5 years was used for this manufacturing
process. According to Product and Process Design Principles, the percentages of Total
Depreciable Capital beginning with year 1 are: 20%, 32%, 19.2%, 11.52%, and 5.76%.
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11.3 Input Summary
General Information
  
  
  
  
  
  
  
  
  
  Product Information
  

Process  Title:  
Product:  
Plant  Site  Location:  
Site  Factor:  
Operating  Hours  per  Year:  
Operating  Days  Per  Year:  
Operating  Factor:  

Manufacturing of Insect Cell Culture VLP-based Influenza Vaccine
API for Influenza Vaccine
  
  
Research Triangle Park, NC
  
  
1.10
  
  
  
4383
  
  
  
183
  
  
  
0.5003
  
  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  

  
  
  
  
  
  
  

  
  
  
  
  
  
  

This  Process  will  Yield  
  
  
  
  
  
  
  Chronology
Year
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
  

  
  
  
  Price  

$8.12

  

  
Action

Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
  

10,924
262,177
47,880,000

  
  
  
doses  of  
API  for  Influenza  Vaccine  per  hour  
doses  of  API  for  Influenza  Vaccine  per  day  
doses  of  API  for  Influenza  Vaccine  per  year  
  
/doses
  

Distribution of
Permanent Investment
100%  
0%  
0%  
0%  
  
  
  
  
  
  
  

  
  
  

  
  
Production
Capacity
81.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
  

Depreciation
7  year  MACRS  
14.29%  
24.49%  
17.49%  
12.49%  
8.93%  
8.92%  
8.93%  
4.46%  
  
  
  

Product Price

  
  
  
  
  
  
  
  
  
  
  

   $8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
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11.4. Profitability A nalysis
11.4.1 Profitability A nalysis Results for 20% E fficiency in Downstream
	
  
E quipment Costs
E quipment Description

Bare Module Cost

Test Tubes
1 Shaker Flasks (250 mL)
6 Shaker Flasks (2 L)
6 Shaker Flasks (3 L)
4 Disposable Bioreactors (50 L)
4 Disposable Bioreactors (500 L)
4 Disposable Bioreactors (2000 L)
4 Reactor Totes (50 L)
4 Reactor Totes (500 L)
4 Reactor Totes (2000 L)
4 Depth Filtration Units
8 Sterile Filtration Units
8 Chromatography Columns
4 Disk-Stack Centrifuges
4 Viral Inactivation Tanks
16 Holding Tanks
8 Resin Tanks
4 Tangential Flow Filtration Units
27 Pumps
9 Heat Exchangers
4 Incubators
8 Storage Tanks
8 Media Storage Tanks (200 L)
8 Media Storage Tanks (500 L)
Biosafety Cabinet
18 Bag Holders
Filter Integrity Tester
Bioinactivation System
Tube Fusers
Tube Sealers

	
  
	
  

Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Storage
Storage
Storage
Storage
Storage
Storage
Spares
Spares
Spares
Spares

	
  

$255
$596
$5,106
$1,969
$3,552,956
$3,889,051
$15,482,621
$4,400
$4,400
$4,400
$39,600
$79,200
$1,460,800
$3,248,000
$74,880
$111,954
$55,977
$1,856,000
$413,424
$3,229,942
$25,752
$55,977
$55,977
$97,011
$11,000
$19,800
$4,500
$35,000
$15,300
$10,200

136	
  

	
  
11.4.1 Profitability A nalysis Results for 20% E fficiency in Downstream
Variable Cost Summary
Variable Costs at 100% Capacity:
  
  
  
   General
  
  
  
  
  
Expenses
  
  
  
  
     
  
Selling  /  Transfer  
  
  
  
Expenses:  
     
  
  
Direct  Research:  
     
  
  
Allocated  Research:  
     
  
  
Administrative  Expense:  
     
  
  
Management  Incentive  Compensation:  
     
  
   Total
  
  
  
  
General Expenses   
  
  
  
  
     
  
  
  
per  doses  of  API  for  Influenza  
  
Raw Materials
$0.015991   Vaccine  
  
  
  
  
  
per  doses  of  API  for  Influenza  
  
Byproducts
$0.000000   Vaccine  
  
  
  
  
  
  
per  doses  of  API  for  Influenza  
  
Utilities
$0.018525   Vaccine  
  
  
     Total Variable Costs
  
  
  
  

	
     
	
  

  

	
  

  

  

  
  
  
  
  $11,667,303    
  $38,891,009    
  $149,730,384    
  $7,778,202    
  $4,861,376    
  

  $212,928,273    

  
$765,658    
  
$0    
  
  

$886,971    
$214,580,902
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11.4.1 Profitability A nalysis Results for 20% E fficiency in Downstream
Fixed Cost Summary
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

	
     
	
  

  
  
Operations

  
  
  
  
  
  
  
  
  
  
  
  
  
Direct  Wages  and  Benefits  
  
Direct  Salaries  and  
  
Benefits  
  
  
Operating  Supplies  and  Services  
  
Technical  Assistance  to  Manufacturing  
  
Control  Laboratory  
  
  
  
  
  
  
Total
Operations
  
  
  
  
  
  
Maintenance
  
  
Wages  and  Benefits  
  
  
Salaries  and  Benefits  
  
  
Materials  and  Services  
  
  
Maintenance  Overhead  
  
  
  
  
  
  
Total
Maintenance
  
  
  
  
  
  
Operating
Overhead
     
  
  
     
General  Plant  Overhead:  
  
  
Mechanical  Department  Services:  
  
Employee  Relations  Department:  
  
Business  Services:  
  
  
  
  
Total
Operating
  
  
Overhead
  
  
  
  
  
  
Property
Taxes and Insurance
  
  
  
  
Property  Taxes  and  Insurance:  
  
  
  
  
Other
Annual Expenses   
  
  
  
  
Rental  Fees  (Office  and  Laboratory  
  
  
Space):  
  
Licensing  Fees:  
  
  
Miscellaneous:  
  
  
  
  
  
Total
Other Annual
Expenses  
  
  Total Fixed Costs
  
  
  
  

	
  

  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  
  
  
  

  $364,000    
  $54,600    
  $21,840    
  $-        
  $-        

  
  
  

  
  
  
  

$440,440
  $1,522,744    
  $380,686    
  $1,522,744    
  $76,137    
$3,502,310

  $164,864    
  $55,729    
  $137,000    
  $171,830    

  
$529,423
  
  
  

  $676,775    

  
  
  
  $-        
  $-        
  $-        
  

$-

  

$5,148,948
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11.4.1 Profitability A nalysis Results for 20% E fficiency in Downstream
	
  
Investment Summary
      Module Costs
  
Bare
Fabricated Equipment   
Process Machinery
   Spares
   Storage
  
   Other Equipment
  
   Catalysts
   Computers, Software, Etc.  
  
     Total Bare Module Costs:   

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  

  
  
  
  
  
  
   Cost
  
  
  
of Site Preparations:  
   Cost of Service Facilities:
  
  
   Allocated Costs for utility plants and   related facilities:
  
  
   Direct
  
  
  
  
Permanent Investment

  
  
  
  
  
  
  
  

  
  
  
  

  
     
      Depreciable Capital
Total

  
  
  
  
  
  
  
  

  
  
  
  
  

  
  
  
  

  

  
  
  
  
  
  
  
  
  
  

  

  

  

  
      Permanent Investment  
Direct

  
  
  
  
  
  
   Cost
  
  
  
of Contingencies & Contractor
Fees
  
     
  
  
     Total Depreciable Capital   
  
  
      Permanent Investment   
Total
  
  
  
  
  
  
  
  	
  
	
  

  
  
  
  
  
  
Cost
of Land:
  
Cost of Royalties:
  
Cost of Plant Start-Up:
  
  
   - Unadjusted
  
Total
Permanent Investment
Site Factor
  
  
Total Permanent Investment

	
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  

  
  $24,518,054       
  $8,990,177       
  $65,000       
  $265,517       
  $-           
  $-           
  $-           
  
  
  
  
  $-           
  $-           
  $-           
  

  

  
  

  
  
  

$33,838,748

$33,838,748
  
  
  $-           
  
  
  
  
  
  $-           
  $-           
  $-           
  
  

$33,838,748

  $33,838,748    
1.10  
$37,222,623
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11.4.1 Profitability A nalysis Results for 20% E fficiency in Downstream

Profitability  Measures  

    

    

    

    

  

  

Negative  IRR  

  

  

   Net Present Value
      (NPV) of this project
  
The
in 2013 is  

  

     
     
  
  ROI
   Analysis (Third   Production
  
Year)   

  
  

  
  
  

  
  
  
  
  
  
  
  	
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  The
   Internal Rate of   Return
  
   project is
(IRR) for this

	
  

  
     
Annual
Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI

350,019,079
(198,271,760)
(2,977,810)
(6,694,628)
142,074,882

  
  
  
  
  
  

152.22%
  

	
  

93,336,250

  $619,244,200    

  

  

	
  
11.4.1 Profitability A nalysis Results for 20% E fficiency in Downstream
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11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
General Information
Process  Title:  
  
Product:  
  
Plant  Site  Location:  
  
Site  Factor:  
  
Operating  Hours  per  Year:  
  
Operating  Days  Per  Year:  
  
Operating  Factor:  
  
  
  
  Product Information
  

Manufacturing of Insect Cell Culture VLP-based Influenza Vaccine
API for Influenza Vaccine
  
  
  
Research Triangle Park, NC
  
  
  
1.10
  
  
  
  
4383
  
  
  
  
183
  
  
  
  
0.5003
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  

  
  
  
  
  
  
  

This  Process  will  Yield  
  
  
  
  
  
  
  Chronology
Year
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  

	
  
	
  

19,663
471,918
86,184,000

  
  
  
  Price  
  

$8.12
  

  doses  of  API  for  Influenza  Vaccine  per  hour  
  
  
doses  of  API  for  Influenza  Vaccine  per  day  
doses  of  API  for  Influenza  Vaccine  per  year  
  /doses
  

Distribution of
Permanent Investment
100%  
0%  
0%  
0%  

Action
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  

  
  
  
  
  
  

	
  

  
  
  

  
  
Production
Capacity
81.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  

Depreciation
7  year  MACRS  
14.29%  
24.49%  
17.49%  
12.49%  
8.93%  
8.92%  
8.93%  
4.46%  
  
  

  
  
  
  
  
  
  

Product Price

  
  
  
  
  
  
  
  
  
  

  $8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
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11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
E quipment Costs
E quipment Description

Bare Module Cost

Test Tubes
1 Shaker Flasks (250 mL)
6 Shaker Flasks (2 L)
6 Shaker Flasks (3 L)
4 Disposable Bioreactors (50 L)
4 Disposable Bioreactors (500 L)
4 Disposable Bioreactors (2000 L)
4 Reactor Totes (50 L)
4 Reactor Totes (500 L)
4 Reactor Totes (2000 L)
4 Depth Filtration Units
8 Sterile Filtration Units
8 Chromatography Columns
4 Disk-Stack Centrifuges
4 Viral Inactivation Tanks
16 Holding Tanks
8 Resin Tanks
4 Tangential Flow Filtration Units
27 Pumps
9 Heat Exchangers
4 Incubators
8 Storage Tanks
8 Media Storage Tanks (200 L)
8 Media Storage Tanks (500 L)
Biosafety Cabinet
18 Bag Holders
Filter Integrity Tester
Bioinactivation System
Tube Fusers
Tube Sealers

	
  
	
  

Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Storage
Storage
Storage
Storage
Storage
Storage
Spares
Spares
Spares
Spares

	
  

$255
$596
$5,106
$1,969
$3,552,956
$3,889,051
$15,482,621
$4,400
$4,400
$4,400
$39,600
$79,200
$1,460,800
$3,248,000
$74,880
$111,954
$55,977
$1,856,000
$413,424
$3,229,942
$25,752
$55,977
$55,977
$97,011
$11,000
$19,800
$4,500
$35,000
$15,300
$10,200
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11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
Variable Cost Summary
Variable Costs at 100% Capacity:
  
  
  
   General
  
  
  
  
  
Expenses
  
  
  
  
     
  
Selling  /  Transfer  
  
  
  
Expenses:  
     
  
  
Direct  Research:  
     
  
  
Allocated  Research:  
     
  
Administrative  Expense:     
     
  
  
Management  Incentive  Compensation:  
     
  
   Total
  
  
  
  
General Expenses   
  
  
  
  
     
  
  
  
per  doses  of  API  for  Influenza  
  
Raw Materials
$0.008884   Vaccine  
  
  
  
  
  
per  doses  of  API  for  Influenza  
  
Byproducts
$0.000000   Vaccine  
  
  
  
  
  
  
per  doses  of  API  for  Influenza  
  
Utilities
$0.010292   Vaccine  
  
  
     Total Variable Costs
  
  
  
  

	
     
	
  

  

	
  

  

  

  
  
  
  
  $21,001,145    
  $70,003,816    
  $269,514,691    
  $14,000,763    
  $8,750,477    
  
  
  

  $383,270,892    
$765,658    
$0    

  
$886,971    
  

$384,923,520
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11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
	
  
Fixed Cost Summary
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  
  
Operations

  
  
  
  
  
  
  
  
  
  
  
  
  
Direct  Wages  and  Benefits  
  
Direct  Salaries  and  
  
Benefits  
  
  
Operating  Supplies  and  Services  
  
Technical  Assistance  to  Manufacturing  
  
Control  Laboratory  
  
  
  
  
  
  
Total
Operations
  
  
  
  
  
  
Maintenance
  
  
Wages  and  Benefits  
  
  
Salaries  and  Benefits  
  
  
Materials  and  Services  
  
  
Maintenance  Overhead  
  
  
  
  
  
  
Total
Maintenance
  
  
  
  
  
  
Operating
Overhead
     
  
  
     
General  Plant  Overhead:  
  
  
Mechanical  Department  Services:  
  
Employee  Relations  Department:  
  
Business  Services:  
  
  
  
  
Total
Operating
  
  
Overhead
  
  
  Property Taxes and Insurance
  
  
  
  
  Property  Taxes  and  Insurance:  
  
  
  
  Other Annual Expenses   
  
  
  
  
  
  
Rental  Fees  (Office  and  Laboratory  
  
  
Space):  
  
Licensing  Fees:  
  
  
Miscellaneous:  
  
  
  
  
  
Total
Other Annual
Expenses  
  
  Total Fixed Costs
  
  
  

  
	
        

	
  

  
  

  

	
  

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  
  
  
  

  $364,000    
  $54,600    
  $21,840    
  $-        
  $-        

  
  
  

  
  
  
  

  
  
  
  

$440,440
  $1,522,744    
  $380,686    
  $1,522,744    
  $76,137    
$3,502,310

  $164,864    
  $55,729    
  $137,000    
  $171,830    
$529,423

  $676,775    

  
  
  
  $-        
  $-        
  $-        
  

$-

  

$5,148,948
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11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
	
  
Investment Summary
      Module Costs
  
Bare
Fabricated Equipment   
Process Machinery
   Spares
   Storage
  
   Other Equipment
  
   Catalysts
   Computers, Software, Etc.  
  
     Total Bare Module Costs:   

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  

  
  
  
  
  
  
   Cost
  
  
  
of Site Preparations:  
   Cost of Service Facilities:
  
  
   Allocated Costs for utility plants and   related facilities:
  
  
   Direct
  
  
  
  
Permanent Investment

  
  
  
  
  
  
  
  

  
  
  
  

  
     
      Depreciable Capital
Total

  
  
  
  
  
  
  
  

  
  
  
  
  

  
  
  
  

  

  
  
  
  
  
  
  
  
  
  

  

  

  

  
      Permanent Investment  
Direct

  
  
  
  
  
  
   Cost
  
  
  
of Contingencies & Contractor
Fees
  
     
  
  
     Total Depreciable Capital   
  
  
      Permanent Investment   
Total
  
  
  
  
  
  
  
  	
  
	
  

  
  
  
  
  
  
Cost
of Land:
  
Cost of Royalties:
  
Cost of Plant Start-Up:
  
  
   - Unadjusted
  
Total
Permanent Investment
Site Factor
  
  
Total Permanent Investment

	
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  

  
  $24,518,054       
  $8,990,177       
  $65,000       
  $265,517       
  $-           
  $-           
  $-           
  
  
  
  
  $-           
  $-           
  $-           
  

  

  
  

  
  
  

$33,838,748

$33,838,748
  
  
  $-           
  
  
  
  
  
  $-           
  $-           
  $-           
  
  

$33,838,748

  $33,838,748    
1.10  
$37,222,623
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11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
	
  

Profitability  Measures  

    

  The
   Internal Rate of Return
     
  
(IRR) for this project
is
   Net Present Value
     (NPV) of this project
   in 2013 is
The
     
     
  ROI
   Analysis (Third Production
     
Year)
  
  
  
  
  
  
  
	
     

	
  

  
     
Annual
Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI

630,034,343
(351,580,117)
(2,977,810)
(12,396,439)
263,079,977
190.87%

	
  

  
  
  
  
  
  
  
  
  

137,831,826

    

    

    

  

  

Negative  IRR  

  

  

  

  

  
  

  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  $1,168,887,900    

  

  

	
  
11.4.2 Profitability A nalysis for 36% E fficiency for Downstream
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11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
General Information
Process  Title:  
  
Product:  
  
Plant  Site  Location:  
  
Site  Factor:  
  
Operating  Hours  per  Year:  
  
Operating  Days  Per  Year:  
  
Operating  Factor:  
  
  
  
  Product Information
  

Manufacturing of Insect Cell Culture VLP-based Influenza Vaccine
API for Influenza Vaccine
  
  
Research Triangle Park, NC   
  
  
  
1.10
  
  
  
  
4383
  
  
  
  
183
  
  
  
  
0.5003
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  

  
  
  
  
  
  
  

This  Process  will  Yield  
  
  
  
  
  
  
  Chronology
Year
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
  

	
  

  
  
  
  Price  
  
Action
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  

27,310
655,441
119,700,000
$8.12

  

  
  
  
doses  of  
API  for  Influenza  Vaccine  per  hour  
doses  of  API  for  Influenza  Vaccine  per  day  
doses  of  API  for  Influenza  Vaccine  per  year  
  
/doses
  

Distribution of
Permanent Investment
100%  
0%  
0%  
0%  
  
  
  
  
  
  
  

  

	
  

  
  
  

  
  
Production
Capacity
81.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
  

Depreciation
7  year  MACRS  
14.29%  
24.49%  
17.49%  
12.49%  
8.93%  
8.92%  
8.93%  
4.46%  
  
  
  

  
  
  
  
  
  
  

Product Price

  
  
  
  
  
  
  
  
  
  
  

  $8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
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11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
	
  
E quipment Costs
E quipment Description

Bare Module Cost

Test Tubes
1 Shaker Flasks (250 mL)
6 Shaker Flasks (2 L)
6 Shaker Flasks (3 L)
4 Disposable Bioreactors (50 L)
4 Disposable Bioreactors (500 L)
4 Disposable Bioreactors (2000 L)
4 Reactor Totes (50 L)
4 Reactor Totes (500 L)
4 Reactor Totes (2000 L)
4 Depth Filtration Units
8 Sterile Filtration Units
8 Chromatography Columns
4 Disk-Stack Centrifuges
4 Viral Inactivation Tanks
16 Holding Tanks
8 Resin Tanks
4 Tangential Flow Filtration Units
27 Pumps
9 Heat Exchangers
4 Incubators
8 Storage Tanks
8 Media Storage Tanks (200 L)
8 Media Storage Tanks (500 L)
Biosafety Cabinet
18 Bag Holders
Filter Integrity Tester
Bioinactivation System
Tube Fusers
Tube Sealers

	
  
	
  

Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Storage
Storage
Storage
Storage
Storage
Storage
Spares
Spares
Spares
Spares

	
  

$255
$596
$5,106
$1,969
$3,552,956
$3,889,051
$15,482,621
$4,400
$4,400
$4,400
$39,600
$79,200
$1,460,800
$3,248,000
$74,880
$111,954
$55,977
$1,856,000
$413,424
$3,229,942
$25,752
$55,977
$55,977
$97,011
$11,000
$19,800
$4,500
$35,000
$15,300
$10,200
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11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
Variable Cost Summary
Variable Costs at 100% Capacity:
  
  
  
   General
  
  
  
  
  
Expenses
  
  
  
  
     
  
Selling  /  Transfer  
  
  
  
Expenses:  
     
  
  
Direct  Research:  
     
  
  
Allocated  Research:  
     
  
Administrative  Expense:     
     
  
  
Management  Incentive  Compensation:  
     
  
   Total
  
  
  
  
General Expenses   
  
  
  
  
     
  
  
  
per  doses  of  API  for  Influenza  
  
Raw Materials
$0.006396   Vaccine  
  
  
  
  
  
per  doses  of  API  for  Influenza  
  
Byproducts
$0.000000   Vaccine  
  
  
  
  
  
  
per  doses  of  API  for  Influenza  
  
Utilities
$0.007410   Vaccine  
  
  
     Total Variable Costs
  
  
  
  
  

  

  

  

  
  
  
  
  $29,168,257    
  $97,227,522    
  $374,325,960    
  $19,445,504    
  $12,153,440    
  
  
  

  $532,320,683    
$765,658    
$0    

  
$886,971    
  

$533,973,312
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11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
Fixed Cost Summary
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

	
     
	
  

  
  Operations

  
  
  
  
  
  
  
  
  
  
  Direct  Wages  and  Benefits  
  
  
  
Direct  Salaries  and  
  
Benefits  
  
  
Operating  Supplies  and  Services  
  
Technical  Assistance  to  Manufacturing  
  
Control  Laboratory  
  
  
  
  
  
  
Total
Operations
  
  
  
  
  
  
Maintenance
  
  
Wages  and  Benefits  
  
  
Salaries  and  Benefits  
  
  
Materials  and  Services  
  
  
Maintenance  Overhead  
  
  
  
  
  
  
Total
Maintenance
  
  
  
  
  
  
Operating
Overhead
     
  
  
     
General  Plant  Overhead:  
  
  
Mechanical  Department  Services:  
  
Employee  Relations  Department:  
  
Business  Services:  
  
  
  
  
Total
Operating
  
  
Overhead
  
  
  
  
  
  
Property
Taxes and Insurance
  
  
  
  
Property  Taxes  and  Insurance:  
  
  
  
  
Other
Annual Expenses   
  
  
  
  
Rental  Fees  (Office  and  Laboratory  
  
  
Space):  
  
Licensing  Fees:  
  
  
Miscellaneous:  
  
  
  
  
  
Total
Other Annual
Expenses  
  
  Total Fixed Costs
  
  
  
  

	
  

  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  
  
  
  

  $364,000    
  $54,600    
  $21,840    
  $-        
  $-        

  
  
  

  
  
  
  

  
  
  
  
  
  
  

$440,440
  $1,522,744    
  $380,686    
  $1,522,744    
  $76,137    
$3,502,310

  $164,864    
  $55,729    
  $137,000    
  $171,830    
$529,423

  $676,775    

  $-        
  $-        
  $-        

  

$-

  

$5,148,948
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11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
	
  
Investment Summary
      Module Costs
  
Bare
Fabricated Equipment   
Process Machinery
   Spares
   Storage
  
   Other Equipment
  
   Catalysts
   Computers, Software, Etc.  
  
     Total Bare Module Costs:   

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  

  
  
  
  
  
  
   Cost
  
  
  
of Site Preparations:  
   Cost of Service Facilities:
  
  
   Allocated Costs for utility plants and   related facilities:
  
  
   Direct
  
  
  
  
Permanent Investment

  
  
  
  
  
  
  
  

  
  
  
  

  
     
      Depreciable Capital
Total

  
  
  
  
  
  
  
  

  
  
  
  
  

  
  
  
  

  

  
  
  
  
  
  
  
  
  
  

  

  

  

  
      Permanent Investment  
Direct

  
  
  
  
  
  
   Cost
  
  
  
of Contingencies & Contractor
Fees
  
     
  
  
     Total Depreciable Capital   
  
  
      Permanent Investment   
Total
  
  
  
  
  
  
  
  	
  
	
  

  
  
  
  
  
  
Cost
of Land:
  
Cost of Royalties:
  
Cost of Plant Start-Up:
  
  
   - Unadjusted
  
Total
Permanent Investment
Site Factor
  
  
Total Permanent Investment

	
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  

  
  $24,518,054       
  $8,990,177       
  $65,000       
  $265,517       
  $-           
  $-           
  $-           
  
  
  
  
  $-           
  $-           
  $-           
  

  

  
  

  
  
  

$33,838,748

$33,838,748
  
  
  $-           
  
  
  
  
  
  $-           
  $-           
  $-           
  
  

$33,838,748

  $33,838,748    
1.10  
$37,222,623
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11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
	
  

Profitability  Measures  

    

  The
   Internal Rate of Return
     
  
(IRR) for this project
is
   Net Present Value
     (NPV) of this project
   in 2013 is
The
     
     
  ROI
   Analysis (Third Production
     
Year)
  
  
  
  
  
  
  
	
     

	
  

  
     
Annual
Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI

875,047,698
(485,724,929)
(2,977,810)
(17,385,523)
368,959,436
208.73%

	
  

  
  
  
  
  
  
  
  
  

176,765,455

    

    

    

  

  

Negative  IRR  

  

  

  

  

  
  

  
  
  

  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  

  $1,649,826,200    

  

  

	
  
11.4.3 Profitability A nalysis for 50% E fficiency for Downstream
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11.4.4	
   P rofitability A nalysis for Pandemic	
  Case
	
  
General  Information  
Process  Title:  
Product:  
Plant  Site  Location:  
Site  Factor:  
Operating  Hours  per  Year:  
Operating  Days  Per  Year:  
Operating  Factor:  

  
  
  
  
  
  
  
  
  
  Product  Information  
  

This  Process  will  Yield  

    

  

  
  
  
  
  
  Chronology  

  
  
  
  Price  

  

      

      

  

  

  

Year  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  

	
  

Action  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
Production  
  

    

    

    

Manufacturing  of  Insect  Cell  Culture  VLP-based  Influenza  Vaccine  
API  for  Influenza  Vaccine  
  
  
Research  Triangle  Park,  NC  
  
  
1.10  
  
  
  
4383  
  
  
  
183  
  
  
  
0.5003  
  
  
  
  
  
  
  
      
      
      
      
78,653  
1,887,671  
344,736,000  

  doses  of  API  for  Influenza  Vaccine  per  hour  
  
  
doses  of  API  for  Influenza  Vaccine  per  day  
doses  of  API  for  Influenza  Vaccine  per  year  

$5.44       /doses  
      
Distribution  of  
Permanent  Investment  
100%  
0%  
0%  
0%  

	
  

  
  
  
  
  
  
  

  
  
      

  
  
      
Production    
Capacity  
81.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
90.0%  
  

Depreciation  
7  year  MACRS  
14.29%  
24.49%  
17.49%  
12.49%  
8.93%  
8.92%  
8.93%  
4.46%  
  
  
  

    

    

    

  
  
  
  
  
  
  
      

  
  
  
  
  
  
  
  
      

  
  
  
  
  
  
  
  
      

  
  
  
  
  
  
      

  
  
  
  
  
  
      

  
  
  
  
  
  
      

Product  Price  
  
  
  
  
  
  
  
  
  
  
  
  

  $8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
$8.12    
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11.4.4 Profitability A nalysis for Pandemic C ase
	
  
E quipment Costs
E quipment Description

Bare Module Cost

Test Tubes
1 Shaker Flasks (250 mL)
6 Shaker Flasks (2 L)
6 Shaker Flasks (3 L)
4 Disposable Bioreactors (50 L)
4 Disposable Bioreactors (500 L)
4 Disposable Bioreactors (2000 L)
4 Reactor Totes (50 L)
4 Reactor Totes (500 L)
4 Reactor Totes (2000 L)
4 Depth Filtration Units
8 Sterile Filtration Units
8 Chromatography Columns
4 Disk-Stack Centrifuges
4 Viral Inactivation Tanks
16 Holding Tanks
8 Resin Tanks
4 Tangential Flow Filtration Units
27 Pumps
9 Heat Exchangers
4 Incubators
8 Storage Tanks
8 Media Storage Tanks (200 L)
8 Media Storage Tanks (500 L)
Biosafety Cabinet
18 Bag Holders
Filter Integrity Tester
Bioinactivation System
Tube Fusers
Tube Sealers
	
  

Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Fabricated Equipment
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Storage
Storage
Storage
Storage
Storage
Storage
Spares
Spares
Spares
Spares
	
  

$255
$596
$5,106
$1,969
$3,552,956
$3,889,051
$15,482,621
$4,400
$4,400
$4,400
$39,600
$79,200
$1,460,800
$3,248,000
$74,880
$111,954
$55,977
$1,856,000
$413,424
$3,229,942
$25,752
$55,977
$55,977
$97,011
$11,000
$19,800
$4,500
$35,000
$15,300
$10,200
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11.4.4	
   P rofitability A nalysis for Pandemic	
  Case
	
  
	
  
	
  
Variable  Cost  Summary  
    
    
    
    
Variable  Costs  at  100%  Capacity:  
  
  
  
   General  Expenses  
  
  
  
  
  
  
  
  
  
     
  
Selling  /  Transfer  
  
  
  
Expenses:  
     
  
  
Direct  Research:  
     
  
  
Allocated  Research:  
     
  
  
Administrative  Expense:  
     
  
  
Management  Incentive  Compensation:  
     
  
   Total  General  Expenses  
  
  
  
  
  
  
  
  
  
     
  
  
  
per  doses  of  API  for  Influenza  
  
Raw  Materials  
$0.002221   Vaccine  
  
     
  
  
  
per  doses  of  API  for  Influenza  
  
Byproducts  
$0.000000   Vaccine  
  
  
     
  
  
  
per  doses  of  API  for  Influenza  
  
Utilities  
$0.002573   Vaccine  
  
  
     Total  Variable  Costs  
  
  
  
  
  

  

  

  

    
  
  
  
  
  $56,260,915    
  $187,536,384    
  $722,015,078    
  $37,507,277    
  $23,442,048    
  
  
  

  $1,026,761,702    
$765,658    
$0    

  
$886,971    
  

  $1,028,414,331    
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11.4.4	
   P rofitability A nalysis for Pandemic	
  Case
Fixed  Cost  Summary  
  
  
  
  
  

    

    

    

  
  
Operations  

  
  
  
  
  
  
  
  
  
  
  
  
  
Direct  Wages  and  Benefits  
  
Direct  Salaries  and  
  
Benefits  
  
  
Operating  Supplies  and  Services  
  
Technical  Assistance  to  Manufacturing  
  
Control  Laboratory  
  
  
  
  
  
  
Total  Operations  
  
  
  
  
  
  
Maintenance  
  
  
Wages  and  Benefits  
  
  
Salaries  and  Benefits  
  
  
Materials  and  Services  
  
  
Maintenance  Overhead  
  
  
  
  
  
  
Total  Maintenance  
  
  
  
  
  
  
Operating  Overhead  
     
  
  
     
General  Plant  Overhead:  
  
  
Mechanical  Department  Services:  
  
Employee  Relations  Department:  
  
Business  Services:  
  
  
  
  
  
  
Total  Operating  Overhead  
  
  
  
  
  
  
Property  Taxes  and  Insurance  
  
  
  
  
  
Property  Taxes  and  Insurance:  
  
  
  
  
  
Other  Annual  Expenses  
  
  
  
  
Rental  Fees  (Office  and  Laboratory  
  
  
Space):  
  
Licensing  Fees:  
  
  
Miscellaneous:  
  
  
  
  
  
  
Total  Other  Annual  Expenses  
  
  Total  Fixed  Costs  
  
  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   	
  

	
  

  

	
  

  

    

    

  
  
  
  
  

  
  
  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  $364,000    
  $54,600    
  $21,840    
  $-        
  $-        

  
  
  

  
  
  
  

  $440,440    
  $1,522,744    
  $380,686    
  $1,522,744    
  $76,137    
  $3,502,310    

  $164,864    
  $55,729    
  $137,000    
  $171,830    

  

  $529,423    

  
  
  

  $676,775    

  
  
  

  
  

  $-        
  $-        
  $-        
  $-        
  $5,148,948    
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11.4.4	
   P rofitability A nalysis for Pandemic	
  Case
	
  
Investment  Summary  

    

    

    

    

    

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  
  
  
  
  
  
  
  
  

  
  

  
  
  
  
  
  
   Cost  of  Site  Preparations:  
  
  
  
  
   Cost  of  Service  Facilities:  
  
  
   Allocated  Costs  for  utility  plants  and  related  facilities:  
  
  
  
   Direct  Permanent  Investment  
  
  
  
  

  
  
  
  
  
  
  
  

  
  
  
  

  
  
  
  
  
  
  
  

  
  
  
  
  

  
  
  
  

  

  
  
  
  
  
  
  
  
  
  

  

  

  

     
  
Bare  Module  Costs  
  
Fabricated  Equipment  
   Process  Machinery  
   Spares  
   Storage  
  
   Other  Equipment  
  
   Catalysts  
   Computers,  Software,  Etc.     
  
     Total  Bare  Module  Costs:     
  
     
  
Direct  Permanent  Investment  

  
     
     
Total  Depreciable  Capital  

  
  
  
  
  
  
   Cost  of  Contingencies  &  Contractor  Fees  
  
  
  
  
     
  
  
     Total  Depreciable  Capital     
  
  
     
  
Total  Permanent  Investment  
  
  
  
  
  
  
  
   	
  

  
  
  
  
  
  
Cost  of  Land:  
  
Cost  of  Royalties:  
  
Cost  of  Plant  Start-Up:  
  
  
  
  
Total  Permanent  Investment  -  Unadjusted  
Site  Factor  
  
  
Total  Permanent  Investment  

	
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  

  

  
  

  
  
  

    
  
  $24,518,054       
  $8,990,177       
  $65,000       
  $265,517       
  $-           
  $-           
  $-           
  
  

  $33,838,748    

  
  
  $-           
  $-           
  $-           
  
  

  $33,838,748    

  
  
  
  $-           
  
  
  

  $33,838,748    

  
  
  $-           
  $-           
  $-           
  
  

  $33,838,748    
1.10  
  $37,222,623    
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11.4.4	
   P rofitability A nalysis for Pandemic	
  Case
	
  
Profitability  Measures  

    

    

    

    

  

  

  

  

	
  
Negative  IRR  

  

  

  
  

  
  
  

  
  
  
  
  
  
  374,328,533       
  
  

  
  
  
  
  
  
  
  
  

  The  Internal  Rate  of  Return  (IRR)  for  this  project  is  
  
     
  
     
  
     
The  Net  Present  Value  (NPV)  of  this  project  in  2013  is  
     
     
  ROI  Analysis  (Third  Production  Year)  
  
     

  
  

  
  
  
  
  
  
  
   	
  

  
  
  
  
  
  

  
     
Annual  Sales  
  
Annual  Costs  
  
Depreciation  
  
Income  Tax  
  
Net  Earnings  
  
Total  Capital  Investment  
ROI  
  

  2,520,137,370    
  (930,721,846)  
  (2,977,810)  
  (71,389,697)  
  1,515,048,017    
404.74%  

	
  

  

	
  
	
  
	
  
  
	
  
	
  
	
  
	
  
	
  
	
  
  
	
  

  $7,038,423,300    
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   P rofitability A nalysis for Pandemic	
  Case
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11.5 Sensitivity A nalysis
11.5.1 E fficacy and Dosing

Presently, live attenuated influenza virus vaccines are considered to be both safe
and effective in preventing acute illness and serious complications (Nichol). The
effectiveness of the vaccine changes seasonally as the virus evolves, so the WHO must
identify strains that will be a threat each influenza season for vaccine manufacturers to
target. This annual process requires that the vaccine be reformulated. Influenza vaccines
were first manufactured in 1943, and use among high-risk patients has been
recommended since 1963. At that point in history, organizations began to collect data to
determine vaccine efficacy.
A common method for measuring the efficacy of a vaccine in preventing the virus
from infecting the patient is Vaccine Effectiveness (VE). The Center for Disease Control
&'& RIWKH8QLWHG6WDWHVGHILQHV9(DVWKH³RYHUDOOHIIHFWLYHQHVVRIVHDVRQDO
[influenza] vaccine for preventing laboratory-confirmed [influenza] virus infection
³,QIOXHQ]D´ ´
The CDC reported the 2012-2013 VE to be 62% on January 11, 2013
³,QIOXHQ]D«´). This was reported with a 95% confidence interval of 51% to 71% for the
VE. A 95% confidence interval sets the range of VE for which there is a 95% chance of
the VE being between for a larger data sample. On February 21, 2013, the CDC reported
the VE for the influenza vaccine to be 56% with a 95% confidence interval of 47% to
63% EDVHGRQDODUJHUGDWDVDPSOH ³,QIOXHQ]D«´). Note that this data was collected
based solely on 2697 United States SDWLHQWVRUYDU\LQJDJHV ³,QIOXHQ]D´ . This level of
efficacy for the seasonal influenza vaccine is considered low compared to that of
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vaccines for Rubella and tetanus, which have efficacies larger than 95% and 90%,
respectively (Palache).

The magnitude of these values seems to be consistent over time. Data collected by
the NIH shows that for 2011, aggregated vaccine efficacy for patients 18 to 65 was 59%
(Hombach). A similar study conducted in 2003 by the NIH revealed a vaccine efficacy of
68% with a 95% confidence interval of 49% to 79% for the 2003 seasonal influenza
vaccine for healthy patients age 18 to 65 (Hombach). Despite the slight change the
seasonal influenza vaccine, the 95% interval for the vaccine efficacy is consistent year to
year.
There is a variance in efficacy between the Type A and Type B influenza strains.
The influenza virus is classified into three types: A, B, and C. Types A and B are
responsible for epidemic respiratory illness, which is why they are primarily included in
the seasonal influenza vaccine. A recent study shows that the human body generally
elicits a larger and more effective response to Type B vaccinations. A study released
February 18, 2003 proved that the influenza vaccine for Type B had a VE of 78% in
European patients (Golec). The vaccine administered was trivalent, and the VE for both
Type A strains were only 62% and 42% for the same patients (Golec). This was
consistent with data collected by the CDC for United States Patients. The data collected
by the CDC showed a vaccine efficacy of 70% for Type B and 55% for Type A
³,QIOXHQ]D«´). Both studies showed an overall VE of 62% for the 2013 influenza
vaccine (Golec).
For the influenza vaccine, VE tends to vary depending on the age of the patient
group. Data for childhood vaccinations for the influenza virus will regularly record a 90%
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vaccine efficacy in the United States (Hombach). Global data disagrees; one study
conducted on 247517 patients aged 18 years and younger showed that the vaccine

prevented 61% of clinical cases of influenza (Hickling). This is excluding data from the
Russia. When data from Russia was included, the vaccine effectively prevented 36% of
clinical cases of influenza (Hickling). The discrepancy is most likely due to harsher
winter conditions as well as a lower standard of living in the region for which the data
was excluded. The data for children shows a large discrepancy from data for the age 65
and older group. The data collected by the CDC for the patients age 65 and up group
showed a VE of 9%, far below the 51% to 71% interval presented for the 2012-2013
influenza vaccine for all age groups aggregated ³,QIOXHQ]D«´ 
Current egg-based vaccine production methods for preventing influenza consist
primarily of monomeric hemagglutinin (HA) antigen. There has been no industry or
regulatory standard for neuraminidase (NA) antigen in the vaccines. Live viruses contain
both HA and NA antigens arranged in a particular pattern giving them biological activity.
This may explains why vaccines containing monomeric units of mostly the HA antigen
does not elicit a broad level immune response necessary to fully protect the larger
population from the influenza virus (Palkonyay).
Virus-like Particles (VLPs) are a noninfectious and non-replicating method of
presenting the proper influenza antigens to B and T cells to elicit an immune response.
Since VLPs are self-assembling, they correctly fold and display the trimeric HA spikes of
DOLYHLQIOXHQ]DYLUXV ³6HDVRQDO«´). These self-assembling particles are multivalent
because they display multiple antigens as well, which innately gives them a larger
immunogenicity than monomeric antigens present in egg-based influenza vaccines.
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Joel R Haynes, Senior Director of Vaccine Development at TakedaTM, believes
that producing VLPs in insect cells will lead to enhanced immunogenicity. This is due to
the insect-cell glycosylation patterns and the possibility that the VLPs produced in insect
cells also contain a finite quantity of insect cell-derived lipid raft-associated proteins.
Patients immune systems will recognize these as foreign bodies and potentially enhance
the immunogenicity compared to the live or attenuated virus vaccines (Bodimeade).
Recent studies have shown that VLPs have a higher immunogenicity compared to
live or attenuated viruses, as well as recombinant hemagglutinin. One study conducted by
Rick A. Bright et al. showed that VLPs produced in insect cells for hemagglutinin (HA),
neuraminidase (NA), and influenza core matrix (M1) proteins all elicited an immune
response that protected mice from a deadly dose of the H5N1 strain of the avian influenza
virus. Both intramuscular (IM) injection and intranasal (IN) injection elicited the proper
response to protect the mice from the deadly dose of H5N1. Bright et al. used a
hemagglutinin inhibition (HAI) assay to determine the functionality of the antigens
produced in the subject mice. An HAI titer greater than 40 is usually considered to be
50% effective in preventing the seasonal influenza virus strain of interest. Both IM and
IN injected VLPs in mice had measured HAI titers greater than 40; similar results were
obtained in ferrets (Wood). VLP vaccines present a promising and viable future in
protecting against the avian influenza strain based on the studies conducted by Bright et
al. (Bright 2007)
The WHO has collected data from many clinical trials over the past 20 years to
KHOSGHWHUPLQHDQHIIHFWLYHGRVLQJOHYHOIRUWKHLQIOXHQ]DYLUXV³«LWLVJHQHUDOO\
accepted that one dose of vaccine containing 15ȝJRIKHPDJJOXWLQLQSHUVWUDLQSHUGRVH
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will stimulate hemagglutination-inibition antibody levels consistent with immunity in
most primed individuals. (Suresh ´7KHVWDQGDUGGRVHDGPLQLVWHUHGWRSDWLHQWVDJH
years to 65 years old is 0.5mL (Angelmar), therefore a trivalent vaccine must contain

45ȝJRI+$SURWHLQSHUP/RU90ȝJP/<RXQJFKLOGUHQDQGDGXOWVRYHU\HDUVRI
age must receive a more concentrated dose in order to overcome lower efficacy of the
vaccine of such patients. Typically, children 6 months to 35 months of age will receive
an influenza vaccine dose of 0.25mL (Angelmar). Patients 65 years and older qualify for
6DQRIL3DVWHXU¶V)OX]RQH+LJK-Dose®, which contains four times the amount of antigen
as other vaccines (Angelmar).
Due to the larger immune response typically affiliated with VLPs, our group has
chosen a dosage of 5 micrograms of each strain of influenza antigen per dose. For our
trivalent seasonal influenza vaccine, the total dose will be 15 micrograms. The
formulation group will concentrate the protein so that the suspension concentration is 5
micrograms of each of the three identified vaccine strain antigens in 0.5mL. Since VLPs
have been shown to elicit up to 5-fold larger immune response compared to other
vaccination methods (Kushnir), a 3-fold reduction in dose compared to current
vaccination dosing should elicit a broad immune response capable of protecting the
patient from influenza transmission. Our clinical trials group will confirm the
immunogenicity of a dose on an annual basis and assess the need to increase or decrease
the dose accordingly.
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11.5.2 G ross Revenue
A sensitivity analysis was conducted on production capability to account for

unpredictable events, market trends, market demand, production level, and other factors
capable of affecting the number of doses produced annually. Unpredictable events can be
beneficial or detrimental to gross revenue.
The number of doses produced annually can increase if the amount of protein
required to elicit an immune response decreases. Due to antigenic drift, the strain of
influenza targeted by an influenza vaccine changes each season. Some strains are more
immunogenic to the general population, in which case, it may be plausible for a vaccine
to contain less protein. On the contrary, some strains may elicit a smaller than usual
immune response, in which case, the protein per dose must be increased. This process is
uncommon with the influenza vaccine, and generally the only variable that affects dosing
is addition of adjuvants in order to increase the immunogenicity of the VLP influenza
vaccine.
The number of batches produced annually will also affect the gross revenue of the
company. If the company is able to increase the number of batches produced in a 6 month
time period, protein production and therefore the number of doses produced will increase.
If a batch becomes contaminated, protein is lost; this decreases the number of doses
provided to the market, decreasing gross revenue. If a batch is lost due to contamination,
production may need to be extended to fulfill market share. Our company expects to
produce 6 batches of each strain, allowing us to produce approximately 86,000,000 doses
of trivalent seasonal influenza vaccine. A Gantt chart is included in section 10.1 to show
the time period needed to produce 6 batches.
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Downstream processing of the VLPs will heavily affect the number of doses sent
to market. If the equipment is not running properly, the efficiency of the process
decreases, and protein is removed with adventitious materials. Downstream processing
equipment must be properly maintained, calibrated, and tested regularly to ensure
maximum unit efficiency. The sensitivity of the gross revenue generated by this process
is primarily a function of the number of doses produced annually, which is highly
dependent upon the downstream process efficiency. Thus, efficiency of VLP retention
throughout the purification process is the variable having the greatest effect on gross
revenue.	
  
If a pandemic occurs, the government may approve production of a monovalent
influenza vaccine. The WHO is responsible for determining the strain of relevance for
each year. Our production facility has 4 operating lines, and, typically, three are used for
production of a seasonal trivalent vaccine. All 4 lines can be converted to pandemic
production lines for production of monovalent vaccines when the WHO declares a
pandemic. During a pandemic our facility is capable of accommodating up to four-fold
greater vaccine production than the traditional annual trivalent VLP vaccine. Our plant
has a greater capacity for transfer to pandemic production mode compared to traditional
egg-based plants, since recombinant technology including BEVS produces a much
smaller lag time associated with growth and upstream production of the virus than the lag
time associated with egg-based production. This change over can occur at the beginning
of the next batch cycle, contingent upon R&D providing baculovirus to properly infect 4
production lines with the single pandemic strain identified by the WHO. For a pandemic
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situation, it is expected that the selling price of a vaccine will match the buying price of
the government during non-pandemic conditions.
Our design process is capable of maximally producing 0.1995 kg of VLP, given a
95% efficiency of the upstream process. In industry, the lowest recovery of VLP is
typically occurs downstream in the purification process. For the purposes of our process,
we have assumed 95% recovery from fermentation in the upstream process and 36%
recovery from the purification process downstream. Producing 6 batches of each strain
annually, we are able to produce 86,184,000 doses of trivalent influenza vaccine
containing 5 micrograms of each strain. Of the vaccines produced, 77.8% will be sold to
the private sector at $8.50 (USD) per dose. The remaining 22.2% of the doses will be
sold to government organizations at $6.80 (USD) per dose. The weighted average price
per dose sold is $8.12 (USD). These calculations are based off of data collected by the
Center for Disease Control (CDC) in 2007 and 2008 (HIDA Market Brief). The
profitability analysis for this scenario is found in section 11.4. The calculated Net Present
Value is found; to account for potential inefficiency on the downstream side, we
conducted a sensitivity analysis for a range of 20% to 50% efficiency on the downstream
side. This gives a production range of 47,880,000 to 119,700,000	
  doses of trivalent 5microgram influenza vaccine. The net earnings for 86,184,000 is predicted to be
$263,079,977 (USD). The spread sheets demonstrating the sensitivity analysis are
contained in $SSHQGL[%6HHWKHSDUWHQWLWOHG³&DVK)ORZ´LQVHFWLRQIRUPRUH
information.
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F igure 11.1. This shows the percent of doses supplied to private and public sector. It was used to calculate the
weighted value of a dose of influenza vaccine based on the markets to which we supply. We have chosen to supply
77.8% of our doses to the private sector and 22.2% of doses to the government sector. (HIDA Market Brief)

During a pandemic, the facility will run 4 lines in parallel, each producing 6
batches in total. Each line will produce the same strain, allowing a maximum production
of 334,736,000 doses of a monovalent 5-microgram influenza vaccine. During pandemic
production, it is more likely that the doses will be sold at a government sector price, and
even more likely at a reduced government sector price. Our group estimates that the
purchasing price per dose will decrease 20% from $6.80 (USD) to $5.44 (USD) in the
government sector during a pandemic. This would generate $1,515,048,017 (USD) in net
earnings. A more dynamic range of purchasing prices at which the vaccines may be sold
can be found in Appendix B section 11.4.
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12.0 Conclusions and Recommendations

This proposal has explored in depth the feasibility of starting up a flexible facility
to produce an influenza vaccine from SF2 insect cells. This vaccine company aims to
remain a large competitor in the influenza vaccine industry for the United States and
European markets by supplying vaccines to fulfill regular demand, as well as having the
capability of scaling up during a pandemic. With the use of a non-egg based platform,
this new vaccine avoids potential limitations from egg allergies or shortages. In addition,
the production of VLPs for use in the vaccine increases the safety and consistency of the
product. In regards to the manufacturing facility, the selection of single-use disposable
equipment enables increased efficiency of product turnover and flexibility to produce a
separate product during the off-season for influenza.
By analyzing the current influenza vaccine market, it was established that the VLP
can be produced at approximately $0.01 per dose, which will be sold for an average of
$8.12 per dose. It should be noted that this cost does not include formulation and
packaging, only manufacturing of the VLP. Based on the economics of facility and
production costs in conjunction with projected revenues, it was found that the project
would be feasible with a return on investment (ROI) of 190.87% (See Section 11.4). As
a result, we recommend this project as a profitable endeavor for the company due to its
safety and efficacy.
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A ppendix A ± C alculations
G rowth Rate
The doubling time of an insect cell in batch suspension culture is given by
െ߬ ൌ

ଶ
ఓೞ

(A.1)

ZKHUHȝs is the growth rate of the SF2 cells during the exponential growth phase (Figure
A.1), defined as the increase in cell mass per unit cell mass per unit time. In our
following calculations, we used a specific growth rate of 0.034hr-1 as a reasonable
estimate of the average growth rate of the SF2 cells. This number was obtained from
studies stating maximal growth rates of Sf9 cells, from which SF2 cells are derived.
Experimentally, SF2 cells grow much more quickly than Sf9 cells, suggesting that our
estimate, while on the upper end of Sf9 growth rates, is conservative when considering
SF2 cells. (Cox 2009)
G rowth C urve
Figure A.1 depicts a typical growth curve for cells in suspension culture, such as
the insect-derived SF2 cell line.

F igure A .1. Cell growth curve consisting of four distinct phases, lag, log, stationary,
and death. The log of the number of cells or cell concentration(y-axis) is plotted
against linear time (x-axis). This basic model of cell growth holds true for most cell
types. From Börje Lindström, LTU, Sweden
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The typical growth curve is split into four distinct phases: lag, log, stationary, and death.
The amount of time a suspension culture will remain in each phase is dependent upon the
cell line. The lag phase occurs when a high density is diluted and the cells must adapt to
the new conditions and a lowered density. This lag may have to do with soluble factors
being less concentrated than in the high density culture or an adjustment to the change in
medium composition. After readjusting to their new environment, the cells enter a
logarithmic (exponential) growth phase, characterized by equation A.1, which we assume
the cells maintain throughout our process for simplicity, a reasonable assumption at lower
cell density and in fed-batch cultures with tight pH, osmolality, and nutrient control.
After reaching a critical cell density where the medium is depleted of many nutrients or
the cells are too crowded to grow, the cells enter the stationary growth phase, where the
cell density changes very little and cells are grow slowly or senesce rather than divide.
Finally, the nutrients are fully depleted from the medium if not replenished, and the cells
begin to die at an exponential rate. We avoided the modeling of the lag, stationary, and
death phases of cell proliferation, since our process aims to maintain cells in the
exponential growth phase through specially configured medium, supplementation, and
minimizing the time spent in each bioreactor.
When infected with Baculovirus, the SF2 cells will reach the death phase soon after
induction, which is the method of VLP production and release into the medium.
Therefore, the death phase is an important factor in designing the infection and harvest
protocols.
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V L P Production & Y ield
The VLP production rate is a function of several key factors: cell line, cell
density, nutrient concentration, and the recombinant protein itself. The VLP works by

combining two essential proteins that associate at the cell surface to induce each budding
event. The HA protein will be produced predominantly, expressed under an earlier
promoter to insure its greater production levels, and the M1 matrix protein will be
produced in smaller amounts to coordinate budding. As discussed previously, these two
proteins are essential and sufficient to induce budding events in SF2 cells to create
influenza VLPs (Section 2.1)
Protein production in SF2 cells will be at minimum the production level attained
in High-Five cells, from which protein production characteristics were derived and
transferred into Sf9 cells. Thus, a conservative estimate of the specific HA production is
on the order of 15mg/109 cells. This figure takes into account the fed-batch operating
mode and escalated protein production levels of SF2 cells compared to Sf9 cells. The
enhanced high density culture cell viability and, therefore, the volumetric protein
production is dependent upon the optimization of the growth medium and feed medium
as well as the TOI and MOI. With all of these parameters optimized in the laboratory
research stage, we can expect a specific HA yield of 15mg/109 cells to be associated with
VLPs (Rausch 2012).
A key assumption in the mass balance is that cells are on average 300pg of dry
mass, which is a good assumption for metabolically normal eukaryotes. (Popescu 2008).
Furthermore, it was assumed that this dry mass accounts for about 30% of the cell
weight, certainly a liberal estimate. From these values, dry mass and wet mass were
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calculated to determine the loss of water from the process due to centrifugation for
biomass removal.

Sf2 cells consume glucose at a rate of 2.07 pmol/cell-day based on an averaged
data set from a number of metabolic measurement literature for insect cells. This value
led to an estimated 53mM glucose concentration required to sustain the cells for the 3.32
days spent in each fermentation culture. This is the same concentration as in prepared
EXCELL-405 medium from Sigma Aldrich, necessitating no additional glucose purchase
or medium formulation. Medium utilization was estimated based on recommendations
from Sigma Aldrich that medium should be changed every 3-4 days. This data implies a
maximum of five days for medium use, so medium consumption was estimated to be
about 66.4% on average.
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A ppendix- Batch T imes
Based on the SF2 cell growth profile, it was found that SF2 cells maintain a
doubling time between 18-24 hours in suspension culture during log phase growth
conditions. Both the lag and stationary phases are neglected, and for the most
conservative analysis, 24 hours is used as the doubling time.

For batch time estimations, it was desired to reach the maximum allowable cell
density for protein production in the 2000L fermenter, which is 1.40x107 cells/mL. To
minimize the scale-up time, the cells will grow at a ten-fold in each reactor. The growth
of cells in the log phase is given by
௧

ܺ ൌ ܺ ʹఛ
where X is the final cell density, X0 is the initial cell density, t is the time spent in the
UHDFWRUDQGĲd is the doubling time. Based on this, it was found that time for each scaleup is 3.32 days. Total scale-up time adds up to 19.93 days, and the initial cell density
needed in the first 100 mL shake flask is 2.80x105 cells/mL

Reactor
250 mL
2L
3L
50 L
500 L
2000 L

Filled
Volume
Size (mL)
50
250
1000
10000
100000
1000000

Cell density
(initial)
(cells/mL)
2.80E+05
5.60E+05
1.40E+06
1.40E+06
1.40E+06
1.40E+06

# cells
(initial)
1.40E+07
1.40E+08
1.40E+09
1.40E+10
1.40E+11
1.40E+12

Cell density
(final)
(cells/mL)
2.80E+06
5.60E+06
1.40E+07
1.40E+07
1.40E+07
1.40E+07

# cells
(final)
1.40E+08
1.40E+09
1.40E+10
1.40E+11
1.40E+12
1.40E+13

Time
(hrs)
79.73
79.73
79.73
79.73
79.73
79.73

Time
(days)
3.32
3.32
3.32
3.32
3.32
3.32

Total

478.36

19.93

To find the total batch time for the upstream process, time for vial thawing,
harvest time after cell growth, and time to transfer the cell broth between reactors must be
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accounted for as well. Furthermore, this table accounts for only the batch time required
for cell growth. Additional time must be provided (an additional two days) at the end of
each batch cycle for virus production. This additional step results in a single-batch time
of about 22 days. Addition of virus occurs ideally one day after beginning the 2000L
bioreactor fermentation. Upon virus addition, the medium is supplemented with 100L
additional medium, bringing the final reaction volume to 1000L and putting the culture in
fed-batch mode. This supplementation is associated with a dramatic increase in the
production of recombinant baculovirus product and sustains the culture in the protein
production phase until the harvest time (Carinhas 2010). The harvest time has similarly
been optimized by the research team to be 72 hours post-infection. This timing insures
that the maximum number of cells has engaged in protein production and that the VLPs
are not subject to proteases and other enzymes that result in degradation (Bright 2007).
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A ppendix -- Toxicology Studies

The toxicological properties of the VLPs and any process reagents must be tested
to insure adequate product safety. Laboratory studies will determine that each batch is
completely void of remaining baculovirus particles and unable to form plaques. The first
few batches produced of each HA strain VLP will be subjected to animal testing to
determine any deleterious effects of over vaccination and the specific dose response to
influenza vaccination on a number of VLP basis. A maximum dose before toxicity will
be determined in several species to prevent potential overdosing of humans in clinical
trials.

Proof of Concept Studies
Each stage of the downstream purification process will undergo rigorous
validation to insure adequate immunogenicity and utmost safety of the VLP product and
to insure that none of the unit operation deactivates the VLPs or renders them unable to
vaccinate. In a laboratory scale, VLP product from fermentation will be subjected to a
variety of chromatography buffer preparations to insure the VLPs remain intact in
processing buffers. They will also be subjected to differing concentrations of detergents
for baculovirus deactivation to reassess the effects on immunogenicity. Finally, the VLP
products will be tested in animals for efficacy and undergo the appropriate clinical trials
in order to garner FDA approval and to demonstrate the validity of VLP vaccines.
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V accine Formulation

Upon final preparation of the VLPs in freeze-dried form, the formulation team
will determine the dose requirements for the specific strains of any particular influenza
season based on vaccine studies and laboratory analysis. This team will also be
responsible to determine the minimum effective vaccine dose and the dose response
curve for a given HA variant. This data will be cross-referenced with the WHO database
each year to determine the required production capacity and operating conditions to best
fulfill the demand for influenza vaccines. The vaccine formulation, mixing of strains,
dosing, and stabilization for transport and sale are outside the scope of this manufacturing
feasibility study.
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H eat E xchanger C alculations

Ti

W ater
47

M edium
4

Tf

14

27

µ
U

0.000404

0.000404

Pa*S

ui

0.042589438 m/s

1000

1000

kg/m3

A ci

0.0002935

0.58

W/mK

Ad

k

0.58

Nt

1.029741615

Di

0.01905

L

1.5

Do

0.0254

At

0.11969468

Ai

0.08977101

Np

4.054970786

Am

0.069344305

Q

0.00075

uo

0.05

Nu

1.441086794

hi

43.87560842

Nuo

3.582558523

ho

81.80645447

Uo est

10

Q dot

72.105

TLM

14.42695041

Ad

0.499793775

1/U

0.047612917

Uo

21.00270411

Q water

0.886738088 kg/s

m/s

53.20428531

Purchase Cost:
Cb
Fp
Fm
Fl
Cp

$22,226.87
0.983253195
3.514991792
1.42
$109,082.82

m3/s

m
Assume F t = 1
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Purchase Cost C alculations:
To determine the purchase cost of the heat exchangers that will be used in this
facility, the following equations were used:

Where,

and F L (the length correction factor), was determined by extrapolating for a tube length
of 5 ft.
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A ppendix A ± L abor Force and Structure
Based on influenza vaccine production of six months, with approximately two
PRQWKVRIUHVHDUFKDQGGHYHORSPHQWIRXUPRQWKVRIODERUDUHQHHGHGIRUWKHSODQW¶V
production. For each of the three influenza strains, two operators will be needed to
operate the upstream process, and two operators will be needed to operate the
downstream process. Assuming the plant operates daily in three 8-hour shifts, with
operators working 5-days a week, approximately 51 operators will need to be hired.
Months of operation
Days of operation
Shifts per day
Total shifts
Upstream process operators per shift
Downstream process operators per shift
Total employees per day
Days/shifts worked per floor engineer
Total floor engineers

4
120
3
360
6
6
36
85.7
51

Salaries were estimated using the average salaries of manufacturing
pharmaceutical employees in Raleigh, North Carolina. The contract specialist manager is
only paid for 40 hours a month, and contractors and operators are paid an hourly wage for
160 hours a week. For the contract specialist manager, an average of 3 hours of overtime
per month are taken into account, and for contractors and operators, 12 hours of overtime
per month are taken into account.
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A ppendix A ± L abor Force and Structure
Position
Quality Assurance group
Contract Specialists
Contract Specialist
Manager
Process Engineering
group
Head engineersupervisory physical
scientist
Systems engineer
Floor engineers
Operators
Procurement group
Warehouse
engineering manager
Contractors

Number of
Positions

Salary (k)

4

53

Hourly

1

Hours per
month

32

Overtime
per month
    
    

40

Total (k)
212

3

17.09

12

82.00
210.00
275.00  
4189.68

12

37.00
234.96

    
1
3
5
51

82
70
55

    

    
    
    

    
38.46

160
    

1
5

37

    
22

160

Total (annual)

71

    
    
    

Total (4 months of
operation)

71

    

1752.58

584.19
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A ppendix A
Cost A nalysis of Single-Use Disposable Facility vs. T raditional Stainless Steel
F acility
Using a 7-year MACRS table, the cost of each facility was estimated based on
depreciable capital, profits, and taxes. Cost estimations were evaluated based on a
monoclonal antibody process in a 2000L fermentation scale from 2012 (Sinclair, Monge).
Doses
Cost per dose
Nominal Interest Rate
Income Tax Rate
Dollars to Euros Exchange Rate

100 million
$8.12
20.7%
4.5%
1.3

Single-Use Disposable Facility Cost (in millions of dollars)
Investment Cost:
Total Depreciable
Capital

Year
1

19,670,3555 Euros
Depreciation

Profit

Discounted Cash
Flow

Net Earnings

25.6

Cash Flow (PV)

Cumulative PV

0

-25.6

-21.2

-21.2

2

3.65

812

772

776

532

511

3

6.26

812

769

776

441

952

4

4.47

812

771

776

365

1320

5

3.19

812

772

776

303

1620

6

2.28

812

772

776

251

1870

7

2.28

812

773

776

208

2080

8

2.28

812

773

776

172

2250

9

812

775

775

143

2390

10

812

775

775

118

2510

Traditional Stainless Steel Facility Cost (in millions of dollars)
Investment Cost:
Total Depreciable
Capital

Year
1

24,970,532 Euros
Depreciation

Profit

32.46

Discounted Cash
Flow

Net Earnings

Cash Flow (PV)

Cumulative PV

0

-32.5

-26.9

-26.9E

2

4.64

812

771

776

532

506

3

7.95

812

768

776

441

947

4

5.68

812

770

776

365

1310

5

4.05

812

772

776

303

1620

6

2.90

812

773

776

251

1870

7

2.90

812

773

776

208

2070

8

2.90

812

773

776

172

2250

9

812

775

775

143

2390

10

812

775

775

118

2510
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A ppendix B ± Sensitivity A nalysis
20% Downstream E fficiency
C hange in Dose due to E fficacy
.
Percent
C hange in
Dose

Dose
(microgr
ams)

-20%

4

-15%

4.25

-10%

4.5

-5%

4.75

0%

5

5%

5.25

10%

5.5

15%

5.75

20%

6

Forcasted Protein
Production per Batch
(kg)
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399

Forecasted
Number of
Batches

Forecas
ted
Doses
59,850,0
00.00
56,329,4
11.76
53,200,0
00.00
50,400,0
00.00
47,880,0
00.00
45,600,0
00.00
43,527,2
72.73
41,634,7
82.61
39,900,0
00.00

6
6
6
6
6
6
6
6
6

$8.5/dose
private sector
G ross Private
Revenue
($USD)

339,150,000.00

$6.8/dose from
Gov.'t
G ross Gov.'t
Revenue
($USD)
406,980,000.0
0
383,040,000.0
0
361,760,000.0
0
342,720,000.0
0
325,584,000.0
0
310,080,000.0
0
295,985,454.5
5
283,116,521.7
4
271,320,000.0
0

G ross Private
Revenue
($USD)
271,320,000.0
0
339,150,000.0
0
406,980,000.0
0
474,810,000.0
0
542,640,000.0
0

G ross Gov.'t
Revenue
($USD)
217,056,000.0
0
271,320,000.0
0
325,584,000.0
0
379,848,000.0
0
434,112,000.0
0

508,725,000.00
478,800,000.00
452,200,000.00
428,400,000.00
406,980,000.00
387,600,000.00
369,981,818.18
353,895,652.17

	
  
C hange in Number of Batches
	
  

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

C hange in
Number of
Batches

Dose
(microgr
ams)

-2

5

-1

5

0

5

1

5

2

5

Forcasted Protein
Production per
Batch (kg)
0.0399
0.0399
0.0399
0.0399
0.0399

	
  

Forecasted
Number of
Batches
4
5
6
7
8

	
  

Forecas
ted
Doses
31,920,
000.00
39,900,
000.00
47,880,
000.00
55,860,
000.00
63,840,
000.00
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A ppendix B ± Sensitivity A nalysis
20% Downstream E fficiency
C hange in Selling Price
Percent
C hange in
Selling
Price

Dose
(micro
grams
)

Forcasted
Protein
Production per
Batch (kg)

Forecaste
d Number
of Batches

47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00
47,88
0,000.
00

0.0399
-20%

5

-15%

5

-10%

5

-5%

5

0%

5

5%

5

10%

5

15%

5

20%

5

Forec
asted
Doses

6
0.0399
6
0.0399
6
0.0399
6
0.0399
6
0.0399
6
0.0399
6
0.0399
6
0.0399
6

Private
Sector
Selling
Price

Gov.'t
Sector
Selling
Price

G ross
Private
Revenue
($USD)

G ross
Gov.'t
Revenue
($USD)

6.8

5.44

325,584,00
0.00

260,467,2
00.00

7.225

5.78

345,933,00
0.00

276,746,4
00.00

7.65

6.12

366,282,00
0.00

293,025,6
00.00

8.075

6.46

386,631,00
0.00

309,304,8
00.00

8.5

6.8

406,980,00
0.00

325,584,0
00.00

8.925

7.14

427,329,00
0.00

341,863,2
00.00

9.35

7.48

447,678,00
0.00

358,142,4
00.00

9.775

7.82

468,027,00
0.00

374,421,6
00.00

10.2

8.16

488,376,00
0.00

390,700,8
00.00

Pandemic Scale-Up
Dose
(microgra
ms)
5
5
5
5
5
5
5
5
5

	
  

Forcasted Protein
Production per Batch
(kg)
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399
0.0399

Forecasted
Number of
Batches
24
24
24
24
24
24
24
24
24

Forecaste
d Doses
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00
191,520,0
00.00

Gov.'t Sector
Selling Price

G ross Gov.'t
Revenue ($USD)

5.44

1,041,868,800.00

5.78

1,106,985,600.00

6.12

1,172,102,400.00

6.46

1,237,219,200.00

6.8

1,302,336,000.00

7.14

1,367,452,800.00

7.48

1,432,569,600.00

7.82

1,497,686,400.00

8.16

1,562,803,200.00
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A ppendix B ± Sensitivity A nalysis
36% Downstream E fficiency
C hange in Dose due to E fficacy
	
  

I.) C hange in
Dose due to
E fficacy

.

Percent
C hange in Dose

Dose
(microg
rams)

Forcasted Protein
Production per
Batch (kg)

Forecasted
Number of
Batches

-20%

4

0.07182

6

-15%

4.25

0.07182

6

-10%

4.5

0.07182

6

-5%

4.75

0.07182

6

0%

5

0.07182

6

5%

5.25

0.07182

6

10%

5.5

0.07182

6

15%

5.75

0.07182

6

20%

6

0.07182

6

	
  
	
  
	
  

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

Forecas
ted
Doses
107,730
,000.00
101,392
,941.18
95,760,
000.00
90,720,
000.00
86,184,
000.00
82,080,
000.00
78,349,
090.91
74,942,
608.70
71,820,
000.00

$8.5/dose
private sector

$6.8/dose
from Gov.'t

G ross Private
Revenue
($USD)
915,705,000.0
0
861,840,000.0
0
813,960,000.0
0
771,120,000.0
0
732,564,000.0
0
697,680,000.0
0
665,967,272.7
3
637,012,173.9
1
610,470,000.0
0

G ross Gov.'t
Revenue
($USD)
732,564,000.0
0
689,472,000.0
0
651,168,000.0
0
616,896,000.0
0
586,051,200.0
0
558,144,000.0
0
532,773,818.1
8
509,609,739.1
3
488,376,000.0
0

G ross Private
Revenue
($USD)
488,376,000.0
0
610,470,000.0
0
732,564,000.0
0
854,658,000.0
0
976,752,000.0
0

G ross Gov.'t
Revenue
($USD)
390,700,800.0
0
488,376,000.0
0
586,051,200.0
0
683,726,400.0
0
781,401,600.0
0

C hange in Number of Batches
C hange in
Number of
Batches

Dose
(microgr
ams)

Forcasted Protein
Production per
Batch (kg)

Forecasted
Number of
Batches

-2

5

0.07182

4

-1

5

0.07182

5

0

5

0.07182

6

1

5

0.07182

7

2

5

0.07182

8

Forecas
ted
Doses
57,456,
000.00
71,820,
000.00
86,184,
000.00
100,548
,000.00
114,912
,000.00
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A ppendix B ± Sensitivity A nalysis	
  
36% Downstream E fficiency
C hange in Selling Price
Percent
C hange in
Selling
Price

Dose
(micro
grams
)

Forcasted
Protein
Production per
Batch (kg)

Forecaste
d Number
of Batches

-20%

5

0.07182

6

-15%

5

0.07182

6

-10%

5

0.07182

6

-5%

5

0.07182

6

0%

5

0.07182

6

5%

5

0.07182

6

10%

5

0.07182

6

15%

5

0.07182

6

20%

5

0.07182

6

Forec
asted
Doses
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00
86,18
4,000.
00

Private
Sector
Selling
Price

Gov.'t
Sector
Selling
Price

G ross
Private
Revenue
($USD)

G ross
Gov.'t
Revenue
($USD)

6.8

5.44

586,051,20
0.00

468,840,9
60.00

7.225

5.78

622,679,40
0.00

498,143,5
20.00

7.65

6.12

659,307,60
0.00

527,446,0
80.00

8.075

6.46

695,935,80
0.00

556,748,6
40.00

8.5

6.8

732,564,00
0.00

586,051,2
00.00

8.925

7.14

769,192,20
0.00

615,353,7
60.00

9.35

7.48

805,820,40
0.00

644,656,3
20.00

9.775

7.82

842,448,60
0.00

673,958,8
80.00

10.2

8.16

879,076,80
0.00

703,261,4
40.00

Pandemic Scale-Up
Dose
(microgra
ms)

Forcasted Protein
Production per Batch
(kg)

Forecasted
Number of
Batches

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

5  

0.07182  

24  

	
  

Forecaste
d Doses
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  
344,736,0
00.00  

Gov.'t Sector
Selling Price

G ross Gov.'t
Revenue ($USD)

5.44  

1,875,363,840.00  

5.78  

1,992,574,080.00  

6.12  

2,109,784,320.00  

6.46  

2,226,994,560.00  

6.8  

2,344,204,800.00  

7.14  

2,461,415,040.00  

7.48  

2,578,625,280.00  

7.82  

2,695,835,520.00  

8.16  

2,813,045,760.00  
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A ppendix B ± Sensitivity A nalysis
50% Downstream E fficiency
C hange in Dose due to E fficacy
I.) C hange in
Dose due to
E fficacy

.

Percent
C hange in Dose

Dose
(microg
rams)

Forcasted Protein
Production per
Batch (kg)

Forecasted
Number of
Batches

-20%

4

0.09975

6

-15%

4.25

0.09975

6

-10%

4.5

0.09975

6

-5%

4.75

0.09975

6

0%

5

0.09975

6

5%

5.25

0.09975

6

10%

5.5

0.09975

6

15%

5.75

0.09975

6

20%

6

0.09975

6

	
  
	
  
	
  
	
  

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

Forecas
ted
Doses
149,625
,000.00
140,823
,529.41
133,000
,000.00
126,000
,000.00
119,700
,000.00
114,000
,000.00
108,818
,181.82
104,086
,956.52
99,750,
000.00

$8.5/dose
private sector

$6.8/dose
from Gov.'t

G ross Private
Revenue
($USD)
1,271,812,500.
00
1,197,000,000.
00
1,130,500,000.
00
1,071,000,000.
00
1,017,450,000.
00
969,000,000.0
0
924,954,545.4
5
884,739,130.4
3
847,875,000.0
0

G ross Gov.'t
Revenue
($USD)
1,017,450,000
.00
957,600,000.0
0
904,400,000.0
0
856,800,000.0
0
813,960,000.0
0
775,200,000.0
0
739,963,636.3
6
707,791,304.3
5
678,300,000.0
0

G ross Private
Revenue
($USD)
678,300,000.0
0
847,875,000.0
0
1,017,450,000.
00
1,187,025,000.
00
1,356,600,000.
00

G ross Gov.'t
Revenue
($USD)
542,640,000.0
0
678,300,000.0
0
813,960,000.0
0
949,620,000.0
0
1,085,280,000.
00

C hange in Number of Batches
C hange in
Number of
Batches

Dose
(microgr
ams)

Forcasted Protein
Production per
Batch (kg)

Forecasted
Number of
Batches

-2

5

0.09975

4

-1

5

0.09975

5

0

5

0.09975

6

1

5

0.09975

7

2

5

0.09975

8

Forecas
ted
Doses
79,800,
000.00
99,750,
000.00
119,700
,000.00
139,650
,000.00
159,600
,000.00
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A ppendix B ± Sensitivity A nalysis	
  
50% Downstream E fficiency
C hange in Selling Price
Percent
C hange in
Selling
Price

Dose
(micro
grams
)

Forcasted
Protein
Production per
Batch (kg)

Forecaste
d Number
of Batches

-20%

5

0.09975

6

-15%

5

0.09975

6

-10%

5

0.09975

6

-5%

5

0.09975

6

0%

5

0.09975

6

5%

5

0.09975

6

10%

5

0.09975

6

15%

5

0.09975

6

20%

5

0.09975

6

Forec
asted
Doses
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00
119,7
00,00
0.00

Private
Sector
Selling
Price

Gov.'t
Sector
Selling
Price

G ross
Private
Revenue
($USD)

G ross
Gov.'t
Revenue
($USD)

6.8

5.44

813,960,00
0.00

651,168,0
00.00

7.225

5.78

864,832,50
0.00

691,866,0
00.00

7.65

6.12

915,705,00
0.00

732,564,0
00.00

8.075

6.46

966,577,50
0.00

773,262,0
00.00

8.5

6.8

1,017,450,
000.00

813,960,0
00.00

8.925

7.14

1,068,322,
500.00

854,658,0
00.00

9.35

7.48

1,119,195,
000.00

895,356,0
00.00

9.775

7.82

1,170,067,
500.00

936,054,0
00.00

10.2

8.16

1,220,940,
000.00

976,752,0
00.00

Pandemic Scale-Up
Dose
(microgra
ms)

Forcasted Protein
Production per Batch
(kg)

Forecasted
Number of
Batches

5

0.09975

24

5

0.09975

24

5

0.09975

24

5

0.09975

24

5

0.09975

24

5

0.09975

24

5

0.09975

24

5

0.09975

24

5

0.09975

24

Forecaste
d Doses
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00
478,800,0
00.00

Gov.'t Sector
Selling Price

G ross Gov.'t
Revenue ($USD)

5.44

2,604,672,000.00

5.78

2,767,464,000.00

6.12

2,930,256,000.00

6.46

3,093,048,000.00

6.8

3,255,840,000.00

7.14

3,418,632,000.00

7.48

3,581,424,000.00

7.82

3,744,216,000.00

8.16

3,907,008,000.00
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A ppendix C ± SuperPro Stream Reports
O verall Process Data
Annual Operating Time
Annual Throughput
Number of Batches per Year

2922
83,790,000
3 per strain

Stream Details
Stream Name
Source
Destination
Activity
Temperature (ࣙͿ
Pressure (bar)
Biomass
Media
Water
Total (g/batch)
Total (L/batch)
Stream Name
Source
Activity (U/ml)
Temperature (ࣙͿ
Pressure
Biomass
Media
Water
Total (g/batch)
Total (L/batch)
Stream Name
Source
Destination
Activity
Temperature (ࣙͿ
Pressure
Biomass
Media
Water
Total (g/batch)
Total (L/batch)
Stream Name
Source
Destination
Activity
Temperature (ࣙͿ
Pressure
Biomass
Media
Water
Total (g/batch)
Total (L/batch)

hours
doses

Upstream Process
Initial C harge
S-101
S-102
Input
P-1
P-2
P-1
P-2
P-3
0.00
0.00
0.00
28.00
28.00
28.00
1.01
1.01
1.01
Component Flowrates (g/batch)
0.04
0.04
0.42
3.08
3.08
7.70
100.00
100.00
250.00
103.12
103.12
258.12
103.12
103.12
258.12
S-106
P-6

S-117
S-118
P-7
P-16
0.00
0.00
0.00
28.00
28.00
28.00
1.01
1.01
1.01
Component Flowrates (g/batch)
4.20
42.00
0.00
308.00
3080.00
34188.00
10000.00
100000.00
1110000.00
10312.20
103122.00
1144188.00
10312.20
103122.00
1144188.00
S-107
P-8
P-9

S-108
S-109
P-9
P-10
P-10
P-11
0.00
0.00
0.00
4.00
4.00
4.00
1.01
1.01
1.01
Component F low rates (g/batch)
0.00
0.00
0.00
3080.00
3080.00
3080.00
100000.00
100000.00
100000.00
103080.00
103080.00
103080.00
103080.00
103080.00
103080.00
S-112
P-12
P-6

S-113
S-114
P-12
P-13
P-7
P-14
0.00
0.00
0.00
28.00
28.00
4.00
1.01
1.01
1.01
Component F low rates (g/batch)
0.00
0.00
0.00
308.00
3080.00
15400.00
10000.00
100000.00
500000.00
10308.00
103080.00
515400.00
10308.00
103080.00
515400.00

S-104
P-3
P-4
0.00
28.00
1.01

S-105
P-4
P-6
0.00
28.00
1.01

4.20
61.60
2000.00
2065.80
2065.80

4.20
308.00
10000.00
10312.20
10312.20

S-119
P-17
0.00
28.00
1.01

S-120
P-18
0.00
4.00
1.01

4200.00
30800.00
1000000.00
1035000.00
1035000.00

38.08
0.00
100000.00
100038.08
100038.08

S-110
P-11
P-12
0.00
28.00
1.01

S-103
P-12
P-4
0.00
28.00
1.01

0.00
3080.00
100000.00
103080.00
103080.00

0.00
138.60
4500.00
4638.60
4638.60

S-115
P-14
P-15
0.00
4.00
1.01

S-116
P-15
P-16
0.00
4.00
1.01

0.00
15400.00
500000.00
515400.00
515400.00

0.00
34188.00
1110000.00
1144188.00
1144188.00
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A ppendix C ± SuperPro Stream Reports
Stream Details
Stream Name
Source
Destination
Activity
Temperature (ࣙͿ
Pressure (bar)
Biomass
Water
VLP
Medium
Baculovirus
TNBP
Triton X-100
Total (g/batch)
Total (L/batch)
Stream Name
Source
Destination
Activity
Temperature (ࣙͿ
Pressure (bar)
Biomass
Water
VLP
Medium
Baculovirus
TNBP
Triton X-100
Total (g/batch)
Total (L/batch)
Stream Name
Source
Destination
Activity
Temperature (ࣙͿ
Pressure (bar)
Biomass
Water
VLP
Medium
Baculovirus
Tris-HCL
NaCl
Total (g/batch)
Total (L/batch)

Downstream Process
F R O M USP
S-102
S-103
Input
P-1
P-12
P-1
P-9
P-9
0.00
0.00
0.00
28.00
28.00
28.00
1.01
1.01
1.01
Component Flowrates (kg/batch)
4200.00
0.00
0.00
1000000.00
990200.00
990200.00
200.00
0.00
200.00
30800.00
30800.00
30800.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1035200.00
1021000.00
1021200.00
1035200.00
1021000.00
1021200.00
S-105
P-3
P-7

S-106
S-107
P-7
P-11
P-4
P-4
0.00
0.00
0.00
28.00
28.00
28.00
1.01
1.01
1.01
Component Flowrates (g/batch)
0.00
0.00
0.00
200000.00
200000.00
0.00
190.00
190.00
0.00
5600.00
5600.00
0.00
0.00
0.00
0.00
573.00
573.00
0.00
1909.00
1909.00
0.00
208272.00
0.00
0.00
208272.00
208272.00
0.00
S-108
P-18
P-5

SE C Resin
Input
P-10
0.00
0.00
28.00
28.00
1.01
1.01
Component Flowrates (g/batch)
0.00
0.00
20000.00
200000.00
162.00
0.00
0.00
864.00
0.00
5680.00
0.00
171.05
0.00
0.00
20162.00
0.00
20162.00
206715.05

S-111
P-5
P-19
0.00
28.00
1.01
0.00
20000.00
154.00
0.00
0.00
4.80
14.00
20172.80
20172.80

Det. C harge
Input
P-12
0.00
28.00
1.01

S-104
P-9
P-3
0.00
28.00
1.01

0.00
200000.00
0.00
0.00
0.00
3150.00
10500.00
213650.00
213650.00

0.00
1100200.00
189.00
30800.00
0.00
3150.00
10500.00
1144839.00
1144839.00

I E X Resin
Input
P-11
0.00
28.00
1.01

S-101
P-4
P-18
0.00
28.00
1.01

0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

0.00
20000.00
162.00
0.00
0.00
0.00
0.00
0.00
20162.00

0.00
28.00
1.01

S-109
P-6
P-8
0.00
28.00
1.01

0.00
20000.00
154.00
0.00
0.00
0.00
0.00
20154.00
20154.00

0.00
10000.00
146.00
0.00
0.00
0.00
0.00
0.00
10146.00

S-114
P-19
P-6
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A ppendix C -- G antt C hart Data
Fermentation

3.32d

Fill Times
1L
10L
100L
1000L

T ask
Innoculate 100 mL
Innoculate 500 mL
Innoculate 4L Flask
Fill 20L Bioreactor
Ferment 20L Bioreactor
Fill 200L Bioreactor
Ferment 200L Bioreactor
Fill 2000L Bioreactor
Ferment 2000L Bioreactor
Fill Hold Tank 1
Centrifuge
Fill Inactivation Tank
Inactivation
Tangential Flow Filtration
Fill Hold Tank 2
Ion Exchange Chromatography
Fill Hold Tank 3
Size Exclusion
Fill Hold Tank 4
Tangential Flow Filtration
Fill Hold Tank 5
Packaging into Vial

0.024min
0.238min
2.38min
23.81min

each stage
Tank charging & draining is always 42 LPM
0days
0days
0days
0days

Batch 1
Start Date
0
3.32
6.64
9.9634725
9.963475255
13.28347525
13.2835028
16.6035028
16.60377838
19.92377838
19.92405396
20.27113729
20.27141287
20.2922462
20.2922462
20.63960512
25.63960512
25.63988069
30.63988069
30.64015627
30.64015627
30.98751519

G ap T ime

T ime (days)
3.32
3.32
3.3234725
2.75463E-06
3.32
2.75463E-05
3.32
0.000275579
3.32
0.000275579
0.347083333
0.000275579
0.020833333
0.347083333
0.347358912
5
0.000275579
5
0.000275579
0.347083333
0.347358912
5.92593

E nd Date
3.32
6.64
9.9634725
9.963475255
13.28347525
13.2835028
16.6035028
16.60377838
19.92377838
19.92405396
20.27113729
20.27141287
20.2922462
20.63932954
20.63960512
25.63960512
25.63988069
30.63988069
30.64015627
30.98723961
30.98751519
36.91344519
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Batch 2
Start Date

G ap T ime 1
0
0
0
9.963475255
13.28347525
13.2835028
16.6035028
16.60377838
19.92377838
19.92405396
20.27113729
3.667358912
20.2922462
19.94461173
20.63960512
25.63960512
25.63988069
30.63988069
30.64015627
30.98723961
30.98751519
36.91344519

0
0
0
3.281803079
0.041669421
3.32
0.041694213
3.32
0.041942245
3.32
4.603423151
4.950506484
4.975783243
4.632594937
4.632319358
0.000275579
5
0.000275579
5
4.652916667
4.652090021
0

T ime (days)

E nd Date
3.32
3.32
3.3234725
0.041669421
3.32
0.041694213
3.32
0.041942245
3.32
1.630782063
0.347083333
0.000275579
0.020833333
0.347083333
0.347358912
5
0.000275579
5
0.000275579
0.347083333
1.273839979
5.92593

3.32
3.32
3.3234725
10.00514468
16.60347525
13.32519701
19.9235028
16.64572063
23.24377838
21.55483602
20.61822063
3.667634491
20.31307954
20.29169506
20.98696403
30.63960512
25.64015627
35.63988069
30.64043185
31.33432294
32.26135516
42.83937519
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Batch 3
Start Date

G ap T ime 2

T ime (days)

E nd Date

0
0
0
10.00514468
16.60347525
13.32519701
19.9235028
16.64572063
23.24377838
21.55483602
4.704076849
3.667634491
20.31307954
19.59697725
20.98696403
30.63960512
25.64015627
35.63988069
30.64043185
31.33432294
32.26135516
42.83937519

0
0
0
3.281803079
0.041669421
3.32
0.041694213
3.32
0.041942245
1.689217937
4.356153585
4.702031255
4.66924063
4.50924063
4.50924063
0.000275579
5
0.000275579
5
4.652916667
3.671233238
0

3.32
3.32
3.3234725
0.041669421
3.32
0.041694213
3.32
0.041942245
3.32
3.013743403
0.347083333
0.000275579
0.020833333
0.347083333
0.347358912
5
0.000275579
5
0.000275579
0.347083333
2.254696762
5.92593

3.32
3.32
3.3234725
10.0468141
19.92347525
13.36689123
23.2435028
16.68766287
26.56377838
24.56857942
5.051160183
3.667910069
20.33391287
19.94406058
21.33432294
35.63960512
25.64043185
40.63988069
30.64070743
31.68140627
34.51605193
48.76530519

Batch 4
Start Date
0
0
0
10.0468141
19.92347525
13.36689123
23.2435028
16.68766287
26.56377838
24.56857942
5.051160183
3.667910069
20.33391287
19.24934277
21.33432294
35.63960512
25.64043185
40.63988069
30.64070743
31.68140627
34.51605193
48.76530519

Gap Time 3
0
0
0
3.281803079
0.041669421
3.32
0.041694213
3.32
0.041942245
0.5452
4.967960212
5.309416241
5.250399148
4.70924063
4.70924063
0.000275579
5
0.000275579
5
4.652916667
2.741330053
0

Time (days)
3.32
3.32
3.3234725
0.041669421
3.32
0.041694213
3.32
0.041942245
3.32
4.755043545
0.347083333
0.000275579
0.020833333
0.347083333
0.347358912
5
0.000275579
5
0.000275579
0.347083333
3.184599947
5.92593

End Date
3.32
3.32
3.3234725
10.08848352
23.24347525
13.40858544
26.5635028
16.72960512
29.88377838
29.32362297
5.398243516
3.668185648
20.3547462
19.5964261
21.68168185
40.63960512
25.64070743
45.63988069
30.64098301
32.02848961
37.70065187
54.69123519
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Batch 5
Start Date

	
  

G ap T ime 4

T ime (days)

E nd Date

0
0
0
10.08848352
23.24347525
13.40858544
26.5635028
16.72960512
29.88377838
29.32362297
5.398243516
3.668185648
20.3547462
18.90170829
21.68168185
40.63960512
25.64070743
45.63988069
30.64098301
32.02848961
37.70065187
54.69123519

0
0
0
3.281803079
0.041669421
3.32
0.041694213
3.32
0.041942245
0.3652
4.592055729
4.969469349
5.033726493
4.688407297
4.688407297
0.000275579
5
0.000275579
5
4.652916667
1.849642068
0

3.32
3.32
3.3234725
0.041669421
3.32
0.041694213
3.32
0.041942245
3.32
4.555043545
0.347083333
0.000275579
0.020833333
0.347083333
0.347358912
5
0.000275579
5
0.000275579
0.347083333
4.076287932
5.92593

3.32
3.32
3.3234725
10.13015294
26.56347525
13.45027965
29.8835028
16.77154736
33.20377838
33.87866651
5.745326849
3.668461227
20.37557954
19.24879162
22.02904076
45.63960512
25.64098301
50.63988069
30.64125859
32.37557294
41.7769398
60.61716519

Batch 6
Start Date
0
0
0
10.13015294
26.56347525
13.45027965
29.8835028
16.77154736
33.20377838
33.87866651
5.745326849
3.668461227
20.37557954
18.55407381
22.02904076
45.63960512
25.64098301
50.63988069
30.64125859
32.37557294
41.7769398
60.61716519

Gap Time 5
0
0
0
3.281803079
0.041669421
3.32
0.041694213
3.32
0.041942245
0.3652
4.714055729
4.934629029
4.924669688
4.688407297
4.688407297
0.000275579
5
0
5
4.652916667
0.957954083
0

Time (days)
3.32
3.32
3.3234725
0.041669421
3.32
0.041694213
3.32
0.041942245
3.32
4.755043545
0.347083333
0.000275579
0.020833333
0.347083333
0.347358912
5
0.000275579
5
0.000275579
0.347083333
4.967975917
5.92593

End Date
3.32
3.32
3.3234725
10.17182236
29.88347525
13.49197387
33.2035028
16.81348961
36.52377838
38.63371006
6.092410183
3.668736806
20.39641287
18.90115714
22.37639968
50.63960512
25.64125859
55.63988069
30.64153417
32.72265627
46.74491572
66.54309519

SIGMA-ALDRICH

sigma-aldrich.com

Material Safety Data Sheet
Version 3.4
Revision Date 04/26/2012
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

D-(+)-Glucose

Product Number
Brand

:
:

G7528
Sigma

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance according to GHS.
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Synonyms

:

Dextrose

Formula
Molecular Weight

:
:

C6H12O6
180.16 g/mol

No ingredients are hazardous according to OSHA criteria.
4. FIRST AID MEASURES

Sigma - G7528
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If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Immersion protection
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: > 480 min
Material tested:Dermatril® (Aldrich Z677272, Size M)
Splash protection
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Sigma - G7528
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Break through time: > 30 min
Material tested:Dermatril® (Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 873000, e-mail sales@kcl.de, test method:
EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as
offering an approval for any specific use scenario.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

crystalline, powder

Colour

white

Safety data
pH

no data available

Melting
point/freezing point

Melting point/range: 150 - 152 °C (302 - 306 °F)

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Autoignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

no data available

Water solubility

soluble

Partition coefficient:
n-octanol/water

no data available

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Sigma - G7528
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Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 25,800 mg/kg
Remarks: Behavioral:Coma. Cyanosis Diarrhoea
Inhalation LC50
no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
Genotoxicity in vitro - mouse - lymphocyte
Mutation in mammalian somatic cells.
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available
Teratogenicity
no data available

Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
Sigma - G7528
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no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: LZ6600000
12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
Sigma - G7528
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SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Glucose

CAS-No.
50-99-7

Revision Date

CAS-No.
50-99-7

Revision Date

New Jersey Right To Know Components
Glucose

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.

Sigma - G7528
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Material Safety Data Sheet
Calcium chloride, Anhydrous MSDS
Section 1: Chemical Product and Company Identification
Product Name: Calcium chloride, Anhydrous

Contact Information:

Catalog Codes: SLC5011, SLC2221, SLC4012, SLC4798,
SLC1006
CAS#: 10043-52-4

Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

RTECS: EV9800000

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400

TSCA: TSCA 8(b) inventory: Calcium chloride, Anhydrous

Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300

CI#: Not available.
Synonym:

International CHEMTREC, call: 1-703-527-3887

Chemical Name: Calcium Chloride, Anhydrous

For non-emergency assistance, call: 1-281-441-4400

Chemical Formula: CaCl2

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

Calcium chloride, Anhydrous

10043-52-4

100

Toxicological Data on Ingredients: Calcium chloride, Anhydrous: ORAL (LD50): Acute: 1000 mg/kg [Rat]. 1940 mg/kg
[Mouse].

Section 3: Hazards Identification
Potential Acute Health Effects:
Hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Slightly hazardous in case of
skin contact (permeator).
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for
bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance
may be toxic to heart, cardiovascular system. Repeated or prolonged exposure to the substance can produce target organs
damage.

Section 4: First Aid Measures
p. 1

Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention.
Skin Contact:
In case of contact, immediately flush skin with plenty of water. Cover the irritated skin with an emollient. Remove contaminated
clothing and shoes. Cold water may be used.Wash clothing before reuse. Thoroughly clean shoes before reuse. Get medical
attention.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: Not available.
Special Remarks on Explosion Hazards: Furan-2-peroxycarboxylic acid + calcium chloride causes explosion at room
temperature.

Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.

Section 7: Handling and Storage
p. 2

Precautions:
Keep locked up.. Do not ingest. Do not breathe dust. Wear suitable protective clothing. In case of insufficient ventilation,
wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the container or the label. Avoid
contact with skin and eyes. Keep away from incompatibles such as moisture.
Storage:
Hygroscopic. Keep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 30°C (86°F).

Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection: Safety glasses. Synthetic apron. Gloves (impervious).
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
handling this product.
Exposure Limits: Not available.

Section 9: Physical and Chemical Properties
Physical state and appearance: Solid. (Crystalline solid.)
Odor: Odorless.
Taste: Saline.
Molecular Weight: 110.99 g/mole
Color: Colorless. White. Off-white.
pH (1% soln/water): 9 [Basic.]
Boiling Point: 1670°C (3038°F)
Melting Point: 772°C (1421.6°F)
Critical Temperature: Not available.
Specific Gravity: 2.15 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water, acetone.
Solubility:
Easily soluble in cold water, hot water, acetone. Freely soluble in alcohol. Soluble in Acetic Acid.

Section 10: Stability and Reactivity Data
p. 3

Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Incompatible materials, moisture.
Incompatibility with various substances: Reactive with moisture.
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity:
Hygroscopic. Reacts violently (violent boiling) with water, generating heat. Forms flammable gases and evolves hydrogen
when reacted with zinc. Solutions attack some metals. Generates heat and violent polymerization occurs when mixed with
methyl vinyl ether. Bromine trifluoride reacts violently with and attacks calcium chloride.
Special Remarks on Corrosivity: Not available.
Polymerization: Will not occur.

Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Inhalation. Ingestion.
Toxicity to Animals: Acute oral toxicity (LD50): 1000 mg/kg [Rat].
Chronic Effects on Humans:
MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. May cause damage to
the following organs: heart, cardiovascular system.
Other Toxic Effects on Humans:
Hazardous in case of skin contact (irritant), of ingestion, of inhalation. Slightly hazardous in case of skin contact (permeator).
Special Remarks on Toxicity to Animals:
Lowest Published Lethal Dose: LDL [Rabbit] - Route: Oral; Dose: 1384 mg/kg
Special Remarks on Chronic Effects on Humans:
May affect genetic material based on animal data. May cause cancer (tumorigenic) based on animal data.
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May cause severe irritation and possible burns, especially if skin is wet. Contact with dry
skin causes mild irritation. Contact of solid with moist/wet skin or skin contact with strong solutions may cause marked irritation
or possible burns. Eyes: May cause severe irritation, possible transient corneal injury, and possible eye burns. Inhalation: May
cause severe irritation of the upper respiratory tract with pain, inflammation and possible burns. Ingestion: May cause severe
gastrointestinal (digestive) tract irritation with nausea, vomiting and possible burns. May affect cardiovascular system (cardiac
disturbances, slow heart beat), behavior (seizures), metabolism, blood, and brain, respiration (rapid respiration). Chronic
Potential Health Effects: effects may be delayed.

Section 12: Ecological Information
Ecotoxicity: Ecotoxicity in water (LC50): 100 mg/l 96 hours [Fish].
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The products of degradation are less toxic than the product itself.
Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
p. 4

Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: Not applicable.
Special Provisions for Transport: Not applicable.

Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Calcium chloride, Anhydrous
Other Regulations: EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): CLASS D-2B: Material causing other toxic effects (TOXIC).
DSCL (EEC):
R36- Irritating to eyes. S2- Keep out of the reach of children. S22- Do not breathe dust. S24- Avoid contact with skin.
HMIS (U.S.A.):
Health Hazard: 2
Fire Hazard: 0
Reactivity: 1
Personal Protection: C
National Fire Protection Association (U.S.A.):
Health: 2
Flammability: 0
Reactivity: 2
Specific hazard:
Protective Equipment:
Gloves (impervious). Synthetic apron. Wear appropriate respirator when ventilation is inadequate. Safety glasses.

Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/09/2005 04:31 PM
Last Updated: 06/09/2012 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.

p. 5
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

1 Identification of the substance/mixture and of the company/undertaking
· Product Identifier
· Product Name: Bacto TC Yeastolate
· Catalog Number: 255771
· Details of the supplier of the safety data sheet
· Manufacturer/Supplier:
BD Diagnostic Systems
7 Loveton Circle
Sparks, MD 21152
Telephone: (410) 771 - 0100 or (800) 638 – 8663
· Information Department: Technical Service
· Emergency telephone number:
In case of a chemical emergency, spill, fire, exposure, or accident, contact BD Diagnostic
Systems (410) 771-0100 or (800)-638-8663, or ChemTrec at (800) 424-9300.

2 Composition/information on ingredients
· Chemical characterization: Substances
· CAS No. Description:
.

3 Hazards identification
· Classification of the substance or mixture
The substance is not classified according to the Globally Harmonized System (GHS).
· Classification according to Directive 67/548/EEC or Directive 1999/45/EC
This product contains no hazardous constituents, or the concentration of all chemical
constituents are below the regulatory threshold limits described by Occupational Safety
Health Administration Hazard Communication Standard 29 CFR 1910.1200, the Canada's
Workplace Hazardous Materials Information System (WHMIS) and the European Directive
67/548/EEC and 1999/45/EC.
Void
· Label elements
· Labelling according to EU guidelines:
Observe the general safety regulations when handling chemicals
The substance is not subject to classification according to the sources of literature known to
us.
The product is not subject to identification regulations pertaining to regulations on hazardous
materials.
· NFPA ratings (scale 0-4)

0

0

0

Health = 0
Flammability = 0
Reactivity = 0
(Contd. on page 2)
USA
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

Product Name: Bacto TC Yeastolate

· HMIS ratings (scale 0-4)
HEALTH

0

FIRE

0

REACTIVITY 0

(Contd. of page 1)

Health = 0
Flammability = 0
Reactivity = 0

· Other hazards

4 First aid measures
· General information No special measures required.
· After inhalation Seek medical treatment in case of complaints.
· After skin contact Immediately wash with water and soap and rinse thoroughly.
· After eye contact
Rinse opened eye for several minutes under running water. If symptoms persist, consult a
doctor.
· After swallowing If symptoms persist consult doctor.
· Information for doctor Show this product label or this MSDS.

5 Firefighting measures
· Suitable extinguishing agents
CO2, ABC multipurpose dry chemical or water spray. Fight larger fires with water spray or
alcohol resistant foam.
· Special hazards arising from the substance or mixture
No further relevant information available.
· Protective equipment: No special measures required.

6 Accidental release measures
· Personal precautions, protective equipment and emergency procedures Not required.
· Environmental precautions: Wipe up with damp sponge or mop.
· Methods and material for containment and cleaning up: No special measures required.
· Reference to other sections No dangerous substances are released.

7 Handling and storage
· Handling
· Precautions for safe handling No special measures required.
· Information about protection against explosions and fires:
No special measures required.
· Storage
· Requirements to be met by storerooms and receptacles: < 30 ഒ
· Information about storage in one common storage facility:
Store away from oxidizing agents.

(Contd. on page 3)
USA
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

Product Name: Bacto TC Yeastolate

· Further information about storage conditions:
Store in cool, dry conditions in well sealed containers.
· Specific end use(s) No further relevant information available.

(Contd. of page 2)

8 Exposure controls/personal protection
· Additional information about design of technical systems:
No further data; see Section 7.
· Components with limit values that require monitoring at the workplace: Not required.
· Additional information: The lists that were valid during the creation were used as basis.
· Personal Protective Equipment
· General protective and hygienic measures
The usual precautionary measures for handling chemicals should be followed.
· Breathing equipment:
In case of brief exposure, use a chemical fume hood or a NIOSH/MSHA-approved respirator.
· Protection of hands:
Chemical resistant gloves (i.e. nitrile, or equivalent).
· Eye protection: Safety glasses
· Body protection: Protective work clothing (lab coat).

9 Physical and chemical properties
· General Information
· Appearance:
Form:
Color:
· Odor:

Solid.
According to product specification
Characteristic

· Change in condition
Undetermined
· Melting point/Melting range: Not determined
· Boiling point/Boiling range: Not determined
· Flash point:

Not applicable

· Flammability (solid, gaseous) Product is not flammable.
· Danger of explosion:

Product does not present an explosion hazard.

· Density:

Not determined

· Solubility in / Miscibility with
Water:
Soluble
Solids content:

100.0 %
(Contd. on page 4)
USA
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

Product Name: Bacto TC Yeastolate
(Contd. of page 3)

· Other information

No further relevant information available.

10 Stability and reactivity
· Thermal decomposition / conditions to be avoided:
No decomposition if used according to specifications.
· Incompatible materials: No further relevant information available.
· Hazardous decomposition products: No dangerous decomposition products known.

11 Toxicological information
· Acute toxicity:
· Primary irritant effect:
· on the skin: No irritating effect.
· on the eye: No irritating effect.
· Sensitization: No sensitizing effects known.
· Additional toxicological information:
The product is not subject to OSHA classification according to internally approved calculation
methods for preparations.
When used and handled according to specifications, the product does not have any harmful
effects according to our experience and the information provided to us.
The substance is not subject to classification.

12 Ecological information
· Aquatic toxicity: No further relevant information available.
· Persistence and degradability No further relevant information available.
· Behavior in environmental systems:
· Bioaccumulative potential No further relevant information available.
· Ecotoxical effects:
· Other information:
The ecological effects have not been thoroughly investigated, but currently none have been
identified.
· Additional ecological information:
· General notes: Generally not hazardous for water.

13 Disposal considerations
· Waste treatment methods
· Recommendation
Smaller quantities can be disposed of with solid waste.
Dispose of material in accordance with federal (40 CFR 261.3), state and local requirements.

(Contd. on page 5)
USA
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

Product Name: Bacto TC Yeastolate

This product is not considered a RCRA hazardous waste.

(Contd. of page 4)

· Uncleaned packagings:
· Recommendation: Disposal must be made according to state and federal regulations.
· Recommended cleansing agent: Water, if necessary with cleansing agents.

14 Transport information
· UN-Number
· DOT, ADR, ADN, IMDG, IATA

Void

· UN proper shipping name
· DOT, ADR, ADN, IMDG, IATA

Void

· Transport hazard class(es)
· DOT, ADR, ADN, IMDG, IATA
· Class

Void

· Packing group
· DOT, ADR, IMDG, IATA

Void

· Environmental hazards:
· Marine pollutant:

No

· Special precautions for user

Not applicable.

· Transport in bulk according to Annex II of
MARPOL73/78 and the IBC Code
Not applicable.
· Transport/Additional information:

If a "void" appears in the Hazard Class section
for the type of transportation, this indicates the
product is not regulated for transportation.

· UN "Model Regulation":

-

15 Regulatory information
· SARA Section 355 (extremely hazardous substances)
Substance is not listed.
· SARA Section 313 (specific toxic chemical listings)
Substance is not listed.
· TSCA (Toxic Substances Control Act)
Substance is not listed.
(Contd. on page 6)
USA
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

Product Name: Bacto TC Yeastolate
(Contd. of page 5)

· California Proposition 65 - Chemicals known to cause cancer
Substance is not listed.
· California Proposition 65 - Chemicals known to cause reproductive toxicity for
females:
Substance is not listed.
· California Proposition 65 - Chemicals known to cause reproductive toxicity for males:
Substance is not listed.
· California Proposition 65 - Chemicals known to cause developmental toxicity:
Substance is not listed.
· Carcinogenic categories
· NTP (National Toxicology Program)
Substance is not listed.
· TLV (Threshold Limit Value established by ACGIH)
Substance is not listed.
· Product related hazard information:
Observe the general safety regulations when handling chemicals
The substance is not subject to classification according to the sources of literature known to
us.
The product is not subject to identification regulations pertaining to regulations on hazardous
materials.
· National regulations
· Water hazard class: Generally not hazardous for water.

16 Other information
To the best of our knowledge, the information contained herein is accurate. However, neither
Becton, Dickinson and Company or any of its subsidiaries assumes any liabilities whatsoever
for the accuracy or completeness of the information contained herein. Final determination of
suitability of any material is the sole responsibility of the user. All materials may present
unknown hazards and should be used with caution. Although certain hazards are described
herein, we can not guarantee that these are the only hazards that exist.
· Department issuing MSDS:
Environmental, Health & Safety
Created by Michael J. Spinazzola
· Contact: Technical Service Representative
· Abbreviations and acronyms:

ADR: Accord européen sur le transport des marchandises dangereuses par Route (European Agreement
concerning the International Carriage of Dangerous Goods by Road)
RID: Règlement international concernant le transport des marchandises dangereuses par chemin de fer
(Regulations Concerning the International Transport of Dangerous Goods by Rail)
IMDG: International Maritime Code for Dangerous Goods
IATA: International Air Transport Association
ICAO: International Civil Aviation Organization
(Contd. on page 7)
USA
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Material Safety Data Sheet
acc. to ISO/DIS 11014
Date Prepared: 11/01/2011

Reviewed On: 07/15/2011

Product Name: Bacto TC Yeastolate
(Contd. of page 6)
ACGIH: American Conference of Governmental Industrial Hygienists
CAS: Chemical Abstracts Service (division of the American Chemical Society)
NFPA: National Fire Protection Association (USA)
HMIS: Hazardous Materials Identification System (USA)
USA
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Material Safety Data Sheet
Version 5.2
Revision Date 11/05/2012
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Sodium pyruvate

Product Number
Brand

:
:

80443
Sigma-Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS).
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Formula
Molecular Weight

:
:

C3H3NaO3
110.04 g/mol

No ingredients are hazardous according to OSHA criteria.
4. FIRST AID MEASURES
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.

Sigma-Aldrich - 80443
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In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Sigma-Aldrich - 80443
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Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

powder

Colour

white

Safety data
pH

7

Melting
point/freezing point

Melting point/range: > 300 °C (> 572 °F) - lit.

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Autoignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

no data available

Water solubility

soluble

Partition coefficient:
n-octanol/water

no data available

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
no data available
Inhalation LC50
Sigma-Aldrich - 80443
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no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available

Teratogenicity
no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: Not available
12. ECOLOGICAL INFORMATION
Sigma-Aldrich - 80443
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Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sodium pyruvate

CAS-No.
113-24-6

Revision Date

CAS-No.
113-24-6

Revision Date

New Jersey Right To Know Components
Sodium pyruvate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
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16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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Material Safety Data Sheet
Version 3.6
Revision Date 04/24/2012
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

L-Glutamine

Product Number
Brand

:
:

G8540
Sigma

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance according to GHS.
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Synonyms

:

(S)-2,5-Diamino-5-oxopentanoic acid
L-Glutamic acid 5-amide

Formula
Molecular Weight

:
:

C5H10N2O3 C5H10N2O3
146.14 g/mol

No ingredients are hazardous according to OSHA criteria.
4. FIRST AID MEASURES
Sigma - G8540
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If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx)
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
Sigma - G8540
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specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

powder

Colour

white

Safety data
pH

5.0 - 6 at 14.6 g/l at 25 °C (77 °F)

Melting
point/freezing point

Melting point/range: 185 °C (365 °F)

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Autoignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

no data available

Water solubility

14.6 g/l at 20 °C (68 °F) - completely soluble

Partition coefficient:
n-octanol/water

log Pow: -4.609

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx)
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
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Acute toxicity
Oral LD50
LD50 Oral - rat - 7,500 mg/kg
Inhalation LC50
no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available

Teratogenicity
no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Sigma - G8540
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Additional Information
RTECS: MA2275100
12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
L-Glutamine

CAS-No.
56-85-9

Revision Date

CAS-No.
56-85-9

Revision Date

New Jersey Right To Know Components
L-Glutamine
Sigma - G8540
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California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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SIGMA-ALDRICH

sigma-aldrich.com

Material Safety Data Sheet
Version 4.3
Revision Date 12/31/2012
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Sodium bicarbonate

Product Number
Brand

:
:

S8875
Sigma-Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS).
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Synonyms

:

Sodium hydrogen carbonate

Formula
Molecular Weight

:
:

CHNaO3
84.01 g/mol

No ingredients are hazardous according to OHSA criteria.
4. FIRST AID MEASURES
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If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash protection
Material: Nitrile rubber
Sigma-Aldrich - S8875
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Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as
offering an approval for any specific use scenario.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

crystalline

Colour

no data available

Safety data
pH

no data available

Melting
point/freezing point

300 °C (572 °F)

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Auto-ignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

2.160 g/cm3

Water solubility

50 g/l

Partition coefficient:
n-octanol/water

no data available

Relative vapor
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Sigma-Aldrich - S8875
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Possibility of hazardous reactions
no data available
Conditions to avoid
Exposure to moisture.
Materials to avoid
Strong acids, Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 4,220 mg/kg
Inhalation LC50
no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
Skin - Human - Mild skin irritation - 3 d
Serious eye damage/eye irritation
Eyes - rabbit - Mild eye irritation - 30 s
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available
Teratogenicity
no data available

Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
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Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
Exposure to large amounts can cause:, Gastrointestinal disturbance, Heavy or prolonged skin exposure may result in the
absorption of harmful amounts of material.
Synergistic effects
no data available
Additional Information
RTECS: VZ0950000
12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
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SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sodium hydrogencarbonate

CAS-No.
144-55-8

Revision Date

CAS-No.
144-55-8

Revision Date

New Jersey Right To Know Components
Sodium hydrogencarbonate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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3050 Spruce Street, Saint Louis, MO 63103, USA
Website: www.sigmaaldrich.com
Email USA:
techserv@sial.com
Outside USA: eurtechserv@sial.com

Product Specification
Product Name:

Product Number:
CAS Number:

K4894
9003-11-6

Formula:

(C3H6O.C2H4O)x

TEST

Specification
________________________________________________________________________
Appearance (Color)

White

Appearance (Form)
Prill/Cast Solid
Solubility (Color)
Solubility (Turbidity)
100 mg/ml H2O
Cloud Point

Conforms

10% Solution
Brookfield Viscosity
at 77 deg C
pH
2.5% solution
Water Content
COLOR TEST (APHA)
(50:50 in MeOH)
Cell Culture Test
Insect Cell Test
Plant Cell Culture Test
Note
Kolliphor is a registered trademark of BASF
Recommended Retest Period
2 years

Colorless
Clear
>_ 100 °C
700 - 1300 cps
5.0 - 7.5
<_ 0.75 %
<_ 100
Pass
Pass
Pass
-------------------------------------------------

Specification: PRD.3.ZQ5.10000023427

Sigma-Aldrich w arrants, that at the time of the quality release or subsequent retest date this product conformed to the information contained in
this publication. The current Specification sheet may be available at Sigma-Aldrich.com. For further inquiries, please contact Technical Service.
Purchaser must determine the suitability of the product for its particular use. See reverse side of invoice or packing slip for additional terms
and conditions of sale.
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Material Safety Data Sheet
Version 4.2
Revision Date 05/08/2012
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Pluronic® F-68

Product Number
Brand

:
:

P1300
Sigma

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
GHS Classification
Skin irritation (Category 3)
GHS Label elements, including precautionary statements
Pictogram

none

Signal word

Warning

Hazard statement(s)
H316
Precautionary
statement(s)

Causes mild skin irritation.
none

HMIS Classification
Health hazard:
Flammability:
Physical hazards:

1
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

1
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Sigma - P1300
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Synonyms

:

Polyoxyethylene-polyoxypropylene block copolymer

Formula

:

(C3H6O.C2H4O)x

No ingredients are hazardous according to OSHA criteria.
4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate
ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Sigma - P1300
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Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

solid

Colour

colourless

Safety data
pH

6.0 - 7

Melting
point/freezing point

no data available

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Autoignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

no data available

Water solubility

no data available

Partition coefficient:
n-octanol/water

no data available

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available

Sigma - P1300
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Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 9,380 mg/kg
LD50 Oral - mouse - 15,000 mg/kg
Inhalation LC50
no data available
Dermal LD50
LD50 Dermal - rabbit - 20,000 mg/kg
Other information on acute toxicity
no data available
Skin corrosion/irritation
Skin - rabbit - Mild skin irritation - 24 h
Serious eye damage/eye irritation
Eyes - rabbit - Mild eye irritation - 24 h
Eyes - rabbit - No eye irritation - OECD Test Guideline 405
Respiratory or skin sensitization
rabbit - Did not cause sensitization on laboratory animals.
Germ cell mutagenicity
Tests on bacterial or mammalian cell cultures did not show mutagenic effects.
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available

Teratogenicity
no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Sigma - P1300
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Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
Effects due to ingestion may include:, Diarrhoea, Weakness, To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: MD0911050
12. ECOLOGICAL INFORMATION
Toxicity
Toxicity to fish

static test LC50 - other fish - > 10,000 mg/l - 96 h
Method: OECD Test Guideline 203

Persistence and degradability
no data available
Bioaccumulative potential
Bioaccumulation is unlikely.
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
Sigma - P1300
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SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Polyethylene glycol, propoxylated

CAS-No.
9003-11-6

Revision Date

CAS-No.
9003-11-6

Revision Date

New Jersey Right To Know Components
Polyethylene glycol, propoxylated

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.

Sigma - P1300
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Material Safety Data Sheet
Version 4.9
Revision Date 02/19/2013
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

7ULWRQ;-100

Product Number
Brand

:
:

X100
Sigma-Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
Harmful by ingestion., Irritant
GHS Classification
Acute toxicity, Oral (Category 4)
Skin irritation (Category 3)
Eye irritation (Category 2A)
Acute aquatic toxicity (Category 2)
Chronic aquatic toxicity (Category 2)
GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H302
H316
H319
H411

Warning
Harmful if swallowed.
Causes mild skin irritation.
Causes serious eye irritation.
Toxic to aquatic life with long lasting effects.

Precautionary statement(s)
P273
Avoid release to the environment.
P305 + P351 + P338
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if
present and easy to do. Continue rinsing.
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

2
1
0

NFPA Rating
Health hazard:

2

Sigma-Aldrich - X100
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Fire:
Reactivity Hazard:

1
0

Health hazard:
Fire:
Reactivity Hazard:

2
1
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. Causes respiratory tract irritation.
Harmful if absorbed through skin. Causes skin irritation.
Causes eye irritation.
Harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Synonyms

:

t-Octylphenoxypolyethoxyethanol
4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol
Polyethylene glycol tert-octylphenyl ether

Formula

:

(C2H4O)nC14H22O

Component

Concentration

p-tertiary-Octylphenoxy polyethyl alcohol
CAS-No.
9002-93-1

90 - 100 %

4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment
must be avoided.
Sigma-Aldrich - X100

Page 2 of 7

Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for
disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
Packaged under inert gas.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose
combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the
respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components
tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial
hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be
construed as offering an approval for any specific use scenario.
Eye protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form
Sigma-Aldrich - X100

liquid, clear
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Colour

light yellow

Safety data
pH

9.7

Melting
point/freezing point

6 °C (43 °F)

Boiling point

> 200 °C (> 392 °F)

Flash point

251 °C (484 °F) - closed cup

Ignition temperature

no data available

Auto-ignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

< 1.33 hPa (< 1.00 mmHg) at 20 °C (68 °F)

Density

1.0700 g/cm3

Water solubility

soluble

Partition coefficient:
n-octanol/water

no data available

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evapouration rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
Strong acids, Strong bases, Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 1,800 mg/kg
Inhalation LC50
no data available
Dermal LD50
LD50 Dermal - rabbit - 8,000 mg/kg
Other information on acute toxicity
no data available
Skin corrosion/irritation
Sigma-Aldrich - X100
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no data available
Serious eye damage/eye irritation
Eyes - rabbit - Moderate eye irritation - 24 h
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available
Teratogenicity
no data available

Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. Causes respiratory tract irritation.
Harmful if swallowed.
Harmful if absorbed through skin. Causes skin irritation.
Causes eye irritation.

Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: MD0907700
12. ECOLOGICAL INFORMATION
Toxicity
Toxicity to fish

LC50 - Pimephales promelas (fathead minnow) - 8.9 mg/l - 96.0 h

Toxicity to daphnia
and other aquatic
invertebrates

EC50 - Daphnia - 26 mg/l - 48 h

Persistence and degradability
Sigma-Aldrich - X100
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Biodegradability

Biotic/Aerobic Biochemical oxygen demand
Result: 36 % - Not readily biodegradable.
Method: Closed Bottle test

Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
Chemical Oxygen
Demand (COD)

2.19 mg/g

An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.
Toxic to aquatic life with long lasting effects.
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
UN number: 3082 Class: 9
Packing group: III
Proper shipping name: Environmentally hazardous substances, liquid, n.o.s. (p-tertiary-Octylphenoxy polyethyl alcohol)
Reportable Quantity (RQ):
Marine pollutant: Marine pollutant
Poison Inhalation Hazard: No
IMDG
UN number: 3082 Class: 9
Packing group: III
EMS-No: F-A, S-F
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (p-tertiary-Octylphenoxy
polyethyl alcohol)
Marine pollutant: No
IATA
UN number: 3082 Class: 9
Packing group: III
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (p-tertiary-Octylphenoxy polyethyl alcohol)
15. REGULATORY INFORMATION
OSHA Hazards
Harmful by ingestion., Irritant
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Sigma-Aldrich - X100
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Pennsylvania Right To Know Components
p-tertiary-Octylphenoxy polyethyl alcohol

CAS-No.
9002-93-1

Revision Date

CAS-No.
9002-93-1

Revision Date

New Jersey Right To Know Components
p-tertiary-Octylphenoxy polyethyl alcohol

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2013 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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SAFETY DATA SHEET
_____________________________________________________________________________________________

1 . I d e n t i f i c a t i o n o f t h e s u b s t a n c e / m i x t u r e a n d o f t h e c o m p a n y/u n d e r t a k i n g
Identification of the substance/preparation
Product code
Product name

11300027
*UDFH¶V,QVHFW&HOO&XOWXUH0HGLXPSRZGHU

Company/Undertaking Identification
Life Technologies
5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
24 hour Emergency Response (Transport):

INVITROGEN CORPORATION
5250 MAINWAY DRIVE
BURLINGTON, ONT
CANADA L7L 6A4
800/263-6236
866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585

For research use only. Not intended for human or animal diagnostic or therapeutic uses.

_____________________________________________________________________________________________
Revision Date
Product code

01-May-2012
11300027
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Product name *UDFH¶V,QVHFW&HOO&XOWXUH0HGLXPSRZGHU
www.lifetechnologies.com

2. H a z a rd s id e n tifi c a tio n
GHS - Classification
Signal Word
not hazardous

Health Hazard
not hazardous
Physical Hazards
not hazardous

Principle Routes of Exposure/
Potential Health effects
Eyes
Skin
Inhalation
Ingestion

May cause eye irritation with susceptible persons.
May cause skin irritation in susceptible persons.
May be harmful by inhalation.
May be harmful if swallowed.

Specific effects
Carcinogenic effects
Mutagenic effects
Reproductive toxicity
Sensitization

none
none
none
none

Target Organ Effects

No known effects under normal use conditions.

HMIS
Health
Flammability
Reactivity

0
0
0

3 . C o m p o s i t i o n/i n f o r m a t i o n o n i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We
recommend handling all chemicals with caution.

4. F irs t a id m e a s ur e s
_____________________________________________________________________________________________
Revision Date
Product code
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Skin contact
Eye contact
Ingestion
Inhalation
Notes to physician

Rinse with plenty of water. If symptoms arise, call a physician.
Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
Move to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
Treat symptomatically.
5 . F i r e -f i g h t i n g m e a s u r e s
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Wear self-contained breathing apparatus and protective
suit.

Suitable extinguishing media
Special protective equipment for firefighters

6. A c c id e n t a l r e l e a s e m e a s ur e s
Personal precautions
Methods for cleaning up

Use personal protective equipment.
Take up mechanically and collect in suitable container for disposal.

Environmental precautions
Prevent further leakage or spillage if safe to do so.
See Section 12 for additional information.
7. H a n dlin g a n d s t or a g e
Always wear reccommended Personal Protective Equipment. No special handling
advice required.
Keep in a dry, cool and well-ventilated place.

Handling
Storage

8 . E x p o s u r e c o n t r o l s/p e r s o n a l p r o t e c t i o n
Exposure limits
The product does not contain any hazardous materials with occupational exposure limits established.
Engineering measures

Ensure adequate ventilation, especially in confined areas.

Personal protective equipment
Respiratory protection

In case of insufficient ventilation wear suitable respiratory equipment.

Hand protection
Eye protection
Skin and body protection.
Hygiene measures

Impervious gloves.
Safety glasses with side-shields.
Lightweight protective clothing.
Handle in accordance with good industrial hygiene and safety practice.

Environmental exposure
controls

Prevent product from entering drains.

_____________________________________________________________________________________________
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9. P h y si c a l a n d c h e m i c a l pro p e rti e s
General Information
Form
Appearance
Odor
Boiling Point/Range
Melting point/range
Flash point
Autoignition temperature
Oxidizing properties
Water solubility

powder
No information available
No information available
°C no data available
°C no data available
°C no data available
°C no data available
No information available.
no data available

°F
°F
°F
°F

no data available
no data available
no data available
no data available

1 0. S t a bilit y a n d r e a c tivit y
Stability
Materials to avoid
Hazardous decomposition
products
polymerization

Stable under normal conditions.
No dangerous reaction known under conditions of normal use.
None under normal use
Hazardous polymerisation does not occur.
1 1. T o x i c olo gi c a l infor m a tio n

Acute toxicity
not hazardous
Principle Routes of Exposure/
Potential Health effects
Eyes
Skin
Inhalation
Ingestion

May cause eye irritation with susceptible persons.
May cause skin irritation in susceptible persons.
May be harmful by inhalation.
May be harmful if swallowed.

Carcinogenic effects
Mutagenic effects
Reproductive toxicity
Sensitization

none
none
none
none

Target Organ Effects

No known effects under normal use conditions.

1 2. E c olo gi c a l infor m a tio n
Ecotoxicity effects
Mobility
Biodegradation
Bioaccumulation

No information available.
No information available.
Inherently biodegradable
Does not bioaccumulate.

_____________________________________________________________________________________________
Revision Date
Product code
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1 3. Dis p o s a l c o n sid e r a tio n s
Dispose of in accordance with local regulations.
1 4. T r a n s p ort infor m a tio n
IATA
Proper shipping name
Hazard class
Subsidiary Class
Packing group
UN-No

Not classified as dangerous in the meaning of transport regulations
none
none
none
None
1 5. R e g ul a t ory infor m a tio n

U.S. Federal Regulations
SARA 313

This product is not regulated by SARA.

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.

U.S. State Regulations
California Proposition 65
This product does not contain chemicals listed under Proposition 65
WHMIS hazard class:
Non-controlled

This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR

1 6. O t h e r infor m a tio n

Reason for Revision

(M)SDS sections updated.

For research use only. Not intended for human or animal diagnostic or therapeutic uses.
The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unkown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.
End of Safety Data Sheet
_____________________________________________________________________________________________
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MSDS ID: 11300
______________________________________________________________________________
1. PRODUCT AND COMPANY INFORMATION
______________________________________________________________________________
INVITROGEN CORPORATION
1600 FARADAY AVE.
CARLSBAD, CA 92008
760/603-7200

GIBCO PRODUCTS
INVITROGEN CORPORATION
3175 STALEY ROAD P.O. BOX 68
GRAND ISLAND, NY 14072
716/774-6700

INVITROGEN CORPORATION
3 FOUNTAIN DR.
INCHINNAN BUSINESS PARK
PAISLEY, PA4 9RF
SCOTLAND
44-141 814-6100

INVITROGEN CORPORATION
P.O. BOX 12-502
PENROSE
AUCKLAND 1135
NEW ZEALAND
64-9-579-3024

INVITROGEN CORPORATION
2270 INDUSTRIAL ST.
BURLINGTON, ONT
CANADA L7P 1A1
905/335-2255

INVITROGEN AUSTRALIA PTY LIMITED
2A/14 LIONEL ROAD
MOUNT WAVERLY VIC 3149
AUSTRALIA
1-800-331-627

EMERGENCY NUMBER (SPILLS, EXPOSURES):

301/431-8585 (24 HOUR)
800/451-8346 (24 HOUR)
800/955-6288

NON-EMERGENCY INFORMATION:
Product Name:
Stock Number:

GRACE'S INSECT CELL CULTURE MEDIUM, POWDER
11300

NOTE: If this product is a kit or is supplied with more than one material,
please refer to the MSDS for each component for hazard information.
Product Use:
These products are for laboratory research use only and are not intended for
human or animal diagnostics, therapeutic, or other clinical uses.
Synonyms:
Not available.
______________________________________________________________________________
______________________________________________________________________________
2. COMPOSITION, INFORMATION ON INGREDIENTS
The following list shows components of this product classified as hazardous
based on physical properties and health effects:
Component
L-GLUTAMINE

CAS No.
56-85-9

Percent
0.5 - 1.5

LTIMSDS1
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3. HAZARDS IDENTIFICATION
______________________________________________________________________________
***************************** EMERGENCY OVERVIEW ****************************
Occupational exposure presents little or no health hazard.
*****************************************************************************
Potential Health Effects:
Eye:
Can cause minor irritation, tearing and reddening.
Skin:
Can cause minor skin irritation, defatting, and dermatitis.
Inhalation:
Can cause minor respiratory irritation, dizziness, weakness, fatigue,
nausea, and headache.
No toxicity expected from inhalation.
Ingestion:
Mildly irritating to mouth, throat, and stomach. Can cause abdominal
discomfort.
Chronic:
No data on cancer.
______________________________________________________________________________
4. FIRST AID MEASURES
______________________________________________________________________________
Eye:
Use an eye wash to remove a chemical from your eye regardless of the level
of hazard. Flush the affected eye for at least twenty minutes. Tilt the
head to prevent chemical from transferring to the uncontaminated eye. Seek
medical advice after flushing.
Skin:
Wash with soap and water. Get medical attention if irritation develops or
persists.
Inhalation:
Remove to fresh air. If breathing is difficult, have a trained individual
administer oxygen.
Ingestion:
Minimal risk of harm if swallowed. Do not induce vomiting. Seek medical
attention immediately. Provide medical care provider with this MSDS.
Note To Physician:
Treat symptomatically.

LTIMSDS2
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5. FIRE FIGHTING MEASURES
______________________________________________________________________________
Flashpoint Deg C:
Upper Flammable Limit %:
Lower Flammable Limit %:
Autoignition Temperature Deg C:

Not available.
Not available.
Not available.
Not available.

Extinguishing Media:
Use alcohol resistant foam, carbon dioxide, or dry chemical when fighting
fires. Water or foam may cause frothing if liquid is burning but it still
may be a useful extinguishing agent if carefully applied to the surface of
the fire. Do Not direct a stream of water into the hot burning liquid.
Use water spray/fog for cooling.
Firefighting Techniques/Equipment:
Do not enter fire area without proper protection including self-contained
breathing apparatus and full protective equipment. Fight fire from a safe
distance and a protected location due to the potential of hazardous vapors
and decomposition products.
Hazardous Combustion Products:
Includes carbon dioxide, carbon monoxide, dense smoke.
______________________________________________________________________________
______________________________________________________________________________
6. ACCIDENTAL RELEASE MEASURES
Accidental releases may be subject to special reporting requirements and other
regulatory mandates. Refer to Section 8 for personal protection equipment
recommendations.
Spill Cleanup:
No health affects expected from the clean-up of this material if contact
can be avoided. Follow personal protective equipment recommendations found
in Section VIII of this MSDS .
No special spill clean-up considerations. Collect and discard in regular
trash.
______________________________________________________________________________
7. HANDLING AND STORAGE
______________________________________________________________________________
Storage of some materials is regulated by federal, state, and/or local laws.
Storage Pressure:
Ambient

LTIMSDS2
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7. HANDLING AND STORAGE (CONT.)
______________________________________________________________________________
Handling Procedures:
Mildly irritating material. Avoid unnecessary exposure.
Keep closed or covered when not in use.
Storage Procedures:
Store in a cool dry place. Isolate from incompatible materials.
Suitable for most general chemical storage areas.
______________________________________________________________________________
______________________________________________________________________________
8. EXPOSURE CONTROLS, PERSONAL PROTECTION
Exposure Limits:
Component
L-GLUTAMINE

OSHA PEL
(ppm)
Not established.

AGCIH TWA
(ppm)
Not established.

Engineering Controls:
No exposure limits exist for the constituents of this product. General
room ventilation might be required to maintain operator comfort under
normal conditions of use.
Personal Protective Equipment:
Eye:
Safety glasses should be the minimum eye protection.
Wear chemical goggles.
Skin:
Not normally considered a skin hazard. Where use can result in skin
contact, practice good personal hygiene and wear a barrier cream and/or
impervious surgical style gloves. Wash hands and other exposed areas with
mild soap and water before eating, drinking, and when leaving work.
Gloves should be used as minimum hand protection.
Respiratory:
No respiratory protection will be needed under normal industrial operating
conditions.
______________________________________________________________________________
______________________________________________________________________________
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance/physical state:
Odor:

Powder.
No odor.
Not established.
Not established.
Not established.
Not established.
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______________________________________________________________________________
9. PHYSICAL AND CHEMICAL PROPERTIES (CONT.)
______________________________________________________________________________
Not
Not
Not
Octanol/water Partition Coeff: Not
Volatiles:
Not
Not
Not

established.
established.
established.
established.
established.
established.
established.

______________________________________________________________________________
______________________________________________________________________________
10. STABILITY AND REACTIVITY
Stability:
Stable under normal conditions.
Conditions to Avoid:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide. Carbon dioxide.
chloride.

Toxic gases.

Nitrogen oxides.

Hydrogen

Hazardous Polymerization:
Hazardous polymerization will not occur.
______________________________________________________________________________
______________________________________________________________________________
11. TOXICOLOGICAL INFORMATION
Acute Toxicity:
Dermal/Skin:
Not determined.
Inhalation/Respiratory:
Not determined.
Oral/Ingestion:
L-GLUTAMINE: 7500 MG/KG
Target Organs: No data found.
Carcinogenicity:
NTP:
Not tested.
IARC:
Not listed.
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11. TOXICOLOGICAL INFORMATION (CONT.)
______________________________________________________________________________
OSHA:
Not regulated.
Other Toxicological Information
______________________________________________________________________________
12. Ecological Information
______________________________________________________________________________
Ecotoxicological Information: No ecological information available.
Environmental Fate (Degradation, Transformation, and Persistence):
Bioconcentration is not expected to occur.
______________________________________________________________________________
13. DISPOSAL CONSIDERATIONS
______________________________________________________________________________
Regulatory Information:
Not applicable.
Disposal Method:
Clean up and dispose of waste in accordance with all federal, state, and
local environmental regulations.
______________________________________________________________________________
______________________________________________________________________________
14. TRANSPORT INFORMATION
Proper Shipping Name:
Subsidiary Hazards:

Not Determined.

______________________________________________________________________________
______________________________________________________________________________
15. REGULATORY INFORMATION
UNITED STATES:
TSCA:
This product is solely for research and development purposes only and may not
be used, processed or distributed for a commercial purpose. It may only be
handled by technically qualified individuals.
Prop 65 Listed Chemicals:
No Prop 65 Chemicals.
No 313 Chemicals

CANADA:

PROP 65

PERCENT

LTIMSDS2
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15. REGULATORY INFORMATION (CONT.)
______________________________________________________________________________
DSL/NDSL:
Not determined.
COMPONENT
L-GLUTAMINE

WHMIS Classification
Not classified as hazardous.

EUROPEAN UNION:
PRODUCT RISK PHRASES:
PRODUCT SAFETY PHRASES:
PRODUCT CLASSIFICATION:

None assigned.
Not applicable.
Not classified as hazardous
EINECS
Number
200-292-1

Component
L-GLUTAMINE

______________________________________________________________________________
______________________________________________________________________________
16. OTHER INFORMATION
HMIS Rating
FIRE:
HEALTH:
REACTIVITY:

0-4:
Not determined.
Not determined.
Not determined.

Abbreviations
N/A - Data is not applicable or not available
SARA - Superfund and Reauthorization Act
HMIS - Hazard Material Information System
WHMIS - Workplace Hazard Materials Information System
NTP - National Toxicology Program
OSHA - Occupational Health and Safety Administration
IARC - International Agency for Research on Cancer
PROP 65 - California Safe Drinking Water and
Toxic Enforcement Act of 1986
EINECS - European Inventory of Existing Commercial
Chemical Substances
The above information was acquired by diligent search and/or investigation
and the recommendations are based on prudent application of professional
judgment. The information shall not be taken as being all inclusive and is
to be used only as a guide. All materials and mixtures may present unknown
hazards and should be used with caution. Since Invitrogen Corporation cannot
control the actual methods, volumes, or conditions of use, the Company shall
not be held liable for any damages or losses resulting from the handling or
from contact with the product as described herein. THE INFORMATION IN THIS
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16. OTHER INFORMATION (CONT.)
______________________________________________________________________________
MSDS DOES NOT CONSTITUTE A WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.
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Material Safety Data Sheet
Version 5.0
Revision Date 12/03/2012
Print Date 03/31/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Tributyl phosphate

Product Number
Brand

:
:

240494
Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen
Target Organs
Blood, Central nervous system
GHS Classification
Acute toxicity, Inhalation (Category 4)
Acute toxicity, Dermal (Category 5)
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2B)
Carcinogenicity (Category 2)
Acute aquatic toxicity (Category 2)
GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H302 + H332
H313
H315 + H320
H351
H401

Warning
Harmful if swallowed or if inhaled
May be harmful in contact with skin.
Causes skin and eye irritation.
Suspected of causing cancer.
Toxic to aquatic life.

Precautionary statement(s)
P281
Use personal protective equipment as required.
P305 + P351 + P338
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if
present and easy to do. Continue rinsing.
Aldrich - 240494
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HMIS Classification
Health hazard:
Chronic Health Hazard:
Flammability:
Physical hazards:

2
*
1
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

3
1
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. Causes respiratory tract irritation.
Harmful if absorbed through skin. Causes skin irritation.
Causes eye irritation.
Harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Formula
Molecular Weight

:
:

C12H27O4P
266.31 g/mol

Component
Tributyl phosphate
CAS-No.
EC-No.
Index-No.

Concentration
126-73-8
204-800-2
015-014-00-2

-

4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate
personnel to safe areas.

Aldrich - 240494
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Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment
must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for
disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Components with workplace control parameters
Components

CAS-No.

Value

Tributyl
phosphate
Remarks

126-73-8

TWA

Control
parameters
0.2 ppm

Basis
USA. ACGIH Threshold Limit Values (TLV)

Eye & Upper Respiratory Tract irritation Headache Nausea Substances for which there is a
Biological Exposure Index or Indices (see BEI® section), see BEI® for Acetylcholinesterase
Inhibiting Pesticide
TWA
TWA
TWA

0.2 ppm
2.5 mg/m3
5 mg/m3
0.2 ppm
2.5 mg/m3

USA. OSHA - TABLE Z-1 Limits for Air Contaminants 1910.1000
USA. Occupational Exposure Limits (OSHA) - Table Z-1
Limits for Air Contaminants
USA. NIOSH Recommended Exposure Limits

Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose
combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the
respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components
tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
Splash protection
Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374
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If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as
offering an approval for any specific use scenario.
Eye protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

liquid

Colour

colourless

Safety data
pH

no data available

Melting
point/freezing point

Melting point/range: -79 °C (-110 °F) - lit.

Boiling point

180 - 183 °C (356 - 361 °F) at 29 hPa (22 mmHg) - lit.

Flash point

145 °C (293 °F) - closed cup

Ignition temperature

410 °C (770 °F)

Auto-ignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

36 hPa (27 mmHg) at 178 °C (352 °F)
9.7 hPa (7.3 mmHg) at 150 °C (302 °F)

Density

0.979 g/cm3 at 25 °C (77 °F)

Water solubility

no data available

Partition coefficient:
n-octanol/water

no data available

Relative vapor
density

9.19
- (Air = 1.0)

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
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Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents, Strong bases
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 1,552 mg/kg
Inhalation LC50
LC50 Inhalation - rat - 1 h - 28,000 mg/m3
Dermal LD50
LD50 Dermal - rabbit - > 3,100 mg/kg
Other information on acute toxicity
no data available
Skin corrosion/irritation
Skin - rabbit - Mild skin irritation
Serious eye damage/eye irritation
Eyes - rabbit - Mild eye irritation
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
Carcinogenicity - rat - Oral
Tumorigenic:Neoplastic by RTECS criteria. Kidney, Ureter, Bladder:Tumors.
Carcinogenicity - mouse - Oral
Tumorigenic:Neoplastic by RTECS criteria. Liver:Tumors.
Limited evidence of carcinogenicity in animal studies

IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
Reproductive toxicity - rat - Oral
Effects on Newborn: Growth statistics (e.g., reduced weight gain).
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no data available
Teratogenicity
Developmental Toxicity - rat - Oral
Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus).

no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. Causes respiratory tract irritation.
Harmful if swallowed.
Harmful if absorbed through skin. Causes skin irritation.
Causes eye irritation.

Signs and Symptoms of Exposure
CNS stimulation., To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: TC7700000
12. ECOLOGICAL INFORMATION
Toxicity
Toxicity to fish

LC50 - Carassius auratus (goldfish) - 8.8 mg/l - 96 h

Toxicity to daphnia
and other aquatic
invertebrates

EC50 - Daphnia magna (Water flea) - 3.6 mg/l - 48 h

Toxicity to algae

EC50 - Desmodesmus subspicatus (green algae) - 1.1 mg/l - 72 h

Persistence and degradability
Bioaccumulative potential
Bioaccumulation
Oryzias latipes - 38 d
Bioconcentration factor (BCF): 21 - 35
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.
Toxic to aquatic life.
no data available
13. DISPOSAL CONSIDERATIONS
Aldrich - 240494

Page 6 of 7

Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
Tributyl phosphate

CAS-No.
126-73-8

Revision Date
1993-04-24

CAS-No.
126-73-8

Revision Date
1993-04-24

CAS-No.
126-73-8

Revision Date
1993-04-24

Pennsylvania Right To Know Components
Tributyl phosphate
New Jersey Right To Know Components
Tributyl phosphate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Tributyl phosphate

Product Number
Brand

:
:

240494
Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen
Target Organs
Blood, Central nervous system
GHS Classification
Acute toxicity, Inhalation (Category 4)
Acute toxicity, Dermal (Category 5)
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2B)
Carcinogenicity (Category 2)
Acute aquatic toxicity (Category 2)
GHS Label elements, including precautionary statements
Pictogram
Signal word
Hazard statement(s)
H302 + H332
H313
H315 + H320
H351
H401

Warning
Harmful if swallowed or if inhaled
May be harmful in contact with skin.
Causes skin and eye irritation.
Suspected of causing cancer.
Toxic to aquatic life.

Precautionary statement(s)
P281
Use personal protective equipment as required.
P305 + P351 + P338
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if
present and easy to do. Continue rinsing.
Aldrich - 240494
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HMIS Classification
Health hazard:
Chronic Health Hazard:
Flammability:
Physical hazards:

2
*
1
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

3
1
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. Causes respiratory tract irritation.
Harmful if absorbed through skin. Causes skin irritation.
Causes eye irritation.
Harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Formula
Molecular Weight

:
:

C12H27O4P
266.31 g/mol

Component
Tributyl phosphate
CAS-No.
EC-No.
Index-No.

Concentration
126-73-8
204-800-2
015-014-00-2

-

4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate
personnel to safe areas.
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Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment
must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for
disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Components with workplace control parameters
Components

CAS-No.

Value

Tributyl
phosphate
Remarks

126-73-8

TWA

Control
parameters
0.2 ppm

Basis
USA. ACGIH Threshold Limit Values (TLV)

Eye & Upper Respiratory Tract irritation Headache Nausea Substances for which there is a
Biological Exposure Index or Indices (see BEI® section), see BEI® for Acetylcholinesterase
Inhibiting Pesticide
TWA
TWA
TWA

0.2 ppm
2.5 mg/m3
5 mg/m3
0.2 ppm
2.5 mg/m3

USA. OSHA - TABLE Z-1 Limits for Air Contaminants 1910.1000
USA. Occupational Exposure Limits (OSHA) - Table Z-1
Limits for Air Contaminants
USA. NIOSH Recommended Exposure Limits

Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose
combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the
respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components
tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
Splash protection
Material: butyl-rubber
Minimum layer thickness: 0.3 mm
Break through time: 480 min
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374
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If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as
offering an approval for any specific use scenario.
Eye protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of
workday.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

liquid

Colour

colourless

Safety data
pH

no data available

Melting
point/freezing point

Melting point/range: -79 °C (-110 °F) - lit.

Boiling point

180 - 183 °C (356 - 361 °F) at 29 hPa (22 mmHg) - lit.

Flash point

145 °C (293 °F) - closed cup

Ignition temperature

410 °C (770 °F)

Auto-ignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

36 hPa (27 mmHg) at 178 °C (352 °F)
9.7 hPa (7.3 mmHg) at 150 °C (302 °F)

Density

0.979 g/cm3 at 25 °C (77 °F)

Water solubility

no data available

Partition coefficient:
n-octanol/water

no data available

Relative vapor
density

9.19
- (Air = 1.0)

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
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Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents, Strong bases
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 1,552 mg/kg
Inhalation LC50
LC50 Inhalation - rat - 1 h - 28,000 mg/m3
Dermal LD50
LD50 Dermal - rabbit - > 3,100 mg/kg
Other information on acute toxicity
no data available
Skin corrosion/irritation
Skin - rabbit - Mild skin irritation
Serious eye damage/eye irritation
Eyes - rabbit - Mild eye irritation
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
Carcinogenicity - rat - Oral
Tumorigenic:Neoplastic by RTECS criteria. Kidney, Ureter, Bladder:Tumors.
Carcinogenicity - mouse - Oral
Tumorigenic:Neoplastic by RTECS criteria. Liver:Tumors.
Limited evidence of carcinogenicity in animal studies

IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
Reproductive toxicity - rat - Oral
Effects on Newborn: Growth statistics (e.g., reduced weight gain).
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no data available
Teratogenicity
Developmental Toxicity - rat - Oral
Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus).

no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. Causes respiratory tract irritation.
Harmful if swallowed.
Harmful if absorbed through skin. Causes skin irritation.
Causes eye irritation.

Signs and Symptoms of Exposure
CNS stimulation., To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: TC7700000
12. ECOLOGICAL INFORMATION
Toxicity
Toxicity to fish

LC50 - Carassius auratus (goldfish) - 8.8 mg/l - 96 h

Toxicity to daphnia
and other aquatic
invertebrates

EC50 - Daphnia magna (Water flea) - 3.6 mg/l - 48 h

Toxicity to algae

EC50 - Desmodesmus subspicatus (green algae) - 1.1 mg/l - 72 h

Persistence and degradability
Bioaccumulative potential
Bioaccumulation
Oryzias latipes - 38 d
Bioconcentration factor (BCF): 21 - 35
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.
Toxic to aquatic life.
no data available
13. DISPOSAL CONSIDERATIONS
Aldrich - 240494
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Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
Tributyl phosphate

CAS-No.
126-73-8

Revision Date
1993-04-24

CAS-No.
126-73-8

Revision Date
1993-04-24

CAS-No.
126-73-8

Revision Date
1993-04-24

Pennsylvania Right To Know Components
Tributyl phosphate
New Jersey Right To Know Components
Tributyl phosphate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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Material Safety Data Sheet
Section 1. Chemical Product and Company Identification
Product Name

Product Code

Formalin Solution 10% Neutral Buff. pH 7.0
Manufacturer's Name

28600
Emergency Telephone Number

StatLab Medical Products, Inc.

800-424-9300

Address (Number, Street, City, State, and ZIP Code)

Telephone Number for Information

407 Interchange st.

800-442-3573 x 2
Date Prepared

McKinney Tx 75071

10/14/2003 (rev 10/20/05)
Signature of Preparer (optional

Section 2. Composition/Information on Ingredients
Component

CAS #

Formaldehyde
Methyl Alcohol

OSHA PEL

Other Limits
Recommended

ACGIH TLV

Percent

3

50-00-0

0.75 ppm

C 0.3 mg/m

3-4

67-56-1

200 ppm

250 ppm

1-1.5

10049-21-5

N/A

N/A

<1

Sodium Phosphate Dibasic

7558-79-4

N/A

N/A

<1

Water, Deionized

7732-18-5

N/A

N/A

Balance

Sodium Phosphate Monobasic
Monohydrate

Section 3. Hazards Identification
Emergency Overview

Contains Formaldehyde, a suspected carcinogen.
system and skin.

be fatal if swallowed.
call a physician.

Irritating to the eyes, respiratory

May cause sensitization by inhalation or skin contact.

May

If ingested, dilute with water, induce vomiting then

Wash areas of contact with water.

If inhaled, remove to

fresh air.
Potential Health Effects
Target Organs

Eyes, skin, respiratory system.

Eye

Causes irritation, redness and pain.

Skin

May cause irritation, redness and pain.

Frequent or prolonged

exposure may cause hypersensitivity leading to contact dermatitis.
Ingestion

May cause severe abdominal pain, vomiting, headache and diarrhea.

Inhalation

Causes irritation of respiratory tract.

Symptoms may include

sore throat, coughing and shortness of breath.
Chronic/Carcinogenicity

IARC-Formaldehyde is probably carcinogenic.

is reasonably anticipated to be a carcinogen.
Teratology

NTP-Formaldehyde

OSHA-Yes (Formaldehyde)

Mutation data cited in "Registry of Toxic Effects of Chemical

Substances" on Formaldehyde.
Reproduction

Reproductive effects cited in "Registry of Toxic Effects

of Chemical Substances"

on Formaldehyde.

Mutagenicity

Statlab Medical Products, Inc.
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Material Safety Data Sheet
Product Name

Formalin Solution 10% Neutral Buff. pH 7.0

28600

Section 4. First Aid Measures
Irrigate immediately with large quantity of water for at

Eye

least 15 minutes.
Skin

Flush with water for at least 15 minutes.

Ingestion

Dilute immediately with water or milk.

Induce vomiting.

Call a physician.
Inhalation

Remove to fresh air.

All Other Means of Exposure

CONTACT POISON CONTROL CENTER IMMEDIATELY.

Give artificial respiration if necessary.
Be prepared to

provide hazardous ingredient information from Section 2.
Section 5. Fire Fighting Measures
Flammable Properties

Flash Point

N/A

Method

N/A

Flammable Limits

Lower

N/A

Upper

N/A

Autoignition Temperature

Hazardous Combustion Products

Extinguishing Media

fire.

Use any means suitable for extinguishing the surrounding

(Water spray, dry chemical, alcohol foam, or carbon dioxide.)

Fire & Explosion Hazards

Not considered to be a fire or explosion hazard.

Fire Fighting Instructions

Use normal procedures/instructions.

Fire Fighting Equipment

Use protective clothing and breathing equipment appropriate

for the surrounding fire.
Section 6. Accidental Release Measures
Ventilate area of leak or spill.
cat litter and sand.

Cover spill with 1:1:1 mixture of Sodium Carbonate, clay

Scoop into container and transport to fume hood.

Add the

mixture to cold water (about 10 mL water for each 1 mL of Formaldehyde solution).
Slowly add household bleach (2.5 mL bleach for each 1 mL of Formaldehyde solution).
Allow to stand for 20 minutes.

Decant liquid to drain.

Flush with water.

Treat

solid residue as normal refuse.
Section 7. Handling and Storage
Handling/Storage

As with all chemicals, wash hands thoroughly after handling.

Avoid contact with eyes.
adequate ventilation.

Protect from freezing and physical damage.

Use with

Store at controlled room temperature, 15-30°C.

SAFETY STORAGE CODE: HEALTH

Statlab Medical Products, Inc.
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Material Safety Data Sheet
Product Name

Formalin Solution 10% Neutral BuffProduct Code

28600

Section 8. Exposure Controls, Personal Protection
Engineering Controls

Use of a fume hood is recommended.

Respiratory Protection

If the exposure level is exceeded, wear a full facepiece

respirator equipped with a formaldehyde cartridge.
Skin Protection

Gloves

Eye Protection

Safety glasses or goggles.

Permissible Exposure Levels (see also Section 2)
Component

CAS #

OSHA PEL

Other Limits
Recommended

ACGIH TLV

Percent

3

Formaldehyde

50-00-0

0.75 ppm

C 0.3 mg/m

3-4

Methyl Alcohol

67-56-1

200 ppm

250 ppm

1-1.5

10049-21-5

N/A

N/A

<1

Sodium Phosphate Dibasic

7558-79-4

N/A

N/A

<1

Water, Deionized

7732-18-5

N/A

N/A

Balance

Sodium Phosphate Monobasic
Monohydrate

Section 9. Physical and Chemical Properties
approx.
100°C

Specific Gravity (H2O = 1)

Vapor Pressure (mm Hg)

Melting Point

Boiling Point

N/A

Vapor Density (AIR = 1)

approx.
1.02
approx.
0°C

Evaporation rate
(Butyl Acetate = 1)
Physical State

Solubility in Water

Infinite
Appearance and Odor

Other

Clear, colorless/pungent odor

pH: 7.0

Section 10. Stability and Reactivity
Chemical Stability

Stable under normal conditions of use and storage.

Incompatibility

Strong oxidizers, strong alkalies, acids, phenol, urea.

Hazardous Decomposition Products

May form Carbon Dioxide, Carbon Monoxide and

Formaldehyde when heated to decomposition.
Hazardous Polymerization

Nonhazardous polymerization may occur, forming

paraformaldehyde, a white solid.
Section 11. Toxological Information
LD50, Oral, Rat: (Formaldehyde) 100 mg/kg;

LD50, Oral, Rat: (Sodium Phosphate

Diabasic) 17,000 mg/kg; Details of toxic effects not reported other than lethal
dose value.

Statlab Medical Products, Inc.
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Material Safety Data Sheet
Product Name

Formalin Solution 10% Neutral BuffProduct Code

28600

Section 12. Ecological Information
Ecotoxicological Information:

Formaldehyde is expected to be slightly toxic

to aquatic life.
Chemical Fate Information:

Formaldehyde is expected to readily biodegrade when

released into water.
Section 13. Disposal Considerations
Whatever cannot be saved for recovery or recycling should be disposed of in a
RCRA approved waste disposal facility.

Dispose of in accordance with local,

state, and federal regulations.
Section 14. Transport Information
GROUND SHIPMENTS:

Not regulated

AIR SHIPMENTS:

Aviation Regulated Liquid n.o.s.

NOTE:

(formaldehyde), 9, UN3334

It is ultimately the shippers responsibility to make hazard class

determination based on their best information available.
Section 15. Regulatory Information
OSHA Status:

This item meets the OSHA Hazard Communication Standard (29 CFR 1910.1200)

definition of a hazardous material.
TSCA Status:
CERCLA

All components of this solution are listed on the TSCA Inventory.

Reportable Quantity:

Formaldehyde, RQ 100 pounds.

SARA TITLE III:
Section 302 Extremely Hazardous Substances: Formaldehyde TPQ 500 pounds
Section 311/312 Hazardous Categories:

No

Section 313 Toxic Chemicals: Formaldehyde, 0.1% De Minimus concentration
RCRA Status:

No

California Proposition 65: No listed (Formaldehyde gas is listed)
Florida:

Formaldehyde is listed on the state Toxic Substances List.

Pennsylvania: Formaldehyde is listed as an environmental and special hazard on the
Hazardous Substances List.
Section 16. Other Information
NFPA Ratings: Health: 2 Flammability: 2 Reactivity: 0 Special Notice Key: None
HMIS® Ratings: Health: 4 Flammability: 2 Reactivity: 0 Protective Equipment: C
(protective eyewear and gloves)
When handled properly by qualified personnel, the product described herein does not present a significant health or safety hazard.
Alteration to its characteristics by concentration, evaporation, addition of other substances, or other means may present hazards
not specifically addressed herein and which must be evaluated by the user. The information furnished herein is believed to be
accurate and represents the best data currently available to us. No warranty, expressed or implied, is made and STATLAB MEDICAL
PRODUCTS, INC. assumes no legal responsibility or liability whatsoever resulting from its use.

Statlab Medical Products, Inc.
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Material Safety Data Sheet
beta-Propiolactone MSDS
Section 1: Chemical Product and Company Identification
Product Name: beta-Propiolactone

Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

Catalog Codes: SLP4486
CAS#: 57-57-8
RTECS: RQ7350000
TSCA: TSCA 8(b) inventory: beta-Propiolactone
CI#: Not available.

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com

Synonym: 2-Oxetanone

CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300

Chemical Formula: C3H4O2

International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

{beta-}Propiolactone

57-57-8

100

Toxicological Data on Ingredients: beta-Propiolactone: VAPOR (LC50): Acute: 25 ppm 4 hour(s) [Rat].

Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of ingestion, of inhalation. Hazardous in case of skin contact (irritant), of eye contact (irritant). Slightly
hazardous in case of skin contact (permeator). Corrosive to skin and eyes on contact. Liquid or spray mist may produce tissue
damage particularly on mucous membranes of eyes, mouth and respiratory tract. Skin contact may produce burns. Inhalation
of the spray mist may produce severe irritation of respiratory tract, characterized by coughing, choking, or shortness of breath.
Severe over-exposure can result in death.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Classified + (PROVEN) by OSHA. Classified 2B (Possible for human.) by IARC. Classified
A2 (Suspected for human.) by ACGIH, 2 (Reasonably anticipated.) by NTP. MUTAGENIC EFFECTS: Not available.
TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance is toxic to kidneys,
lungs, liver, digestive system. Repeated or prolonged exposure to the substance can produce target organs damage.
Repeated or prolonged contact with spray mist may produce chronic eye irritation and severe skin irritation. Repeated or
prolonged exposure to spray mist may produce respiratory tract irritation leading to frequent attacks of bronchial infection.
Repeated exposure to an highly toxic material may produce general deterioration of health by an accumulation in one or many
human organs.
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Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. Immediately flush eyes with running water for at least 15 minutes, keeping eyelids
open. Cold water may be used. Do not use an eye ointment. Seek medical attention.
Skin Contact:
If the chemical got onto the clothed portion of the body, remove the contaminated clothes as quickly as possible, protecting
your own hands and body. Place the victim under a deluge shower. If the chemical got on the victim's exposed skin, such
as the hands : Gently and thoroughly wash the contaminated skin with running water and non-abrasive soap. Be particularly
careful to clean folds, crevices, creases and groin. Cold water may be used. If irritation persists, seek medical attention. Wash
contaminated clothing before reusing.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation: Allow the victim to rest in a well ventilated area. Seek immediate medical attention.
Serious Inhalation:
Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or waistband. If
breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth resuscitation. WARNING: It may
be hazardous to the person providing aid to give mouth-to-mouth resuscitation when the inhaled material is toxic, infectious or
corrosive. Seek immediate medical attention.
Ingestion:
Do not induce vomiting. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that
the toxic material was ingested; the absence of such signs, however, is not conclusive. Loosen tight clothing such as a collar,
tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth resuscitation. Seek immediate medical attention.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Combustible.
Auto-Ignition Temperature: Not available.
Flash Points: OPEN CUP: 70°C (158°F).
Flammable Limits: LOWER: 2.9%
Products of Combustion: These products are carbon oxides (CO, CO2).
Fire Hazards in Presence of Various Substances: Flammable in presence of heat.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions:
SMALL FIRE: Use DRY chemical powder. LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Special Remarks on Fire Hazards: Not available.
Special Remarks on Explosion Hazards: Not available.

Section 6: Accidental Release Measures
Small Spill:
Dilute with water and mop up, or absorb with an inert dry material and place in an appropriate waste disposal container.
p. 2

Large Spill:
Combustible material. Corrosive liquid. Keep away from heat. Keep away from sources of ignition. Stop leak if without risk.
Absorb with DRY earth, sand or other non-combustible material. Do not get water inside container. Do not touch spilled
material. Use water spray curtain to divert vapor drift. Prevent entry into sewers, basements or confined areas; dike if needed.
Eliminate all ignition sources. Call for assistance on disposal. Be careful that the product is not present at a concentration level
above TLV. Check TLV on the MSDS and with local authorities.

Section 7: Handling and Storage
Precautions:
Keep locked up Keep container dry. Keep away from heat. Keep away from sources of ignition. Ground all equipment
containing material. Do not ingest. Do not breathe gas/fumes/ vapour/spray. Never add water to this product Wear suitable
protective clothing In case of insufficient ventilation, wear suitable respiratory equipment If ingested, seek medical advice
immediately and show the container or the label. Avoid contact with skin and eyes
Storage:
Flammable materials should be stored in a separate safety storage cabinet or room. Keep away from heat. Keep away from
sources of ignition. Keep container tightly closed. Keep in a cool, well-ventilated place. Ground all equipment containing
material. Keep container dry. Keep in a cool place.

Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their respective
threshold limit value. Ensure that eyewash stations and safety showers are proximal to the work-station location.
Personal Protection:
Splash goggles. Lab coat. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Vapor respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits:
TWA: 0.5 (ppm) TWA: 1.5 (mg/m3) Consult local authorities for acceptable exposure limits.

Section 9: Physical and Chemical Properties
Physical state and appearance: Liquid.
Odor: Pungent.
Taste: Not available.
Molecular Weight: 72.06 g/mole
Color: Colorless.
pH (1% soln/water): Not available.
Boiling Point: Decomposes. (155°C or 311°F)
Melting Point: -33.4°C (-28.1°F)
Critical Temperature: Not available.
Specific Gravity: 1.48 (Water = 1)
Vapor Pressure: 3.4 mm of Hg (@ 20°C)
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Vapor Density: 2.5 (Air = 1)
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility: Soluble in cold water.

Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Not available.
Incompatibility with various substances: Not available.
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity: Not available.
Special Remarks on Corrosivity: Not available.
Polymerization: Yes.

Section 11: Toxicological Information
Routes of Entry: Eye contact. Inhalation. Ingestion.
Toxicity to Animals:
WARNING: THE LC50 VALUES HEREUNDER ARE ESTIMATED ON THE BASIS OF A 4-HOUR EXPOSURE. Acute toxicity
of the vapor (LC50): 25 ppm 4 hour(s) [Rat].
Chronic Effects on Humans:
CARCINOGENIC EFFECTS: Classified + (PROVEN) by OSHA. Classified 2B (Possible for human.) by IARC. Classified
A2 (Suspected for human.) by ACGIH, 2 (Reasonably anticipated.) by NTP. The substance is toxic to kidneys, lungs, liver,
digestive system.
Other Toxic Effects on Humans:
Very hazardous in case of ingestion, of inhalation. Hazardous in case of skin contact (irritant). Slightly hazardous in case of
skin contact (permeator).
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans: Not available.
Special Remarks on other Toxic Effects on Humans: Not available.

Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
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Toxicity of the Products of Biodegradation: The products of degradation are more toxic.
Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
Waste Disposal:

Section 14: Transport Information
DOT Classification: CLASS 6.1: Poisonous material.
Identification: : Toxic liquids n.o.s. : UN2810 PG: Not available.
Special Provisions for Transport: Not available.

Section 15: Other Regulatory Information
Federal and State Regulations:
California prop. 65: This product contains the following ingredients for which the State of California has found to cause cancer,
birth defects or other reproductive harm, which would require a warning under the statute: beta-Propiolactone California prop.
65: This product contains the following ingredients for which the State of California has found to cause cancer which would
require a warning under the statute: beta-Propiolactone Pennsylvania RTK: beta-Propiolactone Florida: beta-Propiolactone
Minnesota: beta-Propiolactone Massachusetts RTK: beta-Propiolactone New Jersey: beta-Propiolactone TSCA 8(b) inventory:
beta-Propiolactone SARA 313 toxic chemical notification and release reporting: beta-Propiolactone CERCLA: Hazardous
substances.: beta-Propiolactone
Other Regulations: OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
Other Classifications:
WHMIS (Canada):
CLASS B-3: Combustible liquid with a flash point between 37.8°C (100°F) and 93.3°C (200°F). CLASS D-1A: Material causing
immediate and serious toxic effects (VERY TOXIC). CLASS D-2A: Material causing other toxic effects (VERY TOXIC). CLASS
E: Corrosive liquid.
DSCL (EEC):
R26- Very toxic by inhalation. R36/38- Irritating to eyes and skin. R45- May cause cancer.
HMIS (U.S.A.):
Health Hazard: 0
Fire Hazard: 2
Reactivity: 0
Personal Protection: h
National Fire Protection Association (U.S.A.):
Health: 0
Flammability: 2
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Lab coat. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Wear appropriate respirator
when ventilation is inadequate. Splash goggles.
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Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/09/2005 06:12 PM
Last Updated: 06/09/2012 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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SIGMA-ALDRICH

sigma-aldrich.com

Material Safety Data Sheet
Version 5.2
Revision Date 11/05/2012
Print Date 02/11/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Sodium pyruvate

Product Number
Brand

:
:

80443
Sigma-Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS).
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Formula
Molecular Weight

:
:

C3H3NaO3
110.04 g/mol

No ingredients are hazardous according to OSHA criteria.
4. FIRST AID MEASURES
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.

Sigma-Aldrich - 80443
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In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Keep in a dry place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Sigma-Aldrich - 80443
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Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

powder

Colour

white

Safety data
pH

7

Melting
point/freezing point

Melting point/range: > 300 °C (> 572 °F) - lit.

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Autoignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

no data available

Water solubility

soluble

Partition coefficient:
n-octanol/water

no data available

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
no data available
Inhalation LC50
Sigma-Aldrich - 80443
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no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available

Teratogenicity
no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: Not available
12. ECOLOGICAL INFORMATION
Sigma-Aldrich - 80443
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Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sodium pyruvate

CAS-No.
113-24-6

Revision Date

CAS-No.
113-24-6

Revision Date

New Jersey Right To Know Components
Sodium pyruvate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
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16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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SIGMA-ALDRICH

sigma-aldrich.com

Material Safety Data Sheet
Version 4.3
Revision Date 12/31/2012
Print Date 02/11/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

Sodium bicarbonate

Product Number
Brand

:
:

S8875
Sigma-Aldrich

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS).
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
Synonyms

:

Sodium hydrogen carbonate

Formula
Molecular Weight

:
:

CHNaO3
84.01 g/mol

No ingredients are hazardous according to OHSA criteria.
4. FIRST AID MEASURES
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If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
Splash protection
Material: Nitrile rubber
Sigma-Aldrich - S8875
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Minimum layer thickness: 0.11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as
offering an approval for any specific use scenario.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the
specific work-place., The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form

crystalline

Colour

no data available

Safety data
pH

no data available

Melting
point/freezing point

300 °C (572 °F)

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Auto-ignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

2.160 g/cm3

Water solubility

50 g/l

Partition coefficient:
n-octanol/water

no data available

Relative vapor
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Sigma-Aldrich - S8875
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Possibility of hazardous reactions
no data available
Conditions to avoid
Exposure to moisture.
Materials to avoid
Strong acids, Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 4,220 mg/kg
Inhalation LC50
no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
Skin - Human - Mild skin irritation - 3 d
Serious eye damage/eye irritation
Eyes - rabbit - Mild eye irritation - 30 s
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available
Teratogenicity
no data available

Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
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Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
Exposure to large amounts can cause:, Gastrointestinal disturbance, Heavy or prolonged skin exposure may result in the
absorption of harmful amounts of material.
Synergistic effects
no data available
Additional Information
RTECS: VZ0950000
12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
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SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
Sodium hydrogencarbonate

CAS-No.
144-55-8

Revision Date

CAS-No.
144-55-8

Revision Date

New Jersey Right To Know Components
Sodium hydrogencarbonate

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
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SIGMA-ALDRICH

sigma-aldrich.com

Material Safety Data Sheet
Version 5.1
Revision Date 01/20/2012
Print Date 04/07/2013

1. PRODUCT AND COMPANY IDENTIFICATION
Product name

:

EX-CELL(TM) 420 w/L-glutamine

Product Number
Brand

:
:

24420C
Sigma

Supplier

:

Telephone
Fax
Emergency Phone # (For
both supplier and
manufacturer)
Preparation Information

:
:
:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA
+1 800-325-5832
+1 800-325-5052
(314) 776-6555

:

Sigma-Aldrich Corporation
Product Safety - Americas Region
1-800-521-8956

2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
No known OSHA hazards
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS).
HMIS Classification
Health hazard:
Flammability:
Physical hazards:

0
0
0

NFPA Rating
Health hazard:
Fire:
Reactivity Hazard:

0
0
0

Potential Health Effects
Inhalation
Skin
Eyes
Ingestion

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.
May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS
No ingredients are hazardous according to OHSA criteria.
4. FIRST AID MEASURES
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.

Sigma - 24420C
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In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
5. FIREFIGHTING MEASURES
Conditions of flammability
Not flammable or combustible.
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed
and kept upright to prevent leakage.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or type ABEK (EU EN 14387)
respirator cartridges. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH
(US) or EN 166(EU).
Skin and body protection
impervious clothing, The type of protective equipment must be selected according to the concentration and amount
of the dangerous substance at the specific workplace.
Hygiene measures
General industrial hygiene practice.
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form
Sigma - 24420C
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Colour

no data available

Safety data
pH

no data available

Melting
point/freezing point

no data available

Boiling point

no data available

Flash point

no data available

Ignition temperature

no data available

Autoignition
temperature

no data available

Lower explosion limit

no data available

Upper explosion limit

no data available

Vapour pressure

no data available

Density

no data available

Water solubility

no data available

Partition coefficient:
n-octanol/water

no data available

Relative vapour
density

no data available

Odour

no data available

Odour Threshold

no data available

Evaporation rate

no data available

10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
no data available
Hazardous decomposition products
Other decomposition products - no data available
11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
no data available
Inhalation LC50
no data available
Dermal LD50
no data available
Other information on acute toxicity
no data available
Skin corrosion/irritation
no data available
Sigma - 24420C
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Serious eye damage/eye irritation
Eyes: no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available

Teratogenicity
no data available
Specific target organ toxicity - single exposure (Globally Harmonized System)
no data available
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
Ingestion
Skin
Eyes

May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if swallowed.
May be harmful if absorbed through skin. May cause skin irritation.
May cause eye irritation.

Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: Not available
12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
Sigma - 24420C
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no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available
13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.
14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
OSHA Hazards
No known OSHA hazards
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
EX-CELL(TM) 420 w/L-glutamine

CAS-No.
-

Revision Date

CAS-No.
-

Revision Date

New Jersey Right To Know Components
EX-CELL(TM) 420 w/L-glutamine

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for
additional terms and conditions of sale.
Sigma - 24420C
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Biosafe®
Single-Use Aseptic Transfer Systems

turning science into solutions

A Complete Range…
Autoclavable Biosafe Bags
– Open autoclavable Biosafe bags
are filled on-site prior to autoclave
sterilization and aseptic transfer.
– Prefilled autoclavable Biosafe bags
are delivered ready-to-sterilize by
your component supplier.
– Entry of stoppers, tools, pump into
isolators, RABS and cleanrooms.

…of Bags for a Variety of Applications
The Biosafe range of bags is designed
to best fit your requirements for aseptic
transfer of stoppers, pumps, tools,
QC test devices, fluids and powders
into critical processing areas.

Gamma Irradiatable Biosafe Bags
– Prefilled Biosafe bags are delivered gamma sterilized
by your component supplier for the entry of stoppers
(prefillable syringe, vial, carpule), QC test devices and
any other gamma sterilizable parts.
– Gamma irradiated Biosafe bags are used for the removal of
waste, tools, pumps and QC test devices from critical areas.
– Rapid Aseptic Fluid Transfer (RAFT) System is a sterile
system designed for the aseptic transfer of liquids.

Gamma Irradiated
Double-Connector Biosafe Bags
Specifically designed for the two-step
transfer of components from autoclave
(using the Biosafe Biosteam Port) into
an isolator.

Dummy Service Connector
For sterilization and maintenance
of the Biosafe Ports.

The Biosafe® Port

Biosafe Three-Lever Port
For the aseptic transfer of
fluids into cleanrooms.

The Biosafe range of aseptic transfer
ports offers reliable and easy-to-use
solutions that meet your specific
needs and applications. The unique
design of the Biosafe system
enables the secure transfer
of components, fluids and
powders while maintaining
the integrity of the
critical area.

Biosafe Monolever Port
For the aseptic transfer
of components and
fluids into isolators,
RABS and cleanrooms.

The
Highest
Quality
Assurance

Biosafe Biosteam® Port
– When installed on autoclaves, the
steamable version of the Biosafe Port
allows reliable aseptic discharging
of bulk stoppers from the autoclave
into double-connector gamma
irradiated bags prior to transfer
into an isolator.
– Allows the contained addition
of powders into formulation
vessels.

– Manufactured in ISO 9001
and ISO 13485 certified facilities
– 100% quality control on Biosafe
Ports – Dimensional and leak testing
– 100% quality control on Biosafe bag
connector assemblies
– Biosafe bags assembled in Class C
(ISO 7) cleanrooms

Biosafe Automatic Port
Automated aseptic
transfer of components
into isolators and RABS.

Achieving Safe, Easy-to-Use & Reliable Aseptic Transfer

1

2

Biosafe Aseptic Transfer Systems
1. Biosafe bag approach
2. Magnetic docking
3. Transfer

3

Enhanced Sterility Assurance in
Aseptic Processing
– Offers a contained and single-use
technology for safer aseptic transfer.
– Limits the number and complexity of
personnel interventions in the aseptic
processing area.
– Offers a completely closed aseptic
process.
Safer Processing of Potent Drugs
– Maintains the barrier integrity of RABS
and isolators and security of operators.
Ease-of-Use
– The magnet on the port allows easy
centering and secure docking of the
Biosafe bag.
Process Safety
– Mechanical interlock securities prevent
door opening when a bag is not connected or from disconnecting a bag if the
Biosafe Port is not closed.
– Automatic inter-door vacuum integrity
test of Biosafe Port and connector.

Versatile Technoloy
– The range of Biosafe systems is designed
to best fit a variety of applications while
ensuring a high level of containment.
– Biosafe is a unique technology for the
aseptic transfer of components, fluids
and powders.
Simplified Maintenance and Sterilization
– When connected to the Biosafe Port, the
dummy service connector facilitates the
sterilization of the critical area, the inner
side of the Biosafe Port and maintenance
operations.
Proven Containment
– Biosafe Ports and connectors are 100%
leak tested during production.
– Packaging Biosafe bags under vacuum
can offer an additional guaranty of
integrity.
Practical and Economical Benefits
– The Biosafe bags eliminate cleaning and
sterilization required for traditional
transfer containers.
– The RAFT System simplifies facility
layout and reduces higher classification
cleanroom area by keeping large volume
support solutions outside the cleanroom.

In|Out Aseptic Transfer
into

Clean- Isolator RABS
room

Biosafe 110 Three-Lever TTI Port

•

Biosafe 110 Monolever Port

•

Biosafe 110 Automatic Port
Biosafe 110 Biosteam Port

•

•*

•

•*

Autoclave

Formulation
vessel

•

•

* The Biosafe Port with outside opening is the best choise to prevent air turbulence in RABS

Services to Filling Line in Aseptic Processing

Applied to filling lines, the
Biosafe technology is the
answer to a variety af aseptic
transfer applications around
the filling process.

Removal of waste

Removal of
Petri dishes

The RAFT System is used
for the aseptic transfer
of bulk final product
onto the filling line
within an isolator,
RABS or cleanroom.

Entry of sterile fluid

The inner sleeve of Biosafe
bags guides the components
during transfer.
Bulk autoclave discharging
with the Biosafe Biosteam
Port on the autoclave.

Entry of stoppers or caps

Entry of stoppers or caps

Entry of QC test devices

Entry of tools

Upstream & Downstream Processing
Entry of powder
The Biosafe Biosteam Port can
be cleaned and sterilized in-place
along with the formulation vessel.
The Biosafe bags are used for the
contained transfer of powders for
media and buffer preparation.

Transfer of
powder for
buffer and
media
formulation

Seed
transfer

Transfer of
cell culture
media and
other solutions to
bioreactor

Transfer of
buffers for
centrifugation and
clarification

Transfer of
buffers to
chromatography

Transfer of
buffers to
purification

Transfer of
buffers to
recovery
operation

Transfer of
buffers to
chromatography
column

Transfer of
buffers to
UF/DF system

The RAFT System provides easy-to-use and
reliable through-the-wall aseptic transfer
of fluids between biomanufacturing zones.
The attached diagram demonstrates
segregation of media and buffer solutions
maintained in the materials hall, enabling
substantial reduction of higher classification cleanroom areas.

Sales and Service Contacts
For further contacts, visit www.sartorius-stedim.com

America

Asia|Pacific

Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen

Austria
Sartorius Stedim Austria GmbH
Franzosengraben 12
A-1030 Vienna

USA
Sartorius Stedim North America Inc.
131 Heartland Blvd.
Edgewood, New York 11717

Phone +49.551.308.0
Fax +49.551.308.3289

Phone +43.1.7965763.18
Fax +43.1.796576344

Toll-Free +1.800.368.7178
Fax +1.631.254.4253

India
Sartorius Stedim India Pvt. Ltd.
10, 6th Main, 3rd Phase Peenya
KIADB Industrial Area
Bangalore – 560 058

Belgium
Sartorius Stedim Belgium N.V.
Leuvensesteenweg, 248/B
1800 Vilvoorde

Sartorius Stedim SUS Inc.
1910 Mark Court
Concord, CA 94520

www.sartorius-stedim.com
Sartorius Stedim Systems GmbH
Schwarzenberger Weg 73–79
34212 Melsungen
Phone +49.5661.71.3400
Fax +49.5661.71.3702
www.sartorius-stedim.com
France
Sartorius Stedim Biotech S.A.
Z.I. des Paluds
Avenue de Jouques – BP 1051
13781 Aubagne Cedex

Phone +32.2.756.06.80
Fax +32.2.756.06.81
Denmark
Sartorius Stedim Nordic A/S
Hoerskaetten 6D, 1.
DK-2630 Taastrup
Phone +45.7023.4400
Fax +45.4630.4030

Phone +33.442.845600
Fax +33.442.845619

Italy
Sartorius Stedim Italy S.p.A.
Via dell’Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)

Sartorius Stedim France
4, rue Emile Baudot
91127 Palaiseau Cedex

Phone +39.055.63.40.41
Fax +39.055.63.40.526

Phone +33.1.6919.2100
Fax +33.1.6920.0922

Netherlands
Sartorius Stedim Netherlands B.V.
Edisonbaan 24
3439 MN Nieuwegein

Sartorius Stedim Aseptics S.A
Z.I. de Saux
Rue Ampère
65000 Lourdes
Phone +33.5.62.42.73.73
Fax +33.5.62.42.08.44

Phone +31.30.6025080
Fax +31.30.6025099
Spain
Sartorius Stedim Spain SA
C/Isabel Colbrand 10–12,
Planta 4, Oficina 121
Polígono Industrial de Fuencarral
28050 Madrid

Phone +1.925.689.6650
Toll Free +1.800.914.6644
Fax +1.925.689.6988

Phone +91.80.2839.1963|0461
Fax +91.80.2839.8262
Japan
Sartorius Stedim Japan K.K.
KY Building, 8–11
Kita Shinagawa 1-chome
Shinagawa-ku
Tokyo 140-0001
Phone +81.3.3740.5407
Fax +81.3.3740.5406
Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur
Phone +60.3.8996.0622
Fax +60.3.8996.0755
Singapore
Sartorius Stedim Singapore Pte. Ltd.
10, Science Park Road, The Alpha
#02-25, Singapore Science Park 2
Singapore 117684
Phone +65.6872.3966
Fax +65.6778.2494
Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 17/104 Ferntree Gully Road
Waverley Business Park
East Oakleigh, Victoria 3166
Phone +61.3.9590.8800
Fax +61.3.9590.8828

Phone +34.91.3586102
Fax +34.91.3588804
Switzerland
Sartorius Stedim Switzerland GmbH
Lerzenstrasse 21
8953 Dietikon
Phone +41.1.746.50.00
Fax +41.1.746.50.50
U.K.
Sartorius Stedim UK Limited
Longmead Business Park
Blenheim Road, Epsom
Surrey KT19 9 QQ
Phone +44.1372.737159
Fax +44.1372.726171

Biosafe and Biosteam are
registered trademarks of
Sartorius Stedim Aseptics S.A.

Specifications subject to change without notice. Printed in Germany on paper that has been bleached without any use of chlorine. W/sart-000 · G.
Publication No.: SPT1001-e08021 · Order No.: 85034-534-73

Europe

Sterile Tube Fuser &
Hot Lips Tube Sealer®

Catalog
The Sterile Tube Fuser and Hot Lips Tube Sealer II provide a complete solution to aseptic fluid
handling in pharmaceutical and biotech environments. These products allow for leakproof
aseptic connections and thermal seals of large bore thermoplastic tubing. This catalog
includes features, specifications and pricing information for both products. Please contact
Wave Biotech for additional technical or validation information.

Hot Lips Tube Sealer II

Sterile Tube Fuser - IRc

Sterile Tube Fuser - IRcWW

Wave Europe Pvt. Ltd +353 21 497 7014
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The Sterile Tube Fuser
is a fully automated device for welding together thermoplastic tubing in a sterile operation
without the need for a laminar flow cabinet. The machine is useful for connecting tubing
between sterile containers, bags, and process equipment. The unit can connect large diameter
(up to 7/8” OD) tubing for the rapid and easy transfer of large volumes. Major uses are
bioprocessing and aseptic pharmaceutical applications.
The compact Sterile Tube Fuser (STF-IRc) uses infrared technology to control depyrogenation
and welding temperatures. Disposable, single-use, PTFE coated blades are used in the
process. The new, long awaited wet welding model, STF-IRcWW allows welding of liquid-filled
C-Flex tubing.
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Applications
x
x
x
x
x

Sterile media and buffer transfer.
Connection of bioreactors for feed and harvest.
Process fluid transfer.
In-process pooling.
Final fill operations.

Features










Welds any thermoplastic tubing from 6.4mm to 22.2mm OD (! in. to 7/8 in.) using
interchangeable holders.
Wet welding of 6.4,11.2,12.5 and 15.5mm OD C-Flex available in STF-IRcWW model.
Use C-Flex®, PharMed®, Tygon®/PVC or similar tubing.
Thermal weld provides exceptional strength.
Make aseptic connections without a laminar flow cabinet.
New, more compact design; portable.
User-programmable for various tubing types.
Requires only electrical service. 110/220VAC universal voltage.
Proven, validated performance for GMP operations.

Specifications
Power:
Size:
Weight:
Max tubing OD:
Min tubing OD:
Approvals:
Typical fusing cycle:
Cutting blades:

110/220 VAC (auto switching) 1 Amp max.
381mm x 325mm x 254mm (15” L x 13” W x 10” H)
16 Kg (35 lbs)
22mm (7/8”)
6.4mm (!”)
CE, EMV
~2 minutes
non-sterile, PTFE-coated, single-use
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Quick Selection Guide - COMPONENTS
PART NUMBER
STF-IRc

DESCRIPTION

IMAGE

Sterile Tube Fuser -IRc -Compact - equipped with TUBE1-IR
(15.5mm OD tube holder set). Pre-programmed for C-Flex,
Sanipure ,PharMed and Tygon/PVC. 110/220VAC (auto
switching).

STF-IRcWW

Sterile Tube Fuser - IRc for Liquid-Filled Welding - equipped
with TUBE1 -IR/WW (15.5mm OD wet welding tube holder
set). Pre-programmed for C-Flex. 110/220VAC universal
voltage.

TUBE1-IR

Tube holder set for 15.5mm (5/8”) OD tubing.

TUBE2-IR

Tube holder set for 19.1mm (3/4”) OD tubing.

TUBE3-IR

Tube holder set for 11.2mm (7/16” ) OD tubing.

TUBE4-IR

Tube holder set for 6.4mm (1/4”) OD tubing.

TUBE5-IR

Tube holder set for 8.0mm (5/16”) OD tubing.

TUBE6-IR

Tube holder set for 9.6mm (3/8”) OD tubing.

TUBE7-IR

Tube holder set for 12.5mm (1/2”) OD tubing.

TUBE8-IR

Tube holder set for 22.2mm (7/8”) OD tubing.

TUBE1-IR/WW

Tube holder set for 15.5mm (5/8”) OD tubing. For use with
wet welding STF-IRcWW only.

TUBE3-IR/WW

Tube holder set for 11.2mm (7/16”) OD tubing. For use
with wet welding STF-IRcWW only.

TUBE4-IR/WW

Tube holder set for 6.4mm (1/4”) OD tubing. For use
with wet welding STF-IRcWW only.

TUBE7-IR/WW

Tube holder set for 12.5mm (1/2”) OD tubing. For use
with wet welding STF-IRcWW only.

BLADES-IR/50

Single use stainless steel cutting blades with PTFE coating.
Non-sterile. 50 blades/package.

STF-IRc.003214

Two color thermal printer option for compact Sterile Tube
Fuser - IRc. Includes one roll of paper.

STF-IRc-CALKIT

Calibration verification kit for Sterile Tube Fuser. Includes Maintenance manual, Validation
documents, PCKit, BLADESENSOR-K, & security key for access.

Wave Europe Pvt. Ltd +353 21 497 7014

FAX +353 21 497 7590 www.wave-europe.com Sept 2006
Page 4

The Hot Lips Tube Sealer II
is an ultraportable device for heat sealing thermoplastic tubing. The leakproof, tamperproof
seal produced is ideal for ensuring inoculum, products, media and buffers do not leak as with
tubing clamps or plugs on bioprocess bags and other vessels. Hot Lips is a fully automated
device for sealing thermoplastic tubing from 6.4mm (1/4") OD to 31.8mm (1.25") OD in a sterile
operation without the need for a laminar flow hood. Major uses are for sealing bags prior to
transport, or after sampling and process fluid transfer.

Applications
x
x
x
x
x

Use wherever a tamperproof, leakproof seal is desired.
Sealing bioprocess bags and bioreactors.
In-process pooling.
Sampling operations.
Storage vessel closure.

Features










Seals any thermoplastic tubing from 6.4mm (1/4") OD to 31.8mm (1.25") OD.
Use PharMed, C-Flex, PVC, Sanipure or similar tubing.
Thermal seal provides tamperproof protection.
Compact and ultraportable.
User-programmable for various tubing types.
Requires only electrical service 110/220VAC, auto switching.
No compressed air or cooling water needed.
No accessories required for operation.
Made in the U.S.A. Proven, validatable performance.
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Specifications
Power:
Size:
Weight:
Max tubing OD:
Min tubing OD:
Typical sealing cycle:

110/220 VAC universal voltage
165mm x 356mm x 203mm (6.5” W x 14” D x 8” H)
8 Kg (18 lb)
31.8mm (1.25”)
6.4mm (0.25” )
<2 minutes

Quick Selection Guide - COMPONENTS
PART NUMBER

DESCRIPTION

IMAGE

Hot Lips Tube Sealer II - pre-programmed to
thermally seal C-Flex, Sanipure, PVC, Tygon,
& PharMed thermoplastic tubing 6.4mm (1/4")

HLTS-II

OD to 31.8mm (1.25") OD. 110/220VAC
(auto switching) universal voltage. Please
confirm plug type required where applicable.
No accessories or disposables required.

HLTS-PCKIT

PC kit for Hot Lips Tube Sealer. Allows user reset of register and reprogramming.
Includes hardware and software.

HLTS-II-CALKIT

Calibration verification kit includes Maintenance manual, Validation documents, PCKit
with security key and jaw distance calibration tool.
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Fluid Management Systems

Standard Flexel® 3D bioprocessing bags
for Palletank® (US and Canada)

Description
Flexel® 3D standard bags are designed for
processing, storage and transport of large
volume biopharmaceutical solutions in
Sartorius Stedim Biotech’s proven Palletank®
containers. They provide a single-use alternative to traditional stainless steel vessels in a
large variety of applications.
Cost reduction and risk reduction
Single-use systems used in biopharmaceutical
manufacturing improve process safety as they
reduce the risk of cross contamination from
batch-to-batch and product-to-product.
Costly and time consuming CIP & SIP operations are minimized. This results not only
in significant cost savings within the entire
manufacturing process, but also in the
optimization of capacity utilization.
Applications
The multi-layer film construction of different
materials provides a strong structure with low
gas permeability and high chemical resistance
for the safe processing of a wide range of
biopharmaceutical fluids in a variety of
applications such as:
– Buffers and media filtration & storage
– Bulk harvest
– Product pooling
– Fraction collection
– Sample collection
– Bulk intermediate filtration & hold
– Final product storage and transport

Flexibility
Standard Flexel® 3D bags are available as
stand-alone bags with silicone tubing, standalone bags with C-Flex tubing and filter &
bag assemblies incorporating a variety of
filter and bag sizes allowing easy adoption to
process volume and media. Multiple configurations that also integrate thermoweldable
TPE tubing are provided for flexible incorporation into your process. Thus, sterile connection and disconnection devices like the
BioWelder® and the BioSealer® can be used
to allow safe connections and disconnections
from and to another process step.
Female luer fittings with a needle free
sampling port may be used for easy and
convenient sampling, quick connects may
be attached directly or adapted to a variety
of connections and tri-clamps that are
widely used in a production environment
assure maximum flexibility.

Features

Benefits

Multiple manufacturing sites

High security of supply

All connections
extensively qualified

Safe and robust

Full compliance
with ISO11137

Highest sterility
assurance level

Standard design

Most designs available
from stock

Designed to fit
Palletank®

Market leading
space saving bag
containment system

3” ID bottom drain

Quick transfer of
process fluid

Various bag & filter
sizes

High flexibility

Standard Flexel® 3D for Palletank®
Bag Chamber:

Multiple layer film
construction,
including EVOH gas
barrier layer
ULDPE contact layer

Tubing:

Silicone, TPE

Fittings:

MPX Couplings,
Female Luer Lock,
MPC Male Coupling,
Triclamp, Needle-less
sampling port

Filters:

Sartopore® 2 Gamma
Filter Capsule

Volumes:

100 L–1,000 L

Number of Ports:

Standard silicone:
100 L–1,000 L: 3
(2 top, 1 bottom)
Standard TPE:
100 L–1,000 L: 4
(3 top, 1 bottom)

Fast operation
The new defined range of standard Flexel® 3D
bag systems incorporates 1,000 L standard
bag solutions that enable the user to empty
the bags quickly through a 3” ID tubing.

Standard TPE
& Sartopore® 2:
100 L–1,000 L: 4
(3 top, 1 bottom)
Sterilization:

by Gamma Irradiation

US and Canada | SPT2005am10072
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Security of Supply
Sartorius Stedim Biotech has established
multiple manufacturing sites with consistent
industrial processes. The expertise of designing Single Use solutions combined with
collaborative supplier management and
customer demand planning assures a state of
the art product supported by a robust supply
chain that can cope with strong market
growth.
Validation
Flexel® bags have been qualified applying the
most comprehensive and innovative test
regimes. Biological, chemical and physical
tests combined with extensive extractable
testings provide users of Flexel® 3D bags with
data representing the widest range of process
fluids in a variety of processing conditions.

2|
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Full compliance with ISO11137 allows for a
validated claim of sterility on all Sartorius
Stedim Biotech single-use products with
a sterility assurance level of 10-6 over the
shelf life.
Quality Assurance
Sartorius Stedim Biotech Quality Systems for
Single-use products follow applicable ISO and
FDA regulations for Medical Devices. Design,
Manufacture and Sterilization processes are
conducted under conditions that mirror
biopharmaceutical operations and meet
cGMP requirements.
Flexel® 3D bags for Palletank® are tested for
compliance to:
– USP <87>: Biological reactivity tests,
in Vitro
– USP <88>: Biological reactivity tests, in Vivo
– USP <661>: Tests for plastic
– USP <788> and E.P. 2.9.19 : Particulate
– ISO 11737 : Bioburden
– ISO 11137 : Sterilization of Medical Devices

Supply Chain
The majority of standard Flexel® 3D bags
for Palletank® systems are available from
stock.

Ordering Information
1. Standard Flexel® 3D bags with silicone tubes
1

1

1

1

2

1

1

1

1

1

1

1

1

2

1

Bottom port

1

1

1

Bottom port 1

Bottom port 2

Standard Flexel® 3D bags with silicone tubes (100 L to 500 L)

Standard Flexel® 3D bags with silicone tubes (1,000 L)

Part number Description
FXB207591
Flexel® 100L
for Palletank®
with GammaTag™
FXB207592
Flexel® 200L
for Palletank®
with GammaTag™
FXB207593
Flexel® 500L
for Palletank®
with GammaTag™

Tubing
Silicone

Top Port 1
1/2" + 11/16" + 1.5 m (60"),
1/2" MPX female + sealing plug

Top Port 2
1/2" + 11/16" + 1.5 m (60"),
1/2" MPX female + sealing plug

Silicone

1/2" + 11/16" +1.5 m (60"),
1/2" MPX female + sealing plug

1/2" + 11/16" + 1.5 m (60"),
1/2" MPX female + sealing plug

Silicone

1/2" + 11/16" + 1.5 m (60"),
1/2" MPX female + sealing plug

1/2" + 11/16" + 1.5 m (60"),
1/2" MPX female + sealing plug

Part number Description
FXB207595
Flexel® 1000L
for Palletank®
– Silicone

Tubing
Silicone

Top Port 1
1/2" + 11/16" + 1.5 m
(60")
1/2" MPX female
+ sealing plug

Top Port 2
1/2" + 11/16" + 1.5 m
(60")
1/2" MPX male
+ sealing plug

Bottom Port 1
1/2" + 11/16" + 1 m (40")
1/2" MPX male
+ sealing cap
1/2" + 11/16" + 1 m (40"),
1/2" MPX male
+ sealing cap
1/2" + 11/16" + 1 m (40"),
1/2" MPX male
+ sealing cap

Bottom Port 1
1/2" + 11/16" + 1 m
(40")
1/2" MPX male
+ sealing cap

Bottom Port 2
1/2" + 11/16" + 1 m
(40")
1/2" MPX male
+ sealing cap

Qty/Box
10

10

3

Qty/Box
5
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Ordering Information
2. Standard Flexel® 3D bags with TPE tubes

Standard Flexel® 3D bags with TPE tubes (100 L to 500 L)

Part number Description
FXB110925
Flexel® 100L
for Palletank®
– PTE

Tubing
Silicone
+ Clear C-Flex®
374

FXB110927

Flexel® 200L
for Palletank®
– TPE

Silicone
+ Clear C-Flex®
374

FXB110929

Flexel® 500L
for Palletank®
– TPE

Silicone
+ Clear C-Flex®
374

FXB110930

Flexel® 1000L
for Palletank®
– TPE

Silicone
+ Clear C-Flex®
374

FXB111157

Flexel® 1,000L
for Palletank®
– HIGH FLOW
– TPE

Silicone
+ Clear C-Flex®
374
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Standard Flexel® 3D bags with TPE tubes (1,000 L)

Top Port 1
1/2" + 3/4" + 1.5 m
(60")
1/2" MPX male
+ sealing cap
1/2" + 3/4" + 1.5 m
(60")
1/2" MPX male
+ sealing cap
1/2" + 3/4" + 1.5 m
(60")
1/2" MPX male
+ sealing cap
1/2" + 3/4" + 1.5 m
(60")
1/2" MPX male
+ sealing cap
1/2" + 3/4" + 1.5 m
(60")
1/2" MPX male
+ sealing cap

Top Port 2
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp
3/4" + 1-1/8" + 1.5 m
(60")
silicone
1-1/2" Tri-Clamp

Standard Flexel® 3D bags with TPE tubes
High Flow Rate (1,000 L)

Top Port 3
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

Bottom Port 1
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Qty/Box
4

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2

3/4" + 1-1/8" + 1.5 m 2
(60")
silicone
1-1/2" Tri-Clamp

Ordering Information
3. Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MidiCaps

Standard Flexel® 3D bags with TPE tubes and
Sartopore® 2 Gamma MidiCaps (100 L to 500 L)

Standard Flexel® 3D bags with TPE tubes and
Sartopore® 2 Gamma MaxiCaps (1,000 L)

Standard Flexel® 3D bags with TPE tubes and
Sartopore® 2 Gamma MaxiCaps - High Flow rate (1,000 L)

Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MidiCaps, 0.2 µm (100 L to 500 L)
Part number Description
FXB110962
Flexel® 100L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Tubing
Silicone
+ Clear C-Flex®
374

FXB110964

Flexel® 200L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Silicone
+ Clear C-Flex®
374

FXB110966

Flexel® 500L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Silicone
+ Clear C-Flex®
374

Top Port 1
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MidiCaps size 8,
0.2 µm, filter inlet 1.5"
sanitary flange
1,000 cm2
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MidiCaps size 9,
0.2 µm, filter inlet 1.5"
sanitary flange
2,000 cm2
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MidiCaps size 0,
0.2 µm, filter inlet 1.5"
sanitary flange
4,500 cm2

Top Port 2
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Top Port 3
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

Bottom Port 1
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Qty/Box
3

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2
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Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MidiCaps, 0.1 µm (100 L to 500 L)
Part number Description
FXB110975
Flexel® 100L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Tubing
Silicone
+ Clear C-Flex®
374

FXB110976

Flexel® 200L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Silicone
+ Clear C-Flex®
374

FXB110977

Flexel® 500L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Silicone
+ Clear C-Flex®
374

Top Port 1
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MidiCaps size 8,
0.1 µm, filter inlet 1.5"
sanitary flange
1,000 cm2
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MidiCaps size 9,
0.1 µm, filter inlet 1.5"
sanitary flange
2,000 cm2
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MidiCaps size 0,
0.1 µm, filter inlet 1.5"
sanitary flange
4,500 cm2

Top Port 2
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Top Port 3
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

Bottom Port 1
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Qty/Box
3

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

2

Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MaxiCaps, 0.2 and 0.1 µm (1,000 L)
Part number Description
FXB110967
Flexel® 1,000L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Tubing
Silicone
+ Clear C-Flex®
374

FXB110978

Silicone
+ Clear C-Flex®
374

Flexel® 1,000L
for Palletank®
– TPE
– Sartopore® 2
– Gamma

Top Port 1
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MaxiCaps size 2,
0.2 µm, filter inlet 1.5"
sanitary flange
1.2 m2
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MaxiCaps size 2,
0.1 µm, filter inlet 1.5"
sanitary flange
1.2 m2

Top Port 2
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Top Port 3
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

Bottom Port 1
1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

Qty/Box
1

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

1/2" + 3/4" + 1.5 m
(60")
1–1/2" Tri-Clamp

1

Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MaxiCaps (1,000 L - High flow rate)
Part number Description
FXB111153
Flexel® 1,000L
for Palletank®
HIGH FLOW
– TPE
– Sartopore® 2
– Gamma

Tubing
Silicone
+ Clear C-Flex®
374

FXB111154

Silicone
+ Clear C-Flex®
374
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Top Port 1
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MaxiCaps size 2,
0.2 µm, filter inlet 1.5"
sanitary flange
1.2 m2
1/2" + 3/4" + 1.5 m
(60")
Sartopore® 2 Gamma,
MaxiCaps size 2,
0.1 µm, filter inlet 1.5"
sanitary flange
1.2 m2

Top Port 2
3/4" + 1-1/8" + 1.5 m
(60")
silicone
1-1/2" Tri-Clamp

Top Port 3
1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

Bottom Port 1
Qty/Box
3/4" + 1-1/8" + 1.5 m 1
(60")
silicone
1-1/2" Tri-Clamp

3/4" + 1" + 1.5 m
(60")
1–1/2" Tri-Clamp

1/8" + 1/4" + 1.1 m
(40")
LL female + needle free
sampling port

3/4" + 1" + 1.5 m
(60")
1–1/2" Tri-Clamp
Silicone

1
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Flexel® 3D Palletank® for storage

Fluid Management Systems

Key features & benefits
Patented system

Perfect fit and
protection of the
Flexel® 3D Bag in its
Palletank®

Standard design

Most design are
available from stock

Stackable version

Space saving
containment system

Technology integration For a successful
support
Single-Use manufacturing implementation and
validation

Introduction
The Palletank® for storage are stainless steel
containers designed for the safe and robust
storage of biopharmaceutical fluids contained
in Flexel® 3D Bags. They are available in
volumes of 50 L, 200 L and 500 L to be used
with 50 L, 100 L|200 L and 500 L Flexel® 3D
bags. The Flexel® 3D Bag are manufactured
according to a patented design that precisely
fits the Palletank®.
Applications
Palletank® Systems that incorporate Flexel®
3D Bags have been designed for the safe
processing of a wide range of biopharmaceutical fluids in a variety of applications such as:
– Buffers and media storage
– Bulk harvest
– Product pooling
– Fraction collection
– Sample collection
– Bulk intermediate hold
– Final product transport
Space-saving
The stackable version of the Flexel® 3D
Palletank® for storage enables users to meet
the complex in-process demands as well as
the high requirements for storage while
maximizing the utilization of the available
clean room area. It saves up to 50% of the
space required for cylindrical drums.
Safety
Flexel® 3D Bags coupled with the rigid
structure of Palletank® provide a stable
and secure solution for processing, storage
and transportation of buffers, media,
intermediates and final bulk products.

Palletank® family
Besides the Palletank® for storage, the
product range of Palletank® container
includes the following lines specifically
developed for the various application
requirements on fluid management in the
biopharmaceutical industry:
– Palletank® for shipping
– Palletank® for in-process fluid handling
– Palletank® for weighing
– Palletank® for recirculation mixing
Technology Integration Support
Sartorius Stedim Biotech supports users from
the design & implementation phase of a new
production facility with the most comprehensive support program that ensures successful
design implementation and validation of
Single-Use Manufacturing.
Security of Supply
Sartorius Stedim Biotech has established
multiple manufacturing sites with consistent
industrial processes. The expertise of designing Single-Use solutions based on collaborative supplier management and customer
demand planning assures a state of the art
and robust supply chain that can cope with
strong market growth.
Quality Assurance
Flexel® 3D Palletank® Systems are designed,
developed and manufactured in accordance
with a ISO 9001 certified Quality Management System. They undergo extensive testing
before shipping
SPL2002-e10016
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Specifications
1. Palletank® for storage
Description

Palletank® 200 L
for storage

Palletank® 500 L
for storage

Bag Volume(s)

100 L or 200 L

500 L

Construction
Material

304L Stainless Steel

Surface
Finishing

Bead Blasted

Dimensions
(w+ d+h)

789 +592+891 mm
(31.2 +23.3 +35.1 in)

1192+792+1010 mm
(46.9 +31.2 +39.7 in)

Weight

35 kg (77.17 lb)

92 kg (202.8 lb)

Bottom Gate

1

1

Stackability

No

No

2. Palletank® for storage stackable
Description

Palletank® 50 L for
storage stackable

Palletank® 200 L for
storage stackable

Palletank® 500 L for
storage stackable

Bag Volume(s)

50 L

100 L or 200 L

500 L

Construction
Material

304L Stainless Steel

Surface
Finishing

Bead Blasted

Dimensions
(w+ d+h)

490 + 490 + 750 mm
(19,3 + 19,3 + 29,5 in)

789 + 592 + 915 mm
(31.2 + 23.3 + 36 in)

1192 + 792 + 1060 mm
46.9 + 31.2 + 41.7 in

Weight

24 kg (52.8 lb)

48.4 kg (106.7 lb)

87.5 kg (192.9 lb)

Bottom Gate |
Sliding Gate

1

1

1

Stackability
(Static)

3 high

3 high

2 high

Dolly for Palletank®
200 L for Storage
and Shipping

Dolly for Palletank®
500 L for Storage
and Shipping

3. Ancillary products
3.1. Dolly
Description

Dolly for Palletank®
50 L for Storage
and Shipping

Construction
Material

304L and polyamide (wheels)

Surface
Finishing

Glass Bead blasted

Dimensions
(w+ d+h)

490 + 490+185 mm
(19.3 +19.3 +7.3 in)

Weight (approx.) 7 kg (15.4 lb)
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815+ 615+188 mm
(32.1 +24.2 +6.4 in)

1215+815+161 mm
(47.8 +32.1 +6.4 in)

10 kg (22 lb)

18 kg (39.7 lb)

3.2. Weighing platforms
The IFS4 flat-bed scales are entirely constructed of stainless steel and have an extremely low
height, making it ideally suited for floor installation without a pit or anchoring. The ramp is
securely attached to the scale using special retainers for prevention of force shunt. This highquality platform can be connected to any of a wide range of indicators, for use as a Class III
legal measuring instrument or without legal verification. The CIS1 Combics 1 indicator allows
strain gauge weighing with flat bed scales as well as with load cells to be connected.
IFS4-150GG-I

IFS4-300LI-I

IFS4-1000RN-I

Weighing
capacity

150 kg
(330.7 lb)

300 kg
(661.4 lb)

1000 kg
(2204.6 lb)

Platform size

600 + 600 mm
(23.6 + 23.6 in)

1000 + 800 mm
(39.3 + 31.5 in)

1500 + 1250 mm
(59 + 49.2 in)

Height

Standard: 35 mm

Standard: 35 mm

Standard: 45 mm

Load Plate

AISI304 |1.4301 (V2A)
bead-blasted

AISI304 |1.4301 (V2A)
bead-blasted

AISI304 |1.4301 (V2A)
bead-blasted

Resolution

30.000 d

30.000 d

30.000 d

Readability

5g

10 g

50 g

200 L

500 L

Suitable with
50 L
Palletank®
Storage and
Storage Stackable

Refer to specific Sartorius Mechatronics datasheet for Combics indicators ranges,
printers and other accessories specifications and ordering information.

Integrated features
Features

Benefits

Palletank® for storage

Palletank® for storage
stackable

Level marks

allow rapid visual monitoring of the fluid level in the bag

•

•*

Integrated pallet

allows easy carriage by pallet-jack or forklift

•

•

•

•

Tubing & Fitting Tray simplifies fluid handling operations & provides a
convenient and secure place for inlet & outlet tubing
assemblies during transport.
Lid

protects the bag against dust and light

Bottom gate |
Sliding gate

allows passage of large bore tubing, 1,5” tri clamps, QC bags
and filters; facilitates bag positioning and maintain in position

Stacking corner

enables the stacking of Flexel® 3D Systems in order to
maximise the utilisation of available clean room area

Dolly (accessory)

facilitates the movement of material throughout a facility

•*
•

•
•

•

•

* Except 50 L volume

SPL2002-e10016
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Ordering Information
Order Code

Description

FXC110888

Palletank® 200 L for storage

FXC110889

Palletank® 500 L for storage

FXC113946

Palletank® 50 L for storage stackable

FXC110733

Palletank® 200 L for storage stackable

FXC110734

Palletank® 500 L for storage stackable

FXA113988

Dolly for Palletank® 50 L for storage

FXS102254

Dolly for Palletank® 100 L|200 L for storage & shipping

FXS102256

Dolly for Palletank® 500 L for storage & shipping

Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen, Germany
Phone +49.551.308.0
Fax +49.551.308.3289
www.sartorius-stedim.com
USA Toll-Free +1.800.368.7178
UK +44.1372.737159
France +33.442.845600
Italy +39.055.63.40.41
Spain +34.90.2110935
Japan +81.3.3740.5407
Specifications subject to change
without notice. Printed and copyrighted
by Sartorius Stedim Biotech GmbH
W·G
Publication No.: SPL2002-e10016
Order No.: 85030-533-48
Ver. 01 | 2010

Flexel® 3D Plastic Palletank® for Storage

Fluid Management Systems

Features & Benefits
PP and ABS containers

Low cost and robust
storage solution

Stackable when full

Minimize floor
space utilizations

Foldable and collapsible Minimize storage
when empty
volume
Low tare weight

Easy setting and
maneuverability

Smooth scratchClean room
resistant plastic surface compatible
Standard product

Introduction
The Plastic Palletank® for storage represents
a cost-effective containment solution for the
storage and processing of biopharmaceutical
fluids contained in Flexel® 3D Bags. Their flat,
smooth surfaces and rounded corners facilitate cleaning and sanitization for clean room
operations. The Plastic Palletank® for storage
are foldable for minimal storage space when
empty. They are also stackable for optimal
floor space utilization when filled with biopharmaceutical solutions. They are available
as standard products with volumes of
200 L, 500 L and 1000 L that perfectly fit
with 100 L|200 L, 500 L and 1000 L Flexel®
3D Bags.

Optimal space utilization
The Plastic Palletank® for storage allows for
secure stacking, up-to 3-high, to meet the
complex in-process and storage requirements,
while maximizing the utilization of the
available clean room area. It saves up-to 50%
of the space required for cylindrical drums.
When not in use, the collapsible tank can be
folded to approximately half of its height for
intermediate storage.

Applications
The Plastic Palletank® for storage with
Flexel® 3D Bags have been designed for
the safe storage and processing of a wide
range of biopharmaceutical fluids in
a variety of applications such as:

200 L

9 + 200 L
9 + 200 L 50%
Stacked
3.2 m2
3-high
(34.4 sq ft)
1.5 m2 (16.1 sq ft)

500 L

6 + 500 L
6 + 500 L
Stacked
3.7 m2
2-high
(40 sq ft)
3 m2 (32.3 sq ft)

– Buffers and media storage
– Bulk harvest
– Product pooling
– Fraction collection
– Sample collection
– Bulk intermediate hold

Volume Floor space required
Plastic
Palletank®
for storage

Drum

Space
saving

20%

1000 L 2 + 1000 L
2 + 1000 L 40%
Stacked 2-high 2.3 m2
1.3 m2 (14 sq ft) (25 sq ft)

Available from stock

Easy setting and use
One person can easily prepare a Plastic
Palletank® for storage; the walls are raised
and locked in place by hand. Their low tare
weight ensures easier operator manipulation
and facilitates intra facility transfer.
Hygienic design
The Plastic Palletank® for storage is not
subject to rust and corrosion due to all plastic
construction. The containers are made from
a robust, scratch-resistant plastic material.
The dismountable flat, smooth walls and the
rounded corners facilitate cleaning operations. The Plastic Palletank® for storage is
compatible with cleaning and decontaminating agents commonly used in the biopharmaceutical industry.

Specifications

Ordering Information

1. Plastic Palletank® for storage

FXC116215

STD Plastic Palletank® Storage
200 L

FXC116216

STD Plastic Palletank® Storage
500 L

FXC116217

STD Plastic Palletank® Storage
1000 L

FXA116630

STD Palletank® Accessory Dolly
200 L (Plastic Storage)

FXA116631

STD Palletank® Accessory Dolly
500 L (Plastic Storage)

FXA116632

STD Palletank® Accessory Dolly
1000 L (Plastic Storage)

STD Plastic Palletank® for storage

Description

200 L

500 L

1000 L

Part Number

FXC116215

FXC116216

FXC116217

Bag Volume(s)

100 L | 200 L

500 L

1000 L

Main Constrution Material

PP

ABS

ABS

Dimensions
(w + d + h)
Approx.

Unfolded

805 + 607 +
969 mm
32 + 24 + 38 in.

1215 + 805 +
1086 mm
48 + 31 + 43 in.

1225 + 1022 +
1437 mm
48 + 40 + 57 in.

Folded

805 + 607 +
510 mm
32 + 24 + 20 in.

1215 + 805 +
572 mm
48 + 31 + 22 in.

1225 + 1022 +
598 cm
48 + 40 + 23 in.

Weight incl. lid (approx.)

25 kg (55 lb)

79 kg (174 lb)

125 kg (275 lb)

Bottom Gate

1

1

2

Folded

5

3

3

Unfolded
and full

3

2

2

Stackability
-Static

2. Ancillary products
a. Dolly
a. Dolly

Description
Part Number

STD Palletank® Accessory Dolly
200 L

500 L

1000 L

FXA116630

FXA116631

FXA116632

Construction Material 304 L and polyamide (wheels)
Surface Finishing

Glass bead blasted

Dimensions (w + d + h) 807 + 607 + 214 mm
32 + 24 + 8 in.

1207 + 807 + 214 mm 1207 + 1007 + 214 mm
47 + 32 + 8 in.
47 + 39 + 8 in.

Weight (approx.)

10 kg (22 lb)

20 kg (44 lb)

22 kg (48 lb)

IFS4-300LL-I

IFS4-600RN-I

IFS4-1500RN-I

300 kg | 1322 lb

600 kg | 1322 lb

1500 kg | 3306 lb

Platform Size (D + W) 1000 + 1000 mm
39 + 39 in.

1500 + 1250 mm
59 + 49 in.

1500 + 1250 mm
59 + 49 in.

Height

Standard:
35 mm | 1.4 in.

Standard:
45 mm | 1.8 in.

Standard:
45 mm | 1.8 in.

Load Plate

AISI304 | 1.4301 (V2A) AISI304 | 1.4301 (V2A) AISI304 | 1.4301 (V2A)
bead blasted
bead blasted
bead blasted

Resolution

30.000 d

b. Weighing Platform

b. Weighing Platform

Weighing Capacity

30.000 d

30.000 d

Readability

10 g

20 g

50 g

Suitable with Plastic
Palletank® storage

200 L

500 L

1000 L

Please contact your Sartorius Mechatronics Sales Representative for detailed ordering information.
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DATA SHEET

XDR Single-Use Bioreactors
Introduction
The XDR Single-Use Bioreactor is a fully-integrated system that deliv-

SYSTEM SNAPSHOT

ers proven stirred-tank performance across a wide range of cell lines.

X
Fully-integrated, turnkey GMP system

Single use technology eliminates time consuming and costly clean in
place (CIP), steam in place (SIP) and cleaning validation procedures. The
system’s turnkey design enables fast installation and startup as well as
rapid batch-to-batch turnover and increased process flexibility compared to fixed stainless steel hard piped vessels.
5IF9%3JTPòFSFEJOöWFTJ[FT     BOE- XJUI
XPSLJOHWPMVNFTSBOHJOHGSPN-UP -5IFTZTUFNTVOJRVFEF
sign enables each XDR to operate down to 20% of maximum working

X
Proven, scalable stirred tank performance
across a wide range of cell lines
X
Single-use design eliminates CIP/SIP
X
Operating volumes of 10L to 2,000L
X
Essential process instrumentation included
and fully characterized
X
Integrated temperature control and dimpled
vessel jacket for efficient heat transfer

WPMVNF UVSOEPXOSBUJP XIJDIDBOPGUFOFMJNJOBUFUIFOFFEGPSBO

X
Powerful, user-friendly control system

additional seed reactor and related costs. Each reactor system includes

X
Predictive modeling and Xcellerex process
expertise eliminates start-up headaches and
ensures process efficiency

a stainless steel vessel, vital process instrumentation, state-of-the-art
control automation, and an optimized single-use bioreactor bag assembly. For high-density microbial applications, ask about the XDR-50 Turbo
model.
XEfficient, Convenient Vessel Design The vessel features a dimpled jacket

heat transfer surface for efficient heating and cooling, a high performance bottommounted magnetic drive agitator system that facilitates loading and coupling of
the single-use bag assembly, load cells for weight measurement, an exhaust filter
heater box, flexible hoses for the heat transfer fluid, and a tubing manager.
XCritical Process Instrumentation Mass flow controllers,
peristaltic pumps, and probe transmitters are built into the
cabinet adjacent to the vessel, and an external temperature
control unit is available as an option for process heating/cooling.
5IFTZTUFNSFRVJSFTPOMZHBTFT QPXFSBOENJOJNBMXBUFSGPS
full functionality.
XDR 2000 X

XXXYDFMMFSFYDPNt9DFMMFSFY

XPowerful, User-Friendly Controls The XDR is

agitator includes a HDPE bottom mounted impeller and a

FRVJQQFEXJUIBGVMMZJOUFHSBUFEDPOUSPMDPOTPMF 

VOJRVFTQBSHFTZTUFNDPOTJTUJOHPGNJDSPQPSPVTTUBJOMFTT

featuring intuitive process controls,

steel disks and optional drilled holes that together impart

data historian, and robust automa-

the system with tremendous flexibility crucial for today’s cell

tion hardware/software. The system

culture processes. Xcellerex also maintains multiple supply

enables precise process control,
and offers convenient real-time

sources to guard against supply chain disruptions.

Expert process support from Xcellerex With years

trending and other valuable data.

of experience running and supporting GMP biomanufactur-

When coupled with Xcellerex’s

ing operations, Xcellerex designed the XDR system to deliver

process development experience

complete process control from the moment each system

and predictive modeling support,
the XDR control platform assures optimized first-run

starts up. No other single-use bioreactor is available with the
XDR’s depth of characterization, process support, and GMP-

process performance and reliability through tech

SFBEJOFTT9DFMMFSFYJTVOJRVFMZBCMFUPEFMJWFSDSJUJDBMDPOUSPM

transfer and scale-up.

automation with instrumentation, functionality, process modeling, tech transfer, and scalability.

XRobust Single-Use Components The XDR irradiated
TJOHMFVTFCBHBTTFNCMZDPOTJTUTPGB641$MBTT7*-%1&
øVJEDPOUBDUMBZFS UVCJOHTGPSMJRVJEBEEJUJPOTBOEIBSWFTU 
sampling and probe ports, a disposable pressure sensor,
filtered gas lines, and high-functioning agitator system. The

Key XDR Advantages
X 5:1 turndown means each XDR can operate at 20% of maximum working
volume, doing the work of multiple reactors

X XDR Single Use Reactor Systems are Factory Acceptance Tested (FAT) prior
to delivery and Site Acceptance Tested (SAT) upon installation

X True plug-and-play performance: Connect gases and power and get
started

X Each XDR Single Use Reactor System is shipped with a Turnover Package
which includes XDR Operating Manual, System Specifications, FAT
commissioning report, system drawings, component operating manuals,
calibration records, and optional IQ/OQ protocols

X Robust, self-installing magnetically-driven bottom-mount impeller:
No rotating seals, insertable shafts and connection hassles
X Jacketed vessel ensures uniform temperature distribution throughout
reactor

X Xcellerex process experience and know how is built into every XDR
System: our process development expertise ensures that the process is
up and running right the first time

X Flexible control systems automate temperature shifts, feeds, changes to
sparge composition

X Xcellerex offers extensive XDR-specific predictive modeling and expert
scale-up support

X Multiple probe configurations available, including pH, DO, CO2, and
biomass

X Enhanced sparge control and CO2 stripping capabilities not offered on
other single use systems

X Accurate gas control using mass flow controllers on all systems (optional
MFC for headspace on XDR50)

X Designed and fully characterized to deliver scalable cGMP processes from
10L to 2000L

X Bag material sourced from multiple manufacturers for supply chain security

X Xcellerex has years of cGMP manufacturing experience operating the XDR
system. GMP product made in the XDR is currently being used in clinical
trials and commercial XDR facilities are currently being prepared for commissioning.

X Single-use design eliminates time consuming CIP, SIP and cleaning validations procedures

XXXYDFMMFSFYDPNt9DFMMFSFY

$OOVSHFL¿FDWLRQVDUHVXEMHFWWRFKDQJHZLWKRXWQRWLFH

SYSTEM SPECIFICATIONS
XDR-50

XDR-200

XDR-500

XDR-1000

XDR-2000

50

200

500

1000

2000

BIOREACTOR
Max Working Volume (L)
Min Working Volume (L)

10

40

100

200

400

Volume turn-down ratio

5:1

5:1

5:1

5:1

5:1

Tank ID (in)

12

22

30

38

48

H/D

2.5

1.5

1.5

1.5

1.5

Jacketed 304 SS

Jacketed 304 SS

Jacketed 304 SS

Jacketed 304 SS

Jacketed 304 SS

Vessel Material of Construction
Filter Heater Box

1

1

1

1

1

Bag Hoist

NA

NA

NA

Automated

Automated

Impeller

Bottom mounted, magnetically-driven, single-use impeller integrated with bag assembly

Impeller type

M40E

Impeller diameter (in)

8

Di/Dt
Impeller location
Standard
Sparger

Optional

8

10

12

16

0.67

0.36

0.33

0.33

0.33

Center 900

150 off center

150 off center

150 off center

150 off center

Stanless steel sintered disks

Stanless steel sintered disks

Stanless steel sintered disks

Stanless steel sintered disks

Stanless steel sintered disks

Drilled Hole

Drilled Hole

Drilled Hole

Drilled Hole

Drilled Hole

CO2 stripping

CO2 stripping

CO2 stripping

CO2 stripping

CO2 stripping

1

2

2

2

2

PROCESS INSTRUMENTATION
pH probes
DO probes
MFCs (Brooks)

1

2

2

2

2

Standard

4

4

4

4

4

Additional (optional)

2

2

2

2

2

Pumps
Temperature Control Unit

Load Cells
Utility Requirements
E-Stop

3 Pumps are standard. Additional pumps are available as an option
Optional: 3 kw heater

Optional: 9 kw heater

Optional: 3 kw heater/
0.5 ton chiller combo

Optional: 9 kw heater/ 1.5 hp chiller combo

3

4

4

4

4

Process gases / 110V, single phase, 60 hz / TCU: 230V, 3 phase, 60 hz (EU: 380V, 3 phase, 50 hz)
Integrated Safety Circuit for pumps, agitator, TCU, and filter heater

CONTROL UNIT (see page 5 for additional detail)
Integrated Control Panel
Hardware
Operator Interface

Built to GAMP5 standards/ 21 CFR Part 11 Compliant
Rockwell/ Allen Bradley
Wonderware HMI

Data Historian

Wonderware

Programming

Rockwell Allen Bradley/Wonderware Archestra

NOTE: This document describes standard systems and commonly requested options. Additional custom-engineered systems are also available to meet unique application needs. Ask your Xcellerex representative for details.
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PERFORMANCE CONTROL SPECIFICATIONS
XDR-50

pH

DO

$OOVSHFL¿FDWLRQVDUHVXEMHFWWRFKDQJHZLWKRXWQRWLFH

XDR-200

XDR-500

Range

2-12 pH units

Accuracy

± 0.05 pH units

Range

*Additional MFC/sparge
ranges can be supplied
based on application
requirements
Temperature

Bag Pressure

XDR-2000

0-100% atmospheric saturation

Accuracy
Sparge Rate (slpm)

XDR-1000

± 1.0% of setpoint

Air*

0-5

0-5

0-10

0-10

0-20

02*

0-5

0-5

0-10

0-10

0-20

C02*

0-5

0-5

0-10

0-10

0-20

Air Headsweep*

0-10

0-10

0-20

0-20

0-25

0-140

0-115

Range

4-60 0C

Accuracy

± 0.1 0C

Range

0 - 30 psig (0 - 2068 mbar)

Accuracy
Agitation (rpm)

± 0.1 psig (± 6.89 mbar)
0-360

0-360

0-250

Load Cell Accuracy

± 0.02% of max bag volume

NOTE: For high-density microbial applications, please ask about the XDR-50 Turbo system.

SYSTEM DIMENSIONS
XDR-50

XDR-200

XDR-500

XDR-1000

XDR-2000

Width (Vessel & Instrumentation)

43.375 in
(111 cm)

52.25 in
(133 cm)

57 in
(145 com)

64 in
(163 cm)

23.375 in
(182 cm)

Depth (Vessel & Instrumentation)

28 in
(71 cm)

37 in
(94 cm)

48 in
(122 cm)

52 in
(132 cm)

61 in
(155 cm)

Height (Vessel & Instrumentation)

73.5 in
(187 cm)

85.125
(216 cm)

93.75 in
(238 cm)

115 in
(292 cm)

140 in
(356 cm)

HMI Control Unit Dimensions: 23.375 in x 30.75 in x 56.75 in (60 cm x 78 cm x 144 cm)

FULLY-INTEGRATED XDR BIOREACTOR BAG ASSEMBLY
t
t
t
t

Each bag comes complete with:

USP Class VI
-%1&øVJEDPOUBDUMBZFS
Gamma Irradiated
Validation Guide

Standard “off-the-shelf” designs impart flexibility for a wide range of
cell culture and microbial processes.
$VTUPNBQQMJDBUJPOTQFDJöDEFTJHOTBWBJMBCMFVQPOSFRVFTU

t
t
t
t
t
t
t
t
t
t
t
t

C-flex tubing (for tube-to-tube aseptic welding)
Aseptic connectors
Multiple feed/addition lines
Harvest line
Exhaust filter
Sparge filter
Overlay filter
Pressure sensor
Sampling ports
Probe ports
Thermowell (for temperature probe)
Proprietary XDR impeller/sparge system

XXXYDFMMFSFYDPNt9DFMMFSFY

CONTROL AUTOMATION PLATFORM
The XDR Control Platform is comprised of a Rockwell/Allen Bradley controller with Wonderware HMI
and data historian. The platform delivers precise process control and offers a level of flexibility and
convenience that is unmatched in the industry.
In addition to robust control architecture, the XDR features a highly intuitive user interface that speeds
operator training and efficiency.

XIntuitive, Powerful Interface
The XDR control system user interface was designed to provide fast and easy, yet comprehensive
control over process configuration to the operator. The easy-to-read screens enable dynamic adjustment to key variables, and enable the operator to review complete configuration schemes at a glance.
The high clarity touchscreen display provides an intuitive, visual interface that operators can use with
confidence. (See Screen 1)

Screen 1 - System Overview

The XDR system enables rapid understanding and interpretation of active control strategies through
the use of graphical symbols. (See Screen 2)
In addition, set-point automation tables enable the easy automation of set-point changes, permitting
live adjustments to ramp or step to new value. (See Screen 3)

XPowerful Control Strategies for Fast Response, Tight Control
t

Cascade control strategies of pH, DO, and volume result in very tight control of critical process
conditions.

t

Flexible closed loop control of critical process parameters support improved yields:







t"HJUBUJPO
t(BTNJYJOH
t-JRVJEBEEJUJPOBOESFNPWBM
tQ)
t8FJHIU

t

%ZOBNJDSFDPOöHVSJOHPGDBTDBEFDPOUSPMMPPQTFOBCMFTFYDFQUJPOBMQSPDFTTøFYJCJMJUZ

Screen 2 - Cascade Loop Control

t4QBSHF
t(BTPWFSMBZ
t5FNQFSBUVSF
t%0(See Screen 4)

Screen 3 -Set Point Automation Tables

XComprehensive, Real-Time Data Capture, Reporting and Trending
t

5IFSFBMUJNFEBUBIJTUPSJBODBQUVSFTBMMQSPDFTTQBSBNFUFSTBOEUJNFT BOEPòFST
accessible look-up.

t

&YQPSUPGEBUBUPPUIFSNBTUFSEBUBSFQPTJUPSZTZTUFNTJTTVQQPSUFEXJUICVJMUJOGVODUJPOBMJUZ

t

3FBMUJNFBMBSNJOHQSPUFDUTQSPDFTTJOUFHSJUZBOEIFMQTBWPJEMPTUCBUDIFT

t

"MMBMBSNTBSFMPHHFEUPEBUBCBTF

Screen 4 - DO Strategy Set-Up Screen

XXXYDFMMFSFYDPNt9DFMMFSFY

XDR PERFORMANCE DATA

CHO Process -Titer Data

Figures 1-3 illustrate examples of first-run data
for a series of CHO processes, demonstrating the
XDR system’s ability to achieve immediate process
equivalence. Additional, extensive data is available
on request.

XDR
10LGlass
glassReactor)
reactor
Figure 1: CHO Process - Titer Data (XDR
vs.vs10L
120
XDR-1000

100

XDR-200
XDR-200

Titer (ug/mL)

80

10L glass
10L glass

60

40

20

FIGURE 1: XDR achieved equivalent or better titer
during scale-up from a 10 liter glass reactor to a
200 L XDR to a 1000 liter XDR.

0
0

2

4

6

8

10

Day

CHOvs.
Process
Figure 2: CHO Process - Viability Data
(XDR
10L Glass Reactor)
XDR vs 10L glass reactor
14

100

XDR-1000
10

80

XDR-200
XDR-200

8

60

10L glass
10L glass

6

40

Percent Viable Cells

Viable cells (e6 cells/mL)

12

4
20
2

FIGURE 2: XDR achieved equivalent or better cell
viability during scale-up from a 10 liter glass reactor to a 200L XDR to a 1000 liter XDR.

0

0
0

2

4

6

8

10

Day

CHO-Perfuson
Culture
Data Reactor)
Figure 3: CHO Perfusion Process
ViabilityProcess-Cell
Data (XDR vs.
10L Glass
100

FIGURE 3: XDR achieved process equivalence for
a perfusion process at the 200L and 1000L scale.

90

12

80

10
8

XDR-1000

70

10L glass

60

XDR-200

50

6

40
30

4
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20

Percent Viable Cells

Viable Cell Density (e6 cells/mL)

14

FOR ADDITIONAL INFORMATION

To learn more about XDR Single-Use Bioreactors or other Xcellerex systems or services,
please contact customer service at:
5PMM'SFF

9DFMMFSFY 

5FMFQIPOF



&NBJM 

TBMFT!YDFMMFSFYDPN

Xcellerex, Inc.
-PDLF%SJWF
.BSMCPSPVHI ."
USA


Toll Free: 1-866-Xcellerex
5FM
JOGP!YDFMMFSFYDPN
www.xcellerex.com
SFWYES

Zeta Plus™ Single-Use Depth Filtration Product Portfolio

Innovative

Filtration
Fast. Easy. Clean.

Zeta Plus Encapsulated System...
™

The System of Choice for

Single-Use Depth Filtration

Features & Benefits
Ergonomically Designed Holder System:
Large holders (Model# 16EZB and #16EZC [not shown]) can be pivoted between
horizontal and vertical positions.
! Ŷ!"#$%&'(!&)$*+#,!$#*!-#&)$*+#,!$.!/$+(.!0'+,0.1
! Ŷ!2+#+3$&!4&-+*!(5+&&(!/0'#!0$#*&+#,!(5'#.!6$5(-&'(1
! Ŷ!7+#,&'!)8!./)9(.$,'!*'5.0!4+&.8$.+)#!/+.0+#!)#'!4+&.'8!0)&*'81
Vertical flow path.
! Ŷ!:-&&!-.+&+;$.+)#!)4!.0'!4+&.'8!3'*+$1
! Ŷ!73$&&!4)).58+#.!*-8+#,!4+&.8$.+)#1

Model# 16EZB

Innovative Capsule/Manifold Design:
!!!Translucent plastic shell (Standard Capsules).
! Ŷ!"$(<!*'.'6.+)#!)4!.0'!&+=-+*!&'>'&!+#(+*'?!58)>+*+#,!8'$&!.+3'!3)#+.)8+#,!)4!.0'!4+&.8$.+)#!58)6'((1
!!!Solid core design with fully encapsulated shell.
! Ŷ!"&+3+#$.'(!.0'!#''*!4)8!$!(.$+#&'((!(.''&!0)-(+#,!$#*!
! .0'!6&'$#+#,!(.'5!$4.'8!4+&.8$.+)#1
! Ŷ!@)/!0)&*9-5!>)&-3'1
!

Self guiding locking mechanism.
Ŷ!:$(.?!8'&+$%&'!$#*!8)%-(.!6$5(-&'9.)96$5(-&'!6)##'6.+>+.<1
.<1

!
!

Lenticular style capsule design.
Ŷ!@+#'$8!(6$&$%+&+.<!48)3!(3$&&!.)!&$8,'!(<(.'3(1
Ŷ!A)#(+(.'#6<!%'./''#!(+#,&'9-('!$#*!6)#>'#.+)#$&!*'5.0!4+&.8$.+)#1

Zeta Plus™ filter media:
!
!

Ŷ!B).0!*)-%&'!&$<'8!$#*!(+#,&'!&$<'8!C'.$!D&-(!4+&.'8!3'*+$!$8'!$>$+&$%&'1
Ŷ!7-5'8+)8!5'84)83$#6'!+#!.08)-,05-.!$#*!4+&.8$.+)#!'44+6+'#6<1

1

!"#$%#&'$()*+$,$-./'0+*)'&#1$23+&#4$5+$'$+5.6)#7*+#$1#0&"$
85)&9'&5:.$ +3+&#4$ 1#+56.#1$ 8:9$ &"#$ ;5:09:/#++5.6$ 5.1*+&93$
<"#9#$ *0+&9#'4$ /#))$ /*)&*9#$ /)'9585/'&5:.$ :9$ 1:<.+&9#'4$
540*95&3$9#4:=')$5+$9#>*59#1?$!"#$%#&'$()*+$-./'0+*)'&#1$
23+&#4$ /:.+5+&+$ :8$ &"9##$ 09:1*/&$ )5.#+@$ '$ +4'))$ +3+&#4$
&"'&$ 5+$ 51#')$ 8:9$ )';$ +/')#$ 09:1*/&5:.$ :9$ +/')#7*0$ +&*15#+A$
'.1$ &<:$ )'96#9$ +3+&#4+$ &"'&$ '9#$ 1#+56.#1$ 8:9$ 09:1*/&5:.$

Zeta Plus™ Encapsulated
Standard Capsule Offering
With Polycarbonate Shells

+/')#$ ;5:4'.*8'/&*95.6?$ -'/"$ +3+&#4$ 5+$ /:4095+#1$ :8$ '$
85)&#9$":)1#9A$&:0$'.1$;:&&:4$4'.58:)1+A$'.1$&"#$9#>*59#1$
.*4;#9$:8$/'0+*)#+?$
The Zeta Plus Encapsulated Systems for production scale
biomanufacturing feature an ergonomically designed large
holder (Models# 16EZB and 16EZC) that can be pivoted
between horizontal and vertical positions, allowing for
convenient loading and unloading, minimal footprint during filtration, minimal fluid spills during unloading, and
full utilization of the filter media.
!"#$ /'0+*)#$ 1#+56.$ 8#'&*9#+$ '$ &9'.+)*/#.&$ 0)'+&5/$ +"#))$

Zeta Plus™ Encapsulated Capsule Offering
With Alkaline Resistant*
Polyphenylene / Polystyrene Shells

B+&'.1'91$ /'0+*)#+C$ 8:9$ #'+3$ )5>*51$ )#=#)$ 1#&#/&5:.D$ '$ +#)8$
6*515.6$ ):/E5.6$ 4#/"'.5+4$ 8:9$ 8'+&$ '.1$ 9:;*+&$ /'0+*)#7
&:7/'0+*)#$ /:..#/&5:.D$ '.1$ &"#$ 5.1*+&93$ )#'15.6$ %#&'$
()*+$ 1#0&"$ 85)&#9$ 4#15'$ &"'&$ 09:=51#+$ +*0#95:9$ 85)&9'&5:.$
0#98:94'./#?

Self Guiding Locking Mechanism Enables
Fast And Robust
Capsule-To-Capsule Connection

Zeta Plus™ Cartridges and Capsule Family

F$ G'+#1$:.$&#+&5.6$<5&"$HI$J'KL$'.1$MN$J'O)K$BG)#'/"C?$
2##$O"#45/')$O:40'&5;5)5&3$P*51#$BQR7RSRS7SRST7MUVW!(LPRTC$8:9$4:9#$5.8:94'&5:.?
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High Performance filter media
!-+*@+&#*A)2/B*C(4#,/2)#&+$*D0/&+1*2&%)%3+/*&-+*%($2/&"0*)+#$%(5*@+&#*A)2/*$+,&-*.%)&+"*1+$%#;*%(4)2$%(5*&-+*$'2=)+*
)#0+"* @+&#* A)2/* CE!* D+"%+/* .%)&+"* 1+$%#* #($* 1#(0* ,',2)#"* /%(5)+* )#0+"* @+&#* A)2/* .%)&+"* 1+$%#* ',&%'(/* %(4)2$%(5* DA*
1+$%#*#($*@F*1+$%#*5"#$+/9*!-+*@+&#*A)2/*CE!*D+"%+/*%/*#*.#1%)0*'.*#$6#(4+$*$2#)*3'(+*$+,&-*.%)&+"/*$+/%5(+$*&'*
,"'6%$+*',&%1#)*4)#"%.%4#&%'(*'.*=%',"'4+//*#($*=%')'5%4#)*.)2%$/9*G'/&*@+&#*A)2/*,"'$24&/*2/%(5*CE!*D+"%+/*.%)&+"*1+$%#*
4'(/%/&*'.*&7'*$%/&%(4&*)#0+"/;*'"*H3'(+/I*'.*.%)&+"*1+$%#*7%&-*&-+*2,/&"+#1*3'(+*1'"+*',+(*&-#(*&-+*$'7(/&"+#1*'(+9*
!-%/*/&"24&2"+*+(-#(4+/*&-+*4'(&#1%(#(&*-')$%(5*4#,#4%&0*'.*&-+*.%)&+"*1+$%#;*"+$24+/*,"+1#&2"+*,)255%(5*#($*-+),/*
+?&+($*/+"6%4+*)%.+9*F))*@+&#*A)2/*CE!*.%)&+"*1+$%#*5"#$+/*#"+*#6#%)#=)+*%(*/%(5)+J2/+*.'"1#&*%(4)2$%(5*#*/,+4%#)*5"#$+*
KLCMNOPFQ*&-#&*%/*$+/%5(+$*.'"*)%,%$*"+1'6#)9*

Applications
*

Ŷ*R)#"%.%4#&%'(*'.*1#11#)%#(*4+))*42)&2"+*-#"6+/&9

*

Ŷ*C(-#(4+$*,"'&+4&%'(*'.*$'7(/&"+#1*,"'4+//+/9

*

Ŷ*R)#"%.%4#&%'(*'.*=#4&+"%#;*0+#/&*#($*%(/+4&*4+))*)0/#&+/9

*

Ŷ*:'/&*R+))*A"'&+%(/*K:RAQ*"+1'6#)9

*

Ŷ*S%"2/+/*#($*LTF*"+$24&%'(9

*

Ŷ*A"'&+%(*#55"+5#&+/*"+1'6#)9*

*

Ŷ*C($'&'?%(*"+1'6#)9

*

Ŷ*F(&%J.'#1%(5*#5+(&/*"+1'6#)9

Table 1a. Recommended Operating Parameters

Maximum
Operating Pressure
Inlet Pressure
Differential Pressure

Zeta Pluss™
Encapsulated
System

Zeta Pluss™
Scale-Up
Capsules

3.4 bar (50 psi)
2.4 bar (35 psi)

3.1 bar (45 psi)
35 psi (2.4 bar)

Maximum
Operating
Temperature

40°C (104°F)

Recommended
Pre-use Rinse

54 L/m² (1.3 gal/ft²)

!-+* ,"%1#"0* #,,)%4#&%'(* .'"* &-+* @+&#* A)2/* C(4#,/2)#&+$* D0/&+1* %/* 4+))* 42)&2"+* 4)#"%.%4#&%'(* #.&+"* .+"1+(&#&%'(9* !-+*
D0/&+1* 4#(* =+* +1,)'0+$* #)'(+;* '"* %(* 4'1=%(#&%'(* 7%&-* 4+(&"%.25#&%'(* '"* !#(5+(&%#)* >)'7* >%)&"#&%'(* K!>>Q9* F(*
#)&+"(#&%6+*#,,)%4#&%'(*.'"*&-+*@+&#*A)2/*C(4#,/2)#&+$*D0/&+1*%/*$'7(/&"+#1*%1,2"%&0*"+1'6#)9*!#<%(5*#$6#(&#5+*'.*
%&/*,'/%&%6+*4-#"5+*4#,#4%&0;*@+&#*A)2/*.%)&+"*1+$%#*-#/*=++(*/-'7(*&'*=+*+..+4&%6+*%(*"+1'6%(5*4'(&#1%(#(&/*/24-*#/*
-'/&*4+))*,"'&+%(/*K:RAQ;*6%"2/+/;*LTF;*,"'&+%(*#55"+5#&+/;*#($*+($'&'?%(/9*
N(* 1'('4)'(#)* #(&%='$0* ,"'$24&%'(;* @+&#* A)2/* .%)&+"* 1+$%#* %/* %(4"+#/%(5)0* =+%(5* 2/+$* #/* #* ,')%/-%(5* /&+,* #.&+"* &-+*
A"'&+%(*F*4')21(*4#,&2"+*/&+,;*"+,)#4%(5*&"#$%&%'(#)*#(%'(*+?4-#(5+*4-"'1#&'5"#,-09*
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Figure 1. Zeta Plus™ Encapsulated System
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Innovative Capsule/Manifold Design
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Top Manifold

Bottom Manifold

Small Capsule

Large Capsule

0.23 m² Capsule
(with double layer or single layer media)

1.6 m² Capsule (with double layer media)
2.5 m² Capsule (with single layer media)

Figure 2. Nominal Retention Ratings for Zeta Plus™ EXT Grades
(For reference only. Retention ratings may vary depending on application.)
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E01020 (1020 cm²)

BC25
(25 cm²)

E0170 (170 cm²)
and
E0340 (340 cm²)

Small Holder
Double layer: 0.23 - 1.6 m²
Single layer: 0.23 - 2.5 m²

Large Holder
Double layer: 1.6 - 11.2 m²
Single layer: 2.5 - 17.5 m²

Multi-Round System Model
#16EZC5
Contact your 3M Purification
representative.

Figure 3. The Zeta Plus™ Encapsulated System Single-Use Depth Filtration Product Portfolio
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Plus™
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Scale-Up
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Capsules
l
Figure 6. Multi-Round System
Figure 5. Large Holder with Mechanical Polish Finish
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Table 2a. Zeta Pluss™ Encapsulated System Capsule Filter and Manifold Specifications
Configuration
Small Capsule
Dimensions (Height x Diameter)
Weight
Dry
Wet (post Blow-Down)
Materials of Construction
filter media
Outer Shell
O-rings
Separators, Spacers and Connectors
Edge Seals
Handles
Hold-up Volume
Double Layer:
Capsule Fill Volume2
Single Layer:
Post Blow-Down Hold-up Volume3
Maximum Operating Line Pressure
Maximum Differential Pressure
Forward
Sterilization

Large Capsule

Standard
Alkaline Resistant1
5.7 cm x 45.2 cm (2.2” x 17.8”)
3.3 kg (7 lbs)
4.4 kg (10 lbs)

3.4 kg (8 lbs)
4.8 kg (11 lbs)

Standard
Alkaline Resistant1
20.3 cm x 45.2 cm (8.0” x 17.8”)
10.0 kg (22 lbs)
19.3 kg (43 lbs)

Filter aids, cellulose, binding resin
Polycarbonate
Polyphenylene / Polystyrene
Silicone
Polypropylene
Thermoplastic Elastomer
N/A

10.7 kg (24 lbs)
19.7 kg (43 lbs)

Filter aids, cellulose, binding resin
Polycarbonate
Polyphenylene / Polystyrene
Silicone
Polypropylene
Thermoplastic Elastomer
Nylon

~ 1.1 L (~ 0.3 gal)
~ 2.6 L (~ 0.7 gal)
< 100 mL (<0.026 gal)
3.4 bar (50 psig)

~ 5.2 L (~ 1.4 gal)
~ 4.2 L (~1 .1 gal)
< 100 mL (<0.026 gal)
3.4 bar (50 psig)

2.4 bar (35 psid)
1 cycle autoclave (30 mins) at 126°C (259°F)

2.4 bar (35 psid)
1 cycle autoclave (30 mins) at 126°C (259°F)

0.23 m² (2.4 ft²)

Double layer: 1.6 m² (17.2 ft²)
Single layer: 2.5 m² (27.0 ft²)

Effective Filtration Area

Top/Bottom Manifold
Dimensions (Height x Diameter)
5.2 cm x 45.2 cm ( 2.0” x 17.8” )
5.2 cm x 45.2 cm ( 2.0” x 17.8” )
Connector
1.5" Sanitary Style
1.5" Sanitary Style
Material
Polycarbonate
Polyphenylene / Polystyrene
Polycarbonate
Polyphenylene / Polystyrene
Weight
4.5 kg (10 lbs)
4.5 kg (10 lbs)
4.5 kg (10 lbs)
4.5 kg (10 lbs)
Hold up volume
< 250 mL (<0.07 gal)
< 250 mL (<0.07 gal)
1
Based on testing with 1M NaOH and 5% NaClO (Bleach). See Chemical Compatibility Guide (70-0202-2023-5/LITPHG03) for more information.
2
Capsule Fill Volume is defined as the volume of liquid that is required to fill the portion of the capsule outside the filter media.
3
Post Blow-Down Hold-up Volume is defined as the volume of the residual liquid after nitrogen gas blow-down.

Figure 7. Single-Use Manifolds and Capsule Filter Schematic
Female Connector

Female
Connector
ctor

Female Connector

Downstream Vent
Dow

Straigght Handle

Plastic Shell

Manifold Stop

T-Handle

O-Rings
Capsule Stop

Outlet
Male Connector

Top Manifold

Inllett

Manifoldd Stop

Bottom Manifold

E16 Single-Cell Capsule
0.23 m2 Capsule
(with double layer
or single layer media)
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E16 Multi-Cell Capsule
1.6 m2 Capsule
(with double layer media)
2.5 m2 Capsule
(with single layer media)

Table 2b: Zeta Plus Scale-Up Capsule Filter Specifications
170 cm² Capsule

340 cm² Capsule

1020 cm² Capsule

Dimensions
Height x Diameter

4.1” x 8.5” (10.3 cm x 21.6 cm)

6.0” x 8.5” (15.2 cm x 21.6 cm)

Weight
Dry - Single Layer

1.0 kg (2.2 lb)

1.0 kg (2.1 lb)

1.4 kg (3.0 lb)

Dry - Double Layer

1.0 kg (2.2 lb)

1.0 kg (2.3 lb)

1.6 kg (3.5 lb)

Wet Post Blow-Down - Single Layer

1.1 kg (2.4 lb)

1.1 kg (2.5 lb)

1.8 kg (4.0 lb)

Wet Post Blow-Down - Double Layer

1.2 kg (2.6 lb)

1.3 kg (2.9 lb)

2.4 kg (5.2 lb)

Materials of Construction
Capsule Shells

Polysulfone

Separator, Spacer, Vent Cap

Polypropylene

O-ring

Fluorocarbon

Endcap & Edge Seals

Thermoplastic Elastomer

Volume
Capsule1 Fill Volume - Single Layer

0.48 L

0.40 L

0.91 L

Capsule Fill Volume - Double Layer

0.43 L

0.34 L

0.62 L

1

Post Blow-Down Hold-up Volume - Single Layer

< 40 mL

< 40 mL

< 40 mL

Post2 Blow-Down Hold-up Volume - Double Layer

< 40 mL

< 40 mL

< 40 mL

2

Miscellaneous
Sterilization

1 cycle autoclave (30 min) @ 126°C (259°F)

Effective Filtration Area

170 cm² (0.18 ft²)

340 cm² (0.37 ft²)

Connector

1,020 cm² (1.10 ft²)

1/2” Sanitary Style

1

Capsule Fill Volume is defined as the volume of liquid that is required to fill the portion of the capsule outside the filter media.

2

Post Blow-Down Hold-up Volume is defined as the volume of the residual liquid after nitrogen gas blow-down.

IMPORTANT NOTICE: Always operate the filter system within the maximum differential pressure of 2.4 bar (35 psig).

Figure 8. Scale-Up Capsule Filter Schematics
Inlet
(Not Shown)

Inlet

Vent

Outlet

170 cm & 340 cm
Capsules
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Vent

Outlet

1020 cm Capsule

Table 3. Zeta Pluss™ Encapsulated System Holder Specifications
Holder Model
Small Holder
(Model# 16EZA)

Large Holder
(Model# 16EZB)

Multi-Round Holder
(Model# 16EZC)

3.4 bar (50 psi)

3.4 bar (50 psi)

3.4 bar (50 psi)

Frame

304 Stainless Steel

304 Stainless Steel

End Plates

304 Stainless Steel

304 Stainless Steel

Support Rods

440 Stainless Steel

316 Stainless Steel

Stand

304 Stainless Steel

304 Stainless Steel

Maximum Operating Pressure
Materials of Construction

Hand Wheels

300 Series Stainless Steel

300 Series Stainless Steel

Gear Box

N/A

Epoxy Coated Cast Iron Cover

Locking Bar

N/A

304 Stainless Steel

Casters

Stainless Steel

Stainless Steel

Wheels

Phenolic

Polyurethane

Satin Glass Bead Finish
(4814901 and 4815501)
Electropolish Finish
(4814902)

Mechanical Polish Finish
(6123502)

Please contact your
3M Purification
representative for details.

N/A

Surface Finish
Standard
Special

N/A

Table 4. Zeta Pluss™ Encapsulated System Holder Capacity
Single Stage

Model
16EZA
16EZB

Two Stage

E16 Single-Cell
Capsule

E16 Multi-Cell
Capsule

E16 Single-Cell
Capsule

E16 Multi-Cell
Capsule

4
NA

1
7

2
NA

NA
6

Figure 9. Small Holder (Model# 16EZA) Dimensions

129 cm (51”)
Maximum
102 cm (40”)
Minimum

66 cm (26")
Width & Depth

9

Please contact your
3M Purification
representative for details.

Figure 10. Large Holder (Model# 16EZB) Dimensions
205.9 cm (81.1”)
Maximum

113.9 cm
(45.5”)

86.4 cm
(34.0”)

Horizontal Position

210.7 cm
(83”)

108.7 cm
(42.8”)

Vertical Position
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Ordering Guide
Capsule Filter Ordering Information - Double layer (U.S. Customers)
Catalog
Number

Configuration

Number of
Cells

Gasket
Material

E16

E - Standard
R - Alkaline Resistant*

01 - 1 Cell
07 - 7 Cell

A - Silicone

NOTES:
1. All Zeta Plus™ EXT media grades are
available for order.
2. For further information regarding Zeta
Plus EXT Series filter media, please
reference 3M Purification Literature
70-0201-8862-2 (LITZPMEXT) or
70-0201-8863-0 (LITZPMEXTSP1) and
Chemical Compatibility Guide 70-02022023-5 (LITPHG03)
3. DELI08A is a Zeta Plus EXT grade with
two single layers of Delipid (DELI) media.
4. Single layer 05SP media is offered in
0.23 m² and 1.6 m² Capsule format. One
part number example is E16E07A05SP.

Grade
05SP01A
10SP01A
10SP02A
30SP02A
30SP03A
60SP01A

60SP02A
60SP03A
60SP05A
90SP05A
90SP08A

120ZA05A
120ZA08A
120ZA10A
DELI08A
60ZA05A
90ZA05A
90ZA08A

Capsule Filter Ordering Information - Single layer (U.S. Customers)
Catalog
Number

Configuration

Number of
Cells

E16

E - Standard
R - Alkaline Resistant*

01 - 1 Cell
11 - 11 Cell

Gasket
Material

Grade

30LA
50LA
60LA
90LA

A - Silicone

10SP
30SP
50SP
60SP
90SP

30LP
50LP
60LP
90LP

30ZA
60ZA
90ZA
DELI

Manifold Ordering Information
Manifold Part

3M PI
Part Number

3M ID

Manifold Set (Standard)

6128901

70020256221

Manifold Set (Alkaline Resistant*)

6129001

70020262369

Filter Holder Ordering Information
Model
Name

3M Catalog ID
(U.S. Customers)

Description

3M ID

Model
Name

3M Catalog ID
(U.S. Customers)

Description

3M ID

16EZA

4814901

Standard Small Holder

70020233048

16EZB

6123502

Large Holder with
Mechanical Polish Finish

70020252899

16EZA

4814902

Small Holder with
Electropolish Finish

70020253889

16EZA

4815501

Modified Small Holder
Suitable for Autoclaving

70020236512

Scale-Up Capsules - Double Layer
3M Catalog ID
(U.S. Customers)

E

EFA
cm²

0170
0340
1020

Scale-Up Capsules - Single Layer

Material
Code

FSA

3M Catalog ID
(U.S. Customers)

Grade
05SP01A
10SP01A
10SP02A
30SP02A
30SP03A
60SP01A
60SP02A
60SP03A
60SP05A
90SP05A
90SP08A

60ZA05A
90ZA05A
90ZA08A
120ZA05A
120ZA08A
120ZA10A

EFA
cm²

Material
Code

DELI08A
DELP08A
E

0170
0340
1020

FSA

Grade
05SP
10SP
30SP
50SP
60SP
90SP

30LA
50LA
60LA
90LA

30LP
50LP
60LP
90LP

30ZA
60ZA
90ZA
DELI

* Based on testing with 1M NaOH and 5% NaClO (Bleach). See Chemical Compatibility Guide
(70-0202-2023-5/LITPHG03) for more information.
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Capsule 3M ID Numbers for International Customers
Standard Zeta Plus™ Encapsulated System Capsule Filters
3M Catalog ID
(U.S. Customers)

3M ID
(International
Customers)

Alkaline Resistant* Zeta Plus™ Encapsulated System Capsule Filters

3M Catalog ID
(U.S. Customers)

3M ID
(International
Customers)

3M Catalog ID
(U.S. Customers)

3M ID
(International
Customers)

3M Catalog ID
(U.S. Customers)

3M ID
(International
Customers)

E16E01A05SP

70020288414

E16E07A05SP

70020288562

E16R01A05SP

70020288992

E16R07A05SP

70020289008

E16E01A05SP01A

70020239011

E16E07A05SP01A

70020236918

E16R01A05SP01A

70020262609

E16R07A05SP01A

70020262740

E16E01A10SP

70020288422

E16E07A10SP02A

70020236561

E16R01A10SP

70020288794

E16R07A10SP02A

70020262757

E16E01A10SP02A

70020239029

E16E07A120ZA08A

70020236926

E16R01A10SP02A

70020262625

E16R07A120ZA08A

70020262773

E16E01A120ZA08A 70020238526

E16E07A30SP02A

70020236942

E16R01A120ZA08A

70020262641

E16R07A30SP02A

70020262799

E16E01A30LA

70020288430

E16E07A60SP02A

70020236603

E16R01A30LA

70020288802

E16R07A60SP02A

70020262823

E16E01A30LP

70020288448

E16E07A60SP05A

70020236959

E16R01A30LP

70020288810

E16R07A60SP05A

70020262849

E16E01A30SP

70020288455

E16E07A60ZA05A

70020236967

E16R01A30SP

70020288828

E16R07A60ZA05A

70020262856

E16E01A30SP02A

70020238534

E16E07A90SP05A

70020236629

E16R01A30SP02A

70020262948

E16R07A90SP05A

70020262864

E16E01A30ZA

70020288364

E16E07A90ZA05A

70020236975

E16R01A30ZA

70020288364

E16R07A90ZA05A

70020262880

E16E01A50LA

70020288471

E16E07A90ZA08A

70020236983

E16R01A50LA

70020288836

E16R07A90ZA08A

70020262898

E16E01A50LP

70020288489

E16E11A10SP

70020288596

E16R01A50LP

70020288844

E16R11A10SP

70020289024

E16E01A50SP

70020274430

E16E11A30LA

70020288604

E16R01A50SP

70020288851

E16R11A30LA

70020289032

E16E01A60LA

70020288497

E16E11A30LP

70020288612

E16R01A60LA

70020288869

E16R11A30LP

70020289040

E16E01A60LP

70020288505

E16E11A30SP

70020288620

E16R01A60LP

70020288877

E16R11A30SP

70020289057

E16E01A60SP

70020288513

E16E11A30ZA

70020288638

E16R01A60SP

70020288885

E16R11A30ZA

70020289065

E16E01A60SP02A

70020239078

E16E11A50LA

70020288646

E16R01A60SP02A

70020262682

E16R11A50LA

70020289073

E16E01A60SP05A

70020239094

E16E11A50LP

70020288653

E16R01A60SP05A

70020262955

E16R11A50LP

70020289081

E16E01A60ZA

70020283605

E16E11A50SP

70020288661

E16R01A60ZA

70020284587

E16R11A50SP

70020289099

E16E01A60ZA05A

70020238542

E16E11A60LA

70020288679

E16R01A60ZA05A

70020262708

E16R11A60LA

70020289107

E16E01A90LA

70020288521

E16E11A60LP

70020288687

E16R01A90LA

70020288893

E16R11A60LP

70020289115

E16E01A90LP

70020288539

E16E11A60SP

70020288695

E16R01A90LP

70020288901

E16R11A60SP

70020289123

E16E01A90SP

70020288547

E16E11A60ZA

70020288703

E16R01A90SP

70020288919

E16R11A60ZA

70020289131

E16E01A90SP05A

70020239102

E16E11A90LA

70020288711

E16R01A90SP05A

70020262716

E16R11A90LA

70020289149

E16E01A90ZA

70020288356

E16E11A90LP

70020288729

E16R01A90ZA

70020288927

E16R11A90LP

70020289156

E16E01A90ZA05A

70020239128

E16E11A90SP

70020288737

E16R01A90ZA05A

70020262963

E16R11A90SP

70020289164

E16E01A90ZA08A

70020238559

E16E11A90ZA

70020288745

E16R01A90ZA08A

70020262732

E16R11A90ZA

70020289172

E16E01ADELI

70020256130

E16E11ADELI

70020288588

E16R01ADELI

70020288786

E16R11ADELI

70020289016
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Zeta Plus™ ScaleUp Capsule 3M ID Numbers
3M ID
(International
Customers)

3M ID
(International
Customers)

3M Catalog ID
(U.S. Customers)

3M ID
(International
Customers)

3M Catalog ID
(U.S. Customers)

E0170FSA05SP01A

70020290170

E0340FSA05SP01A

70020290543

E1020FSA05SP01A

70020290915

E0170FSA10SP01A

70020290196

E0340FSA10SP01A

70020290568

E1020FSA10SP01A

70020290931

3M Catalog ID
(U.S. Customers)

E0170FSA10SP02A

70020290204

E0340FSA10SP02A

70020290576

E1020FSA10SP02A

70020290949

E0170FSA30SP02A

70020290279

E0340FSA30SP02A

70020290642

E1020FSA30SP02A

70020291012

E0170FSA30SP03A

70020290287

E0340FSA30SP03A

70020290659

E1020FSA30SP03A

70020291020

E0170FSA60SP01A

70020290360

E0340FSA60SP01A

70020290733

E1020FSA60SP01A

70020291103

E0170FSA60SP02A

70020290378

E0340FSA60SP02A

70020290741

E1020FSA60SP02A

70020291111

E0170FSA60SP03A

70020290386

E0340FSA60SP03A

70020290758

E1020FSA60SP03A

70020291129

E0170FSA60SP05A

70020290394

E0340FSA60SP05A

70020290766

E1020FSA60SP05A

70020291137

E0170FSA90SP05A

70020290451

E0340FSA90SP05A

70020290824

E1020FSA90SP05A

70020291194

E0170FSA90SP08A

70020290469

E0340FSA90SP08A

70020290832

E1020FSA90SP08A

70020291202

E0170FSA60ZA05A

70020290410

E0340FSA60ZA05A

70020290782

E1020FSA60ZA05A

70020291152

E0170FSA90ZA05A

70020290485

E0340FSA90ZA05A

70020290857

E1020FSA90ZA05A

70020291228

E0170FSA90ZA08A

70020290493

E0340FSA90ZA08A

70020290865

E1020FSA90ZA08A

70020291236

E0170FSA120ZA05A

70020290212

E0340FSA120ZA05A

70020290584

E1020FSA120ZA05A

70020290956

E0170FSA120ZA08A

70020290220

E0340FSA120ZA08A

70020290592

E1020FSA120ZA08A

70020290964

E0170FSA120ZA10A

70020290238

E0340FSA120ZA10A

70020290600

E1020FSA120ZA10A

70020290972

E0170FSADELI08A

70020290147

E0340FSADELI08A

70020290519

E1020FSADELI08A

70020290881

E0170FSADELP08A

70020290154

E0340FSADELP08A

70020290527

E1020FSADELP08A

70020290899

E0170FSA05SP

70020290162

E0340FSA05SP

70020290535

E1020FSA05SP

70020290907

E0170FSA10SP

70020290188

E0340FSA10SP

70020290550

E1020FSA10SP

70020290923

E0170FSA30SP

70020290261

E0340FSA30SP

70020290634

E1020FSA30SP

70020291004

E0170FSA50SP

70020290329

E0340FSA50SP

70020290691

E1020FSA50SP

70020291061

E0170FSA60SP

70020290352

E0340FSA60SP

70020290725

E1020FSA60SP

70020291095

E0170FSA90SP

70020290444

E0340FSA90SP

70020290816

E1020FSA90SP

70020291186

E0170FSA30ZA

70020290295

E0340FSA30ZA

70020290667

E1020FSA30ZA

70020291038

E0170FSA60ZA

70020290402

E0340FSA60ZA

70020290774

E1020FSA60ZA

70020291145

E0170FSA90ZA

70020290477

E0340FSA90ZA

70020290840

E1020FSA90ZA

70020291210

E0170FSA30LA

70020290246

E0340FSA30LA

70020290618

E1020FSA30LA

70020290980

E0170FSA50LA

70020290303

E0340FSA50LA

70020290675

E1020FSA50LA

70020291046

E0170FSA60LA

70020290337

E0340FSA60LA

70020290709

E1020FSA60LA

70020291079

E0170FSA90LA

70020290428

E0340FSA90LA

70020290790

E1020FSA90LA

70020291160

E0170FSA30LP

70020290253

E0340FSA30LP

70020290626

E1020FSA30LP

70020290998

E0170FSA50LP

70020290311

E0340FSA50LP

70020290683

E1020FSA50LP

70020291053

E0170FSA60LP

70020290345

E0340FSA60LP

70020290717

E1020FSA60LP

70020291087

E0170FSA90LP

70020290436

E0340FSA90LP

70020290808

E1020FSA90LP

70020291178

E0170FSADELI

70020290139

E0340FSADELI

70020290501

E1020FSADELI

70020290873
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Enabling SCALABILITY

for Cell Culture Clarification

from R&D to Large-Scale Production

Zeta Plus™ Encapsulated Depth Filter Platform
Lab /
R&D

Up to 1 Liter

Scale-Up

Up to 50 Liters

Pilot
Production

Large Scale
Production

Multi-Round
Production

Up to 400 Liters

Up to 5,000 Liters

Up to 25,000 Liters
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Innovative

Filtration
Fast. Easy. Clean.
Important Notice
The information described in this literature is accurate to the best of our knowledge. A variety of factors, however, can affect the performance of the Product(s) in a particular
application, some of which are uniquely within your knowledge and control. INFORMATION IS SUPPLIED UPON THE CONDITION THAT THE PERSONS RECEIVING THE
SAME WILL MAKE THEIR OWN DETERMINATION AS TO ITS SUITABILITY FOR THEIR USE. IN NO EVENT WILL 3M PURIFICATION INC. BE RESPONSIBLE FOR DAMAGES
OF ANY NATURE WHATSOEVER RESULTING FROM THE USE OF OR RELIANCE UPON INFORMATION.
It is your responsibility to determine if additional testing or information is required and if this product is fit for a particular purpose and suitable in your specific application.
3M PURIFICATION INC. MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER NATURE HEREUNDER WITH RESPECT TO INFORMATION OR THE PRODUCT TO WHICH
INFORMATION REFERS.

Limitation of Liability
3M Purification Inc. will not be liable for any loss or damage arising from the use of the Product(s), whether direct, indirect, special, incidental, or consequential, regardless of
the legal theory asserted, including warranty, contract, negligence or strict liability. Some states do not allow the exclusion or limitation of incidental or consequential damages,
so the above limitation may not apply to you.

Your Local Distributor:

3M Purification Inc.

400 Research Parkway
Meriden, CT 06450
U.S.A.
(800) 243-6894
(203) 237-5541
Fax (203) 630-4530
www.3Mpurification.com

3M is a trademark of 3M Company.
Zeta Plus is a trademark of
3M Company used under license.
© 3M 2012. All rights reserved.
70020239672
REV 0812

!
!
!
!
!
!
!
!
!
!

GH3$DD!5#6!I'J$!K$52!"LM35#?$!N'#65O$#25DE*!
P$E(?#!5#6!,5E$!H2'6($EQ!!
!
!
"#!$%&'!()!*+,-'.!$&%/01-1!(-2-1-30-1.!4+2!53661.!
!-17!*%8'!9%62"+.!:16&;<%=.!>>?!

!
!
!
!
!
!
!
!
!
!
!

!
!
CRHI4C,IS!
@/! 8+2=-1%6/! 6A-2%16! 306%&! 3+3-B! 8+/3! +C! +=6&-3%+1/.! 616&D#! </-D6! -17! 06-3! &68+,6&#! 76B%,6&!
8+/3! /-,%1D/! 30&+<D0! %18&6-/67! 616&D#! <3%B%E-3%+1! -17! 6CC%8%618#)! F6-3! 6A80-1D6&/! +CC6&!
8+2=-1%6/!306!+==+&3<1%3#!3+!&6</6!616&D#!D616&-367!C+&!-!/=68%C%8!=<&=+/6!%1/36-7!+C!,613%1D!
30-3!616&D#!3+!306!-32+/=06&6)!506BB!-17!3<"6!06-3!6A80-1D6&/!-&6!%1!G%76!</6!30&+<D0+<3!306!
H++7.! I-%&#.! J6,6&-D6.! K0-&2-86<3%8-B.! ?062%8-B/.! K63&+B6<2! (6C%1%1D.! -17! L3%B%3#! %17</3&%6/)!
40%/! =-=6&! "&%6CB#! 6A=B+&6/! 30&66! 2+76/! +C! 06-3! 3&-1/C6&! -17! "-/%8! 76/%D1/! C+<17! %1! /06BB! -17!
3<"6! 06-3! 6A80-1D6&/)! @B/+! %18B<767! -&6! /6,6&-B! 8-/6! /3<7%6/! C&+2! 7%CC6&613! %17</3&%6/! G06&6!
:16&;<%=M/!06-3!6A80-1D6&/!0-,6!/-,67!306!+=6&-3+&/!616&D#!-17!2+16#)!
!
!
"#$%&'()*!++,!-!.//!01%23!4156*!7$681%6*!9:!;<<;/=!,1)>%(?32!.@//@AB/B=!CDD!%(?32E!%$E$%F$6=!

!
*
*
*

@9A+!*BC*,BD@!D@E*
*
*
*
*
*
*
58* A9EF,*GBH!E*BC*I!9@*@J9DEC!J*
*
*
*
?8* I#?2*@$?";L#$*M/*,."=&N2'."*
M8* I#?2*@$?";L#$*M/*,."<#N2'."*
N8* I#?2*@$?";L#$*M/*J?='?2'."*
=8* !O?P(:#*>$.M:#P*Q5*
*
*
*
68* EI!++*9DH*@RA!*I!9@*!S,I9DT!JE* *
*
*
?8* !O?P(:#*>$.M:#P*Q6*
M8* @!G9*E1#::*?"=*@&M#*I#?2*!ON1?"0#$*D.P#"N:?2&$#*
*
*
*
K8* ,9E!*E@RHF!E*
*
*
*
*
*
*
?8* >.2?2.*,1'(*C$/#$*
M8* >&:(*>:?"2*B':**
N8* ,#$#?:*E&0?$*,."N#"2$?2.$*
*
*
*
W8* 9>>!DHFS*9*X*T:.;;?$/*.L*I#?2*!ON1?"0#$*@#$P'".:.0/*

*

*

>?0#*K*

*

*

>?0#*U*

*

*********>?0#*5V*

*

*********>?0#*5Y*

*
*
*
*
*
*
*
*
*
*
*
*
*
*
!

*
*
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**6!

A9BC,*DEF!B*EG*H!9I*IJ9KBG!J*
*
"#$%! %&$'()#&! *++,&(! -.#'! $! %#/0#&$%,&#! 1&$23#'%! #43(%(! -3%.3'! $! (5(%#/6! 7.#&/*25'$/3+(!
(%$%#(!%.$%!#'#&15!+$''*%!8#!+&#$%#2!*&!2#(%&*5#29!*':5!%&$'()*&/#2!)&*/!*'#!(%$%#!%*!$'*%.#&!
$'2!%&$'()#&&#2!8#%-##'!23))#&#'%!/#23$6!;'!8$(3+!.#$%!#4+.$'1#9!%.#&#!$&#!%.&##!/*2#(!*)!.#$%!
%&$'()#&<! +*'2,+%3*'9! +*'=#+%3*'! $'2! &$23$%3*'6! >'#! *&! /*&#! *)! %.#(#! +*'23%3*'(! /$5! *++,&!
(3/,:%$'#*,(:56! ?*::*-3'1! $&#! 8&3#)! 2#(+&30%3*'(9! /$%.#/$%3+$:! #@,$%3*'(! *)! %.#(#! 23))#&#'%!
/*2#(!*)!.#$%!%&$'()#&!$'2!$!($/0:#!0&*8:#/6!
!
H!9I*IJ9KBG!J*AL*,EKFM,ICEK*
"#$%!%&$'()#&!85!+*'2,+%3*'!*++,&(!-.#'!$!%#/0#&$%,&#!1&$23#'%!#43(%(!8#%-##'!23))#&#'%!/#23$!
$+&*((! $! 2#)3'#2! 8*,'2$&56! 7.3(! /*2#! *)! .#$%! %&$'()#&! 3(! (,(%$3'#2! 85! 23)),(3*'! $%! %.#! $%*/3+!
$'2! /*:#+,:$&! :#=#:(! 2,#! %.&*,1.! %.#! 3'%#&$+%3*'! *)! 0$&%3+:#(! $%! 23))#&#'%! #'#&15! :#=#:(6! A3'#%3+!
#'#&15! B#'#&15! *)! /*%3*'C! %&$'()#&! 2,&3'1! %.#(#! +*::3(3*'(! 3(! 0#&+#3=#2! $(! +.$'1#(! 3'!
%#/0#&$%,&#!*&!%.#!):*-!*)!.#$%6!
!
D*'2,+%3*'!/$5!8#!*8(#&=#2!3'!$::!(%$%#(!*)!/$%%#&!B(*:32(9!:3@,32(9!$'2!1$(#(C6!E,#!%*!%.#!/#$'!
)&##!0$%.!*&!%.#!(0$+3'1!8#%-##'!%.#!/*:#+,:#(!3'!%.#(#!%.&##!(%$%#(9!%.#!#4%#'%!*)!+*'2,+%3=#!
.#$%! %&$'()#&! 3(! /*(%! 0&*'*,'+#2! 3'! %31.%:5! (0$+#2! (*:32(! $'2! %.#'! :3@,32(6! F$(#(! .$=#! %.#!
:*-#(%!:#=#:!*)!+*'2,+%3=#!.#$%!%&$'()#&6!!
!
G! 0*%! *)! 8*3:3'1! -$%#&! *'! $'! #:#+%&3+! .*%! 0:$%#! 3::,(%&$%#(! +*'2,+%3*'! .#$%! %&$'()#&6! "#$%! 3(!
+*'2,+%#2!)&*/!%.#!.*%!0:$%#!%*!%.#!0*%!0:$+#2!*'!3%!B(*:32!%*!(*:32!+*'2,+%3*'C6!7.#!.#$%#2!0*%!3'!
%,&'!%&$'()#&(!.#$%!%*!%.#!-$%#&!3'!+*'%$+%!-3%.!3%!B(*:32!%*!:3@,32!+*'2,+%3*'C6!!
!
?*,&3#&H(! :$-! @,$'%3)3#(! %.#! 0&*+#((! *)! .#$%! +*'2,+%3*'6! ;%! 3(! 8$(#2! *'! %.#! *8(#&=#2!
0.#'*/#'*'! %.$%! %.#! &$%#! *)! .#$%! +*'2,+%3*'! 3(! 23&#+%:5! 0&*0*&%3*'$:! %*! %.#! %#/0#&$%,&#!
23))#&#'+#!8#%-##'!%.#!%-*!/#23$!$'2!(,&)$+#!$&#$9!$'29!3'23&#+%:5!0&*0*&%3*'$:!%*!%.#!%.3+I'#((!
*)!%.#!/$%#&3$:6!;%!3(!#40&#((#2!$(<!
!
"!#!$!࣭!%࣭B&'!(!&)*!
!
J.#&#9!!
"!K!&$%#!*)!.#$%!%&$'()#&!BL%,M.C!
I!K!%.#&/$:!+*'2,+%3=3%5!BL%,M)%N.&NO?C!
%!#!(,&)$+#!$&#$!B)%PC!
&'!#!%#/0#&$%,&#!23))#&#'+#!BO?C9!!
&)!#!%.3+I'#((!B)%C!!
B27!M!24C!K!%.#!%#/0#&$%,&#!1&$23#'%6!!
!
H!9I*IJ9KBG!J*AL*,EKN!,ICEK*
"#$%!%&$'()#&!85!+*'=#+%3*'!*++,&(!85!%-*!+*,0:#2!/#+.$'3(/(<!3'%#&$+%3*'!*)!0$&%3+:#(!$%!%.#!
/3+&*(+*03+! :#=#:! $'2! 8,:I! /*%3*'! *)! 0$&%3+:#(! $%! %.#! /$+&*(+*03+! :#=#:! -.#'! $! %#/0#&$%,&#!
23))#&#'%3$:! #43(%(6! 7.3(! /*2#! *)! .#$%! %&$'()#&! 3(! *8(#&=#2! 3'! :3@,32(! $'2! 1$(#(! 8#+$,(#!
/*=#/#'%! 3(! =#&5! &#(%&3+%#2! 3'! (*:32(6! 7.#! 8,:I! %&$'(0*&%! *)! 0$&%3+:#(! 3(! %.#! 0&#2*/3'$'%!
/#+.$'3(/! +*/0$&#2! %*! %.#! 23)),(3=#! %&$'()#&! *)! #'#&15! -.3+.! 3(! *':5! 0&#(#'%! +:*(#! %*! %.#!
8*,'2$&5!*)!$!(*:32!(,&)$+#!3'!+*'%$+%!-3%.!%.#!):,326!
!
7.#!+.$&$+%#&3(%3+!/$+&*(+*03+!/*=#/#'%!*8(#&=#2!3'!+*'=#+%3=#!.#$%!%&$'()#&!/$5!8#!+$,(#2!
85!$'!#4%#&'$:!$1#'+5!B)*&+#2!+*'=#+%3*'C9!2,#!%*!%.#!3'.#&#'%!8,*5$'+5!)*&+#(!B)&##!*&!'$%,&$:!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**@!

"#$%&"'(#$)*! #+! ,! "#-.($,'(#$! #/! .#'0! 1-(2&3! "#$%&"'(#$)4! 5! 67&"(,8! ",6&! #/! "#$%&"'(#$! (6! '0&!
'+,$6/&+! #/! 8,'&$'! &$&+9:! 3;+($9! "0,$9&! #/! 70,6&! ($! 7+#"&66&6! 8(<&! .#(8($9*! &%,7#+,'(#$*! ,$3!
"#$3&$6,'(#$4!
!
=&,'($9!>,'&+!($!,!7#'!#$!,$!&8&"'+("!0#'!78,'&!,86#!6&+%&6!'#!(88;6'+,'&!'0&!"#$"&7'!#/!"#$%&"'(#$4!
?0&$! 0&,'! (6! "#$3;"'&3! /+#-! '0&! 0#'! 78,'&! '#! '0&! 7#'! ,$3! '0&$! '#! '0&! >,'&+*! '0&! 3&$6(':!
3(//&+&$"&! .&'>&&$! '0&! 0#'! ,$3! '0&! "#83! >,'&+! ($"+&,6&6! '0&! .;#:,$":! #/! '0&! 0#'! >,'&+! ,$3!
($3;"&6! -#%&-&$'6! ,'! '0&! -,"+#6"#7("! 8&%&8*! /#+-($9! "#$%&"'(#$! ";++&$'6! ,$3! 0&,'($9! '0&!
>,'&+!>('0($!'0&!7#'4!
!
@0&!+,'&!#/!0&,'!'+,$6/&+!.:!"#$%&"'(#$!(6!A;,$'(','(%&8:!&27+&66&3!.:!B&>'#$C6!&-7(+(",8!8,>!#/!
"##8($9*! >0("0! 6','&6! '0,'! '0&! +,'&! #/! 0&,'! '+,$6/&+! (6! 3(+&"'8:! +&8,'&3! '#! '0&! '&-7&+,';+&!
3(//&+&$"&!,$3!'0&!6;+/,"&!,+&,4!D'!(6!&27+&66&3!($!'0&!9&$&+,8!/#+-!,6E!
!
!"#"$࣭"%࣭1&'""("&)!
!
?0&+&*!!
!"#!+,'&!#/!0&,'!'+,$6/&+!1F';G0)!
$"#!0&,'!'+,$6/&+!"#&//("(&$'!1F';G/'HI#J)!
%#!6;+/,"&!,+&,!1/'H)!
&'"#!'&-7&+,';+&!#/!'0&!6;+/,"&!1#J)!
&!K!'&-7&+,';+&!#/!'0&!/8;(3!1#J)4!!
!
@0&! 0&,'! '+,$6/&+! "#&//("(&$'! (6! ,! /;$"'(#$! #/! '0&+-#3:$,-("*! '+,$67#+'*! ,$3! 9&#-&'+(",8!
7,+,-&'&+64!
!
A!9B*BC9DEF!C*GH*C9IJ9BJKD*
588! -,'&+(,86*! 6#8(36*! 8(A;(36*! ,$3! 9,6&6*! &-('! '0&+-,8! +,3(,'(#$! ($! '0&! /#+-! #/! &8&"'+#-,9$&'("!
>,%&6!>0&$!'0&:!,+&!,'!,!'&-7&+,';+&!,.#%&!,.6#8;'&!L&+#!1M!INOP4QR! #J)4!?0&$!'0&:!($'&+,"'!
>('0!#'0&+!-,'&+(,86*!0&,'!&$&+9:!'+,$6/&+!(6!6,(3!'#!#"";+!'0+#;90!+,3(,'(#$4!@0&!($/+,+&3*!%(6(.8&*!
,$3!7,+'!#/!'0&!;8'+,%(#8&'!7#+'(#$!#/!'0&!&8&"'+#-,9$&'("!67&"'+;-!(6!"#$6(3&+&3!7&+'($&$'!'#!0&,'!
'+,$6/&+4!@0&!>,%&6!#+(9($,'&!,'!'0&!,'#-("!,$3!-#8&";8,+!8&%&8!.;'!,'!'0&!($'&+(#+!8#",'(#$6!'0&:!
,+&!,.6#+.&3!.:!'0&!6;++#;$3($9!7,+'("8&6!,$3!0&$"&!+,3(,'(#$!(6!9&$&+,88:!'+&,'&3!,6!,!6;+/,"&!
70&$#-&$#$4!
!
=&,'! '+,$6/&+! .:! +,3(,'(#$! 3(//&+6! /+#-! "#$3;"'(#$! ,$3! "#$%&"'(#$6! ($! '>#! ,67&"'64! ?0(8&!
"#$3;"'(#$!,$3!"#$%&"'(#$!+&A;(+&!,!-,'&+(,8!-&3(;-*!+,3(,'(#$!3#&6!$#'!,$3!0&,'!'+,$6/&+!",$!
#"";+! &%&$! ;$3&+! "#$3('(#$6! #/! %,";;-! >0&+&! ('! (6! 9&$&+,88:! '0&! -#6'! &//&"'(%&4! 586#*! '0&!
&2(6'&$"&!#/!,!'&-7&+,';+&!9+,3(&$'!3+(%&6!0&,'!'+,$6/&+!.:!"#$3;"'(#$!,$3!"#$%&"'(#$!.;'!'0&!
/($('&!'&-7&+,';+&!#/!,!6($98&!.#3:!(6!6;//("(&$'!'#!($('(,'&!+,3(,'(#$4!@0&!'+,$6/&+!#/!&$&+9:!/+#-!
'0&!6;$!'#!'0&!&,+'0*!'0&!>,+-'0!#/!,!",-7/(+&*!/;+$,"&6*!8(90'!.;8.6*!,$3!($/+,+&3!6",$$&+6!,+&!
6#-&!#/!'0&!/,-(8(,+!&2,-78&6!#/!0&,'!'+,$6/&+!.:!+,3(,'(#$4!
!
@0&! ,-#;$'! #/! &$&+9:! +,3(,'&3! .:! ,! .#3:! (6! A;,$'(/(&3! .:! S'&/,$IF#8'L-,$$C6! 8,>! /#+! (3&,8!
6;+/,"&6!#+!.8,"<!.#3(&6!,$3!(6!9(%&$!,6!/#88#>6E!
"
"
!"#"࣭%࣭"&'N!
!
!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**@!

"#$%$&!!
!!'!%()$!*+!#$()!)%(,-+$%!./)01#2!
"#!3)$+(,4/*5)67(,,8-!9*,-)(,)!./)01#%4+):4*;2!
$"#!-0%+(9$!(%$(!.+):2!
%&"#!)$7<$%()0%$!*+!)#$!-0%+(9$!.*;2!!
!
=#$!%(>?()?*,!*%?@?,()?,@!+%*7!(!-0%+(9$!*990%-!AB!*,$!*%!(!9*7A?,()?*,!*+!-$C$%(5!7$9#(,?-7-D!
(A-*%<)?*,&! %$+5$9)?*,! *%! )%(,-7?--?*,E! =#$! $F)$,)! *+! %(>?()?*,! $7(,()?,@! +%*7! )#$! -0%+(9$! ?-!
>$<$,>$,)!*,!)#$!%()$-!*+!$(9#!*+!)#$-$!7$9#(,?-7-E!
!
!A9B>+!*>CDE+!B*F5!
!
GH! @5(--! 9*,)(?,-! )I*! <(%)-! '()*+" ()" +,,-" )*-.*+()/+*" 012,345" 67" *8*" .(+)" ,7" 9,:;:8<" '()*+"
02=24,3" :>" .,/+*?" :8)," :)@" 'A()" ':;;" 9*" )A*" )*-.*+()/+*" ,7" )A*" *8):+*" >B>)*-" (7)*+" ,8*" A,/+"
(>>/-:8<"("'()*+"A*:<A)",7"1C"(8?"("<;(>>":8)*+8(;"+(?:/>",7"2CDC"
"
Assumptions:
x! J5(--!9*,)(?,$%!?-!K1LM!)#?9N&!?,,$%!%(>?0-!*+!:M&!(,>!#$?@#)!*+!OME!
x! "()$%!?,!@5(--!?-!K1P!A*?5?,@!I()$%!.:K:*;2!(,>!:1P!%**7!)$7<$%()0%$!I()$%!.O:*;2!%$-05)-!?,!
(,!?,?)?(5!I()$%!)$7<!*+!KK:*;E!
x! J5(--!.?,950>?,@!)*<2!?-!<$%+$9)5B!?,-05()$>!.,*!9*,C$9)?*,!5*--!)*!)#$!()7*-<#$%$2E!
x! ;%$$!9*,C$9)?*,!?,!)#$!I()$%!?-!?@,*%$>E!
!
G.:&2'."H!
Q,! *%>$%! )*! +?,>! )#$! $R0?5?A%?07! )$7<$%()0%$! .?@,*%?,@! )#$! ,()0%(5! 9*,C$9)?*,! ?,! )#$! +50?>2&! I$!
70-)! +?,>! )#$! (7*0,)! *+! $,$%@B! )#()! ?-! 9*,)(?,$>! ?,! )#$! KK:*;! I()$%&! (,>! 9*7<(%$! )#()! )*!
(7*0,)! *+! $,$%@B! ?,! )#$! @5(--! 7()$%?(5! ()! O:*;E! ! 3*5C$! +*%! )#$! (7*0,)! *+! $,$%@B! #$5>! ?,! )#$!
C*507$!*+!)#$!KK:*;!I()$%!(,>!)#$!C*507$!*+!)#$!O:*;!@5(--&!)#$,!0-$!)#*-$!C(50$-!)*!+?,>!)#$!
)*)(5!$,$%@BE!!;%*7!)#()!)*)(5!$,$%@B&!-*5C$!+*%!)#$!$R0?5?A%?07!)$7<$%()0%$!*+!)#$!-B-)$7E!
!
=#$! <%*<$%)?$-! *+! I()$%! (,>! @5(--! (%$! ,$$>$>! +*%! )#$! 9(5905()?*,! (,>! (55! )$7<$%()0%$-! ?,! )#$!
+*%705(! 70-)! A$! ?,! >$@%$$-! S(,N?,$! .(,! (A-*50)$! )$7<$%()0%$! 7$(-0%$7$,)! A(-$>! *,! )#$!
;(#%$,#$?)! -9(5$2E! =#$! )*)(5! $,$%@B! *+! )#$! )I*! A*>?$-! 70-)! )#$,! A$! >?-)%?A0)$>! A$)I$$,! )#$7!
$R0(55B!.+*%!$R0?5?A%?072!(,>!(!,$I!=$R0?5!?-!)*!A$!+*0,>E!
!
G2#(*5*I*,?:J&:?2#*21#*<.:&K#*.L*M?2#$*?"=*0:?;;*-**!
!
;%*7!C(%?*0-!)(A5$-!)#$!+*55*I?,@!(%$!)%0$D!
!

!

*

*

=I()$%!'!KK: ;!'!TUKEOU! S! !
!
V$,-?)BI()$%!'!OKELW!5A1+)P!
!
!
Y<ZI()$%!'![EXXX!/=\15A!*S!.-<$9?+?9!#$()2!
)!'!#$?@#)!*+!A(-$!'![EK:T!+)! !
!

!
=#$!C*507$!9(5905()?*,-!(%$!(-!+*55*I-D!
!

!

:

!
!
!
!

=@(5--!'!O:*;!'!T:KEOU!*S!
V$,-?)B@5(--!'!KPLEX!5A1+)P!
Y<Z@5(--!'![EKXX!/=\15A!*S!.-<$9?+?9!#$()2!
#!'!#$?@#)!*+!I()$%!'![ET!+)!

!!

:!

]*507$I()$%!'!ʌ!^!%? !^!#!'!ʌ!^!.:1K:2 ^!.O1K:2!
'![E[WPO!+)P!.)#$!C*507$!*+!)#$!I()$%2!
!
]*507$@5(--!'!ʌ!^!%*:!^!)!_!ʌ!^!.%*:!`!%?:2!^!#'ʌ!^.:EK:T1K:2:!^!.EK:T1K:2!_!ʌ!^!a.EK:T1K:2!:!`!.:1K:2:b!^!.O1K:2!
!
'![E[[OOTO!+)P!.)#$!C*507$!*+!)#$!@5(--!7()$%?(52!
!!

*
N.2#H*O1#*0:?;;*<.:&K#*'"J:&=#;*21#*<.:&K#*.L*21#*P?;#*?"=*21#*;'=#*M?::;*.L*21#*0:?;;8*
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**@!

@2#(*6*A*,?:B&:?2#*21#*#"#$0/*C.$*21#*;/;2#D8*

**

"#$%&'!()!*+$!,-*$%!-*!../!(01!
",-*$%!2345678(9:;$,-*$%!2)*<6!=!>$#?@*',-*$%!29AB)*<6!=!CDE,-*$%2345B9A!(F6!=!4,-*$%2.E6!
",-*$%!234567!GHGI<J!2)*<6!=!J.HKI!29AB)*<6!=!GHLLL!2345B9A!(F6!=!MN.HJN!2.E6!
",-*$%!7!.OMIG!345!!
!
"#$%&'!()!*+$!&9-??!-*!J/!(01!!
"&9-??!2345678(9:;$&9-??!2)*<6!=!>$#?@*'&9-??!29AB)*<6!=!CDE&9-??2345B9A!(F6!=!4&9-??!2.E6!
"&9-??!234567GHGGJJMJ!2)*<6!=!.<KHL!29AB)*<6!=!GH.LL!2345B9A!(F6!=!M/.HJN!2.E6!
"&9-??!7!LJ!345!
!!!

!!

!

!!!

!

!!!

!

!
4+$!*(*-9!$#$%&'!@#!*+$!?'?*$;!@?!",-*$%!P!"&9-??!7!.OJ<J!345!!
QNote: This assumes a fully insulated glass.)
!
@2#(*F*A*,?:B&:?2#*21#*'"'2'?:*#%&':'G$'&D*2#D(#$?2&$#*.C*21#*0:?;;*?"=*H?2#$8**!
0@#R!+(,!*+-*!$#$%&'!@?!R@?*%@A:*$R!-*!$S:@9@A%@:;!A'!?(9T@#&!*+$!)(99(,@#&!$S:-*@(#1!
!
",-*$%Q$S:@9U!P"&9-??Q$S:@9U!7!.OJ<J!345H!
!
5?@#&!*+$!?-;$!$S:-*@(#!-?!-A(T$!4,-*$%!7!4&9-??!Q$S:@9@A%@:;UO!&@T$?!:?!*+$!)(99(,@#&1!
!
8(9:;$,-*$%!2)*<6!=!>$#?@*',-*$%!29AB)*<6!=!CDE,-*$%2345B9A!(F6!=!I!JKL+2.E6!!
P!
8(9:;$&9-??!2)*<6!=!>$#?@*'&9-??!29AB)*<6!=!CDE&9-??2345B9A!(F6!=!I!JKL+!2.E6!!
!
7!.OJ<J!345!
!
V(9T@#&!)(%!4"W5XY!&@T$?!*+$!)(99(,@#&1!
4"W5XY!7!.GKHKK!(0!
!
Z??:;@#&!-!):99'!@#?:9-*$R!&9-??O!@&#(%@#&![(#T$[*@(#!@#!*+$!,-*$%O!-#R!:?@#&!-#!$#$%&'!A-9-#[$O!
*+$!&9-??!-#R!*+$!,-*$%!,@99!%$-[+!-#!@#@*@-9!$S:@9@A%@:;!*$;D$%-*:%$!()!.GKHKK(0H!
!
>?$2*6*A*,?:B&:?2#*21#*B."<#B2'."*2.*21#*?2D.;(1#$#*?C2#$*."#*1.&$*A*Z)*$%![(#)@%;@#&!*+$!
@#@*@-9! $S:@9@A%@:;! *$;D$%-*:%$! ()! *+$! &9-??! -#R! ,-*$%! @?! .GKHKK! (0O! [-9[:9-*$! *+$! $))$[*! *+-*!
[(#T$[*@(#!D9-'?!,+$#!*+$!-*;(?D+$%$!-*!J/(0![(;$?!@#![(#*-[*!,@*+!*+$!(:*?@R$!()!*+$!&9-??H**
*
9;;&D(2'.";M*
x! \9-??![(#*-@#$%!@?!.BK]!*+@[^O!@##$%!%-R@:?!()!/]O!-#R!+$@&+*!()!J]H!!!
x! 4+$!(:*$%!?:%)-[$!@?!#(,!-*!.GKHKK!(0!Q)%(;!_-%*!.UH!
x! 4(D!()!&9-??!@#![(T$%$R!Q#(!+$-*!9(??!*+%(:&+!*+$!*(DU!
x! 4&9-??!7!.GKHKK!(0!QMJKHMM!(FU!B!4-@%!7!J/!(0!QM/.HJN!(FU!)%(;!_-%*!.!
x! 0%$$![(#T$[*@(#!@#!*+$!,-*$%!@?!@&#(%$RH!
x! F-R@-*@(#!*(!*+$!-*;(?D+$%$!@?!@&#(%$RH
*
@.:&2'."M*
X#!(%R$%!*(!)@#R!*+$!*$;D$%-*:%$!()!*+$!&9-??!-#R!,-*$%!-)*$%!.!+(:%O![-9[:9-*$!*+$!-;(:#*!()!+$-*!
9(?*!*(!*+$!-*;(?D+$%$!A'![(#T$[*@(#!(T$%!.!+(:%!:?@#&!`$,*(#a?!9-,!()![((9@#&1!
!
W[(#T$[*@(#!7!+!b!Z?!b!Q4&9-??!c!4-@%U!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**3!

!
A2#(*5*-*,?:B&:?2#*21#*.&2#$*;&$C?B#*?$#?*.C*21#*0:?;;*D'0".$'"0*2.(*?"=*E.22.F*.C*0:?;;GH!
!
"#!$!%&ʌ&'(&)!$!%&ʌ&*%+,%-.,%/&*0.,%/!$!1+--0!23%+!
!
A2#(*6*I*9;;&F#*21#*1#?2*2$?";C#$*B.#CC'B'#"2*.C*?'$*'"*B."2?B2*J'21*?*B/:'"=#$H**
*
*
)!$!,+41!567.)'823%8(9!
!
A2#(*K*I*,?:B&:?2#*21#*B."<#B2'."*1#?2*:.;;*C.$*."#*1.&$*
:;(<=>;3?(<!!
$!)!&!"#!&!*6@AB##!C!6B?'/!!
$,+41!D567.)'823%8E9F!&!+--0!D23%F!&!*-GH+--!C!-%,+0I/DE9F!!
$!K38LM*NOP41$*
*
5B#>J! (<! 3)?#! 3(3BAK! 3)>! #L#3>M! A(#>#! G0+4N! 567! (2! #L#3>M! ><>'@L! O>'! )(P'+! ! 6)>! ><>'@L!
'>MB?<?<@!B23>'!(<>!)(P'!?#Q!
!
,K0G0!567!*('?@?<BA!><>'@L/!C!G0+4N!567!*><>'@L!A(#3!3(!3)>!B?'!$!,K-NN+-,!567!
!
A2#(*L*I*,?:B&:?2#*21#*'"'2'?:*#%&':'E$'&F*2#F(#$?2&$#*.C*21#*0:?;;*?"=*J?2#$8**!
R?<J!)(S!3)B3!><>'@L!?#!J?#3'?TP3>J!B3!>UP?A?T'?PM!TL!#(A=?<@!3)>!2(AA(S?<@!>UPB3?(<Q!
!
VSB3>'*>UP?A/!WV@AB##*>UP?A/!$!,K-NN+-,!567!
!
7#?<@!3)>!#BM>!>UPB3?(<!B#!BT(=>!6SB3>'!$!6@AB##!*>UP?A?T'?PM/K!@?=>#!P#!3)>!2(AA(S?<@Q!
!
X(APM>SB3>'!D23GF!Y!Z><#?3LSB3>'!DAT.23GF!Y![O\SB3>'D567.AT!(9F!Y!6V:7]^D(9F!!
W!
G
G
X(APM>@AB##!D23 F!Y!Z><#?3L@AB##!DAT.23 F!Y![O\@AB##D567.AT!(9F!Y!6V:7]^!D(9F!!
!
$!,K-NN+-,!567!
!
_(A=?<@!2('!6V:7]^!@?=>#!3)>!2(AA(S?<@Q!
O!QPR+*S*M386*.T*
!
]2! ?3! ?#! B##PM>J! 3)B3! (<AL! ;(<=>;3?(<! )>B3! ?#! A(##! 3(! 3)>! B3M(#O)>'>! (;;P'#K! 3)>! #L#3>M!
3>MO>'B3P'>!S?AA!T>!B3!N0+%!(R!B23>'!(<>!)(P'+!
*
>?$2*K*I*,.FE'"#=*,."<#B2'."*?"=*U?='?2'."*2.*21#*92F.;(1#$#*I!]<!BJJ?3?(<!3(!;(<=>;3?(<!
)>B3!3'B<#2>'K!'BJ?B3?(<!)>B3!3'B<#2>'!S?AA!BA#(!B22>;3!3)>!2?<BA!3>MO>'B3P'>!(2!3)>!@AB##!B23>'!(<>!
)(P'+! [BA;PAB3?<@! 3)>! 3>MO>'B3P'>! (2! 3)>! @AB##! B23>'! (<>! )(P'! S)><! T(3)! ;(<=>;3?(<! B<J!
'BJ?B3?(<! )>B3! 3'B<#2>'! (;;P'! #3B'3#! TL! P#?<@! 3)>! ,1H+HH! (R! ?<?3?BA! >UP?A?T'?PM! 3>MO>'B3P'>! 3)B3!
SB#!;BA;PAB3>J!?<!`B'3!,!*S)><!3)>!@AB##!SB#!2PAAL!?<#PAB3>J/+!!!
*
9;;&F(2'.";H*
x! aAB##!;(<3B?<>'!?#!,.Hb!3)?;cK!?<<>'!'BJ?P#!(2!%bK!B<J!)>?@)3!(2!0b+!!!
x! EP3>'!#P'2B;>!?#!<(S!B3!,1H+HH!(R!*-0H+--!(9/!2'(M!`B'3!,!
x! 6)>!B?'!3>MO>'B3P'>!?#!B3!0%!(R!*-%,+0I!(9/!
x! 6(O!(2!@AB##!?#!;(=>'>J!*<(!)>B3!A(##!3)'(P@)!3)>!3(O/!
x! R'>>!;(<=>;3?(<!?<!3)>!SB3>'!?#!?@<('>J+!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**@!

!
A.:&2'."B*
"#$%!&'(!)*%#*&#+$!'(*&!,+--!*$%!*%%!#&!&+!&'(!.+$/(.&#+$!'(*&!,+--!.*,.0,*&(%!#$!1*)&!2!&+!3#$%!*!
&+&*,!'(*&!,+--!3)+4!&'(!-5-&(46!!!
!
"+)!&'(!)*%#*&#+$!7+)&#+$!+3!&'(!'(*&!,+--8!0-(!&'(!3+,,+9#$:!)(,*&#+$-'#7!;$+&(<&(47()*&0)(-!40-&!
=(!#$!+>!3+)!&'#-!.*,.0,*&#+$?!@!
!
C$?='?2'."*D*9;*E*İ*E*ı*E*FG0:?;;H*I*G?'$HJ*
!
A*,.0,*&(!&'(!+0&()!-0)3*.(!*)(*!+3!&'(!:,*--!;#:$+)#$:!&+7!*$%!=+&&+4!+3!:,*--?@!
!
B-!C!2DʌD)+D'!C!2DʌD;26E2FGE2?D;HGE2?!C!I6FFH!3&26!
ı!C!I6EJEK!L!EI<M!NOPG')<3&2<+>K!
FK.2#B*ı*';*A2#L?"-M.:2NO?""P;*Q.";2?"2J*
*

")+4!&*=,(-8!*--04(!&'(!(4#--#/#&5!+3!&'(!:,*--!&+!=(@!
İ!C!I6MF!
!
N*-(%! +$! &'(-(! /*,0(-! .*,.0,*&(! &'(! )*%#*&#+$! '(*&! ,+--! &+! &'(! -5-&(4! 0-#$:! &'(! 3+,,+9#$:!
(Q0*&#+$@!
!
R)*%#*&#+$!C!B-!D!İ!D!ı!D!;O:,*--K!S!O*#)K?!
!
!
C!6FFH!T3&2U!D!I6MF!D!I6EJEK!L!EI<M!TNOPG')<3&2<+>KU!D!V;FHM6FF!+>?K!S!;F2E6HJ!+>?KW!
!
!
C!6H83R*MGS41$8!
!
O'(! .+$/(.&#+$! *$%! )*%#*&#+$! '(*&! (L.'*$:(! ,+--(-! 3)+4! &'(! :,*--! &+! &'(! *&4+-7'()(! .*$! =(!
.*,.0,*&(%!*-!3+,,+9-@!
!
R&+&*,!C!R)*%#*&#+$!X!R.+$/(.&#+$!!
C!2K6HF!NOPG')!X!YH6KZ!NOPG')!!
C!3585H*MGS41$*
!
[3!HE6EK!NOP\-!*)(!,+-&!+/()!+$(!'+0)8!&'(!$(9!&+&*,!($():5!+3!&'(!-5-&(4!;3)+4!1*)&!E!*$%!1*)&!
2?!#-!.*,.0,*&(%!&+!=(@!
!
E8HYH!NOP!;+)#:#$*,!'(*&!*&!(Q0#,#=)#04?!S!HE6EK!NOP!C*5)RTH8@3*MGS*
*
]+,04(9*&()!T3&YU!L!^($-#&59*&()!T,=G3&YU!L!A7_9*&()TNOPG,=!+>U!L!G!CSU+T.VU!!
X!!
]+,04(:,*--!T3&YU!L!^($-#&5:,*--!T,=G3&YU!L!A7_:,*--TNOPG,=!+>U!L!G!CSU+!T.VU!!
*5RTH8@3*MGS8*
!
`+,/#$:!&'#-!3+)!&'(!OaRP[b!:#/(-!&'(!3+,,+9#$:!!
G!CSU+*D*@T83W*XY*
*
,."Q:&;'.";* -* O'(! (L*47,(! .*,.0,*&(-! &'(! (33(.&! &'*&! &'(! /*)#+0-! '(*&! &)*$-3()! 4(.'*$#-4-!
'*%!+$!&'(!:,*--6![&!-'+9-!&'*&!*!:,*--!*&!)++4!&(47()*&0)(!+3!H2I"!3#,,(%!9#&'!EE2I"!9*&()!*$%!
#$-0,*&(%!3)+4!*,,!'(*&!,+--!&+!&'(!*&4+-7'()(!9#,,!)(*.'!*$!(Q0#,#=)#04!&(47()*&0)(!+3!EIM6MM+"6!
[3!&'*&!-*4(!:,*--!#-!(L7+-(%!&+!.+$/(.&#+$!'(*&!&)*$-3()!9#&'!*#)!*&!H2+"!9#&'!$+!)*%#*&#+$!'(*&!

!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**@!

"#$$%! &'(! )"*$$! +,""! -(*.'! *! &(/0(-*&1-(! #2! 3456#7! *2&(-! #8(! '#1-5! ! 92! -*:,*&,#8! '(*&! "#$$! *"$#!
#..1-$%!&'(!)"*$$!-(*.'($!;<54=!#7!*2&(-!#8(!'#1-5!
!
98! &',$! (>*/0"(%! &'(! :#/,8*8&! '(*&! &-*8$2(-! 2-#/! &'(! +*&(-! ,$! .#8:1.&,#8! ,8&#! &'(! )"*$$! ,&$("2%!
+',"(!&'(!.#8?(.&,#8!*8:!-*:,*&,#8!0"*@!"($$(-!-#"($5!!92!&',$!$*/(!)"*$$!+(-(!&#!A(!(>0#$(:!&#!
2#-.(:!.#8?(.&,#8!BC5)5!D!*!2*8!A"#+$!*,-!*.-#$$!&'(!)"*$$!$1-2*.(E!'(*&!&-*8$2(-!2-#/!.#8?(.&,#8!
+#1":!A(!/#-(!0-#8#18.(:!A(.*1$(!&'(!'(*&!&-*8$2(-!.#(22,.,(8&!B'E!+#1":!A(!/1.'!',)'(-!&'*8!
&'(!#8(!,8!&'(!(>*/0"(5!
!
!

A1#::*?"=*B&C#*D#?2*!EF1?"0#$;*
!
F(*&!(>.'*8)(-$!#0(-*&(!A(.*1$(!'(*&!&-*8$2(-!#..1-$!+'(8!&'(-(!,$!*!&(/0(-*&1-(!:,22(-(8.(!
A(&+((8!*!.#":!0-#.($$!$&-(*/!*8:!*!'#&!0-#.($$!$&-(*/5!G'(!&+#!$&-(*/$!*-(!$(0*-*&(:!A@!*!
&',8%! $#",:! +*""5! G',$! +*""! /1$&! A(! .#8:1.&,?(! ,8! #-:(-! 2#-! '(*&! (>.'*8)(! &#! #..1-! @(&! $&-#8)!
(8#1)'! &#!+,&'$&*8:! *8@! 0-($$1-(! A@! &'(! 2"1,:$! #-! )*$($5!98! *! $'(""! *8:! &1A(! '(*&! (>.'*8)(-%!
&+#!."#$(:!0-#.($$!$&-(*/$!/#?(!&'-#1)'!&'(!18,&!D!#8(!#8!&'(!&1A(!$,:(!B,8$,:(!&'(!&1A(E!*8:!
#8(!#8!&'(!$'(""!$,:(5!H8(!,$!'#&!*8:!&'(!#&'(-!,$!.#":5!I$,8)!.#8?(.&,#8!*8:!.#8:1.&,#8%!'(*&!
0*$$($!2-#/!&'(!'#&!$&-(*/!&#!&'(!.#":!$&-(*/!2-#/!&'(!&1A(!$,:(!#-!2-#/!&'(!$'(""!$,:(5!!
!
G'(! -*&(! #2! '(*&! &-*8$2(-! ,$! *22(.&(:! A@! &'(! &(/0(-*&1-(! :,22(-(8.(! A(&+((8! &'(! &+#! 0-#.($$!
$&-(*/$5! J$! &'(! &(/0(-*&1-(! :,22(-(8.(! ,8.-(*$($! A(&+((8! &'(! &+#! 0-#.($$! $&-(*/$%! &'(! '(*&!
(>.'*8)(! -*&(! 0(-! 18,&! #2! $1-2*.(! *-(*! ,8.-(*$($5! K#8?(-$("@%! &'(! '(*&! (>.'*8)(-! 0(-! 18,&! #2!
$1-2*.(!*-(*!:-#0$!*&!*!8#8L",8(*-!-*&(!*$!&'(!&(/0(-*&1-(!:,22(-(8.(!A(&+((8!&'(!&+#!0-#.($$!
$&-(*/$!:-#0$5!M*,$,8)!&'(!(22(.&,?(!$1-2*.(!*-(*!#2!&'(!&#&*"!$@$&(/!'("0$!&#!/*,8&*,8!&#&*"!'(*&!
&-*8$2(-! A(&+((8! &'(! &+#! $&-(*/$! A1&! (?(8&1*""@! *! 0#,8&! ,$! -(*.'(:! +'(-(! *::,&,#8*"! $1-2*.(!
*-(*!.*88#&!*22(.&!*8@!$,)8,2,.*8&!*::,&,#8*"!'(*&!&-*8$2(-5!!
!
J8#&'(-!?*-,*A"(!*22(.&,8)!'(*&!(>.'*8)(!,8!*!$'(""!*8:!&1A(!(>.'*8)(-!,$!&'(!?("#.,&@!#2!(*.'!
0-#.($$!$&-(*/5!N("#.,&@!.#8&-,A1&($!:,-(.&"@!&#!,8.-(*$(:!.#8?(.&,#8!A(&+((8!&'(!.#":!*8:!'#&!
0-#.($$!$&-(*/$5!O(0(8:,8)!#8!&'(!&@0(!#2!$'(""!*8:!&1A(!'(*&!(>.'*8)(-%!,8.-(*$,8)!?("#.,&@!
,8.-(*$($! '(*&! (>.'*8)(%! ($0(.,*""@! ,8! *! .#18&(-.1--(8&! :($,)85! C?(8&1*""@%! ?("#.,&@! ,8.-(*$($!
*-(!",/,&(:!A@!&'(!/*>,/1/!*""#+(:!2#-!*!$0(.,2,.!/(&*""1-)@!.#/0-,$,8)!&'(!$'(""!#-!&'(!&1A(5!98!
.*-A#8!$&(("%!?("#.,&@!.*88#&!)#!*A#?(!,$!4!2&P$(.5!+',"(!,8!$&*,8"($$!*8:!',)'!*""#@!$&(("%!&'(!-*&(!
,$!Q6!2&P$(.5!2#-!",R1,:$5!
!
G'(! &'-((! S,8:$! #2! $'(""! *8:! &1A(! '(*&! (>.'*8)(-$! 0-#:1.(:! *-(! 0*-*""("%! .-#$$! 2"#+! *8:!
.#18&(-.1--(8&!2"#+5!G'(!8*/($!,8:,.*&(!&'(!:,-(.&,#8!#2!&'(!0-#.($$!$&-(*/$!,8!-("*&,#8$',0!+,&'!
(*.'! #&'(-5! 98! *! .#18&(-.1--(8&! '(*&! (>.'*8)(-%! &'(! *?(-*)(! &(/0(-*&1-(! :,22(-(8.(! A(&+((8!
&'(!&+#!0-#.($$!$&-(*/$!,$!/*>,/,T(:!#?(-!&'(!"(8)&'!#2!&'(!(>.'*8)(-%!(>',A,&,8)!&'(!',)'($&!
'(*&! &-*8$2(-! -*&(! (22,.,(8.@! 0(-! 18,&! #2! $1-2*.(! *-(*5! 98! &(-/$! #2! *?*,"*A"(! &(/0(-*&1-(!
:,22(-(8.($!#A$(-?(:!:1-,8)!#0(-*&,#8%!0*-*""("!(>.'*8)(-$!(>',A,&!&'(!"#+($&%!2#""#+(:!A@!.-#$$!
2"#+%! &'(8! .#18&(-.1--(8&! (>.'*8)(-$5! G'(! 7,)1-(! A("#+! $'#+$! :($,)8$! #2! .#18&(-.1--(8&! *8:!
0*-*""("!2"#+!'(*&!(>.'*8)(-$5!!

!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**@!

!
!
!
"#$! %&'! ($)*! +$(,$-)+.-$! /011$-$*2$! 3)%4&! 5*&6*! 78! 0+4! )2-&*8(! 9:";! &-! ¨"%(<! 04! .4$/! +&!
/$+$-(0*$! +#$! +$(,$-)+.-$! /-0=0*'! 1&-2$! 1&-! #$)+! +-)*41$-! 0*! 1%&60*'! 484+$(4>! (&4+! *&+)7%8! 0*!
#$)+!$?2#)*'$-4@!"#$!¨"%(!04!)!%&')-0+#(02!)=$-)'$!&1!+#$!+$(,$-)+.-$!/011$-$*2$!7$+6$$*!+#$!
#&+! )*/! 2&%/! 4+-$)(4! )+! $)2#! $*/! &1! +#$! $?2#)*'$-@! "#$! %)-'$-! +#$! ¨"%(>! +#$! (&-$! $11020$*+%8!
#$)+!04!+-)*41$--$/@!¨"%(!)44.($4!2&*4+)*+!1%&6!-)+$!)*/!1%.0/!+#$-()%!,-&,$-+0$4@!A+!04!2)%2.%)+$/!
.40*'!+#$!1&%%&60*'!$B.)+0&*C!

*
ο ܂ൌ 

οʹ െ  οͳ
*
ο
 ʹ
οͳ

!
D*2$! 2)%2.%)+$/>! +#$! ¨"%(! 04! .4.)%%8! ),,%0$/! +&! 2)%2.%)+$! +#$! -)+$! &1! #$)+! +-)*41$-! 0*! )*!
$?2#)*'$-!)22&-/0*'!+&!+#$!1&%%&60*'!40(,%$!$B.)+0&*C!
!

@*A*B.*C*9.*C*¨D:E*

!
E#$-$C!

@!F!G$)+!+-)*41$-!-)+$!3H"IJ#-<!
B.!F!D=$-)%%!#$)+!+-)*41$-!2&$11020$*+!3H"IJ#-K1+LK&M<*
9.!F!N-&44!4$2+0&*!#$)+!+-)*41$-!)-$)!31+L<!
¨D:E!F!9&'!($)*!+$(,$-)+.-$!/011$-$*2$!3&M<!

!
!

!

!

OP&+$C!$4+0()+0*'!+#$!#$)+!+-)*41$-!2&$11020$*+!()8!7$!B.0+$!+-0258@!

!
H$%&6!04!)!4)(,%$!,-&7%$(!+#)+!2)%2.%)+$4!+#$!#$)+!+-)*41$-!-)+$!7$+6$$*!)!2&.*+$-2.--$*+!)*/!
)!,)-)%%$%!4#$%%!)*/!+.7$!#$)+!$?2#)*'$-@!
!
!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**57!

!@9A>+!*>BCD+!A*E6"! #$%&'%$()!(*)!*)$(!(+$,-.)+!+$()!/,!0$+$%%)%!$,1!&2',()+&'++),(!*)$(!
)3&*$,4)+-!20)+$()1!',1)+!(*)!-$5)!&2,1/(/2,-!6/(*!(*)!-$5)!(62!%/7'/1-8!
!
F5!9!(*)!*2(!.%'/1!()50)+$('+)!
F5'"!9!(*)!*2(!.%'/1!()50)+$('+)!/,!9!5GH*.I!
F5.&2!9!(*)!*2(!.%'/1!()50)+$('+)!2'(!9!5JH*.I!
!
F6!9!(*)!&2%1!.%'/1!()50)+$('+)!!
F6'"!9!(*)!&2%1!.%'/1!()50)+$('+)!/,!9!37*.I!
F6.&2!9!(*)!&2%1!.%'/1!()50)+$('+)!2'(!9!577*.I!
!
K.!9!L7*DFK41$-M26-.I!
9.!9!577*M26!
!
N.:&2'."O*
:/+-(;!&$%&'%$()!(*)!%24!5)$,!()50)+$('+)!.2+!)$&*!2.!(*)!(62!-<-()5-"*
ሺૢିሻିሺିሻ

,.&"2#$-P&$$#"2*I:.Q*¨F:R*S*



****S**TG8G*

ሺૢషሻ
ሺషሻ

I!

.

*
ሺૢିሻିሺିሻ

*>?$?::#:*I:.Q*¨F:R*S*
!

!



ሺૢషሻ
ሺషሻ

*****S**T58G*

I!

.

*
=)&2,1;!&$%&'%$()!(*)!+$()!2.!*)$(!(+$,-.)+!.2+!)$&*!2.!(*)!(62!-<-()5-"!
,.&"2#$-P&$$#"2*I:.Q*K*UDFK41$V*9!>?@!ABCD*+E.(FE2:G!H!>I@@!.(FG!H!JK8K!2:!
***S*36G)W77*UDFK41$V*
!
>?$?::#:*I:.Q*K*UDFK41$V*9!>?@!ABCD*+E.(FE2:G!H!>I@@!.(FG!H!JI8K!2:!
***S*HLW)W77*UDFK41$V*

!
L-! 1)52,-(+$()1! M<! (*)! -$50%)! 0+2M%)5;! 20)+$(/,4! $! -*)%%! $,1! ('M)! *)$(! )3&*$,4)+! /,! (*)!
&2',()+E&'++),(! 521)! +)-'%(-! /,! 4+)$()+! *)$(! )3&*$,4)! M)(6)),! (*)! (62! -(+)$5-! (*$,! 6*$(!
&2'%1!M)!)30)&()1!/,!$!0$+$%%)%!.%26!)3&*$,4)+8!!N(!$%-2!-*26-!(*$(!(*)!&2',()+&'++),(!)3&*$,4)+!
+)7'/+)-!%)--!(2($%!-'+.$&)!$+)$!(2!$&*/)O)!(*)!-$5)!%)O)%!2.!*)$(!)3&*$,4)+8!>N.!(*)!C!O$%')!$,1!
(*)!PQBR!$+)!./3)1;!-'+.$&)!$+)$!5'-(!/,&+)$-)G8!
!
L&('$%!*)$(!)3&*$,4)+-!$+)!52+)!&250%)3!(*$,!(*)!-/50%)!&2502,),(-!-*26,!/,!(*)!/1)$%/S)1!
./4'+)-! '-)1! $M2O)8! Q$,<! .$&(2+-! /50$&(! *)$(! )3&*$,4)+! 1)-/4,8! B*)-)! /,&%'1)! -/S);! &2-(;!
6)/4*(;! )../&/),&<;! .%'/1! (<0)-;! 20)+$(/,4! 0+)--'+)-;! ()50)+$('+)-! $,1! .2'%/,4! .$&(2+-8! T$&*!
/,1/O/1'$%! &*$+$&()+/-(/&! /50$&(-! (*)! +)-'%(/,4! 1)-/4,! $,1! 5'-(! M)! &2,-/1)+)1! /,! (*)! ./,$%!
(*)+521<,$5/&-!&$%&'%$(/2,-8!
!
U,)!$00+2$&*!'-)1!M<!*)$(!)3&*$,4)+!1)-/4,)+-!(2!5$3/5/S)!(*)!$O$/%$M%)!*)$(!(+$,-.)+!6/(*/,!
(*)!)3&*$,4)+!/-!*$O/,4!(62!-(+)$5-!0$--!)$&*!2(*)+!-)O)+$%!(/5)-!6/(*/,!$!-/,4%)!)3&*$,4)+8!
B*/-! /,&+)$-)-! (*)! 0)+.2+5$,&)! $,1! +)1'&)-! (*)! -/S)! ,))1)1! .2+! $! -0)&/./&! *)$(! )3&*$,4)!
$00%/&$(/2,8!V*),!$!*)$(!)3&*$,4)+W-!.%'/1-!0$--!)$&*!2(*)+!52+)!(*$,!2,&);!$!*)$(!)3&*$,4)+!
/-! &$%%)1! $! 5'%(/E0$--! *)$(! )3&*$,4)+8! N.! (*)! .%'/1-! 0$--! )$&*! 2(*)+! 2,%<! 2,&);! (*)! *)$(!
)3&*$,4)+! /-! &$%%)1! $! -/,4%)E0$--! *)$(! )3&*$,4)+8! #2552,%<;! (*)! 5'%(/E0$--! *)$(! )3&*$,4)+!
+)O)+-)-! (*)! .%26! /,! (*)! ('M)-! M<! '-)! 2.! 2,)! 2+! 52+)! -)(-! 2.! XCX! M),1-! /,! (*)! ('M)-8! B*)! XCX!
M),1-!$%%26!(*)!.%'/1!(2!.%26!M$&Y!$,1!.2+(*!$&+2--!(*)!%),4(*!2.!(*)!*)$(!)3&*$,4)+8!B*)!./4'+)!
M)%26!-*26-!M2(*!-/,4%)E!$,1!5'%(/0%)!0$--!1)-/4,-8!
!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**55!

!

!
!

!

!
!
"#$%! #&'($)*#+! ,#-.*)-! /$+0! 1$-#,! 2)! %(+23*(43%5! %(#+6$7! ,3%05! 72'$7! 6$.)%#)$)'#!
+#83.+#6#)%-5!-.9#!+#83.+#6#)%-5!(#$%!%+$)-:#+!6#,.$5!%(#!'(#6.'$7!-%$%#!2:!%(#!6$%#+.$7-!;7.83.,!
2+! *$-<! $),! 4(0-.'$7! 4+24#+%.#-! 2:! %(#! 6$%#+.$7-! ;#=*=! -4#'.:.'! (#$%5! /.-'2-.%05! -4#'.:.'! *+$/.%05!
:237.)*!:$'%2+-5!#%'=<=!>$'(!,#-.*)!.)'2+42+$%#-!$77!2:!%(#-#!:$'%2+-=!?:%#+!722@.)*!$%!(#$%!%+$)-:#+!
+#83.+#6#)%-5!%(#!,#-.*)#+!%$@#-!%(#!:2772A.)*!.)%2!'2)-.,#+$%.2)B!
!
x! C31#! D.9#! E! -6$77#+! ,.$6#%#+! %31#-! 6#$)! 62+#! -3+:$'#! $+#$! $),! .)'+#$-#,! :73.,!
%3+137#)'#!13%!$7-2!(.*(#+!4+#--3+#!,+24!
x! C31#!F23)%!E!62+#!%31#-!6#$)!62+#!-3+:$'#!$+#$!13%!%(#+#!6.*(%!)2%!1#!#)23*(!+226!
.)!%(#!*./#)!,.$6#%#+!
x! C31#!G#)*%(!E!72)*#+!%31#-!6#$)!62+#!-3+:$'#!$+#$!13%!47$)%!-4$'#!2+!4+#--3+#!,+24!
6$0!7.6.%!%(#!:.)$7!7#)*%(!2:!$!-4#'.:.'!,#-.*)!
x! H+2'#--!D%+#$6!I#72'.%0!E!(.*(#+!/#72'.%0!;3-3$770!'+#$%#,!.)!$!,#-.*)!10!.)'+#$-.)*!%(#!
)361#+!2:!4$--#-<!.)'+#$-#-!(#$%!#&'($)*#!13%!.-!7.6.%#,!10!6$%#+.$7-!2:!'2)-%+3'%.2)5!
/.-'2-.%0!2:!%(#!4+2'#--!-%+#$6!$),!$/$.7$17#!4+#--3+#!,+24!
x! J$::7#-!E!.)'+#$-.)*!%(#!)361#+!2:!1$::7#-!.)'+#$-#-!(#$%!%+$)-:#+!$),!4+#--3+#!,+24!
x! D(#77!K.$6#%#+!E!.)'+#$-.)*!,.$6#%#+!$772A-!62+#!%31#-!13%!*+#$%70!.)'+#$-#-!%(#!'2-%!!
x! L$%#+.$7-! 2:! F2)-%+3'%.2)! E! -%$.)7#--! -%##75! (.*(#+! $7720! -%##7-5! '$+12)! -%##7! $::#'%! %(#!
4#+:2+6$)'#!2:!%(#!#&'($)*#+!,3#!%2!%(#!%(#+6$7!'2),3'%./#!4+24#+%.#-!2:!#$'(!6$%#+.$7=!
!

!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**56!

"#$%&! '($))! *+,! -./$! ($*-!
$01(*+2$%!
.'$'!
'$#$%*)!
.+34.$! './*''$5/)3$'! -6!
$+'.%$! 7%67$%! ($*-! -%*+'8$%!
611.%'9! :($! 7%61$''! 8)6;!
%$4.3%$'! -($! -./$! '3,$! '-%$*5!
-6! 8)6;! 3+-6! *! 1(*5/$%! 6%!
A?2#$B.C! -(*-! 3'! ,$'32+$,! -6!
$4.*))&! ,3'-%3/.-$! -($! '-%$*5!
*1%6''! -($! -./$'($$-! 3+-6! -($!
D&B#* E&"=:#9! :($! '-%$*5!
7%62%$''$'! -(%6.2(! -($! -./$'!
.+-3)!3-!$03-'!*1%6''!*!-./$'($$-!
3+-6! *! ;*-$%/609! <8! -($!
$01(*+2$%! 3'! '-%*32(-! -(%6.2(=! -($! '-%$*5! $03-'! -($! .+3-9! <8! 3-! 3'! *! >?@! -./$! ,$'32+=! -($! '-%$*5!
8)6;'!/*1A!3+-6!*!,388$%$+-!B6+$!68!-($!6%323+*)!;*-$%/60!86%!*+6-($%!7*''!6%!$03-'!-($!$01(*+2$%9!
C%65!-($!'($))!'3,$=!-($!7%61$''!'-%$*5!$+-$%'!-($!'($))!*+,!5*&!3573+2$!6+!*!,$8)$1-36+!7)*-$!
-6!56#$!3-!-(%6.2(!-($!'($))9!D$7$+,3+2!6+!-($!,$'32+=!*!7%$'$)$1-$,!+.5/$%!68!/*88)$'!86%1$!-($!
'-%$*5!-(%6.2(!*+!3+,3%$1-!7*-(!'6!-(*-!3-!7*''$'!*%6.+,!*))!68!-($!-./$'!.+-3)!3-!$03-'9!9((#"='C*
9!16+-*3+'!*!2)6''*%&!68!16556+!($*-!$01(*+2$%!-$%5'9!
!
D.$! -6! )61*)! 5*3+-$+*+1$! %$4.3%$5$+-'! 6%! -($! 5*-$%3*)'! 68! $01(*+2$=! -($! -./$! /.+,)$! 1*+! /$!
,$'32+$,! -6! /$! %$56#*/)$! 86%! '1($,.)$,! 1)$*+3+2! 6%! %$7)*1$5$+-! 6+! *! %$2.)*%! '1($,.)$9! :($!
,$'32+!16.),!*)'6!.-3)3B$!*!=.&B:#*2&B#*;1##2!;($%$!*!'$16+,!-./$!'($$-!16++$1-'!-($!/.+,)$!
-6! -($! '($))! 86%! 4.31A! )$*A! ,$-$1-36+! *+,! '*+3-*%&! 16+'-%.1-36+9! E6'-! '*+3-*%&! '($))! *+,! -./$!
$01(*+2$%'!
(*#$!
-($!
%$4.3%$5$+-! -6! /$! ,%*3+*/)$! '6!
*))! 1)$*+3+2! '6).-36+'! 1*+! /$!
1657)$-$)&! %$56#$,9! :($'$!
,$'32+'! %$4.3%$! F##(* 1.:#;=! *!
B.F2'#* 16+832.%*-36+! 86%! -($!
(?;;*(?$2'2'.";!3+!-($!;*-$%/60=!
6.-)$-! (6)$'! 8).'(! ;3-(! -($! $,2$!
68! -($! $01(*+2$%! ;*))=! *+,!
'.776%-'! -(*-! *+2)$! -($! $+-3%$!
.+3-!')32(-)&9!!
!
!
!
:($!FGE"!HF5$%31*+!G613$-&!68!E$1(*+31*)!"+23+$$%'I!'$-'!-($!/*'31!5*+.8*1-.%3+2!'-*+,*%,'!
86%!7%$''.%$!#$''$)'!)3A$!($*-!$01(*+2$%'9!J-($%!3+,.'-%&!2%6.7'!3+1).,$!KLF=!:"EF=!M"D=!*+,!
N"9! :($'$! '-*+,*%,'! *%$! 5$*+-! -6! ,$83+$! /*'31! 16+'-%.1-36+! -&7$'=! ;$),3+2! 7%61$''$'=! *+,!
5*-$%3*)! -(31A+$''$'! ;(3)$! 7%6#3,3+2! '*8$-&=! %$*'6+*/)$! 16'-! *+,! '$%#31$*/3)3-&9! N6556+!
+65$+1)*-.%$!;*'!,$#$)67$,!/&!:"EF!-6!,$'1%3/$!-($!8%6+-!($*,=!'($))=!%$*%!($*,!*+,!-./$'9!
"#$%&!#*%3$-&!68!'($))!*+,!-./$!($*-!$01(*+2$%!-(*-!1*+!/$!,$'1%3/$,!.'3+2!-(3'!+65$+1)*-.%$!3'!
86.+,!3+!-($!-*/)$!/$)6;!8%65!-($!:"EF!;$/'3-$9!

!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**5@!

!
!
"#$%&''! %$((&%)*$('! +#&! ),&! -+')! &-&.&()! $/! ),&! 0&'*1(2! 3+(1*(1! /#$.! '+(*)+#4! )#*5%-+.6'! )$!
),#&+0&0!%$((&%)*$('!)$!789:!/-+(1&';!),&'&!<(*=<&!+%%&''$#*&'!+#&!),&!6#$%&''!-*(>!)$!),&!#&')!
$/!),&!$6&#+)*$(2!
!
7)! ?(&#=<*6;! .$')! $/! ),&! 0&'*1('! @&! A<*-0! +#&! /$#! '+(*)+#4! +66-*%+)*$('! /$#! <'&! A4! 6-+()'!
6#$0<%*(1! /$$0;! A&B&#+1&';! .*->;! %,&&'&;! +(0! 6,+#.+%&<)*%+-! 6#$0<%)'2! C&! +-'$! 0&'*1(! +(0!
A<*-0! +! (<.A&#! $/! *(0<')#*+-! 1#+0&! <(*)'! /$#! <'&!A4! /*(&! %,&.*%+-;! 6&)#$-&<.! #&/*(*(1;! 6<-6! +(0!
6+6&#;!<)*-*)4;!+(0!%-&+(!/<&-'!6-+()'2!!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**5@!

,?;#*A2&='#;*
"#$%&! &%'(%)(*+! $,%! -./(0! #1*2.3%*$.4/! 5#! ,%.$! %60,.*+%! .*2! /,%44! .*2! $1-%! ,%.$! %60,.*+%&!
2%/(+*7! ($! (/! $(3%! $5! /,5)! ,5)! $,%/%! ,%.$! %60,.*+%! 8&(*0(8.4/! .&%! .884(%2! $5! &%.4! )5&42!
.884(0.$(5*/9!
!
:%.$!%60,.*+%&/!8%&#5&3!8&50%//!)5&;9!<,%=!.4/5!&%05'%&!%*%&+=7!.!;%=!(//1%!+('%*!$,%!05/$!5#!
%*%&+=! (*! &%/51&0%/! .*2! ($/! %##%0$! 5*! $,%! %*'(&5*3%*$9! "#$%&! 455;(*+! .$! ,%.$! %60,.*+%!
#1*2.3%*$.4/7!.!;%=!5->%0$('%!5#!$,(/!8.8%&!)./!$5!/,5)!,5)!0538.*(%/!1/%!,%.$!%60,.*+%&/!
.*2! -%*%#($!#&53! &%210%2! +&%%*,51/%! +./! %3(//(5*/9! ?5&! $,%! 81&85/%! 5#! $,(/! 2(/01//(5*7! 5*4=!
@AB!%3(//(5*/!,.'%!-%%*!0.4014.$%29!!
!
<,&%%! 0./%! /$12(%/! )%&%! 2%'%458%2! #&53! &%.4! 01/$53%&! 84.*$! /($1.$(5*/9! <,%! 0538.*=! *.3%/!
.*2!05384%$%!.884(0.$(5*!.&%!)($,,%42!1*2%&!05*#(2%*$(.4($=9!C.0,!0./%!)(44!2(/01//!$,%!/($1.$(5*7!
$,%! 05*2($(5*/7! $,%! ,%.$! %60,.*+%&! 2%$.(4/! .*2! $,%! &%/14$/9! D/(*+! %*%&+=! 0.4014.$(5*/! #&53!
/%'%&.4! 2(##%&%*$! )%-/($%/7! $,%! E$1F/! G! ,51&! $,.$! )%&%! &%05'%&%2! ,.'%! -%%*! 05*'%&$%2! (*$5!
851*2/!5#!@AB!/.'%2!.*2!$,%!%##(0(%*0=!5#!1/(*+!$,.$!#1%4!.&%!#51*2!(*!$,%!#5445)(*+!#.0$5&!$.-4%9!
!
?1%4!
D/.+%!H.$%!
@AB!G!IE$1!
C##(0(%*0=!H.$(*+!
?1%4!A(4!
JK9LM!G!+.4!
MLM!4-/!
NOP!
Q.$1&.4!R./! JM9SLT!G!00#!
MMN!4-/!
UOP!
!
"$! $,%! %*2! 5#! %.0,! 0./%! (/! .! /133.&=! 5#! $,%! 05/$! /.'(*+/! .*2! $5*/! 5#! R&%%*,51/%! R./!
&%210$(5*!VR:RW9!
!
,?;#*5*B*>.2?2.*,1'(*C$/#$;*
!
A'2&?2'."!
"!85$.$5!0,(8!84.*$!58%&.$%2!/%'%&.4!4(*%/!),%&%!L7OOO!851*2/!8%&!,51&!5#!85$.$5!
0,(8/!.&%!#&(%2!(*!,5$!5(49!<,%!'.85&!#&53!$,%!#&=%&!4(*%!05*$.(*%2!/$%.3!.*2!.(&9!X$!
)./! -%(*+! '%*$%2! $5! .$35/8,%&%! )($,51$! .*=! 5885&$1*($=! $5! &%05'%&! ($! #5&! 1/%!
%4/%),%&%!(*!$,%!84.*$9!
*
,."='2'.";* Y$&%.3!G!"(&!I(6$1&%!Z!BL7[OO!\G,&!]!BKO5?!
*
A*!/$%.3!C##(0(%*0=!?.0$5&!Z!KKO!2.=/!
!
D#?2*!EF1?"0#$*G#2?':;*
!
^(.3%$%&_!
KL!X*0,%/!
`%*+$,_!
BSO!X*0,%/!
@5*#(+1&.$(5*_!
ECI:! V/$&.(+,$! $,&51+,! 2%/(+*! ,5&(a5*$.44=! 351*$%2! 5*!
$58!5#!$,%!&55#W!
:%.$!<&.*/#%&!"&%._!
K7SNM!Yb9!?$!
<1-%!/(2%!?41(2_!
Y$%.3!G!"(&!I(6$1&%!VBL7[OO!\G,&W!
<1-%!/(2%!05*2($(5*/_! X*4%$!Z!BKO5?!!
!
A1$4%$!Z!MSN5?!]!.$35/8,%&(0!05*2($(5*/!
Y,%44!Y(2%!?41(2_!
c&58=4%*%!R4=054!VSOPW!VBN[7OOO!\G,&W!
Y,%44!/(2%!05*2($(5*/_! X*4%$!$%38%&.$1&%!Z!MBO5?!
!
A1$4%$!$%38%&.$1&%/!Z!MN[5?!
:%.$!C60,.*+%2_!
MS7OOO7OOO!E$1!G!:&!
D!@4%.*_!
MUU9NL!V1*($!,./!%60%//!/1&#.0%!.&%.!(*!04%.*!05*2($(5*W!
D!^(&$=_!
MS[9TS!V%60%//!/1&#.0%!.&%.!;(0;/!(*!21&(*+!#514%2!/$.$%W!
Q5$%_!
d.$%&!'.85&!05*2%*/%2!(/!MK7OUO!\G,&!V8,./%!0,.*+%W! !
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**5@!

!
@#;&:2*

"#$!%&'()*+!,-$.!/#$!01!23/,4#5!5$6&7$5$.!8+!/#$!#$)/!$96#)*:$5!/&!(5$#$)/!
6;/+! <)/$5! ,-;*:! )! (5&(+=$*$! :=+6&=! =&&(>! -)7;*:! ?,$=! 6&-/-! )*.! 5$.,6;*:!
$';--;&*-@! A#$*! .$-;:*;*:! /#;-! -&=,/;&*>! )==&<)*6$! #).! /&! 8$! ').$! ?&5! /#$!
6&*.$*-)/;&*!&?!/#$!-/$)'!?&5'$.!<#$*!/#$!(&/)/&$-!6&&B$.!;*!/#$!#&/!&;=@!"#;-!
)??$6/-!/#$!#$)/!$96#)*:$!/#5&,:#!#$)/!&?!6&*.$*-)/;&*!)*.!/#$!7)(&5!(5$--,5$!
?&5!/#$!$*/;5$!-+-/$'@!C-!-/$)'!6&*.$*-$->!()5/;)=!(5$--,5$!6)*!.5&(!)*.!=&<$5!
/#$!6&*.$*-)/;&*!/$'($5)/,5$!)-!/#$!-+-/$'!'&7$-!;*/&!)!()5/;)=!7)6,,'!5)*:$@!
"#;-! <)-! *&/! /#$! 6)-$! ;*! /#;-! )((=;6)/;&*! )-! /#$! /,8$! -;.$! &,/! -/)+$.! )/!
)/'&-(#$5;6! 6&*.;/;&*-@! "#$! 6&'()*+! <)-! )=-&! )8=$! /&! 5$6&7$5! )==! &?! /#$! <)/$5!
)*.!5$,-$!;/!$=-$<#$5$!;*!/#$!(=)*/!;*-/$).!&?!5$=$)-;*:!;/!/&!)/'&-(#$5$!<;/#!/#$!
#$)/@!

!!
"#$! $*$5:+! )*.! DED! $';--;&*! -)7;*:-! ?5&'! /#$! (5&F$6/! )5$! ;*! /#$! /)8=$@! G&!
)//$'(/!<)-!').$!/&!'$)-,5$!/#$!7)=,$!?5&'!/#$!5$6&7$5$.!<)/$5@!!
!
A&#:*
H,$=!I;=!
G)/,5)=!D)-!

B&?"2'2/*4*C$8*
0>01J>KLM!:)=!
0OM>KL0>OLO?/O!

D?<'"0;*4*C$8*
N1>01O>MPL!
NL>RRQ>QRP!

!E';;'.";4C$*
K>QLM!/&*-!
!!!PLL!/&*-!

*
*
,?;#*6*F*G':*,..:#$*4*H?2#$*I#?2#$*
!
D'2&?2'."!
C!(,=(!(=)*/!<)*/$.!/&!5$,-$!#$)/!?5&'!STI!OL!D5).$!&;=!UTCV!D5).$!0RW!/&!#$)/!
<)/$5!;*!/#$!/&<$5!)*.!6&&=!/#$!&;=!-$57;6;*:!)!=)5:$!$*:;*$@!S*!/#;-!6)-$>!/#$!#$)/!
/5)*-?$5!6&$??;6;$*/!7)=,$-!?&5!&;=!)5$!=&<!-&!)!=)5:$5!#$)/!/5)*-?$5!)5$)!;-!*$$.$.!
/&!6)(/,5$!/#$!=)/$*/!#$)/@!!
!
,."='2'.";* I;=!?=&<!X!M0>JRO!Y4#5!Z!0LQ!&H!
I*!-/5$)'!V??;6;$*6+!H)6/&5![!O1P!.)+-!
!
I#?2*!JK1?"0#$*L#2?':;*
!
\;)'$/$5]!
0K!S*6#$-!
^$*:/#]!
0LR!S*6#$-!
%&*?;:,5)/;&*]!
L! $96#)*:$5-! 3VA! UT/5);:#/! /#5&,:#! .$-;:*! <;/#!
5$'&7)8=$!/,8$!8,*.=$W!
!
I;=!X!-$5;$-!?=&<!/#5&,:#!8&/#!$96#)*:$5-!
!
A)/$5!X!()5)==$=!?=&<!-(=;/!PR4PR!;*/&!$)6#!$96#)*:$5!
E$)/!"5)*-?$5!C5$)]!
QKL!?/L!U1Q0!?/L!;*!$)6#!$96#)*:$5W!
",8$!-;.$!H=,;.]!
"&<$5!<)/$5!U0RP>0PR!Y4#5!_!L!,*;/-!Z!PL>PJP!Y4#5!$)6#W!
",8$!-;.$!6&*.;/;&*-]! S*=$/!/$'($5)/,5$![!QR&H!
!
I,/=$/!/$'($5)/,5$![!QM@J&H!U)7$5):$W!!
T#$==!T;.$!H=,;.]!
STI!OL!I;=!UM0>JRO!Y4#5!_!-$5;$-!?=&<!/#5&,:#!L!,*;/-W!
T#$==!-;.$!6&*.;/;&*-]! S*=$/!/$'($5)/,5$![!0LQ&H!!
!
I,/=$/!/$'($5)/,5$![!0R1&H!U)?/$5!L*.!$96#)*:$5W!
E$)/!V96#)*:$.]!
JRM>00L!3/,!4!E5!!
`!%=$)*]!
11@JO!U,*;/!#)-!$96$--!-,5?)6$!)5$)!;*!6=$)*!6&*.;/;&*W!
`!\;5/+]!
1R@KR!U$96$--!-,5?)6$!)5$)!B;6B-!;*!.,5;*:!?&,=$.!-/)/$W!
!
!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**53!

A#;&:2*

"#$%$! $&'#()*$+%! ,$+$! -$%.*)$-! /0! '001! /#$! 0.12! /+()%3$++.)*! #$(/! (/! (! +(/$! 03!
4562778!9/:;#+<!=./#!/#$!>00+$+!#$(/!/+()%3$+!'0$33.'.$)/!0)!/#$!%#$11!%.-$!30+!/#$!
0.1! ()-! ()! .)1$/! ,(/$+! /$?>$+(/:+$! /#(/! ,(%! 0)1@! A50B! 10,$+! /#()! /#$! 0.1! .)1$/2! (!
10,$+!):?C$+!03!9/:D%!,$+$!/+()%3$++$-!/#()!.3!/#$!%#$11!%.-$!,$+$!%/$(?!0+!#0/!
,(/$+<!"#$!$)$+*@!()-!EFE!$?.%%.0)!%(G.)*%!(+$!.)!/#$!/(C1$!C$10,<!

!
B&#:*
B:$1!H.1!
M(/:+(1!E(%!

C&?"2'2/*4*D$8*
652I8A!*(1!
4287A2A47!3/N!

E?<'"0;*4*D$8*
J87K2AL7!
J75I2LK5!

!F';;'.";4D$*
A45<4!/0)%!
!!!84<I!/0)%!

!
,?;#*G*H*,."I#"2$?2#*E&0?$*E:&$$/*!
!
E'2&?2'."!
O!'$+$(1!?():3('/:+$+!)$$-$-!/0!'0)'$)/+(/$!(!%:*(+!%01:/.0)!3+0?!64!9+.&!/0!K7!
9+.&! .)! ./%! >+0'$%%! /0! ('#.$G$! (! #.*#$+! '0)'$)/+(/.0)! #0?0*$)0:%! %1:++@<! O3/$+!
'0)'$)/+(/.0)2!'$+$(1%!(+$!'0(/$-!,./#!G(+.0:%!31(G0+$-!.)*+$-.$)/%<!!"#.%!.%!(!/,0!
>#(%$!(>>1.'(/.0)!,#$+$!1.P:.-!%1:++@!.%!'(++.$-!C@!G(>0+.Q.)*!31:.-<!
!!
,."='2'.";* R0)G$+/*%:*(+!%1:++@!3+0?!64!9+.&!SN2588!T;#+U!/0!K7!9+.&!S82I55!T;#+U!
H)!%/+$(?!V33.'.$)'@!B('/0+!W!NN5!-(@%!
!
J#?2*!KI1?"0#$*L#2?':;*
!
X.(?$/$+Y!
K<68I!Z)'#$%!!
[$)*/#Y!
L6!Z)'#$%!
R0)3.*:+(/.0)Y!
9V\]!S]$+/.'(1!^/+(.*#/!/#+0:*#!X$%.*)U!
F$(/!"+()%3$+!O+$(Y!
75L!^P<!B/!
":C$!%.-$!B1:.-Y!
Z)1$/!%:*(+!%1:++@!W!64!9+.&!SN2588!T;#+U!!
!
H:/1$/!%:*(+!%1:++@!W!K7!9+.&!S82I55!T;#+U!
":C$!%.-$!'0)-./.0)%Y! Z)1$/!/$?>$+(/:+$!W!7K50B!!
!
H:/1$/!/$?>$+(/:+$!W!8NI0B!!
^#$11!^.-$!B1:.-Y!
^(/:+(/$-!^/$(?!S6K4!T;#+U!
^#$11!%.-$!'0)-./.0)%Y! K5!_^ZE!(/!N8A0B!!
F$(/!V&'#()*$-Y!
6772856!9/:!;!F+!!
`!R1$()Y!
7NK<6L!S:)./!#(%!$&'$%%!%:+3('$!(+$(!.)!'1$()!'0)-./.0)U!
`!X.+/@Y!
4A<L6!S$&'$%%!%:+3('$!(+$(!a.'a%!.)!-:+.)*!30:1$-!%/(/$U!
!
A#;&:2*
"#.%!,(%!(!>+0'$%%!-+.G$)!(>>1.'(/.0)!+$:%.)*!10,!>+$%%:+$!%/$(?!3+0?!()0/#$+!
(+$(!03!/#$!>1()/<!Z)!300-!(>>1.'(/.0)%2!30:1.)*!3('/0+%!'()!G(+@!,.-$1@<!R0?>(+$-!
/0! /#$! 0/#$+! '(%$%2! /#.%! %:*(+! '(%$! +$P:.+$%! ?0+$! $&'$%%! %:+3('$! (+$(! /0!
?(.)/(.)!#$(/!/+()%3$+!,#$)!30:1.)*!0'':+%<!"0!?.).?.Q$!/#.%!.%%:$2!(!G(>0+.Q.)*!
31:.-!.%!:%$-!()-!/#$!#$(/!$&'#()*$!0'':+%!.)!/,0!%/(*$%<!_1$(%$!)0/$!/#(/!/#$!0)!
%/+$(?!$33.'.$)'@!3('/0+!.%!0)1@!NN5!-(@%!>$+!@$(+!-:$!/0!/#$!-0,)/.?$!+$P:.+$-!
30+!'1$().)*!(3/$+!30:1.)*!+$('#$%!(!'$+/(.)!1$G$1<!"#$!$)$+*@!()-!EFE!$?.%%.0)!
%(G.)*%!(+$!.)!/#$!/(C1$!C$10,<!
!
B&#:*
C&?"2'2/*4*D$8*
E?<'"0;*4*D$8*
!F';;'.";4D$*
B:$1!H.1!
I52777!*(1!
J7K52L58!
NKL<4!/0)%!
M(/:+(1!E(%!
I2L4N28K4!3/N!
JK424AK!
!!!88<K!/0)%!

*
*
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**5@!

*
9((#"='A*9*-*B:.;;?$/*.C*D#?2*!AE1?"0#$*F#$G'".:.0/*
!
9HI!**

*
J?CC:#**

*
J?CC:#*H(?E'"0**

"#$%! &'()*&! +,-! ./01! "21-34()! &,431'5! ,+! $140()34(6! %)73)11-&8! /01! "#$%!
9,361-!()*!:-1&&;-1!<1&&16!=,*1!3&!4,2>-3&1*!,+!(!&1'!,+!2();+(4';-3)7!&'()*(-*&!
'0('! (-1! 21()'! ',! *1+3)1! ?(&34! 4,)&'-;4'3,)! '5>1&! ()*! 2('1-3(6! '034@)1&&! A0361!
>-,B3*3)7! &(+1'5C! -1(&,)(?61! 4,&'! ()*! &1-B341(?363'58! "#$%! #14'3,)! <DDD! E3B! F!
#'()*(-*&! +,-! ;)+3-1*! >-1&&;-1! B1&&16&! (6A(5&! 7,B1-)! &0166! ()*! ';?1! 01('!
1G40()71-&8! $('1-3(6&! ;&1*! 3)! +(?-34('3,)! ,+! '01&1! 01('! 1G40()71-&! (-1! 3)!
(44,-*()41! A3'0! "#$%! #14'3,)! DD! ()*! (66! A16*3)7! >-,41&&1&! (&&,43('1*! A3'0!
+(?-34('3,)!(-1!3)!(44,-*()41!A3'0!"#$%!#14'3,)!<8!
/5>34(665!'01&1!(-1!>6('1&!A3'0!0,61&!(?,;'!'01!&3H1!,+!';?1!*3(21'1-&8!/015!>-,B3*1!
&'-;4';-(6!3)'17-3'5!',!';?1!?;)*61!'0('!3&!('!'321&!-1+1--1*!',!(&!.&'(4@!,+!';?1&I8!/01!
>-32(-5!+;)4'3,)!,+!?(++61&!3&!',!>-,B3*1!';-?;61)41!()*!>-,>1-!23G3)7!!,+!&0166!&3*1!
+6;3*&8!
9(++61!&>(43)7!3&!'01!*3&'()41!?1'A11)!?(++61&!3)!(!';?1!?;)*618!"&!3'!+,-41&!63J;3*!',!
40()71!*3-14'3,)!+-,2!,)1!1)*!',!'01!,'01-C!'01!?(++61!&>(43)7!0(&!()!1++14'!,)!+6;3*!
B16,43'5C!>-1&&;-1!*-,>!()*!01('!'-()&+1-!-('18!/03&!1++14'!3&!2,-1!>-,),;)41*!A01)!
'01-1! 3&! 63J;3*! 21*3(! ,)! '01! &0166! &3*18! ")! ,>'32(6! *1&37)! ;&1&! '01! (B(36(?61!
>-1&&;-1!*-,>!3)!()!(>>634('3,)!?5!&>(43)7!'01!?(++61&!(44,-*3)765!',!2(G323H1!'01!
1++14'3B1!01('!'-()&+1-!-('18!!

*
J&"=:#*9;;#GK:/** "! 4,22,)! '1-2! ;&1*! 3)! KL';?1! 01('! 1G40()71-&8! /01! ?;)*61! 4,)'(3)&! ';?1&C! '31!
-,*&C!?(++61&!()*!';?1&011'M';?1&011'&8!
*
,1?""#:*J.A**
"6&,! -1+1--1*! ',! (&! 01(*! ,-! A('1-?,G! ,+! '01! 01('! 1G40()71-8! /015! 4,)'(3)! >(&&!
>(-'3'3,)&! '0('! 4,)&'-(3)! +6;3*! ',! +6,A! '0-,;70! *1+3)1*! );2?1-! ,+! ';?1&8! D)! &'-(370'!
'0-,;70! *1&37)&! '01-1! (-1! 'A,! 40())16! ?,G1&N! ,)1! *1+3)1*! (&! +-,)'! 1)*! ()*! '01!
,'01-!(&!-1';-)!1)*8!!
*
,.$#*9;;#GK:/**
"! 4,22,)! '1-2! ;&1*! 3)! &'-(370'! '0-,;70! +3G1*! ';?1&011'! *1&37)&8! /01! 4,-1!
(&&12?65!4,)'(3)&!';?1&C!'31!-,*&C!?(++61&!()*!';?1&011'&8!!
*
L#;'0"*>$#;;&$#** /01! >-1&&;-1! ;&1*! ',! *1'1-23)1! '01! '034@)1&&! ,+! 4,2>,)1)'&! ()*! &1-B1&! (&!
4-3'1-3(!+,-!*1'1-23)3)7!'01!05*-,'1&'!>-1&&;-18!!
*
M#$$&:#;**
/01&1!(-1!(6&,!-1+1--1*!',!(&!/-346(2>&!'0('!(-1!;&1*!3)!#()3'(-5!O1('!%G40()71-&!
A01-1!'0-1(*1*!,-!+6()71*!4,))14'3,)&!(-1!;)(441>'(?618!!
*
M'A#=*F&K#;1##2** "!';?1&011'!'0('!3&!>1-2()1)'65!A16*1*!',!'01!&0166!(&!3)!'01!4(&1!,+!),)-12,B(?61!
4,-1!(&&12?658!!
*
M:.?2'"0* F&K#;1##2* * "! ';?1&011'! '0('! 3&! ),'! >1-2()1)'65! A16*1*! ',! '01! &0166! (&! 3)! '01! 4(&1! ,+! (! 9%:!
&'561! *1&37)8! "! +6,('3)7! ';?1&011'! *1&37)! (66,A&! +,-! '01-2(6! 1G>()&3,)! ()*!
4,)'-(4'3,)!,+!'01!';?1!?;)*61!3)*1>1)*1)'!,+!'01!&01668!!
*
M..2*H&((.$2;**
"*P;&'(?61! &(**61! &;>>,-'&! A3'0! &'-(>L(-,;)*! +,-! 0,-3H,)'(6! 01('! 1G40()71-&8! Q,-!
B1-'34(6!01('!1G40()71-&C!2,;)'3)7!&;>>,-'&! (-1! A16*1*! ',! (! ?1665?()*! '0('! 3&! 3)L
';-)!A16*1*!',!'01!1G'1-3,-!,+!'01!&01668!!
*
NG('"0#G#"2*>:?2#** "! >6('1! '0('! 3&! A16*1*! 3)&3*1! (! &0166! 1)'-()41! >,-'! 3)! (! *,21*! *1&37)! ,-! A16*1*!
*3-14'65!',!'01!';?1!?;)*618!D2>3)7121)'!>6('1&!016>!-1*;41!+6;3*!B16,43'5C!>-,B3*1!
?1''1-! +6;3*! *3&'-3?;'3,)! (4-,&&! '01! ';?1! ?;)*61! ()*! >-,'14'! ';?1&! +-,2! &;-+(41!
!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**5@!

"#$%&$'(!)'!*+,-."!/"0,!"12/0'3"#%!&,!&%!2$44$'!,$!/05"!,/"!%/"66!%&7"!&'6",!$88!,/"!
"'7!$8!,/"!,-."!.-'76"!#"'7"#&'3!0'!&49&'3"4"',!960,"!-''"2"%%0#:(!!
*
+?"2#$"*A'"0**
*
B?C#(:?2#**
*
D-$'"0;**

*
>?EF#=*G#?=**
*
>?;;*>?$2'2'."**
*
H1#::*G#?=**
*
H:'(*D"*I:?"0#**
*
H(?E#$**
*
H2&=*J.:2**
*
K!L9**
*
K#;2*>$#;;&$#**

*
K'#*A.=**
*
K&M#*+?/.&2**

;!4",06!#&'3!$'!<=>!%,:6"!7"%&3'%?!@/&2/!0#"!3"'"#066:!&'%,066"7!$5"#!,/"!$-,%&7"!$8!
7&04","#!$8!#"0#!86$0,&'3!,-."%/"",%!,$!/$67!,/"!%"06%!&'!9602"(!!
A/&%!20##&"%!,/"!;BC=!*!B,049!0'7!506-0.6"!&'8$#40,&$'!%-2/!0%!7"%&3'!9#"%%-#"?!
7"%&3'!,"49"#0,-#"!0'7!4"0'!7"%&3'!4",06!,"49"#0,-#"(!
A/&%! %"#5"%! 0%! 0! %"06&'3! 7"5&2"! .",@""'! ,@$! 2$49$'"',%(! D+#&'3%! 0#"! 3"'"#066:!
-%"7!.",@""'!,/"!,-."!%/"",!0'7!2/0''"6!.$1?!.",@""'!,/"!,-."!%/"",!0'7!%/"66!
860'3"!&'!*+,-."!2$'%,#-2,&$'(!D+#&'3!40,"#&06%!0#"!-%-066:!=>EC?!F&,$'!$#!&'!/&3/!
9#"%%-#"!0996&20,&$'%?!%9&#06!@$-'7!4",06(!!
A/"!"'7!$8!,/"!,-."!.-'76"!,/0,!2$',0&'%!,/"!86$0,&'3!/"07!7"%&3'!0'7!60',"#'!#&'3%!
&'!0!<=>!%,:6"!7"%&3'(!!
A/"! #&.! %"2,&$'! &'%&7"! 0! 2/0''"6! /"07! ,/0,! 2$'%,#0&'%! ,-."! %&7"! 86$@! ,/#$-3/!
7"8&'"7!'-4."#!$8!,-."%!&'!0!4-6,&+90%%!/"0,!"12/0'3"#(!!
;!8$#4"7!960,"!@/&2/!&%!@"67"7!,$!,/"!%/"66!9&9"(!)'!4$%,!&'%,0'2"%?!0!860,!"'7!960,"!
2$5"#!&%!4$#"!"2$'$4&206(!!
;! 860'3"! 7"%&3'! ,/0,! 8"0,-#"%! 0! 860'3"! #&'3! ,/0,! %6&7"%! $5"#! 0'7! &%! @"67"7! $',$! 0!
9&9"!%"2,&$'!$#!'$GG6"!9&9"(!!
;! 9&"2"! $8! ,-.&'3! ,/0,! %6&7"%! $5"#! ,/"! ,&"! #$7! .",@""'! .0886"! 960,"%! ,$! %"2-#"! ,/"!
.0886"!9$%&,&$'!&'!0!,-."!.-'76"(!!
;!%,-7!.$6,!&%!,/#"07"7!#$7!,/0,!"1,"'7%!,/#$-3/!/$6"%!&'!,@$!40,&'3!%-#802"%!0'7!
&%!%"2-#"7!@&,/!/"1!'-,%!$'!"02/!"'7(!!
),!%,0'7%!8$#!A-.-60#!=12/0'3"#!C0'-802,-#"#%!;%%$2&0,&$'(!A=C;!3-&7"6&'"%!2$5"#!
40'-802,-#&'3?! &'%,0660,&$'?! $9"#0,&$'! 0'7! 40&',"'0'2"! $8! %/"66! 0'7! ,-."! /"0,!
"12/0'3"#%(!!
>#"%%-#"! 0,! @/&2/! /:7#$%,0,&2! ,"%,&'3! &%! 20##&"7! $-,! $'! /"0,! "12/0'3"#%! ,$! 7","2,!
0':! 6"0H%! $'! %/"66! 0'7! ,-."! %&7"%! $8! ,/"! /"0,! "12/0'3"#(! A"%,! 9#"%%-#"%! 0#"!
7"8&'"7! .:! ;BC=! ,/0,! &%! 3"'"#066:! I(J! ,&4"%! 7"%&3'! 9#"%%-#"! 96-%! 9#"%%-#"!
2$49"'%0,&$'!8$#!04.&"',!@0,"#!-%"7!7-#&'3!/:7#$%,0,&2!,"%,(!!
;! %4066! 7&04","#! #$7! ,/0,!,/#"07%! &',$! ,/"! ,-."%/"",! 0'7!%"2-#"%! ,/"! .0886"%!0'7!
%902"%!,$3",/"#(!!
E"8&'"%! ,/"! %&G"! $8! ,-."?! ,-."! 9&,2/! 0'7! 90,,"#'! $8! ,-."%! @&,/&'! 0! ,-."! .-'76"! $#!
2$#"!0%%"4.6:(!!

*
K&M#;1##2**

A:9&2066:! 407"! $-,! $8! 0! 960,"(! A-."! %/"",%! /05"! /$6"%! ,/0,! 2$##"%9$'7! @&,/! ,-."!
60:$-,(! A-."%! 0#"! %"2-#"7! &'! /$6"%! .:! #$66"#! "190'%&$'! 0'7! %"06! @"67&'3(! A-."!
%/"",%!20'!2$',0&'!3#$$5"%!&'%&7"!,-."!/$6"%!,$!9#$5&7"!%,#"'3,/!,$!K$&',%(!!
N#:=*B#EF*I:?"0#** A/"%"!,:9"%!0#"!3"'"#066:!-%"7!$'!9-66"7!'$GG6"!9$#,%(!)'!%$4"!20%"%?!@"67&'3!&%!
4$#"!"88&2&"',!.:!-%&'3!0!.02H&'3!#&'3!."/&'7!,@$!40,&'3!."5"6"7!"73"%(!
!

!

!"#$%&'()*++,*-*,.(/$'012*3455467578*9::*$'012;*$#;#$<#=8*

>?0#**5@!

L/S

Drives

®

L/S ® Cartridge Pump Systems
Tech Information

Low-flow capability with a high-accuracy digital drive
Cartridges accept multiple tubing sizes
for wide flow range
■ Cartridges snap in and out for tubing
changes; change tubing in one channel
without disturbing others
■ Finely adjust occlusion to increase
accuracy
■ Use only one cartridge, or load to
capacity
■ Digital dispensing drive features
maintenance-free brushless motor
■ Program dispensing parameters,
including delay interval, for automated
dispensing
■ Four-channel, eight-roller pump offers
lowest pulsation for better accuracy
■ 1⁄10-hp continuous-duty brushless drive
■ Tach feedback for ±0.1% drive speed
control
■ Remote control via DB25 female
connector on drive
■ IP33 rated, stackable ABS housing
■ Membrane keypad with lockout
■ See pages 1540–1541 for complete
drive specifications
■

Multiple-channel
low-flow transfer
and perfusion!

Masterflex ® C/L®

77919-20

2. Snap cartridge into place on
pump head.

3. Adjust occlusion using
index scale on cartridge.

Specifications & Ordering Information

†Flow

Drive speed
range (rpm)

Drive IP
rating

Power
(50/60 Hz)

0.02 to 100

IP33

90 to 130 VAC, 2.2 A;
190 to 260 VAC, 1.1 A

0.02 to 100

IP33

90 to 130 VAC, 2.2 A;
190 to 260 V AC, 1.1 A

Price

range with included tubing; extend the flow range of these systems with additional sizes of tubing; order microbore two-stop tube sets below and L/S tubing on pages 1521–1527.

Additional Microbore Two-Stop Pump Tube Sets
Pump tubing
Flow rate per
channel (mL/min)

Santoprene®
Tygon® E-LFL
Viton®

0.89 mm ID
0.0015 to 7.4
0.0010 to 5.2
T-06421-26
/pk of 6
T-06431-26
/pk of 12
T-06447-26
/pk of 12
T-96428-26
/pk of 12

1.42 mm ID
0.0034 to 18
0.0024 to 12
T-06421-34
/pk of 6
T-06431-34
/pk of 12
T-06447-34
/pk of 12
T-96428-34
/pk of 12

2.06 mm ID
0.0074 to 37
0.0044 to 22
T-06421-42
/pk of 6
T-06431-42
/pk of 12
T-06447-42
/pk of 12
T-96428-42
/pk of 12

2.79 mm ID
0.0126 to 63
0.0068 to 34
T-06421-48
/pk of 6
T-06431-48
/pk of 12
T-06447-48
/pk of 12
T-96428-48
/pk of 12

Additional Cartridges
T-07519-80 Additional small cartridge
for pump system 77919-20
T-07519-85 Additional small cartridge
for pump system 77919-30

US Toll-free: 800-323-4340
•
Outside the US: 1-847-549-7600
•
www.coleparmer.com
Canada 800-363-5900 • India 91-22-6716-2222 • UK 0500-345-300

Accessories & Parts

Platinum-cured
silicone

Cartridge head 07519-06
Cartridge head 07519-20

Masterflex ® B/T ®

Catalog
Flow range†
Pump head
Tubing
Tubing sizes
Drive
number
(mL/min)
included
included
accepted
included
L/S eight-channel four-roller cartridge pump system
L/S Cartridge head 07519-06 Tygon E-LFL microbore tube
Microbore tube sets;
T-77919-20
07523-90
set, 1.42-mm ID 06447-34;
0.0034 to 18
with eight small cartridges
L/S 13, L/S 14
pk of 12
07519-80
L/S reduced-pulsation four-channel eight-roller cartridge pump system
L/S Cartridge head 07519-20 Tygon E-LFL microbore tube
Microbore tube sets;
T-77919-30
07523-90
set, 1.42-mm ID 06447-34;
0.0024 to 12
with four small cartridges
L/S 13, L/S 14
pk of 12
07519-85

Masterflex ® I/P ®

1. Select tubing, load tubing
into cartridge, and set
tubing retainers.

Masterflex ® L/S®

How to Load Your Pump Head

07519-80

1543

GE Healthcare
Data file 28-9159-87 AC

BioProcess prepacked columns

ReadyToProcess™ Columns
ReadyToProcess columns are prepacked, prequalified, and
presanitized process chromatography columns available
with a range of BioProcess™ media in four different sizes:
1.0 l, 2.5 l, 10 l, and 20 l (Fig 1).
ReadyToProcess columns are designed for purification of
biopharmaceuticals for clinical phase I and II studies.
Depending of the scale of operations they can also be used
for full-scale manufacturing, as well as for preclinical studies.
The columns can, however, be used in any chromatographic
application for separation of various compounds, for example
proteins, endotoxins, DNA, plasmids, vaccines, and viruses.
ReadyToProcess columns provide:
~ CX\TbPeX]VbQh\PZX]VbTeTaP[cX\TR^]bd\X]V
steps redundant
~ 2^bcbPeX]VbQh[^fTaX]VQdUUTaR^]bd\_cX^]P]S
reducing cleaning validation demands
~ ?a^RTbbbTRdaXchX]cTa\b^Ua^QdbcR^[d\]_TaU^a\P]RT
~ BRP[PQX[Xchc^UPRX[XcPcTR^]eT]cX^]P[P__a^PRWX]
larger scale
~ =^Ra^bbR^]cP\X]PcX^]_a^Q[T\b
ReadyToProcess columns make several steps redundant
(column packing, column qualification, and sanitization), and
significant time saving can be achieved in the downstream
processing. ReadyToProcess columns are closed units and
the design allows easy disposal after completed production.
ReadyToProcess chromatography columns offer the possibility
to work in a fully flexible mode in early clinical phases while
keeping a conventional re-use option for large-scale
manufacturing open. The chromatography media used in
ReadyToProcess columns have a long track-record of use
in full-scale manufacturing using conventional, large-scale
chromatography, where columns can be used for tens or
hundreds of cycles. The transition from ReadyToProcess format
to full-scale manufacturing is therefore straightforward.

imagination at work

Fig 1. ReadyToProcess columns are easily connected to a chromatography
system and can be disposed of after completed production.

Currently, the following BioProcess media are available in
cWTATPShC^?a^RTbbU^a\Pc)<PQBT[TRcBdAT2P_c^@
2P_c^B2P_c^PSWTaTP]S?WT]h[BT_WPa^bT%5Pbc5[^f
(low sub). On request, also the following media are available:
2P_c^<<2@BT_WPa^bT55B?BT_WPa^bT55P]S3404
BT_WPa^bT55

ReadyToProcess column characteristics
The hardware of ReadyToProcess columns follows the
construction of BPG™ columns, with a media packing valve
added, and is designed for upwards flow (Fig 2).
The columns have fixed bed heights of 200 mm, which
is the optimum for contact time, flow, and capacity for
modern chromatography media. Pressure/flow curves for
ATPShC^?a^RTbb2P_c^PSWTaT<PQBT[TRcBdATP]S?WT]h[
BT_WPa^bT%5Pbc5[^fR^[d\]bPaTbW^f]X]5XVdaT"U^a
operation with water at room temperature (20°C).
The polymer materials used to manufacture ReadyToProcess
columns have been chosen for their biological and chemical
compatibility with the samples, buffers, and solutions used
during operation and during sanitization procedures.

Table 2. Characteristics of ReadyToProcess columns

1l

2.5 l

10 l

20 l

Inner diameter (mm)

80

!%

251

"$(

Inner cross section (cm2)

50

124

495

1012

Column volume (l)
Packed bed height (mm)
Net mesh (µm)

CWT\PcTaXP[b\TTccWTDB?D]XcTSBcPcTb?WPa\PR^_TXP
R[PbbE8aT`dXaT\T]cbPRR^aSX]Vc^DB?+''-1X^[^VXRP[
Reactivity Tests, “In Vivo” and FDA CFR 177. The material is
free from material of animal origin or has been produced
under manufacturing conditions complying with EMEA/410/01.
The columns are designed to comply with hygienic
requirements. Table 1 below lists the wetted materials.
Table 1. List of wetted materials in ReadyToProcess columns

Trade name

Material

Column part

PP

Polypropylene

Column tube, lids, TC
connections, support
nets, support screens,
stream stoppers, hose
connections, welded
tubing for inlet/outlet
protection

PEEK

Polyetheretherketone

Plug at inlet tubing, filter
holder, media packing
valve

Tygon™ 2275 Polyolefin

Hose (inlet tubing)

FPM

Fluorocarbon rubber

O-rings

EPDM

Ethylenepropylenediene TC gaskets

A

20.2
200

!"

!"

!"

!"

≤15

≤15

≤15

Outer height (mm)

"'!

"&'

"''

407

Outer diameter incl. lid (mm)

155

195

"#!

484

m"

m%

~25

~55

Inlet TC25 connectors,
tubing i.d.

4.8 mm %"\\ 9.5 mm 12.7 mm
0.19”
0.25” "&$}
0.5”

Outlet TC25 connectors,
tubing i.d.

4.8 mm %"\\ 9.5 mm 12.7 mm
0.19”
0.25” "&$}
0.5”

Ambient temperature† (°C)

#"

#"

#"

#"

Liquid temperature† (°C)

4-40

4–40

4–40

4–40

Maximum liquid pressure, bar

4

4

4

4

Estimated shelf life (months)

18

18

18

18

‡

* The mechanical compression factor varies depending on the medium.
†

The temperature difference between the fluid running through the column and the ambient
temperature in the room should never be greater than 20°C.

‡

While the maximum liquid pressure stated depends on the pressure rating of the column,
restrictions for the maximum pressure drop over the column depend on the packed
RWa^\Pc^VaP_Wh\TSXd\X]^aSTac^T]bdaTQTSbcPQX[XchBTTDbTa<P]dP[U^aSTcPX[b

The most important characteristics of the ReadyToProcess
columns are listed in Table 2.
On delivery, ReadyToProcess columns are ready for immediate
use. The columns are packed in clean-room environment
R[Pbb8B>'dbX]VeP[XSPcTS_PRZX]V_a^c^R^[bC^VdPaP]cTT
a well-packed column, each individual ReadyToProcess
column is qualified by efficiency testing, that is, by analysis
of theoretical plates per m packed bed (N/m) and asymmetry
factor (As), as a part of the production procedure. Acceptance
limits have been established for efficiency testing at 100 cm/h
and the analysis results are specified in the Certificate of
Analysis accompanying each column. After qualification, the
columns are sanitized and equilibrated with storage solutions.
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Fig 2. ReadyToProcess column with assembled nets and media packing
valve. Arrows show flow direction.
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Fig 3. Examples of pressure/flow curves for 2.5 and 20 l ReadyToProcess columns prepacked with (A)<PQBT[TRcBdAT(B) Capto adhere, and
(C) ?WT]h[BT_WPa^bT%5Pbc5[^f[^fbdQ
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1.4

Acceptance criteria for the testing procedure performed at
P ^feT[^RXch^U"R\WfTaTbTcPc"&=\
=,]d\QTa^UcWT^aTcXRP[_[PcTbU^a2P_c^@2P_c^BP]S
?WT]h[BT_WPa^bT%55[^fbdQ*"(U^a<PQBT[TRcBdAT
and 4400 for Capto adhere. The asymmetry factor should be
within the range 0.8 to 1.8, both before and after the testing.
The results in Figure 4 show that these parameters lie within
the set limits, demonstrating that ReadyToProcess columns
are stable and robust and can be transported without effect
on their performance.

Characteristics of some of the chromatography media
PePX[PQ[TX]ATPShC^?a^RTbbR^[d\]bPaT[XbcTSX]CPQ[T"
Detailed information about each medium is available in the
respective BioProcess medium data file.
Lane
1 Capto adhere
2 Capto Q
3 Capto S
4 MabSelect SuRe
5 Phenyl Sepharose 6 Fast Flow (low sub)

Column ReadyToProcess 2.5 l
1.6

Column ReadyToProcess 20 l

1.8 AS

1.8

(a)

1.8

Before
After

1.4
1.2
1.0

0.8 AS

0.8
0.6

1.6

1.2
1.0

0.8 AS

0.8
0.6

0.4

0.4

0.2

0.2

0
Lane:

1.8 AS

(b)

1.4
Asymmetry (A S)

Four column sizes, ReadyToProcess 1 l, ReadyToProcess 2.5 l,
ReadyToProcess 10 l, and ReadyToProcess 20 l, were subjected
to testing and the asymmetry factor and plate number were
measured.

In addition, BioProcess media are supported with Regulatory
Bd__^ac5X[TbAB5P]SR^\_aTWT]bXeTS^Rd\T]cPcX^]Pb
well as security of supply service.
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Lane:

1
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3

1
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4

5

8000
7000

Plates/meter (N/m)

Transport simulation studies were performed at a certified
testing facility (Packforsk AB) as follows: Vibration testing
842%'!%BW^RZcTbcX]V842%'!!&P]S3a^_cTbcX]V
842%'!" 

BioProcess media are specifically designed to meet the
demands of industrial biotechnology. This means that the
medium is scalable from laboratory to production, is produced
with validated manufacturing procedures, and can withstand
standard CIP and sanitization-in-place procedures.

Asymmetry (A S)

Transport simulation studies

BioProcess media characteristics

Plates/meter (N/m)

The sanitization procedure removes both micro-organisms,
including spore-forming organisms, and endotoxins. The
columns are sampled for endotoxin analysis (acceptance
[X\XcXb+!$4D\[P]S\XRa^QX^[^VhVa^fcW25D+  \[
The results including the curve from the efficiency test as
well as the endotoxin and microbiology analysis results are
presented in the Certificate of Analysis, which is a part of
the Product Documentation accompanying each column.
As a last step, the column is equilibrated in 20% ethanol
(20% ethanol with 0.2 M sodium acetate, pH 5.5 when
applicable). There is no need to repeat either the efficiency
test or the sanitization procedure.
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Fig 4. Transport simulation studies on ReadyToProcess 2.5 l (a) and
ReadyToProcess 20 l (b) columns show that both the number of theoretical
plates, N/m, and the Asymmetry factor, As, were within the predefined
ranges after testing.

Table 3. Characteristics of some of the chromatography media available in ReadyToProcess columns

MabSelect SuRe

Capto Q

Capto S

Capto adhere

Phenyl Sepharose 6
Fast Flow (low sub)

Matrix

Rigid, highly crosslinked agarose

Rigid, highly crosslinked agarose with
dextran surface
extenders

Rigid, highly crosslinked agarose with
dextran surface
extenders

Rigid, highly crosslinked agarose

Highly cross-linked
agarose

Average particle size

85 µm

90 µm

90 µm

75 µm

90 µm

Functional group

Alkali-stabilized
protein A-derived

Bca^]VP]X^]
TgRWP]VTa@ch_T

Bca^]VRPcX^]
TgRWP]VTaBch_T

Multimodal strong
anion exchanger

Phenyl

Dynamic binding
capacity data

ģ"\VWd\P]8V6 - \V1B0\[
ml medium at 2.4 min
residence time

- !\V
lysozyme/ml
medium

NA

!#\V7B0\[

pH working range

" !

2–12

4–12

"–12

"– "

Cleaning-in-place
stability

0.1–0.5 M NaOH

2–14

" #

2–14

2–14

!'( $('&02"

Regulatory Product Documentation
Each ReadyToProcess column is accompanied with an
extensive documentation package to help customers
register a production process containing a chromatography
step on a ReadyToProcess column. The documentation is
divided into three parts.

~ Product Documentation – A certificate of conformance
is provided, showing each wetted material’s conformance
fXcW! 25A &&DB?2[PbbE8P]SP]X\P[UaTT^aXVX]^a
EMEA/410/01). The certificate of conformance ensures
full traceability of materials. The product documentation
also contains a certificate of analysis showing packing
performance as well as endotoxin and microbiology test
results for the delivered column. The documentation is
delivered with each column.
~ Regulatory Support Files (RSF) Addendum – Gives access
to product information of the ReadyToProcess column
including stability and quality, as well as a brief description
of the preparation.
~ RSFRdaaT]cAB5X]R[dSTbPSSXcX^]P[X]U^a\PcX^]^]
each BioProcess chromatography medium.

CWTaTbd[cbX]SXRPcTcWPcbRP[Td_Ua^\P]G: %#c^cWT
ReadyToProcess columns was possible and the results were
similar regardless of the chromatography system used (Fig 5).

ReadyToProcess columns in the purification
of monoclonal antibodies (MAbs)
When choosing a process for large-scale purification, the
possibility to scale up operations without too much process
development is important.
To further demonstrate the scalability and assess the overall
performance of ReadyToProcess columns, they were
R^\_PaTSfXcWP]TbcPQ[XbWTSb\P[[bRP[TU^a\PcG: %
in the purification of a MAb from cell culture supernatant.
The processes were run side-by-side using a generally
P__[XRPQ[TcWaTTbcT__a^RTbbR^]bXbcX]V^U<PQBT[TRcBdAT
2P_c^@P]S2P_c^PSWTaTCWTATPShC^?a^RTbbR^[d\]b
QTWPeTSbX\X[Pa[hc^cWTG: %#R^[d\]bX]P[[Pb_TRcb
studied, demonstrating that the purification process is directly
scalable between XK and ReadyToProcess.
A

280

AB50SST]SPP]SAB5PaTPePX[PQ[TPc
www.gelifesciences.com/rsf

Scale-up study
A study was performed to verify that the results of a protein
separation experiment give the same result regardless of
column size or chromatography system used. A mixture of
cf^_a^cTX]bQ^eX]TbTad\P[Qd\X]1B0<r%%P]S
lactoferrin (Mr 90 000), was applied to columns of different
sizes, and eluted. The elution peaks in the resulting
RWa^\Pc^VaP\bfTaTR^\_PaTSCWTR^[d\]bfTaTG: %#
_PRZTSfXcW2P_c^BP]S1?6_PRZTSfXcW $[2P_c^BQ^cW
c^Pc^PQTSWTXVWc^U!R\ATPShC^?a^RTbb2P_c^B!$
ATPShC^?a^RTbb2P_c^B P]SATPShC^?a^RTbb2P_c^B!

Volume

Fig 6. >eTa[PhRWa^\Pc^VaP\^U<PQBT[TRcBdATRhR[T $

To investigate the effects of multiple runs on column
_TaU^a\P]RTcWT<PQBT[TRcBdATR^[d\]bfTaTad] eT
cX\TbR^]bTRdcXeT[h5XV%0[[RWa^\Pc^VaP\bfTaT_aPRcXRP[[h
identical, showing that multiple runs with CIP between cycles
could be run with retained performance.

mAU
5000

mS/cm
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50

Operation

40

Fast method development – fully scalable

3000

30
2000
20
1000

10

0
0.0

5.0
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15.0

20.0 min

0

= 20 l ReadyToProcess
= 2.5 l ReadyToProcess
= 10 l ReadyToProcess
= 1.5 l BPG 100
= XK 16/40

Fig 5. BcPRZTSRWa^\Pc^VaP\R^\_PaX]VbcT_T[dcX^]^]cWTUXeTSXUUTaT]c
R^[d\]bCWTT[dcX^]QdUUTabfTaT$\<b^SXd\PRTcPcT"<=P2[
_7$P]S$\<b^SXd\PRTcPcT%$<=P2[_7$CWTT[dcX^]bcT_b
fTaT"2ETPRWCWTRWa^\Pc^VaP\bfTaT^QcPX]TSdbX]V«:C0aTPSh
bhbcT\TgRT_cU^aG: %#fWXRWfPbad]^]P]«:C0Tg_[^aTabhbcT\
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The matrices used in ReadyToProcess columns are also
available as bulk media. Fast method development can
be achieved using Tricorn™ or XK columns for the first
experiments. After optimizing the purification at laboratory
scale, the process can be scaled up by keeping the
residence time constant in order to maintain capacity.
This can be achieved by increasing the column diameter
and keeping the mobile phase velocity and sample-to-bed
volume ratio constant.

BRP[Td_Xbch_XRP[[h_TaU^a\TSQhZTT_X]VQTSWTXVWcP]S
liquid velocity (cm/h) constant (i.e., constant residence time)
while increasing column bed diameter and flow rate (l/min).
Yield and clearance of critical impurities may change when
column bed height or residence time is changed and should
be validated using the final bed height.

Ordering information

[

!'($ (

Storage

ATPShC^?a^RTbb2P_c^@!$

!$[

!'( &!"

ATPShC^?a^RTbb2P_c^@ 

[

!'( &!#

ReadyToProcess columns are delivered packed with
chromatography media in a storage solution consisting
^U!TcWP]^[ATPShC^?a^RTbb2P_c^BR^[d\]bPaT
delivered in 20% ethanol and 0.2 M sodium acetate pH 5.5.

ATPShC^?a^RTbb2P_c^@!

![

!'( &!$

[

!'($ ("

ATPShC^?a^RTbb2P_c^B!$

!$[

!'( &!(

ATPShC^?a^RTbb2P_c^B 

[

!'( &"

0[[R^[d\]bTgRT_cATPShC^?a^RTbb<PQBT[TRcBdATPaT
preferably stored at room temperature but can also be stored
in a cold room (the storage temperature range for these
R^[d\]bXb#2c^"2ATPShC^?a^RTbb<PQBT[TRcBdAT
columns should be stored at 4°C to 8°C.

ATPShC^?a^RTbb2P_c^B!

![

!'( &"

ReadyToProcess Capto adhere 1

1l

28-9511-09

ReadyToProcess Capto adhere 2.5

2.5 l

28-9017-14

ReadyToProcess Capto adhere 10

10 l

28-9017-15

ATPShC^?a^RTbb2P_c^PSWTaT!

![

!'( & %

The column needs to be washed to clear it from the storage
solution before starting the purification process. The wash
will also adjust the temperature of the column to the
working temperature.

Equipment
ReadyToProcess columns are intended for use with
«:C0aTPShRWa^\Pc^VaP_WhbhbcT\QdcRP]P[b^QT
used with standard chromatography systems, for example
«:C0_a^RTbbATPShC^?a^RTbb [P]S!$[R^[d\]bRP]
P[b^QTdbTSfXcW«:C0_X[^cbhbcT\bfXcWX]P[X\XcTS[X`dXS
velocity range. Alarm setting of pressure must be set in order
not to exceed the maximal pressure for the packed column.

ReadyToProcess Columns
Product

Column size

ATPShC^?a^RTbb2P_c^@ 

ATPShC^?a^RTbb2P_c^B 

ATPShC^?a^RTbb<PQBT[TRcBdAT 
ATPShC^?a^RTbb<PQBT[TRcBdAT!$

[

Code no.

!'($

 

!$[

!'( & &

ATPShC^?a^RTbb<PQBT[TRcBdAT 

[

!'( & '

ATPShC^?a^RTbb<PQBT[TRcBdAT!

![

!'( & (

ReadyToProcess Phenyl
BT_WPa^bT%55[^fbdQ 

[

!'($



ReadyToProcess Phenyl
BT_WPa^bT%55[^fbdQ!$

!$[

!'( &"$

ReadyToProcess Phenyl
BT_WPa^bT%55[^fbdQ 

[

!'( &"%

ReadyToProcess Phenyl
BT_WPa^bT%55[^fbdQ!

![

!'( &"&

ReadyToProcess Capto MMC 1

1l

28-9511-18

ReadyToProcess Capto MMC 2.5

2.5 l

28-9291-20

ReadyToProcess Capto MMC 10

10 l

28-9291-21

ReadyToProcess Capto MMC 20

20 l

28-9291-22

ATPShC^?a^RTbb@BT_WPa^bT55 
ATPShC^?a^RTbb@BT_WPa^bT55!$

[

!'($

!$

!$[

!'(!(&%

ATPShC^?a^RTbb@BT_WPa^bT55 

[

!'(!(&(

ATPShC^?a^RTbb@BT_WPa^bT55!

![

!'(!('!

ATPShC^?a^RTbbB?BT_WPa^bT55 

[

!'($ (&

ATPShC^?a^RTbbB?BT_WPa^bT55!$

!$[

!'(!( $

ATPShC^?a^RTbbB?BT_WPa^bT55 

[

!'(!( %

ATPShC^?a^RTbbB?BT_WPa^bT55!

![

ATPShC^?a^RTbb3404BT_WPa^bT55 

[

!'(!( &
!'($

!%

ATPShC^?a^RTbb3404BT_WPa^bT55!$

!$[

!'(!(  #

ATPShC^?a^RTbb3404BT_WPa^bT55 

[

!'(!(  $

ATPShC^?a^RTbb3404BT_WPa^bT55!

![

!'(!(  %
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Application notes

Code no.

Efficiency test of ReadyToProcess columns

28-9198-21

Purification of a monoclonal antibody using
ATPShC^?a^RTbbR^[d\]b

!'( ('$%

Data files

Code no.

«:C0aTPSh

!'( $('%

Capto adhere

28-9078-88

2P_c^<<2

"$#$

2P_c^@P]S2P_c^B

!$&%

<PQBT[TRcBdAT



%$

?WT]h[BT_WPa^bT%5Pbc5[^f[^fbdQ

' !$"

BT_WPa^bT5Pbc5[^fX^]TgRWP]VTab

' !%%

For local office contact information, visit
www.gelifesciences.com/contact
www.gelifesciences.com/ReadyToProcess
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Mobius FlexReady Solution for TFF
®

Fast setup. Maximum adaptability.
Pre-designed and optimized.

Part of the Mobius FlexReady family of application-specific
solutions, the Mobius FlexReady Solution for Tangential
Flow Filtration (TFF) is an easy-to-use system featuring
an optimized single-use flowpath, and is designed to fully
support your TFF needs. The system uses Millipore’s leading
Pellicon® cassettes, which are ideally suited for purification or
concentration/diafiltration of monoclonal antibodies, vaccines
and therapeutic proteins.
The Mobius FlexReady Solution for TFF consists of
single-use Flexware® assemblies, innovative separation
devices and process-ready hardware systems to deliver
optimal operational flexibility, from process development to
clinical production to small-scale commercial manufacturing.
Accompanied by extensive Millipore support and services,
the Mobius FlexReady Solution for TFF can help you maximize
resource productivity and reduce risk.
• Fast setup of hardware with easy installation of
optimally designed Flexware assemblies
• Maximum adaptability to your changing operational
needs with single-use flowpaths
• Pre-designed and optimized for TFF to give you
confidence and peace of mind

MODULAR, OPTIMIZED DESIGN
Mobius FlexReady Solutions are ergonomically designed for

TWO SYSTEMS FOR
OPTIMUM SCALABILITY

fast setup, maximum adaptability to changing process needs

The TF-1 system contains a 10L retentate recycle container

and reduced operator error. Specially designed hardware

and, in typical conditions, will use Pellicon cassettes of up to

conveniently holds filters and containers, right where you

0.5 m2 filtration area. The TF-2 system is designed with a 50L

need them. The modular, interlocking multi-cart design lets

retentate recycle container and, in typical conditions, will use

you easily and safely move your system from one space

Pellicon cassettes of up to 2.5 m2 filtration area.

to another. The filter end cart is designed to work with all

• Designed for minimum working volume and high recovery of

Mobius FlexReady Solutions, leveraging your investment in
capital equipment and maximizing resource utilization.

protein at high concentrations
• Novel retentate recycle container with levitating magnetic impeller, retentate divertor, and vortex breaker for
efficient mixing
• Retentate recycle tank mounted on load cells and integrated transfer pump to enable fed batch and constant
volume diafiltration operations
• Innovative low dead volume t-connectors, enabling
the use of traditional pressure transducers
• Flexware assemblies designed to fit the hardware and
install quickly and easily
• Constant ∆P and constant feed flow (calculated) operation
• Ease of operation with an intuitive touch screen interface
and user-defined process and alarm set points

Figure 1. The filter end cart works with all Mobius
FlexReady Solutions for optimum equipment
utilization.

Tank Designed for Efficient Mixing
The retentate recycle tank is specifically designed for
efficient concentration and diafiltration of proteins. An
innovative single-use process container design incorporates
a magnetically coupled levitating impeller, ensuring efficient
mixing at high tank levels.
The Mobius FlexReady Solution for TFF provides maximum
adaptability to your changing process needs, such as varying
volume levels. The low-point retentate return with patented
retentate diverter plate and vortex breaker on the container
outlet, reduces air entrapment and ensures efficient mixing
at low tank levels. The retentate recycle tank is mounted on
load cells to enable fed-batch operation, diafiltration and final
concentration based on set-point input.

Figure 2. Hardware system components move
and connect easily for maximum mobility.
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Figure 3. A pivoting retentate recycle tank
design facilitates container loading.

Low Dead Volume T-connector
The Mobius FlexReady Solution for TFF features our innovative
low dead volume t-connector built into the flowpath which
is designed for use with traditional pressure transducers.
A LLDPE septum provides the barrier between the process
fluid and the transducer thereby eliminating the risk of
contamination.

The system features a user-configurable set point for
controlling tank volume during fed batch processing and
diafiltration, as well as a final tank volume end point during
ultrafiltration. The TMP value is calculated and shown on the
main piping and instrumentation diagram (P&ID) on the interface screen.
The onscreen P&ID provides an easy way to monitor your
process in real time, including pump speed, mixer speed, feed,
retentate and filtrate pressures, tank temperature, calculated
feed flow rate, ∆P, TMP, calculated filtrate flow rate, and totalized filtrate weight (requires optional weigh scale). A separate
screen shows key process parameter changes over the course
of the run.

Figure 4. The innovative low dead volume
t-connector prevents pressure sensor contact with
the fluid path.

Pellicon® Cassettes
Pellicon cassettes are the optimum tangential flow
filtration (TFF) devices for solutions containing monoclonal
antibodies, therapeutic proteins, albumin, hormones, vaccines
and growth factors. These advanced, high-performance cassettes are ideal for today’s higher titer therapeutic antibodies as well as the more demanding filtration processes that

Figure 6. The Automated Pressure Control Valve
(PCV) features a clear outer door enabling a clear
view during operation. If the door is opened during
operation, the valve automatically shuts off ensuring
operator safety.

require greater operating pressures and temperatures.

Simple Data Management
The system automatically captures time-stamped data for
the active parameters and separately logs the alarm and
event history. These tab delimited/CSV files can be uploaded
directly to your computer. The standard design includes a
Profibus card allowing data export to a DCS. The data can also
be exported to meet 21CFR Part 11 compliance. An option is
available to allow data export through an Ethernet IP protocol.

Figure 5. Pellicon Cassettes are ideal for higher
titers and more demanding filtration processes.

Easy and Intuitive Operation
An intuitive, touch screen interface, makes the Mobius
FlexReady Solution for TFF easy to operate. The system uses
a combination of configurable process alarm set points and
automated data acquisition. Transmembrane pressure (TMP)
can be set with the help of an automated pressure control
valve, and controlled through the touch screen interface
along with set point operation for constant pump speed or
constant ∆P.

Figure 7. The P&ID provides real-time display of all
active parameters.
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Standardized Configurations for
Reliable Results

• Sterilizing-grade filter assembly for final collection
with sampling bag and NovaSeal™ Crimping Sleeve
for sterile disconnect

The flowpath has been carefully designed and tested by our
design and applications engineers, resulting in a consistent,

• Optional Flexware assemblies including process

standardized flowpath. You are guaranteed that the flowpath is

containers for source, NaOH, buffer, WFI, filtrate,

designed to fit the system and your TFF needs. The flowpath

and waste, and integrity tester (IT) connector line

(See Fig. 8) consists of:

• Pellicon cassettes

• Core Flexware assemblies which includes the
transfer manifold line and vent filter, retentate
recycle container, retentate and feed lines,
retentate flush line, and filtrate drain line

Figure 8. TFF Flowpath

Retentate
Retentate
Recycle
Recycle
Tank
Tank

Pellicon
Pellicon
Cassette
Cassette

Filtrate
Filtrate

Vent
Filter
Vent
Filter

Fig. 7
Fig. 7

CORE FLEXWARE ASSEMBLIES
CORE FLEXWARE ASSEMBLIES
STERILIZING-GRADE FILTER ASSEMBLY
STERILIZING-GRADE FILTER ASSEMBLY
OPTIONAL FLEXWARE ASSEMBLIES
OPTIONAL FLEXWARE ASSEMBLIES

Select from Standard Flowpath Configurations for Each System
TF-1

TF-2

Core Flexware Assemblies

10L retentate recycle container

50L retentate recycle container

Sterilizing-grade filter assembly for final
collection

5L or 10L collecting container featuring
Opticap® XL 600 capsule with Millipore
Express® SHC membrane

10L or 20L collecting container featuring
Opticap® XL 600 capsule with Millipore
Express® SHC membrane

Process container for source

10L, 20L, 50L

50L, 250L

Process container for NaOH

10L, 20L, 50L

250L, 500L, 1,000L

Process container for buffer

10L, 20L, 50L

250L, 500L, 1,000L

Process container for WFI

10L, 20L, 50L, 250L

250L, 500L, 1,000L

Process container for filtrate

10L, 20L, 50L

250L (accommodates up to 2 process
containers for filtrate)

Process container for waste

250L

1,000L

Pellicon 2 cassettes

0.1 m2 (1-5 cassettes)

0.5 m2 (1-5 cassettes)
2.5 m2 (1 cassette)

Pellicon 3 cassettes

0.11 m2 (1-4 cassettes)

0.56 m2 (1-4 cassettes)
1.14 m2 (1-2 cassettes)
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SPECIFICATIONS

TF-1

TF-2

Retentate recycle tank

10L

50L

Flowrate

0.4 - 4.0 L/min

2 – 18 L/min

Surface area Pellicon 2

0.1 – 0.5 m2

0.5 - 2.5 m2

Surface area Pellicon 3

0.11 – 0.44 m2

0.56 – 2.28 m2

Min. working volume (based on feed flow of
8 L/min/m2)

320 mL @ 0.1 m2
490 mL @ 0.5 m2

1,350 mL @ 0.5 m2
2,400 mL @ 2.5 m2

Recommended Operating Parameters

Min. working volume is the volume in the retentate
recycle container, feed line, Pellicon filters, and
retentate line.
Min. working volume is a function of the membrane
surface area and the feed flowrate.

Fluid operating temperature

20 - 45 °C (68 - 113 °F)

Max. operation pressure

50 psi (3.45 bar)

Environmental Requirements

20-25 °C, (68 - 113 °F) Relative humidity 10-90% (non condensing)

Utilities
Supply voltage

100 - 110 VAC,
50/60 Hz, 1 phase

230 VAC,
50/60 Hz, 1 phase

200 - 208 VAC,
50/60 Hz, 3 phase

400 VAC,
50/60 Hz, 3 phase

Compressed Air/N2

Clean, dry air or nitrogen source at 3.5 to 6.0 bar (50 – 90 psi) for connecting to Integritest® 4 and
for bag inflation

Instrumentation
Filtrate weigh scale (optional)

up to 60 kg (132.3 lbs)

up to 600 kg (1,328 lbs)

Pressure transducer

Sanitary diaphragm pressure transducer located at retentate and filtrate lines

High pressure cut-off switch

Sanitary diaphragm pressure transducer located at feed and transfer pump outlet

Temperature sensor

Located at retentate recycle container outlet

Weight load cells

Located at retentate recycle tank (qty. of 4)

Control Modes: Operations will be supervised by alarm setpoints
Set point

Details

Constant ∆P (Pfeed – Pretentate)

Operate at constant ∆P or calculated constant feed flow rate

Constant TMP
(Pfeed + Pretentate)
- Pfiltrate
2

Operate at constant TMP or retentate pressure

Constant retentate tank weight

For fed batch concentration, for constant-volume diafiltration

Cumulative filtrate

For concentration or diafiltration endpoint determination volume/weight

Languages Supported
English
Weight (Approx.)
Filter support kit

10 kg (22 lbs)

Pump cart

330 kg (727.5 lbs)

Filter cart

150 kg (330.7 lbs)

Manifold plate

5 kg (11 lbs)

30 kg (66.1 lbs)

Dimensions (H x W x D)
Pump cart

1910 x 1250 x 800 mm (75.1 x 49.2 x 31.5 in.)

Filter cart

1050 x 1100 x 800 mm (41.3 x 43.3 x 31.5 in.)
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SPECIFICATIONS
TF-1

TF-2

Pellicon cassette liners

UDEL P-1700

Polysulfone

Process container

ULDPE (PureFlex™ film)

Low dead volume
t-connector

LLDPE film (septum), Polysulfone (body nut), LLDPE (Gauge Protector), Silicone (o-ring)

Tubing

Nylon-braided silicone, Bioprene®, Platinum-cured silicone tubing

Fittings

Polypropylene, HDPE, polysulfone, silicone o-rings/gaskets, polyvinylidene difluoride

Connectors

Polypropylene, silicone

Filters

See individual datasheets

Materials of Construction
(product contact)

Materials of Construction
(non-product contact)
Retentate recycle tank

HDPE

Frame

Stainless steel 304L

Panels

Stainless steel 304L, Epoxy coating PMS233

Drip tray

Stainless steel 304L

Non-painted exposed surfaces, e.g. shelves, installation bar, installation support, handle bars

Stainless steel 304L Polished 220 grid

Bench

Laminated glass

Pellicon holder

Stainless steel 316L

Trays/bins

Polyethylene

NovaSeal crimp

Nickel-coated brass

Wheels

Nylon non-marking wheels with locks

Low dead volume t-connector

Polysulfone (body nut), nylon (washer), PVC (plug)

Manifold Plate
Plate

Polycarbonate

Supports

Stainless steel 316L

Pinch valves

Glass-reinforced nylon

Filter Support Kit
Frame

Stainless steel 304L

Support

Stainless steel 304L/316L

Holder nuts

Bronze

Pinch valves

Glass-reinforced nylon

Filtrate Weigh Scale (Optional)
60 kg (132.3 lbs)

Stainless steel 316TI

600 kg (1,328 lbs)

Stainless steel 304

Flexware Assemblies
Mobius Bronze Certification: Each assembly is exposed to a gamma irradiation level of 25-40 kGy.
Component materials meet criteria for USP<88> Biological Reactivity Test, Class VI Plastics.
Flexware assemblies are compliant with EMEA410/01 Rev. 2.
Regulatory Information
The system is manufactured according to the ISO® 9001 quality standard.
The system is designed to be compliant with CE and EN 60204.
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ORDERING INFORMATION
Description

Catalogue No.

Description

Catalogue No.

Core Hardware System

Services

The core hardware system includes the pumping cart,
filter cart with 2 trays (10L and 50L), and filter supports.

Choose from a suite of services, including installation,
commissioning validation, training and annual performance
review to meet your specific processing requirements. All
services are performed by Mobius FlexReady services certified
engineers.

Mobius FlexReady System, TF-1 (10L retentate recycle tank)
100-110VAC 50/60Hz
1 phase (North American)

MBSTA1

230VAC 50/60Hz
1 phase (European)

MBSTA2

Mobius FlexReady System, TF-2 (50L retentate recycle tank)

Factory Acceptance Testing

SVCMBSTFAT

Installation and Operational Qualification
Protocol Performance Zone* 1

SVCMBSTIQOQZ1

MBSTB1

Installation and Operational Qualification
Protocol Performance Zone* 2

SVCMBSTIQOQZ2

200 - 208VAC, 50/60Hz
3 phase (North American)

SVCMBSTIQOQZ3

400VAC 50/60Hz
3 phase (European)

MBSTB2

Installation and Operational Qualification
Protocol Performance Zone* 3
Installation and Operational Qualification
Protocol, TF-1

DOCMBST1IQOQ

Installation and Operational Qualification
Protocol, TF-2

DOCMBST2IQOQ

Annual Performance Review Zone* 1

SVCMBSTAPRZ1

Annual Performance Review Zone* 2

SVCMBSTAPRZ2

Annual Performance Review Zone* 3

SVCMBSTAPRZ3

Hardware Accessories
Collapsible Containers
250L bin (holds 100L or 250L process
containers)

MBSACC006U

1,000L bin (holds 500L, 750L, or 1,000L
process containers)

MBSACC007U

Containment trays
10L tray (holds 5 or 10L process
containers)

MBSACC005U

50L tray (holds 20L or 50L process
container)

MBSACC004U

Filtrate Weigh Scale
60 kg (132.3 lbs) for TF-1

MBSACC019U

600 kg (1,328 lbs) for TF-2

MBSACC020U

* For Zone and pricing information, contact your local Millipore
representative.
Flexware Assemblies (Pellicon cassettes sold separately)
For flowpath drawing, see Fig. 7 on pg. 4. Consult with your sales
representative to configure your TFF flowpath using standard,
optimized options.
Each system has a dedicated flowpath, and the flowpath
components are not interchangeable between TF-1 and TF-2.
Ensure you order the flowpath for the hardware system you
have selected.
Pellicon Cassettes
All Pellicon cassettes must be purchased separately.
See datasheets DS1324EN00 Rev. B, DS1209EN00 (Pellicon 3)
and DS1210EN00 (Pellicon 2) for ordering information.

NovaSeal Crimping Solution
The flowpath includes the NovaSeal Crimping Sleeve for sterile
disconnect of sample containers. The NovaSeal Crimping Tool is
sold separately. See datasheet DS1040EN00 Rev. B for ordering
information.
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TO PLACE AN ORDER OR RECEIVE
TECHNICAL ASSISTANCE
For additional information call your nearest Millipore office:
In the U.S. and Canada, call toll-free
1-800-MILLIPORE (1-800-645-5476)
In the U.S., Canada and Puerto Rico, fax orders to
1-800-MILLIFX (1-800-645-5439)
Outside of North America contact your local office.
To find the office nearest you: www.millipore.com/offices
Internet: www.millipore.com
Technical Service: www.millipore.com/techservice

www.millipore.com/mobius

Millipore, Mobius, Flexware, Pellicon, Integritest, and Millipore Express are registered
trademarks of Millipore Corporation. ISO is a registered trademark of the International
Standards Organization. Bioprene is a registered trademark of Watson-Marlow Ltd.
The M mark and Advancing Life Science Together, PureFlex and NovaSeal are trademarks
of Millipore Corporation.
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